{
    "0": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the range of stage II breast cancer (less than or equal to 5 cm in size).\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, which meets the criteria for women of any age.\n\nStep 3: Compare the patient's breast cancer stage to the inclusion criteria.\nThe patient's cancer is stage II, which meets the criteria for stage II breast cancer.\n\nStep 4: Compare the patient's tumor size to the inclusion criteria.\nThe patient's tumor is 3 cm, which is less than or equal to 5 cm.\n\nStep 5: Compare the patient's axillary lymph nodes to the inclusion criteria.\nThe patient has 5 positive lymph nodes, which is within the range of stage II breast cancer.\n\nStep 6: Compare the patient's tumor histology to the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative, which is consistent with the criteria for an invasive primary breast neoplasm of epithelial origin.\n\nStep 7: Compare the patient's eligibility for the trial's exclusion criteria.\nThe patient does not have any exclusion criteria that apply to her.\n\nStep 8: Determine the patient's trial-level eligibility.\nBased on the comparison of the patient's information to the inclusion and exclusion criteria, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "1": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient Note:\n- Age: 45 years old\n- Gender: Female\n- Disease: 3 cm invasive ductal breast carcinoma, HER2-positive, ER/PR negative\n- Stage: Not specified, but likely Stage I or II\n- Tumor size: 3 cm\n- Axillary lymph nodes: 5 positive lymph nodes\n- No prior chemotherapy\n- Surgical candidate\n\nInclusion Criteria:\n- Histologically confirmed nonlobular invasive breast cancer\n- Stage I or II (T1-2 N0-1 M0)\n- Tumor no greater than 3 cm\n- Prior tylectomy and axillary lymph node dissection required\n- No more than 3 positive axillary lymph nodes and no extracapsular extension\n- At least 6 lymph nodes sampled OR Negative sentinal node\n- Surgical clips in place delineating margins of tylectomy cavity\n- Negative, or close but negative, inked histologic margins of tylectomy or re-excision specimen\n- Negative post-tylectomy or post-reexcision mammogram required if disease presented with malignancy-associated microcalcifications\n- No remaining suspicious microcalcifications\n- No extensive intraductal carcinoma by the Harvard definition\n- No proven multicentric carcinoma\n- No skin or chest wall invasion\n- No matted or fixed axillary adenopathy\n- No metastatic internal mammary or supraclavicular nodes\n- No Paget's disease of the nipple\n- No previously treated contralateral breast carcinoma or synchronous bilateral breast carcinoma\n- Hormone receptor status: Not specified (not an exclusion)\n- Age: Any age (not specified)\n- Sex: Female (not specified)\n- Menopausal status: Not specified (not an exclusion)\n- Performance status: Not specified (not an exclusion)\n- Hematopoietic: Not specified (not an exclusion)\n- Hepatic: Not specified (not an exclusion)\n- Renal: Not specified (not an",
        "label": 0
    },
    "2": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note with inclusion criteria\n\n1.1 Age: Patient is 45 years old, which is within the adult age range.\n\n1.2 Gender: Patient is female, which matches the trial's requirement.\n\n1.3 Menopausal status: Patient is postmenopausal, which matches the trial's requirement.\n\n1.4 Disease characteristics:\n\n1.4.1 Histologically proven diagnosis: Patient has invasive ductal breast carcinoma, which matches the trial's requirement.\n\n1.4.2 Stage: Patient has stage II breast cancer, which matches the trial's requirement for stage I, IIA, or IIB breast cancer.\n\n1.4.3 No recurrent invasive breast cancer: Patient does not have a history of recurrent invasive breast cancer.\n\n1.4.4 No evidence of distant disease: Patient has metastatic lesions on CXR, which is not allowed in the trial.\n\n1.4.5 Prior local treatment: Patient has not received prior definitive local treatment, which is not allowed in the trial.\n\n1.4.6 Surgical margins: Patient has not undergone surgery, which is not allowed in the trial.\n\n1.4.7 No endometrial simple or cystic hyperplasia, proliferative changes, complex (adenomatous) or atypical hyperplasia, or carcinoma: Patient has not undergone endometrial biopsy, which is not allowed in the trial.\n\n1.4.8 Hormone receptor status: Patient's cancer is HER2-positive and ER/PR negative, which is not allowed in the trial.\n\n1.5 Prior concurrent therapy:\n\n1.5.1 Biologic therapy: Patient has not received prior biologic therapy, which is not specified in the trial.\n\n1.5.2 Chemotherapy: Patient has not received prior chemotherapy, which is not specified in the trial.\n\n1.5.3 Endocrine therapy: Patient has not received prior hormonal treatment for breast cancer, which is not specified in the trial.\n\n1.5.4 Radiotherapy: Patient has not received prior radi",
        "label": 0
    },
    "3": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the trial includes patients aged 18 and over. The patient meets this criterion.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a female, and the trial includes females. The patient meets this criterion.\n\nStep 3: Compare the patient's disease characteristics to the inclusion criteria.\nThe patient has a histologically confirmed breast cancer with a 3 cm invasive ductal carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes, and there are metastatic lesions. The patient meets the criteria for histologically confirmed breast cancer and positive lymph nodes. The tumor diameter is greater than 1.0 cm, which meets the criterion. The patient has undergone axillary dissection, which meets the criterion. The patient does not have locally advanced or inflammatory or metastatic breast cancer, so she meets this criterion. The hormone receptor status is not specified, but it is not an exclusion criterion. The patient meets this criterion.\n\nStep 4: Compare the patient's other characteristics to the inclusion criteria.\nThe patient is not specified as postmenopausal, but it is not an exclusion criterion. The patient's performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, and other conditions are not specified, but they are not exclusion criteria. The patient has not received prior chemotherapy for this malignancy, which meets the criterion. The patient has not received concurrent tamoxifen, which meets the criterion. The patient has not received prior radiotherapy for this malignancy, which meets the criterion. The patient has undergone surgery, which meets the criterion. The patient has not had a surgical procedure within 84 days, which meets the criterion.\n\nStep 5: Determine the trial-level eligibility.\nThe patient meets all the inclusion criteria and does not have any exclusion criteria. Therefore, the trial-level elig",
        "label": 1
    },
    "4": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which falls within the age range of any age specified in the inclusion criteria.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a female, which matches the inclusion criteria for women.\n\nStep 3: Compare the patient's disease characteristics to the inclusion criteria.\nThe patient has cytologically confirmed stage IIA invasive breast cancer, which is within the specified range of T0, T1, or T2 (no greater than 3 cm) and N0 Noninflammatory Nonmetastatic in the inclusion criteria. The patient's cancer is not ductal carcinoma in situ, and she is eligible for breast-conserving surgery. Her hormone receptor status is positive or negative, which matches the inclusion criteria.\n\nStep 4: Compare the patient's other characteristics to the inclusion criteria.\nThe patient's menopausal status, performance status, life expectancy, hematopoietic, hepatic, renal, and pregnancy status are not specified in the inclusion criteria, so we cannot determine her eligibility based on these factors.\n\nStep 5: Compare the patient's prior therapy to the inclusion criteria.\nThe patient has not received prior biologic therapy, chemotherapy, endocrine therapy, radiotherapy, or breast surgical biopsy or axillary surgery, which matches the inclusion criteria.\n\nStep 6: Determine the trial-level eligibility.\nSince the patient meets the inclusion criteria for disease characteristics and prior therapy, and her other characteristics are not specified in the inclusion criteria, she is considered eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "5": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state that the patient must be 18 years or older. The patient meets this criterion.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a female, and the inclusion criteria state that the patient must be female. The patient meets this criterion.\n\nStep 3: Compare the patient's menopausal status to the inclusion criteria.\nThe inclusion criteria do not specify the patient's menopausal status. The patient is postmenopausal, but this does not exclude her from the trial.\n\nStep 4: Compare the patient's disease characteristics to the inclusion criteria.\nThe patient has a resectable invasive adenocarcinoma of the breast, confirmed by core biopsy. The patient has 5 positive lymph nodes and metastatic lesions. These criteria do not match the inclusion criteria, which state that the patient must have clinically negative lymph nodes and no positive ipsilateral axillary lymph nodes. The patient is excluded based on these criteria.\n\nStep 5: Compare the patient's prior therapy to the inclusion criteria.\nThe patient has not received prior chemotherapy, hormonal therapy, or radiotherapy for this cancer. The inclusion criteria state that the patient must not have received prior chemotherapy, hormonal therapy, or radiotherapy for this cancer. The patient meets this criterion.\n\nStep 6: Compare the patient's other characteristics to the inclusion criteria.\nThe patient meets all other inclusion criteria, including age, gender, menopausal status, performance status, life expectancy, hematopoietic, hepatic, renal, cardiovascular, and other factors.\n\nConclusion:\nTrial-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).",
        "label": 0
    },
    "6": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state that patients must be postmenopausal. The patient is postmenopausal, so she meets this criterion.\n\nStep 2: Compare the patient's breast cancer type with the inclusion criteria.\nThe patient has invasive ductal breast carcinoma, and the inclusion criteria state that patients must have histologically confirmed resectable adenocarcinoma of the breast. The patient meets this criterion.\n\nStep 3: Compare the patient's disease stage with the inclusion criteria.\nThe patient has 5 positive lymph nodes and metastatic lesions, which indicates a stage IIIa cancer. The inclusion criteria state that patients with stage I, II, or IIIa cancer are allowed if the tumor is completely removed macroscopically and margins of the resected tumor are microscopically free of tumor. The patient meets this criterion.\n\nStep 4: Compare the patient's hormone receptor status with the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative. The inclusion criteria state that patients must have at least 10% hormone receptor-positive tumor cells. The patient does not meet this criterion.\n\nStep 5: Compare the patient's other characteristics with the inclusion criteria.\nThe patient meets all other inclusion criteria, including being postmenopausal, having no distant metastases, and having no prior or concurrent malignancy within the past 5 years.\n\nSince the patient meets all the inclusion criteria except for the hormone receptor status, she is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).",
        "label": 0
    },
    "7": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria do not specify an age range. Therefore, this factor is not relevant.\n\nStep 2: Compare patient's gender with the inclusion criteria.\nThe patient is a female, and the inclusion criteria specify that the patient must be a female. Therefore, this factor is eligible.\n\nStep 3: Compare patient's menopausal status with the inclusion criteria.\nThe inclusion criteria do not specify a menopausal status. Therefore, this factor is not relevant.\n\nStep 4: Compare patient's disease characteristics with the inclusion criteria.\nThe patient has HER2-positive and ER/PR negative breast cancer, and the inclusion criteria require the patient to have HER2 overexpressing metastatic breast cancer. The patient also has 5 positive lymph nodes and metastatic lesions, which are not specified in the inclusion criteria. Therefore, this factor is not relevant.\n\nStep 5: Compare patient's other medical conditions and prior treatments with the inclusion criteria.\nThe patient does not have any medical conditions that would exclude her from the trial. She does not have significant lymphedema, no CNS metastases, and no severe hypersensitivity to products containing Cremophor EL. She has not received prior trastuzumab or other concurrent immunotherapy, and she has not received chemotherapy in the past year. Therefore, this factor is eligible.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "8": {
        "output": "GPT4 Correct Assistant: Age: The patient is 45 years old, which is within the range for the trial.\n\nGender: The patient is a woman, which matches the trial criteria.\n\nType and stage of disease: The patient has invasive ductal breast carcinoma, which is a type of breast cancer included in the trial. The tumor is 3 cm, which is within the range for the trial (T1-3). The patient has 5 positive lymph nodes, which is within the range for the trial (pN1-2). The patient has metastatic lesions, which may be included in the trial depending on the specific subtype of breast cancer.\n\nPrevious treatment history: The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which is compatible with the trial criteria. She is not taking any hormonal agents, which is allowed in the trial.\n\nOther medical conditions: The patient is not taking any medications, which is compatible with the trial criteria. She does not smoke or consume alcohol, which is compatible with the trial criteria. She is not sexually active and has no children, which is compatible with the trial criteria.\n\nInclusion criteria: The patient meets all the inclusion criteria for the trial, including being a woman with HER2-positive, ER/PR-negative breast cancer, having 1 or more positive lymph nodes, and having no other exclusionary medical conditions.\n\nExclusion criteria: The patient does not meet any exclusion criteria for the trial, such as having cN2 disease, having a history of non-breast malignancies within the last 5 years, or having any other medical conditions that would disqualify her from participating in the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "9": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n- Age: 45 years old\n- Sex: Female\n- Menopausal status: Postmenopausal\n- Disease: Stage IIIA breast cancer (3 cm invasive ductal breast carcinoma, 5 positive lymph nodes)\n- HER2-positive and ER/PR negative\n- No previous treatment\n- No metastases in the brain, liver, or lungs\n- No prior malignancies\n\nStep 2: Compare the patient's characteristics to the inclusion and exclusion criteria of the clinical trial.\n\nInclusion criteria:\n- Histologically confirmed stage IIB, IIIA, IIIB, IIIC, or previously untreated stage IV primary carcinoma of the breast\n- Fine needle aspiration, core needle biopsy, or incisional biopsy allowed\n- No excisional biopsy\n- Any of the following: T2N1, T3N0, N2, N3, T4, inflammatory breast cancer, adjuvant patients with at least 4 positive lymph nodes and HER-2 overexpressing tumor, supraclavicular or infraclavicular positive lymph nodes without distant metastases, distant metastases with measurable disease in breast or lymph nodes, synchronous bilateral primary breast cancer allowed if the more serious cancer meets entry criteria\n- Measurable or evaluable disease\n- Age: Not specified\n- Sex: Female\n- Menopausal status: Not specified\n- Performance status: Not specified\n- Life expectancy: Not specified\n- Hematopoietic: White cell count > 3000 / mm3, Platelet count > 100,000 / mm3, Hemoglobin > 9 mg / dl, Bilirubin < 1.5 x normal, Creatinine < 1.5 x normal, left ventricular ejection fraction (LVEF) normal by resting nuclear ventriculogram\n- Not pregnant or nursing\n- Negative pregnancy test\n- Fertile patients must use effective contraception\n\nExclusion criteria:\n- Prior malignancies except: effectively treated squamous cell or basal cell skin cancer, Carcinoma in situ",
        "label": 2
    },
    "10": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient note:\n- 45-year-old postmenopausal woman\n- Breast cancer (HER2-positive and ER/PR negative)\n- 5 positive lymph nodes\n\nInclusion Criteria - Menstrual Cycle Study:\n- Must be premenopausal\n- Must be at least 25 years of age and less than 46 years of age\n- Must have undergone genetic counseling and risk assessment\n- Must be a known mutation carrier or be a first- or second-degree relative of an individual with a tumor associated with the Breast-Ovarian Cancer Syndrome in a family with a known BRCA mutation\n\nStep 2: Compare patient note and exclusion criteria\n\nExclusion Criteria - Menstrual Cycle Study:\n- History of menstrual cycle irregularities over the previous 6 months\n- Steroid therapy, use of selective estrogen receptor modulators (SERMs) or hormonal agents within 6 months prior to study entry\n- Pregnancy or lactation within 12 months of enrollment\n- History of invasive cancer except for non-melanoma skin cancer or cervical carcinoma in situ\n- Creatinine greater than 2\n- Previous bilateral mastectomy, bilateral radiation therapy to the breast, or oophorectomy\n- History of DCIS or LCIS\n- Weight over 136 kilograms\n- Allergy to gadolinium\n- Allergy to lidocaine or Marcaine (bupivacaine)\n- Medical or psychiatric disorder which, in the opinion of the Principal Investigator, would preclude informed consent or ability to participate in clinical research\n\nStep 3: Assess eligibility based on the comparison\n\nBased on the patient note and inclusion/exclusion criteria, the patient is not eligible for the Menstrual Cycle Study due to the following reasons:\n- The patient is postmenopausal, which excludes her from the study.\n\nSince the patient is not eligible for the Menstrual Cycle Study, we do not need to evaluate her eligibility for the Training Cohort.\n\nTrial-level eligibility: 0)",
        "label": 0
    },
    "11": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note with inclusion criteria\n\n1. Disease Characteristics:\n- Histologically or triple diagnosis confirmed operable invasive breast cancer: Yes\n- T0-2, N0: Unknown (T stage not specified)\n- Diagnosis by excisional tumorectomy allowed: Not specified\n- Clinically occult invasive disease must be histologically confirmed: Yes\n- Only 1 tumor in 1 breast: Not specified\n- Tumor between 5 and 50 mm in largest diameter, within 1 quadrant by mammogram, ultrasound or MRI: Unknown (tumor size not specified)\n- Multifocal is allowed: Not specified\n- Multicentric breast cancer is not allowed: Not specified\n- Clinically negative axillary lymph nodes: Yes\n- No metastatic disease: Yes\n- No previous treatment of the primary breast tumor by neoadjuvant hormonal or systemic treatment: Yes\n- Hormone receptor status: Not specified\n\n1. Patient Characteristics:\n- Age: Yes (45 years old)\n- Sex: Yes (female)\n- Menopausal status: Yes (postmenopausal)\n- Performance status: Not specified\n- Life expectancy: Not specified\n- Hematopoietic: Not specified\n- Hepatic: Not specified\n- Renal: Not specified\n- Other: Yes (fit to undergo sentinel node biopsy, axillary clearance, breast surgery, and/or axillary radiotherapy)\n- No psychological, familial, sociological, or geographical condition that would preclude study compliance: Yes\n- No other prior malignancy except basal cell skin cancer or carcinoma in situ of the cervix: Yes\n- Not pregnant: Yes\n\n1. Prior Concurrent Therapy:\n- Biologic therapy: Not specified\n- Chemotherapy: Not specified\n- Endocrine therapy: Not specified\n- Radiotherapy: No prior radiotherapy to axilla\n- Surgery: No prior surgery to axilla\n- Other: See Disease Characteristics\n\nStep 2: Determine eligibility based on the comparison\n\nBased on the comparison, the patient meets most of the inclusion criteria. However, there are some unknown factors such",
        "label": 1
    },
    "12": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria.\nPatient's age: 45 years\nInclusion criteria: Age: 18 and over\nThe patient meets the age criteria.\n\nStep 2: Compare patient's gender with the inclusion criteria.\nPatient's gender: Female\nInclusion criteria: Sex: Male or female\nThe patient meets the gender criteria.\n\nStep 3: Compare patient's menopausal status with the inclusion criteria.\nPatient's menopausal status: Postmenopausal\nInclusion criteria: Menopausal status: Not specified\nThe patient meets the menopausal status criteria.\n\nStep 4: Compare patient's disease with the inclusion criteria.\nPatient's disease: Cytologically confirmed metastatic breast cancer with HER2 overexpression\nInclusion criteria: Disease characteristics: Histologically or cytologically confirmed metastatic breast cancer with HER2 overexpression\nThe patient meets the disease criteria.\n\nStep 5: Compare patient's hormone receptor status with the inclusion criteria.\nPatient's hormone receptor status: ER/PR negative\nInclusion criteria: Hormone receptor status: Not specified\nThe patient meets the hormone receptor status criteria.\n\nStep 6: Compare patient's performance status with the inclusion criteria.\nPatient's performance status: Not mentioned\nInclusion criteria: Performance status: ECOG 0-2\nThe patient does not have sufficient information to qualify for the trial based on performance status.\n\nStep 7: Compare patient's other characteristics with the inclusion criteria.\nThe patient does not have information about life expectancy, hematopoietic, hepatic, renal, prior concurrent therapy, surgery, and other factors. Therefore, the patient does not have sufficient information to qualify for the trial based on these criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "13": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with inclusion criteria\nThe patient is a 45-year-old postmenopausal woman. The inclusion criteria state that the patient must be postmenopausal, but there is no specific age requirement. Since the patient meets the postmenopausal requirement, this factor is not relevant for exclusion.\n\nStep 2: Compare patient's cancer type with inclusion criteria\nThe patient has cytologically confirmed breast cancer. The inclusion criteria state that the patient must have metastatic breast cancer suitable for endocrine therapy. The patient's breast cancer is metastatic, and she is a candidate for tumor resection and agrees to do so prior to chemotherapy. This factor is not relevant for exclusion.\n\nStep 3: Compare patient's hormone receptor status with inclusion criteria\nThe patient's tumor is HER2-positive and ER/PR negative. The inclusion criteria state that the patient must have positive hormone receptor status. The patient's hormone receptor status does not match the inclusion criteria. Therefore, the patient is excluded based on this factor.\n\nStep 4: Compare patient's HER2 status with inclusion criteria\nThe patient's tumor is HER2-positive. The inclusion criteria state that the patient must have Human epidermal growth factor receptor 2 (HER2) overexpression. The patient's HER2 status matches the inclusion criteria.\n\nConclusion: Since the patient is excluded based on hormone receptor status, the trial-level eligibility is 0) Excluded.",
        "label": 1
    },
    "14": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient note:\n- 45-year-old postmenopausal woman\n- HER2-positive and ER/PR negative breast cancer\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions in CXR\n- Candidate for tumor resection and chemotherapy\n\nInclusion criteria for breast cancer patients:\n- Age greater than or equal to 18 years and less than or equal to 74 years\n- Women with a unilateral invasive or noninvasive (DCIS) breast cancer of epithelial origin\n- Women without breast cancer, but with a Gail Index greater than 1.67 percent, or a cumulative lifetime risk greater than or equal to double the age- and race-matched general population risk\n- Women known to be BRCA1/2 or other hereditary genes mutation carriers\n- Women with cytologic or histologic evidence of ductal hyperplasia, atypical ductal hyperplasia, or LCIS\n- Women may be either premenopausal or postmenopausal\n- Breast cancer may be invasive or noninvasive, and in the past or the present\n- The contralateral breast of women with breast cancer, or the normal breast of high-risk subjects, must be free of any suspicious areas by physical examination and mammogram, and without a history of invasive ductal or in situ ductal carcinoma\n- Women who are from a family with heritable breast cancer with a known deleterious BRCA1/2 or other hereditary genes mutation, who themselves have been tested and to not carry this mutation\n- WBC greater than 2,500\n- Platelets greater than 50,000\n\nStep 2: Compare patient note and exclusion criteria\n\nExclusion criteria for breast cancer patients:\n- Contralateral breast prosthesis\n- Pregnancy\n- History of radiation therapy to the contralateral breast\n- Lactating breasts\n- Chemotherapy within the past 1 month\n- Current antiestrogen therapy\n- Current hormonal replacement therapy or oral contraceptives\n- Concurrent infection\n- Previous contralateral major duct exc",
        "label": 2
    },
    "15": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the range of 0-3 positive axillary lymph nodes.\n\nStep 2: Compare patient's gender to the inclusion criteria.\nThe patient is female, which is consistent with the inclusion criteria.\n\nStep 3: Compare patient's cancer type and stage to the inclusion criteria.\nThe patient has invasive ductal breast cancer, which is consistent with the inclusion criteria.\n\nStep 4: Compare patient's number of positive axillary lymph nodes to the inclusion criteria.\nThe patient has 5 positive axillary lymph nodes, which is more than the 3 positive axillary lymph nodes allowed in the inclusion criteria.\n\nStep 5: Compare patient's tumor characteristics to the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative, which is consistent with the inclusion criteria.\n\nStep 6: Compare patient's medical history to the inclusion criteria.\nThe patient is not pregnant or nursing, which is consistent with the inclusion criteria.\n\nStep 7: Compare patient's organ function to the inclusion criteria.\nThe patient's ANC, platelet count, creatinine, and bilirubin levels are within the acceptable ranges, which is consistent with the inclusion criteria.\n\nStep 8: Compare patient's use of medications to the inclusion criteria.\nThe patient is using multivitamins and iron supplements, which are not specified in the inclusion criteria. However, they are not excluded.\n\nStep 9: Compare patient's eligibility for adjuvant therapy to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which is consistent with the inclusion criteria.\n\nTrial-level eligibility: 0) Excluded",
        "label": 2
    },
    "16": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria do not specify any age restrictions. Therefore, the patient meets this criterion.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nThe patient is a woman, and the inclusion criteria do not specify any gender restrictions. Therefore, the patient meets this criterion.\n\nStep 3: Compare the patient's cancer type with the inclusion criteria.\nThe patient has breast cancer, and the inclusion criteria specify that patients must have histologic confirmation of invasive, but non-inflammatory carcinoma of the breast. Therefore, the patient meets this criterion.\n\nStep 4: Compare the patient's cancer stage with the inclusion criteria.\nThe patient has axillary sampling revealing 5 positive lymph nodes, which corresponds to pN2a (metastasis in four to nine axillary lymph nodes). The inclusion criteria state that patients with pN2a are eligible. Therefore, the patient meets this criterion.\n\nStep 5: Compare the patient's tumor characteristics with the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative, and the inclusion criteria state that patients with overexpression of the her-2/neu oncogene are eligible. Therefore, the patient meets this criterion.\n\nStep 6: Compare the patient's medical history with the inclusion criteria.\nThe patient does not have any medical conditions listed in the exclusion criteria. Therefore, the patient meets this criterion.\n\nStep 7: Compare the patient's laboratory values with the inclusion criteria.\nThe patient's laboratory values are not specified in the note, so we cannot determine if they meet this criterion. Therefore, the patient's eligibility is 1) Not relevant.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "17": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient note:\n- 45-year-old postmenopausal woman\n- Breast cancer (HER2-positive and ER/PR negative)\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions\n\nInclusion criteria:\n- Histologically confirmed breast cancer\n- Stage IV or locally advanced disease\n- HER2/neu positive\n- Measurable or evaluable disease\n- Estrogen receptor and/or progesterone receptor positive\n- Postmenopausal (defined by various criteria)\n\nStep 2: Assess patient eligibility based on inclusion criteria\n\n- Histologically confirmed breast cancer: Yes (patient has breast cancer)\n- Stage IV or locally advanced disease: Yes (patient has metastatic lesions)\n- HER2/neu positive: Yes (patient is HER2-positive)\n- Measurable or evaluable disease: Yes (patient has measurable disease)\n- Estrogen receptor and/or progesterone receptor positive: No (patient is ER/PR negative)\n- Postmenopausal: Yes (patient is 45 years old and postmenopausal)\n\nStep 3: Determine trial-level eligibility\n\nSince the patient meets all inclusion criteria except for estrogen receptor and/or progesterone receptor positivity, she is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).",
        "label": 1
    },
    "18": {
        "output": "GPT4 Correct Assistant: Let's analyze the patient note and the inclusion criteria of the clinical trial step by step.\n\n1. Disease Characteristics: The patient has cytologically confirmed breast cancer, but the note does not specify if it is confined to the breast and axillary nodes. The patient also has metastatic lesions, which disqualify her from the trial. So, this criterion is not met.\n\n2. Prior Concurrent Therapy: The patient is using multivitamins and iron supplements, but they are not considered prior or concurrent therapy for the trial. The patient has not received neoadjuvant or adjuvant chemotherapy, endocrine therapy, or any other concurrent oral or transdermal hormonal therapy. So, this criterion is met.\n\n3. Patient Characteristics: The patient is a postmenopausal woman, but the trial is for premenopausal women. So, this criterion is not met.\n\nBased on the above analysis, the patient does not meet the inclusion criteria for the clinical trial. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "19": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age with the age criteria.\nThe patient is 45 years old, which is within the age range of 18 and over specified in the trial.\n\nStep 2: Compare patient gender with the gender criteria.\nThe patient is a female, which matches the gender criteria for both male and female.\n\nStep 3: Compare patient menopausal status with the menopausal status criteria.\nThe patient's menopausal status is not specified in the patient note, but it is not a required criterion in the trial.\n\nStep 4: Compare patient performance status with the performance status criteria.\nThe patient's performance status is not specified in the patient note, but it is not a required criterion in the trial.\n\nStep 5: Compare patient life expectancy with the life expectancy criteria.\nThe patient's life expectancy is not specified in the patient note, but it is not a required criterion in the trial.\n\nStep 6: Compare patient hematopoietic parameters with the hematopoietic criteria.\nThe patient's absolute neutrophil count and platelet count are not specified in the patient note, but they are not required criteria in the trial.\n\nStep 7: Compare patient hepatic parameters with the hepatic criteria.\nThe patient's bilirubin, alkaline phosphatase, SGOT, and SGPT are not specified in the patient note, but they are not required criteria in the trial.\n\nStep 8: Compare patient renal parameters with the renal criteria.\nThe patient's creatinine is not specified in the patient note, but it is not a required criterion in the trial.\n\nStep 9: Compare patient cardiovascular parameters with the cardiovascular criteria.\nThe patient's cardiovascular status is not specified in the patient note, but it is not a required criterion in the trial.\n\nStep 10: Compare patient other parameters with the other criteria.\nThe patient's pregnancy status, fertility, other malignancies, and HIV status are not specified in the patient note, but they are not required criteria in the trial.\n\nStep 11: Compare patient prior concurrent therapy with the prior con",
        "label": 2
    },
    "20": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note\n- Patient is a 45-year-old postmenopausal woman\n- Diagnosed with cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma, 3 cm tumor\n- HER2-positive, ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR\n\nStep 2: Compare patient note to inclusion criteria\n\nDisease Characteristics:\n- Clinical, mammographic, ultrasonographic, or pathologic diagnosis of unicentric and unifocal breast carcinoma: Yes\n- Largest tumor lesion \u2264 5 cm: Yes (3 cm tumor)\n- Palpable or nonpalpable breast lesion: Yes\n- Prior (preoperative) or planned (intraoperative) sentinel node biopsy required: Not specified\n- At least 1 micrometastatic (i.e., no greater than 2 mm) sentinel lymph node with no extracapsular extension: Not specified\n- No clinical evidence of distant metastases: Yes (metastatic lesions on CXR, but not clinical evidence)\n- No suspicious manifestation of metastases that cannot be ruled out by x-ray, MRI, or CT scan: Not specified\n- No palpable axillary lymph node(s): No (5 positive lymph nodes)\n- No Paget's disease without invasive cancer: Yes\n- Hormone receptor status: Yes (Estrogen receptor and progesterone receptor known)\n\nPatient Characteristics:\n- Age: Yes (45 years old)\n- Sex: Yes (Female)\n- Menopausal status: Yes (Postmenopausal)\n- Performance status: Not specified\n- Life expectancy: Not specified\n- Hematopoietic: Not specified\n- Hepatic: Not specified\n- Renal: Not specified\n- Other: Not specified\n- Not pregnant or nursing: Yes\n- No other prior or concurrent malignancy except the following: Not specified\n- No psychiatric, addictive, or other disorder that may compromise ability to give informed consent: Not specified\n- Geograph",
        "label": 0
    },
    "21": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\n1.1 Disease Characteristics:\n- The patient has breast cancer, but it is not ductal carcinoma in situ.\n- The patient has not been diagnosed within the past 6 months.\n- The patient has undergone surgery, but the note does not mention tumor-free margins.\n- The patient's hormone receptor status is ER/PR negative, not positive.\n\n1.2 Patient Characteristics:\n- The patient is 45 years old, within the age range of 40 to 70.\n- The patient is a female.\n- The patient is postmenopausal.\n- The patient's performance status is not specified.\n- The patient's life expectancy is at least 10 years.\n- The patient's hematopoietic, hepatic, renal, and cardiovascular statuses are not specified.\n- The patient has no prior deep vein thrombosis, transient ischemic attack, cerebrovascular accident, pulmonary embolism, or unexplained postmenopausal bleeding.\n- The patient has no other cancer within the past 5 years, except nonmelanoma skin cancer or carcinoma in situ of the cervix.\n- The patient has no other concurrent medical condition that would preclude study therapy, place the patient at unusual risk, or confound study results.\n- The patient has no evidence of osteoporosis.\n- The patient has fragility fractures within the spine allowed if T-score level is greater than -4 and consist of no more than 2 fractures.\n- The patient is psychologically and physically suitable for 5 years of study therapy.\n\n1.3 Prior Concurrent Therapy:\n- The patient is using multivitamins and iron supplements, but this does not conflict with the trial's exclusion criteria.\n- The patient does not smoke or consume alcohol, which is not mentioned in the inclusion criteria.\n- The patient is not sexually active and has no children, which is not mentioned in the inclusion criteria.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which is not mentioned in the inclusion criteria.\n\nStep 2: Det",
        "label": 0
    },
    "22": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's key characteristics from the patient note:\n- Age: 45 years old\n- Gender: Female\n- Disease: Cytologically confirmed breast cancer\n- Tumor type: 3 cm invasive ductal breast carcinoma (HER2-positive, ER/PR negative)\n- Axillary sampling: 5 positive lymph nodes\n- CXR: Metastatic lesions\n- Other treatments: Multivitamins and iron supplements, no smoking or alcohol, not sexually active, no children, candidate for tumor resection\n\nStep 2: Compare the patient's characteristics to the inclusion criteria of the clinical trial:\n\nInclusion Criteria 1: Female patients with histologically/cytologically proven metastatic breast carcinoma (stage IV, or recurrent with local or regional spread or distant metastatic disease)\n- Patient is a female with cytologically confirmed breast cancer (metastatic)\n\nInclusion Criteria 2: Adequate bone marrow, liver, and renal function\n- The patient note does not provide information about bone marrow, liver, or renal function.\n\nStep 3: Determine the patient's eligibility based on the comparison:\n- The patient meets Inclusion Criteria 1, but there is insufficient information to determine if she meets Inclusion Criteria 2.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "23": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 45 years old, which falls within the range of 45 years or older for postmenopausal women.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nThe patient is a female, which matches the inclusion criteria for females.\n\nStep 3: Compare the patient's menopausal status with the inclusion criteria.\nThe patient is postmenopausal, which matches the inclusion criteria for postmenopausal women.\n\nStep 4: Compare the patient's disease characteristics with the inclusion criteria.\nThe patient has cytologically confirmed breast cancer, which matches the inclusion criteria for histologically or cytologically confirmed breast cancer.\n\nStep 5: Compare the patient's hormone receptor status with the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative, which does not match the inclusion criteria for hormone receptor-positive breast cancer.\n\nStep 6: Compare the patient's other characteristics with the inclusion criteria.\nThe patient's performance status is not specified, but it is within the range of ECOG 0-3. The patient's life expectancy, hepatic, and renal functions are not specified, but there is no information suggesting they would be excluded. The patient has no other prior or concurrent cancer, which matches the inclusion criteria.\n\nConclusion: The patient does not meet the inclusion criteria for hormone receptor status, so the trial-level eligibility is 0) Excluded.",
        "label": 0
    },
    "24": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note with inclusion criteria\n\n1. Age: Patient is 45 years old, which meets the requirement of being greater than or equal to 18 years old.\n2. Life expectancy: The patient has a diagnosis of breast cancer, but there is no information about her life expectancy. Therefore, this criterion is Not relevant (1).\n3. Interval between surgery and randomization: The patient's last surgery was 83 days ago, which is within the 84-day limit.\n4. Tumor type: The tumor is invasive ductal breast carcinoma, which meets the requirement.\n5. Primary tumor stage: The primary tumor is T1-3, which meets the requirement.\n6. Lymph node stage: The patient has 5 positive lymph nodes, which is not eligible as the requirement is pN0.\n7. Receptor status: The tumor is HER2-positive and ER/PR negative, which meets the requirement.\n8. Treatment history: The patient has not received any treatment for breast cancer prior to randomization, which meets the requirement.\n9. Menopausal status: The patient is postmenopausal, which meets the requirement.\n10. Other criteria: The patient meets all other criteria, including no clinical or radiologic evidence of metastatic disease, no history of non-breast malignancies, and no ineligible conditions.\n\nStep 2: Compare patient note with exclusion criteria\n\n1. Gender: The patient is female, which meets the requirement.\n2. Malignancy: The patient has a history of breast cancer, which is ineligible.\n3. Bilateral malignancy: The patient has no bilateral malignancy, which meets the requirement.\n4. Primary tumor staged as T4: The patient's tumor is not staged as T4, which meets the requirement.\n5. Suspicious palpable nodes: The patient does not have suspicious palpable nodes, which meets the requirement.\n6. Prior history of breast cancer: The patient has a history of breast cancer, which is ineligible.\n7. Treatment history: The patient has not received any treatment for breast cancer prior to randomization, which meets the requirement.\n8.",
        "label": 0
    },
    "25": {
        "output": "GPT4 Correct Assistant: First, let's compare the patient note and the inclusion criteria of the clinical trial.\n\n1. Patient has breast cancer, not lung cancer.\n2. Patient is undergoing surgery for breast cancer, not lung cancer.\n3. Patient has already received treatment (multivitamins and iron supplements).\n4. Patient does not meet the age requirement (18 years or older).\n5. Patient does not meet the ECOG performance status requirement (0-2).\n\nBased on these comparisons, the patient does not meet the inclusion criteria for the clinical trial. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "26": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the range of \u226518 years old.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, which is not specified in the inclusion criteria, but there is no exclusion based on gender.\n\nStep 3: Compare the patient's medical condition to the inclusion criteria.\nThe patient has breast cancer, not malignant glioma. This is an exclusion criterion.\n\nStep 4: Compare the patient's treatment history to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This is not specified in the inclusion criteria, but there is no exclusion based on this factor.\n\nStep 5: Compare the patient's other medical conditions to the inclusion criteria.\nThe patient does not have any other medical conditions mentioned in the inclusion criteria.\n\nStep 6: Compare the patient's ability to participate in the trial to the inclusion criteria.\nThe patient understands the investigational nature of the study and its potential risks and benefits and has signed an informed consent. This is not specified in the inclusion criteria, but there is no exclusion based on this factor.\n\nTrial-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).",
        "label": 0
    },
    "27": {
        "output": "GPT4 Correct Assistant: First, let's compare the patient's characteristics with the inclusion and exclusion criteria of the clinical trial.\n\n1. Patient consent and life expectancy: The patient has consented to participate and has a life expectancy of at least 10 years.\n2. Performance status: The patient has a Zubrod performance status of 0 or 1.\n3. Interval between surgery and randomization: The interval between the patient's surgery for breast cancer staging or treatment and randomization is no more than 84 days.\n4. Tumor type and stage: The patient has invasive ductal breast carcinoma, which is a type of invasive carcinoma of the breast. The patient's tumor is T1-3, which falls within the range of T1-3 for primary tumor stage. The patient has 5 positive lymph nodes, which falls within the range of pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN3a, or pN3b (only if due to microscopic involvement of internal mammary node detected by sentinel lymph node dissection and with more than 3 positive axillary lymph nodes). The patient's tumor is HER2-positive and ER/PR negative, which is not an exclusion criterion.\n5. Surgical procedure and pathologic nodal staging: The patient has undergone a lumpectomy, which is an eligible surgical procedure for the trial. The patient has completed one of the following procedures for evaluation of pathologic nodal status: sentinel lymphadenectomy followed by removal of additional non-sentinel lymph nodes, sentinel lymphadenectomy alone, or axillary lymphadenectomy without sentinel node isolation procedure.\n6. Evidence of metastatic disease: The patient has metastatic lesions detected by CXR, which is an exclusion criterion.\n7. AST, alkaline phosphatase, total bilirubin, and serum creatinine: The patient's AST and alkaline phosphatase are within the acceptable range, and the patient has a normal total bilirubin and serum creat",
        "label": 1
    },
    "28": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note with inclusion criteria\n\n1. Diagnosis of invasive breast cancer: Yes (patient has cytologically confirmed breast cancer)\n2. Tumor \u2265 3 cm and palpable: Yes (tumor is 3 cm)\n3. Multiple masses allowed (at least 1 mass \u2265 3 cm): Not applicable (patient has only one mass)\n4. Clinically positive axillary or supraclavicular lymph nodes allowed: Yes (5 positive lymph nodes)\n5. Fine needle aspiration or core needle biopsy positive for invasive breast cancer AND/OR fine needle aspiration of lymph nodes positive: Yes (patient has a core biopsy)\n6. HER2/neu-positive OR negative: Yes (tumor is HER2-positive)\n7. No inflammatory breast cancer: Not applicable (patient does not have inflammatory breast cancer)\n8. No distant metastases: Yes (patient has metastatic lesions)\n9. Hormone receptor status: Estrogen receptor (ER)-negative: Yes (tumor is ER/PR negative)\n\nStep 2: Compare patient note with exclusion criteria\n\n1. Age: 18 and over: Yes (patient is 45 years old)\n2. Sex: Female: Yes (patient is female)\n3. Menopausal status: Postmenopausal: Yes (patient is postmenopausal)\n4. Performance status: Not specified (patient's performance status is not mentioned)\n5. Life expectancy: Not specified (patient's life expectancy is not mentioned)\n6. Hematopoietic: Granulocyte count \u2265 1,000/mm^3: Not applicable (patient's granulocyte count is not mentioned)\n7. Hematopoietic: Platelet count \u2265 100,000/mm^3: Not applicable (patient's platelet count is not mentioned)\n8. Hepatic: Bilirubin \u2264 2 times upper limit of normal (ULN): Not applicable (patient's bilirubin level is not mentioned)\n9. Hepatic: SGOT",
        "label": 2
    },
    "29": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age with the age criteria\nThe patient is 45 years old, which is within the age range of 18 and over specified in the trial.\n\nStep 2: Compare patient gender with the sex criteria\nThe patient is female, which matches the sex criteria for the trial.\n\nStep 3: Compare patient menopausal status with the menopausal status criteria\nThe patient is postmenopausal, which matches the menopausal status criteria for the trial.\n\nStep 4: Compare patient disease characteristics with the disease characteristics criteria\nThe patient has a HER2-positive and ER/PR-negative 3 cm invasive ductal breast carcinoma, which matches the disease characteristics criteria for stage II tumors.\n\nStep 5: Compare patient axillary lymph nodes with the axillary lymph nodes criteria\nThe patient has 5 positive axillary lymph nodes, which is within the allowed range of no more than 3 positive axillary nodes.\n\nStep 6: Compare patient history and physical exam with the patient characteristics criteria\nThe patient has undergone a history and physical exam within the past 4 months and a bilateral mammogram within the past 6 months, which match the patient characteristics criteria.\n\nStep 7: Compare patient prior therapy with the prior concurrent therapy criteria\nThe patient has not received prior chemotherapy, hormonal therapy, or radiotherapy for this malignancy, which matches the prior concurrent therapy criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "30": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Diagnosis: Cytologically confirmed breast cancer\n- Tumor stage: Invasive ductal breast carcinoma, 3 cm, HER2-positive, ER/PR negative, 5 positive lymph nodes, metastatic lesions\n- Treatment history: Multivitamins and iron supplements, not smoking or consuming alcohol, not sexually active, no children, candidate for tumor resection\n\nStep 2: Compare the patient's information with the inclusion criteria.\n\n1. Histological or cytological diagnoses of breast cancer, with metastases: Yes\n2. Metastatic lesions should not be curable with surgery or radiotherapy: Yes (metastatic lesions)\n3. Women of age > 18: Yes\n4. Previously treated with anthracyclines and taxanes: Unknown (patient note does not mention previous treatment)\n5. Maximum of 2 previous chemotherapy treatment lines for metastatic disease: Unknown (patient note does not mention previous treatment)\n6. Previous radiotherapy is allowed: Not applicable (patient note does not mention previous radiotherapy)\n7. At least 4 weeks since the last previous antineoplastic treatment; patient must have recovered from all previous toxicities: Not applicable (patient note does not mention previous treatment)\n8. Performance status < 2 in World Health Organization (WHO) scale: Not applicable (patient note does not mention performance status)\n9. Clinically measurable, non measurable or really non measurable disease, as per Response Evaluation Criteria in Solid Tumors (RECIST) criteria: Not applicable (patient note does not mention disease status)\n10. Life expectancy of at least 12 weeks: Not applicable (patient note does not mention life expectancy)\n11. Patients able to comply and to receive an adequate follow-up: Not applicable (patient note does not mention compliance or follow-up)\n12. Adequate bone marrow function: Not applicable (patient note does not mention bone marrow function)\n13. Calcium within normal limits: Not applicable (patient note does not mention calcium levels)\n14. Prem",
        "label": 0
    },
    "31": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Disease: Cytologically confirmed breast cancer\n- Tumor type: 3 cm invasive ductal breast carcinoma, HER2-positive, ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- Other factors: Not sexually active, no children, candidate for tumor resection, agrees to do so prior to chemotherapy\n\nStep 2: Compare the patient's characteristics with the inclusion criteria of the clinical trial.\n\nInclusion Criteria:\n- Clinically node negative operable breast cancer\n- No prior incision or excision biopsy\n\nPatient Characteristics:\n- Has breast cancer\n- Has positive lymph nodes (axillary sampling revealed 5 positive lymph nodes)\n- No information about prior incision or excision biopsy\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\nThe patient has breast cancer but has positive lymph nodes, which does not meet the inclusion criteria of being clinically node negative. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "32": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age to the inclusion criteria\nThe patient is 45 years old, which is within the range of 18 years old or older.\n\nStep 2: Compare patient diagnosis to the inclusion criteria\nThe patient has metastatic breast cancer with lytic, sclerotic, or mixed bone lesions. This matches the inclusion criteria for metastatic breast cancer patients with lytic, sclerotic, or mixed bone lesions.\n\nStep 3: Compare patient bone lesions to the inclusion criteria\nThe patient has non-symptomatic bone lesions, as she has no pain, no bone complications, and does not need analgesic chronic administration for bone disease. This matches the inclusion criteria for non-symptomatic bone lesions.\n\nStep 4: Compare patient chemotherapy lines to the inclusion criteria\nThe patient has received a maximum of two chemotherapy lines for metastatic disease, which matches the inclusion criteria.\n\nStep 5: Compare patient hormone therapy lines to the inclusion criteria\nThe patient has received a maximum of two hormone therapy lines for metastatic disease, which matches the inclusion criteria.\n\nStep 6: Compare patient renal function to the inclusion criteria\nThe patient has normal renal function, as indicated by the normal serum creatinine value. This matches the inclusion criteria for normal, minimally altered renal function.\n\nStep 7: Compare patient serum calcium levels to the inclusion criteria\nThe patient has normal serum calcium levels, which matches the inclusion criteria.\n\nStep 8: Compare patient performance status to the inclusion criteria\nThe patient has a performance status of 0 or 1, which matches the inclusion criteria.\n\nStep 9: Compare patient pregnancy status to the inclusion criteria\nThe patient has a negative pregnancy test before study recruitment, which matches the inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "33": {
        "output": "GPT4 Correct Assistant: Step 1: Check the patient's age.\nThe patient is 45 years old, which is older than 18 years old. This meets the age requirement.\n\nStep 2: Check the patient's gender.\nThe patient is a woman, which meets the gender requirement.\n\nStep 3: Check the patient's HER2 status.\nThe patient's tumor is HER2-positive, which meets the HER2 status requirement.\n\nStep 4: Check the patient's disease status.\nThe patient has metastatic breast cancer, which meets the disease status requirement.\n\nStep 5: Check the patient's previous treatment history.\nThe patient has not been treated with trastuzumab and taxanes, which meets the previous treatment history requirement.\n\nStep 6: Check the patient's performance status.\nThe patient's performance status is not provided, so we cannot determine if they meet this requirement.\n\nStep 7: Check the patient's life expectancy.\nThe patient's life expectancy is not provided, so we cannot determine if they meet this requirement.\n\nStep 8: Check the patient's laboratory values.\nThe patient's laboratory values are not provided, so we cannot determine if they meet this requirement.\n\nStep 9: Check the patient's ability to comply with treatment and follow-up.\nThe patient's ability to comply with treatment and follow-up is not provided, so we cannot determine if they meet this requirement.\n\nStep 10: Check the patient's pregnancy status.\nThe patient's pregnancy status is not provided, so we cannot determine if they meet this requirement.\n\nSince we cannot determine the patient's performance status, life expectancy, laboratory values, ability to comply with treatment and follow-up, and pregnancy status, we cannot definitively determine if the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "34": {
        "output": "GPT4 Correct Assistant: Step 1: Determine the patient's age.\nThe patient is 45 years old.\n\nStep 2: Determine the patient's gender.\nThe patient is female.\n\nStep 3: Determine the patient's disease.\nThe patient has invasive ductal breast carcinoma.\n\nStep 4: Determine the patient's tumor type.\nThe tumor is HER2-positive and ER/PR negative.\n\nStep 5: Determine the patient's axillary lymph node status.\nThe patient has 5 positive lymph nodes.\n\nStep 6: Determine the patient's metastatic disease status.\nThe patient has metastatic lesions.\n\nStep 7: Determine the patient's previous treatment history.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nStep 8: Determine the patient's eligibility for the clinical trial based on the inclusion criteria.\n\n1. Written informed consent: Not specified in the patient note.\n2. Histological diagnoses of operable invasive adenocarcinoma of the breast (T1-T3): Not specified in the patient note.\n3. Tumours must be HER2 negative: The patient's tumor is HER2-positive. Excluded.\n4. Time window between end of adjuvant chemotherapy and study randomization must be less than 8 weeks: Not specified in the patient note.\n5. Surgery must consist of mastectomy or conservative surgery with axillary lymph node dissection: Not specified in the patient note.\n6. Margins free of disease and ductal carcinoma in-situ (DCIS) are required: Not specified in the patient note.\n7. Node negative patients with tumor size > 2 cm: The patient has positive axillary lymph nodes. Excluded.\n8. Patients belonging to the following classifications are eligible: pN1a, pN2a, pN3a: The patient has positive axillary lymph nodes. Excluded.\n9. Status of hormone receptors in primary tumour: Not specified in the patient note.\n10. Patients must not present evidence of",
        "label": 0
    },
    "35": {
        "output": "GPT4 Correct Assistant: Step 1: Determine the patient's age and postmenopausal status.\nThe patient is a 45-year-old postmenopausal woman.\n\nStep 2: Determine the type of cancer and its characteristics.\nThe patient has cytologically confirmed breast cancer, and a core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative.\n\nStep 3: Compare the patient's characteristics with the inclusion criteria.\n\n1. Female patient: The patient is a woman.\n2. Postmenopausal: The patient is postmenopausal.\n3. Age 60 years or older or Age 45 years or older with amenorrhea for > 12 months with an intact uterus: The patient is 45 years old and meets this criterion.\n4. Histologically or cytologically proven adenocarcinoma of the breast: The patient has breast cancer.\n5. Subjects must have archived tumor tissue available: The patient's tumor tissue is available.\n6. HER2-positive disease: The patient's tumor is HER2-positive.\n7. ER-positive and/or PR-positive disease: The patient's tumor is ER/PR negative, which is not a match.\n8. ECOG performance status 0-2: The patient's ECOG performance status is not provided.\n9. Life expectancy > 24 weeks: The patient's life expectancy is not provided.\n10. Left ventricular ejection fraction > lower limit of normal: The patient's left ventricular ejection fraction is not provided.\n11. No prior chemotherapy, endocrine therapy, Herceptin, or other biologic or investigational therapy for metastatic breast cancer: The patient's prior treatments are not provided.\n12. No more than two prior endocrine agents in the adjuvant setting as single- or sequential-therapy is permitted, but no prior Faslodex therapy is permitted: The patient's prior endocrine therapy is not provided.\n13. At least 1 month since prior surgery",
        "label": 0
    },
    "36": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Cancer type: Invasive ductal breast carcinoma\n- HER2 status: Positive\n- ER/PR status: Negative\n- Axillary sampling: 5 positive lymph nodes\n- Metastatic lesions: Present\n- Other medications: Multivitamins and iron supplements\n- Alcohol and smoking: No\n- Sexual activity and children: Not sexually active, no children\n- Treatment plan: Tumor resection before chemotherapy\n\nStep 2: Compare the patient's characteristics with the inclusion and exclusion criteria of the clinical trial.\n\nInclusion Criteria:\n1. Biopsy proven, measurable metastatic breast cancer\n2. HER-2 neu positive by standard immunohistochemical criteria (2+ positivity)\n3. No prior chemotherapy for distant metastatic disease\n4. Prior paclitaxel in the adjuvant setting is allowed\n5. Karnofsky performance status equal to 70 or greater\n6. ANC > 1500, Hgb > 10, plt > 100\n7. Patients with some degree of hepatic dysfunction and renal dysfunction are encouraged\n\nExclusion Criteria:\n1. Bone-only, and/or effusion-only disease\n2. Prior chemotherapy for distant metastatic disease (excludes patient)\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\nThe patient meets all the inclusion criteria except for the exclusion criterion of prior chemotherapy for distant metastatic disease. Therefore, the patient is excluded from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "37": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's condition\nThe patient has breast cancer, not cervical cancer.\n\nStep 2: Compare the patient's condition with the inclusion criteria\nThe inclusion criteria specify that the patient must have cervical cancer. The patient does not meet this criterion.\n\nStep 3: Determine the patient's eligibility\nSince the patient does not meet the inclusion criteria, they are excluded from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "38": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the age requirement in the inclusion criteria.\nThe patient is 45 years old, which meets the requirement of being >= 40 years old.\n\nStep 2: Compare the patient's type of breast cancer to the inclusion criteria.\nThe patient has invasive ductal breast cancer, which meets the requirement of having invasive ductal carcinoma or ductal carcinoma in situ.\n\nStep 3: Determine if the patient chooses lumpectomy as treatment for breast cancer.\nThe patient is a candidate for tumor resection, which implies that she chooses lumpectomy rather than mastectomy.\n\nStep 4: Compare the patient's tumor size and margin to the inclusion criteria.\nThe patient's tumor is 3 cm in size, which is greater than the requirement of being < 2.5 cm. Therefore, the patient does not meet this criterion.\n\nStep 5: Repeat Trial-level eligibility.\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "39": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to inclusion criteria\nThe patient is 45 years old, which meets the inclusion criteria of age >= 18 years.\n\nStep 2: Compare patient's gender to inclusion criteria\nThe patient is female, which meets the inclusion criteria of female gender.\n\nStep 3: Compare patient's ECOG performance status to inclusion criteria\nThe patient's ECOG performance status is not provided, so we cannot determine if she meets this criterion.\n\nStep 4: Compare patient's diagnosis to inclusion criteria\nThe patient has a histologically proven diagnosis of breast cancer, which meets the inclusion criteria of histologically proven diagnosis of breast cancer.\n\nStep 5: Compare patient's disease stage to inclusion criteria\nThe patient has locally advanced and/or metastatic disease, which meets the inclusion criteria of locally advanced and/or metastatic disease.\n\nStep 6: Compare patient's life expectancy to inclusion criteria\nThe patient's life expectancy is not provided, so we cannot determine if she meets this criterion.\n\nStep 7: Compare patient's medical history to inclusion criteria\nThe patient has no concurrent second malignancy and meets the exclusion criteria for no other serious illness or medical condition, chronic lung disease, history of significant neurological or psychiatric disorders, active concurrent infection, no symptomatic central nervous system (CNS) metastases, no rapidly progressive visceral metastases requiring immediate chemotherapy, and no concurrent anti-cancer treatment.\n\nStep 8: Compare patient's previous treatments to inclusion criteria\nThe patient's previous treatments are not provided, so we cannot determine if she meets this criterion.\n\nStep 9: Compare patient's organ function to inclusion criteria\nThe patient's organ function is not provided, so we cannot determine if she meets this criterion.\n\nStep 10: Compare patient's HER-2 status to inclusion criteria\nThe patient's HER-2 status is HER2-positive, which meets the inclusion criteria of overexpression of HER-2.\n\nStep 11: Compare patient's LVEF to inclusion criteria\nThe patient's LVEF is not provided, so we cannot determine if she meets this criterion",
        "label": 2
    },
    "40": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria\nThe patient is 45 years old, which meets the age requirement of \u2265 18 years.\n\nStep 2: Check if the patient has given written consent\nThe patient note does not provide information about whether the patient has given written consent or not.\n\nStep 3: Compare patient's cancer type with the inclusion criteria\nThe patient has breast cancer, which is a solid tumor. This meets the requirement of being picked up for solid tumor treatment.\n\nStep 4: Check if the patient has moderate anemia\nThe patient note does not provide information about the patient's hemoglobin levels.\n\nStep 5: Compare the planned chemotherapy cycles with the inclusion criteria\nThe patient note does not provide information about the planned chemotherapy cycles.\n\nStep 6: Check if the patient has a life expectancy higher than three months\nThe patient note does not provide information about the patient's life expectancy.\n\nStep 7: Check if the patient's general conditions are compatible with the study's follow-up\nThe patient note does not provide information about the patient's general conditions.\n\nSince we do not have sufficient information about the patient's hemoglobin levels, planned chemotherapy cycles, and life expectancy, we cannot determine if the patient is eligible for the clinical trial. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "41": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Diagnosis: Invasive ductal breast carcinoma\n- Tumor size: 3 cm\n- HER2-positive, ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- Metastatic lesions on CXR\n\nStep 2: Compare the patient's information with the inclusion criteria of the clinical trial.\n- Invasive breast cancer or DCIS: Yes (patient has invasive ductal breast carcinoma)\n- Tumor stage: T2 (patient has a 3 cm tumor)\n- N0 or N1: Yes (patient has 5 positive lymph nodes, which falls within the range of 1-3 + nodes)\n\nStep 3: Determine the trial-level eligibility based on the comparison.\n- The patient meets all the inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "42": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient note to the inclusion criteria.\n\n1. Disease Characteristics:\n- Histologically confirmed invasive breast cancer: Yes (cytologically confirmed breast cancer)\n- Locally advanced or early metastatic disease: Yes (5 positive lymph nodes, metastatic lesions on CXR)\n- Clinically or radiographically measurable disease: Yes (metastatic lesions on CXR)\n- Planning to receive neoadjuvant chemotherapy for locally advanced or early metastatic disease: Yes (patient is a candidate for tumor resection prior to chemotherapy)\n- Hormone receptor status: Yes (HER2-positive, ER/PR negative)\n\n2. Patient Characteristics:\n- Age: Not specified\n- Sex: Not specified\n- Menopausal status: Yes (postmenopausal woman)\n- Performance status: Not specified\n- Life expectancy: Not specified\n- Hematopoietic: Not specified\n- Hepatic: Not specified\n- Renal: Not specified\n\n3. Prior Concurrent Therapy:\n- Biologic therapy: Not specified\n- Chemotherapy: No prior chemotherapy for this malignancy\n- Endocrine therapy: Not specified\n- Radiotherapy: Not specified\n- Surgery: Not specified\n\nStep 2: Determine the trial-level eligibility based on the comparison.\n\nThe patient meets all the inclusion criteria for the clinical trial. The patient's menopausal status, age, and other patient characteristics are not specified in the inclusion criteria, so they are not relevant to the eligibility assessment. The patient does not have any exclusion criteria mentioned in the clinical trial summary.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "43": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\n\nPatient age: 45 years old\nInclusion criteria: No specific age requirement mentioned.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\n\nPatient gender: Female\nInclusion criteria: Female patients with histologically-confirmed advanced or metastatic, ER and/or PR positive breast cancer.\n\nStep 3: Compare the patient's breast cancer status to the inclusion criteria.\n\nPatient diagnosis: Cytologically confirmed breast cancer, 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, HER2-positive and ER/PR negative.\nInclusion criteria: Histologically confirmed advanced or metastatic breast cancer.\n\nStep 4: Compare the patient's hormone receptor status to the inclusion criteria.\n\nPatient hormone receptor status: ER/PR negative\nInclusion criteria: ER &/or PR positive\n\nStep 5: Compare the patient's previous treatment history to the inclusion criteria.\n\nPatient previous treatment: Axillary sampling revealed 5 positive lymph nodes, CXR was remarkable for metastatic lesions.\nInclusion criteria: previous adjuvant hormone therapy > 12 months prior to enrolment, previous adjuvant chemotherapy > 6 months prior to enrolment.\n\nStep 6: Compare the patient's life expectancy and performance status to the inclusion criteria.\n\nPatient life expectancy: Not mentioned in the patient note.\nInclusion criteria: Life expectancy of at least 12 weeks.\n\nPatient performance status: Not mentioned in the patient note.\nInclusion criteria: World Health Organisation (WHO) performance status (PS) of 0 to 1.\n\nStep 7: Determine the trial-level eligibility based on the comparison.\n\nThe patient does not meet all the inclusion criteria, specifically, the patient is ER/PR negative and does not have a life expectancy of at least 12 weeks.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "44": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nThe patient is a 45-year-old postmenopausal woman.\n\nStep 2: Identify the patient's disease and stage.\nThe patient has cytologically confirmed breast cancer, specifically a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n\nStep 3: Check if the patient's disease is suitable for endocrine treatment.\nThe patient's tumor is HER2-positive and ER/PR negative.\n\nStep 4: Check if the patient has a life expectancy of more than 6 months.\nThe patient has metastatic lesions, but the life expectancy is not mentioned in the note.\n\nStep 5: Check if the patient has normal biological parameters.\nNo information about the patient's biological parameters is provided in the note.\n\nStep 6: Compare the patient's information to the inclusion criteria.\nThe patient is not premenopausal, and the trial is specifically for premenopausal women.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "45": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's cancer type.\nThe patient note states that the patient has \"cytologically confirmed breast cancer.\"\n\nStep 2: Compare the patient's cancer type with the inclusion criteria.\nThe inclusion criteria state that the study is focused on subjects diagnosed with breast, lung, and ovarian malignancies and low-grade lymphomas. The patient's cancer type, breast cancer, is included in the list of eligible cancer types.\n\nStep 3: Check if the patient has de novo malignancies and no previous chemotherapy.\nThe patient note does not provide information about whether the patient has de novo malignancies or previous chemotherapy history.\n\nStep 4: Check if the patient has advanced refractory malignancies who received no more than 2 standard chemotherapy treatment protocols.\nThe patient note does not provide information about whether the patient has advanced refractory malignancies or how many chemotherapy treatment protocols the patient has received.\n\nStep 5: Check if the patient's age is within the eligible age group.\nThe inclusion criteria state that patients of any age group are eligible. The patient is 45 years old, which is within the eligible age group.\n\nStep 6: Check if the patient's tumor is accessible and if the patient agrees to undergo biopsies or drainage of effusions.\nThe patient note does not provide information about whether the patient's tumor is accessible or if the patient agrees to undergo biopsies or drainage of effusions.\n\nStep 7: Check if chemotherapy is a treatment option for the patient.\nThe patient note states that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This means that chemotherapy is a treatment option for the patient.\n\nSince we do not have enough information to determine if the patient meets the criteria for de novo malignancies, previous chemotherapy history, and tumor accessibility, we cannot definitively determine the patient's eligibility. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "46": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state that the patient must be postmenopausal. The patient is postmenopausal, so this criterion is met.\n\nStep 2: Compare the patient's disease characteristics to the inclusion criteria.\nThe patient has a 3 cm invasive ductal breast carcinoma, which meets the criteria for invasive carcinoma. The patient also has HER2-positive and ER/PR negative breast cancer, but the inclusion criteria do not mention HER2 status or ER/PR status. However, the patient has stage I-III breast cancer, which meets the criteria.\n\nStep 3: Compare the patient's surgical history to the inclusion criteria.\nThe patient has undergone a core biopsy and has 5 positive lymph nodes, but the inclusion criteria state that the patient must have undergone breast cancer surgery within the past 6 months. The patient's surgical history is not clear, so this criterion is not relevant.\n\nStep 4: Compare the patient's hormone receptor status to the inclusion criteria.\nThe patient's hormone receptor status is ER/PR negative, which does not meet the criteria for hormone receptor-positive tumor by immunohistochemical staining. This criterion is not met.\n\nStep 5: Compare the patient's other characteristics to the inclusion criteria.\nThe patient is not sexually active and has no children, which meets the criteria for female sex and no children. The patient's life expectancy, hematopoietic, hepatic, and renal status are not specified, but this does not disqualify the patient based on the inclusion criteria.\n\nStep 6: Compare the patient's prior therapy to the inclusion criteria.\nThe patient is not using any concurrent investigational or commercial drugs or therapies for the treatment of DCIS or invasive breast cancer, and this meets the criteria for no other concurrent investigational or commercial drugs or therapies.\n\nTrial-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).",
        "label": 1
    },
    "47": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Disease: Cytologically confirmed breast cancer\n- Tumor type: 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- Receptors: HER2-positive and ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- Metastatic lesions: CXR was remarkable for metastatic lesions\n- Medications: Multivitamins and iron supplements\n- Lifestyle: Does not smoke or consume alcohol, not sexually active, no children\n- Treatment plan: Candidate for tumor resection and agrees to do so prior to chemotherapy\n\nStep 2: Compare the patient's characteristics to the inclusion criteria of the clinical trial.\n\nInclusion Criteria:\n1. Recurrent or metastatic breast cancer: The patient has metastatic breast cancer.\n2. Estrogen receptor (ER), progestin receptor (PR), and HER2/neu receptor (HER2) negative status: The patient is HER2-positive and ER/PR negative.\n3. Prior treatment with an anthracycline and a taxane in the adjuvant or advanced disease setting: The patient's treatment history is not provided in the note.\n4. Relapse following adjuvant chemotherapy within 6 months of last treatment and/or received one or two chemotherapy regimens for advanced disease: The patient's treatment history is not provided in the note.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\nThe patient meets some inclusion criteria, but the patient's treatment history is not provided in the note, making it impossible to determine if they have received anthracycline and taxane treatments.\n\nStep 4: Assign the appropriate scale for the assessment of eligibility.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "48": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria\nThe patient is 45 years old, which is within the age range of 18 years or older.\n\nStep 2: Compare patient's gender with the inclusion criteria\nThe patient is a woman, which is included in the study for both women and men.\n\nStep 3: Compare patient's cancer type with the inclusion criteria\nThe patient has histologically confirmed breast cancer, which matches the inclusion criteria.\n\nStep 4: Compare patient's tumor size and stage with the inclusion criteria\nThe patient has a 3 cm invasive ductal breast carcinoma, which falls within the T2 lesion category. The patient also has axillary lymph node involvement, which is included in the T3 N0-N2; T4 any N; or any T with N2 or N3 categories.\n\nStep 5: Compare patient's life expectancy with the inclusion criteria\nThe patient has a life expectancy of greater than 6 months, which is included in the inclusion criteria.\n\nStep 6: Compare patient's disease measurability with the inclusion criteria\nThe patient has measurable disease, as indicated by the fixed or marked ipsilateral axillary nodes and/or ipsilateral internal mammary nodes.\n\nStep 7: Compare patient's contraception requirements with the inclusion criteria\nThe patient is postmenopausal, so this criterion does not apply.\n\nStep 8: Compare patient's metastatic disease status with the inclusion criteria\nThe patient has metastatic lesions, which is not included in the inclusion criteria.\n\nBased on the comparison of the patient note and the inclusion criteria of the clinical trial, the patient is excluded due to the presence of metastatic disease.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "49": {
        "output": "GPT4 Correct Assistant: 1) Not relevant (patient does not have sufficient information to qualify for the trial)\n\nReasoning:\n- The patient's age and menopausal status match the criteria.\n- The patient has breast cancer, but the specific stage is not provided. The trial includes T2-T4c, any N, M0 disease, but the patient's stage is not specified.\n- The patient's tumor is HER2-positive and ER/PR negative, which does not match the inclusion criteria of ER positive tumor with an Allred score of 6, 7, or 8.\n- The patient has metastatic lesions, which is not allowed in the trial.\n- The patient is taking multivitamins and iron supplements, which are not mentioned in the exclusion criteria.\n- The patient's lifestyle and family history are not specified in the trial criteria.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which aligns with the trial's requirement of undergoing mastectomy or lumpectomy after neoadjuvant aromatase inhibitor therapy.\n- The patient does not have a history of other malignancies within the past 5 years, which is a requirement of the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "50": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age, gender, and disease type.\n- Age: 45 years old\n- Gender: Female\n- Disease type: Breast cancer\n\nStep 2: Compare the patient's disease characteristics to the inclusion criteria.\n- Inclusion Criteria: Moderate to severe fatigue >6 months after last chemotherapy or radiation treatment >5 years from diagnosis\n\nStep 3: Determine if the patient meets the inclusion criteria.\n- The patient note does not provide information on the patient's fatigue levels, duration since last chemotherapy or radiation treatment, or time since diagnosis.\n\nStep 4: Assign the appropriate eligibility scale based on the information available.\n- Trial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "51": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria for age.\nThe patient note states that the patient is 45 years old. The clinical trial does not specify an age range for participants. Therefore, we can proceed to the next step.\n\nStep 2: Compare the patient's gender to the inclusion criteria for gender.\nThe patient note states that the patient is a woman. The clinical trial does not specify a gender requirement for participants. Therefore, we can proceed to the next step.\n\nStep 3: Compare the patient's disease type and stage to the inclusion criteria.\nThe patient note states that the patient has cytologically confirmed breast cancer. The clinical trial is focused on lung cancer, lung metastases from a primary site other than lung, mesothelioma, or a radiographic lesion highly suspicious for malignancy. The patient's condition does not meet any of the inclusion criteria. Therefore, the patient is not eligible based on the disease type and stage.\n\nStep 4: Compare the patient's previous treatment history to the inclusion criteria.\nThe patient note does not provide information on the patient's previous treatment history. Therefore, we cannot determine if the patient meets the inclusion criteria based on previous treatment history.\n\nStep 5: Compare the patient's other medical conditions to the inclusion criteria.\nThe patient note states that the patient is using multivitamins and iron supplements, does not smoke or consume alcohol, is not sexually active, and has no children. The clinical trial does not specify any additional medical conditions that would exclude a patient from participating. Therefore, we can proceed to the next step.\n\nStep 6: Compare the patient's eligibility for a biopsy or surgical resection to the inclusion criteria.\nThe patient note states that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The clinical trial requires participants to be scheduled for a biopsy or surgical resection. The patient meets this criterion.\n\nStep 7: Determine the patient's trial-level eligibility based on the comparison of the patient note and the inclusion criteria.\nBased on the comparison, the patient does not meet the inclusion criteria for disease type and stage. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility:",
        "label": 0
    },
    "52": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note with inclusion criteria\n\n- Disease characteristics:\n  - Histologically confirmed breast cancer: Yes\n  - Disease must be confined to the breast and axillary nodes without detected masses elsewhere: Unknown (no information about other masses)\n  - No history of prior ipsilateral or contralateral invasive breast cancer: Yes\n  - Resected disease: Yes\n  - No more than 16 weeks since last surgery to remove the tumor: Unknown (no information about the time since surgery)\n  - No known clinical residual locoregional disease: Unknown (no information about residual locoregional disease)\n  - Margins must be negative for invasive breast cancer and ductal carcinoma in situ: Unknown (no information about margins)\n  - No locally advanced, inoperable breast cancer: Unknown (no information about locally advanced or inoperable breast cancer)\n  - Must not be a candidate for endocrine therapy or standard chemotherapy: Unknown (no information about endocrine therapy or chemotherapy)\n  - Hormone receptor-negative disease: Yes (HER2-positive and ER/PR negative)\n\n- Patient characteristics:\n  - Female: Yes\n  - Menopausal status: postmenopausal: Yes\n  - ECOG performance status 0-2: Unknown (no information about ECOG performance status)\n  - Platelet count \u2265 100,000/mm^3: Unknown (no information about platelet count)\n  - Granulocyte count \u2265 1,500/mm^3: Unknown (no information about granulocyte count)\n  - WBC \u2265 3,000/mm^3: Unknown (no information about WBC)\n  - AST and ALT \u2264 1.5 times upper limit of normal (ULN): Unknown (no information about AST and ALT)\n  - Bilirubin normal: Unknown (no information about bilirubin)\n  - Creatinine clearance \u2265 50 mL/min: Unknown (no information about creatinine clearance)\n  - Creatinine < 1.35 mg/dL",
        "label": 0
    },
    "53": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state \"Menopausal status not specified.\" Therefore, we cannot determine if the patient meets the age requirement based on the given information.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is female, and the inclusion criteria state \"Female.\" The patient meets the gender requirement.\n\nStep 3: Compare the patient's disease characteristics to the inclusion criteria.\nThe patient has cytologically confirmed breast cancer, but the inclusion criteria specify a diagnosis of stage IIB HER2/neu-expressing breast cancer 6\u00bd years ago. The patient's cancer is HER2-positive and ER/PR negative, but the inclusion criteria do not specify these characteristics. The patient has undergone a core biopsy, but the inclusion criteria state \"Disease limited to the thoracic cavity\" and \"Operable tumor with at least 1 cm of surgically accessible lesion.\" The patient's cancer has metastasized to the lungs, but the inclusion criteria state \"Pulmonary metastases progressed after prior allogeneic SCT.\" The patient has not undergone a stem cell transplantation. The patient has not responded to prior allogeneic lymphocyte infusion, post-transplantation chemotherapy, and trastuzumab (Herceptin\u00ae). Therefore, the patient does not meet the disease characteristics requirements based on the given information.\n\nStep 4: Compare the patient's prior therapy to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The inclusion criteria state \"At least 4 weeks since prior systemic immunosuppressive therapy\" and \"At least 2 weeks since prior cytotoxic therapy and immunotherapy (e.g. trastuzumab [Herceptin\u00ae]).\" The patient has not undergone the required waiting period for prior therapy. Therefore, the patient does not meet the prior therapy requirements based on the given information.\n\nStep 5: Compare the patient's other characteristics to the inclusion criteria.\nThe patient does not smoke or consume alcohol, and the inclusion criteria state \"No active psychiatric disorder that would",
        "label": 0
    },
    "54": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with inclusion criteria\nThe patient is a 45-year-old woman. The inclusion criteria state that the patient must be a male or female greater than or equal to 18 years of age. The patient meets this criterion.\n\nStep 2: Compare patient's gender with inclusion criteria\nThe patient is a woman. The inclusion criteria state that the patient must be a male or female greater than or equal to 18 years of age. The patient meets this criterion.\n\nStep 3: Compare patient's disease with inclusion criteria\nThe patient has cytologically confirmed breast cancer. The inclusion criteria state that the patient must have metastatic breast cancer with documented HER2- or HER2+ (IHC3+ or FISH+) disease. The patient meets this criterion.\n\nStep 4: Compare patient's treatment history with inclusion criteria\nThe patient has not had prior treatment with Doxil or carboplatin. The inclusion criteria state that the patient must have had no prior treatment with Doxil or carboplatin. The patient meets this criterion.\n\nStep 5: Compare patient's treatment history with exclusion criteria\nThe patient has had no adjuvant chemotherapy within 1 year prior to the study. The exclusion criteria state that the patient must not have had adjuvant chemotherapy within 1 year prior to the study. The patient meets this criterion.\n\nStep 6: Compare patient's cardiac function with inclusion criteria\nThe patient's cardiac function is not mentioned in the patient note. The inclusion criteria state that the patient must have normal cardiac function as evidenced by a LVEF within institutional normal limits by multiple gated acquisition (MUGA) scan. The patient does not have sufficient information to qualify for the trial.\n\nStep 7: Compare patient's ECOG Performance Status with inclusion criteria\nThe patient's ECOG Performance Status is not mentioned in the patient note. The inclusion criteria state that the patient must have an ECOG Performance Status (PS) 0-2. The patient does not have sufficient information to qualify for the trial.\n\nStep 8: Compare patient's pregnancy status with inclusion criteria\nThe patient is a postmenopausal woman. The inclusion criteria state that",
        "label": 2
    },
    "55": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient note:\n- 45-year-old postmenopausal woman with cytologically confirmed breast cancer\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n\nInclusion criteria:\n- Patients with infiltrative breast cancer (diagnosed pre-operatively by core biopsy)\n\nStep 2: Determine if the patient meets the inclusion criteria\n\nThe patient has a cytologically confirmed breast cancer, and the core biopsy revealed a 3 cm invasive ductal breast carcinoma, which is a form of infiltrative breast cancer. Therefore, the patient meets the inclusion criteria.\n\nStep 3: Check for exclusion criteria (if any)\n\nThere are no exclusion criteria mentioned in the clinical trial summary.\n\nStep 4: Assess the patient's eligibility\n\nSince the patient meets the inclusion criteria and there are no exclusion criteria, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "56": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is a 45-year-old postmenopausal woman. The inclusion criteria state that the patient must be postmenopausal, which is true.\n\nStep 2: Compare the patient's disease characteristics with the inclusion criteria.\nThe patient has cytologically confirmed breast cancer, specifically a 3 cm invasive ductal breast carcinoma. However, the inclusion criteria state that the patient must have a diagnosis of ductal carcinoma in situ (DCIS) within the past 6 months. The patient does not meet this criterion.\n\nStep 3: Compare the patient's hormone receptor status with the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative. The inclusion criteria state that the patient must have an estrogen or progesterone receptor positive tumor. The patient does not meet this criterion.\n\nStep 4: Compare the patient's prior concurrent therapy with the inclusion criteria.\nThe patient is using multivitamins and iron supplements. The inclusion criteria state that patients must not have had medication affecting bone metabolism within 12 months, including bisphosphonates. The patient does not meet this criterion.\n\nStep 5: Compare the patient's other characteristics with the inclusion criteria.\nThe patient has metastatic lesions on CXR, which is not mentioned in the inclusion criteria. However, this does not disqualify the patient based on the given information.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "57": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nPatient age: 45 years\nInclusion criteria: Age >= 18 years\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nPatient gender: Female\nInclusion criteria: Women\n\nStep 3: Compare the patient's cancer type to the inclusion criteria.\nPatient cancer type: Invasive ductal breast carcinoma\nInclusion criteria: Histologic Documentation: Patients will have histologically confirmed Unicentric Stage I (T1 N0 M0) invasive ductal breast cancer.\n\nStep 4: Compare the patient's cancer stage to the inclusion criteria.\nPatient stage: T1 N0 M0\nInclusion criteria: Histologic Documentation: Patients will have histologically confirmed Unicentric Stage I (T1 N0 M0) invasive ductal breast carcinoma.\n\nStep 5: Compare the patient's tumor margin to the inclusion criteria.\nPatient tumor margin: 2 mm or more from any inked edges\nInclusion criteria: Histologically negative tumor margin 2 mm or more from any inked edges, or no tumor in a re-excision specimen or final shaved specimen.\n\nStep 6: Compare the patient's cancer type to the exclusion criteria.\nPatient cancer type: HER2-positive and ER/PR negative\nExclusion criteria: Invasive Lobular Carcinoma\n\nStep 7: Compare the patient's cancer stage to the exclusion criteria.\nPatient stage: T1 N0 M0 with metastatic lesions\nExclusion criteria: Tumor > 2.0 cm, nodal involvement on H&E staining, or metastatic involvement\n\nStep 8: Compare the patient's treatment history to the inclusion criteria.\nPatient treatment: Multivitamins and iron supplements, no chemotherapy or hormonal therapy\nInclusion criteria: Patient may have been treated with adjuvant chemotherapy. Patients may be on adjuvant hormonal therapy or begin hormonal therapy following XRT at the discretion of the medical oncologist.\n\nStep 9: Compare the patient's treatment history to",
        "label": 0
    },
    "58": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age, gender, and disease type.\n- Patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n\nStep 2: Compare the patient's age, gender, and disease type with the inclusion criteria.\n- Inclusion Criteria: Histological or cytological confirmation of a solid, malignant tumour\n\nStep 3: Determine if the patient's age, gender, and disease type meet the inclusion criteria.\n- The patient meets the inclusion criteria for having a solid, malignant tumor (breast cancer).\n\nStep 4: Identify any other relevant information in the patient note.\n- The patient is HER2-positive and ER/PR negative, and has 5 positive lymph nodes.\n\nStep 5: Compare the patient's additional information with the inclusion criteria.\n- The patient's additional information does not affect the eligibility based on the given inclusion criteria.\n\nStep 6: Determine if the patient meets the remaining inclusion criteria.\n- The patient has at least one measurable or non-measurable site of disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.\n\nStep 7: Determine if the patient meets all the inclusion criteria.\n- The patient meets all the inclusion criteria.\n\nStep 8: Check for any exclusion criteria.\n- There are no exclusion criteria provided in the given information.\n\nStep 9: Determine the patient's trial-level eligibility based on the inclusion and exclusion criteria.\n- Trial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "59": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state that the patient must be between 18 and 45 years old. The patient meets this criterion.\n\nStep 2: Compare the patient's cancer type and treatment eligibility to the inclusion criteria.\nThe patient has breast cancer, and the inclusion criteria state that the patient must have histologically or cytologically confirmed adenocarcinoma of the breast and be appropriate for treatment with Doxorubicin and Cyclophosphamide. The patient meets this criterion.\n\nStep 3: Compare the patient's ECOG performance status to the inclusion criteria.\nThe patient's ECOG performance status is not mentioned in the patient note. Therefore, we cannot determine if the patient meets this criterion.\n\nStep 4: Compare the patient's menstrual cycle or serologic estradiol and FSH levels to the inclusion criteria.\nThe patient is postmenopausal, as indicated by the cytologically confirmed breast cancer and the presence of metastatic lesions. The patient does not meet this criterion.\n\nStep 5: Compare the patient's informed consent to the inclusion criteria.\nThe patient's informed consent is not mentioned in the patient note. Therefore, we cannot determine if the patient meets this criterion.\n\nSince the patient does not meet the inclusion criteria for being premenopausal and does not have sufficient information to qualify for the trial (ECOG performance status and informed consent), the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "60": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is a 45-year-old woman, and the inclusion criteria state that subjects must be women >/= 18 years of age. The patient meets this criteria.\n\nStep 2: Compare the patient's breast cancer diagnosis with the inclusion criteria.\nThe patient has cytologically confirmed breast cancer, and the inclusion criteria state that subjects must have histologically proven breast cancer. The patient meets this criteria.\n\nStep 3: Compare the patient's surgery and axillary sampling with the inclusion criteria.\nThe patient had a core biopsy revealing a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, and axillary sampling revealed 5 positive lymph nodes. The inclusion criteria state that subjects must have definitive surgical treatment either mastectomy or breast conserving surgery with axillary lymph node dissection, and subjects must be either lymph node-positive (pN1-3) or lymph node-negative (pN0) with high-risk features. The patient meets this criteria.\n\nStep 4: Compare the patient's tumor characteristics with the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative, and the inclusion criteria state that HER2/neu positive or negative tumors are eligible. The patient meets this criteria.\n\nStep 5: Compare the patient's other medical conditions and treatments with the inclusion criteria.\nThe patient is using multivitamins and iron supplements, does not smoke or consume alcohol, and is a candidate for tumor resection and agrees to do so prior to chemotherapy. The inclusion criteria do not mention any specific requirements or exclusions related to these factors.\n\nStep 6: Compare the patient's hematology and hepatic function with the inclusion criteria.\nThe patient's hematology and hepatic function results are not provided in the patient note. The inclusion criteria state that subjects must have normal cardiac function confirmed by left ventricular ejection fraction (LVEF) or shortening fraction (multiple-gated acquisition [MUGA] scan or echocardiography respectively), and hematology evaluation within 2 weeks prior to study entry must meet",
        "label": 2
    },
    "61": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Disease: Cytologically confirmed breast cancer\n- Tumor type: 3 cm invasive ductal breast carcinoma, HER2-positive, ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- CXR: Metastatic lesions\n- Other medical conditions: None\n\nStep 2: Compare the patient's characteristics to the inclusion criteria of the clinical trial.\n- Breast cancer with evidence of unresectable, locally recurrent, or metastatic disease: Yes (metastatic lesions in CXR)\n- Tumors over-expressing Her-2: Yes (HER2-positive)\n- Candidate for treatment with docetaxel/trastuzumab: Yes (patient is a candidate for tumor resection and agrees to do so prior to chemotherapy)\n\nStep 3: Determine the patient's eligibility based on the comparison.\n- The patient meets all the inclusion criteria for the clinical trial.\n\nStep 4: Output the scale for the assessment of eligibility.\n- Trial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "62": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's diagnosis and breast cancer-related bone lesions.\nPatient note: \"The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions.\"\n\nThe patient has a confirmed diagnosis of breast cancer and metastatic lesions, which are breast cancer-related bone lesions.\n\nStep 2: Check if the patient has received bisphosphonates within 6 months prior to inclusion.\nPatient note: \"The patient is using multivitamins and iron supplements.\"\n\nThe patient is not using bisphosphonates, as they are using multivitamins and iron supplements.\n\nStep 3: Assess the patient's health status.\nPatient note: \"The patient does not smoke or consume alcohol. She is not sexually active and has no children.\"\n\nThe patient's health status is not mentioned in the patient note. However, there is no information suggesting that the patient has a poor health status.\n\nStep 4: Check for abnormal renal function, diseases with influence on bone metabolism, pregnancy, lactation, and dental problems.\nPatient note: \"The patient does not smoke or consume alcohol. She is not sexually active and has no children.\"\n\nThere is no information about the patient's renal function, bone metabolism diseases, pregnancy, lactation, or dental problems in the patient note.\n\nStep 5: Determine the trial-level eligibility.\nThe patient meets the inclusion criteria for confirmed diagnosis of breast cancer with at least one breast cancer-related bone lesion and no treatment with bisphosphonates within 6 months prior to inclusion. There is not enough information to determine if the patient has abnormal renal function, diseases with influence on bone metabolism, pregnancy, lactation, or dental problems, which are exclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "63": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender\nThe patient is a 45-year-old postmenopausal woman. The clinical trial includes women aged 18 years or older.\n\nStep 2: Identify the patient's cancer type and stage\nThe patient has cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma. The trial includes high-risk lymph node positive breast cancer.\n\nStep 3: Check the number of involved axillary lymph nodes\nThe patient has 5 positive lymph nodes. The trial includes patients with 5 or more involved axillary lymph nodes.\n\nStep 4: Check if the patient has undergone surgical local therapy\nThe patient is a candidate for tumor resection. The trial includes patients who have undergone surgical local therapy (modified radical mastectomy or breast conserving surgery).\n\nStep 5: Check if the patient's tumor margins are negative\nThe patient's tumor margins are not mentioned in the note. The trial includes patients with negative tumor margins for invasive cancer.\n\nStep 6: Check for evidence of distant metastasis\nThe patient has metastatic lesions. The trial includes patients with no evidence of distant metastasis.\n\nStep 7: Check for normal cardiac ejection fraction and adequate organ function\nThe patient's cardiac ejection fraction is not mentioned in the note. The trial includes patients with a normal cardiac ejection fraction.\n\nStep 8: Check the patient's performance status\nThe patient's performance status is not mentioned in the note. The trial includes patients with a performance status of 0-1.\n\nStep 9: Check for prior treatment history\nThe patient has not undergone chemotherapy, hormonal therapy, or radiation therapy for the primary breast cancer. The trial includes patients with no prior chemotherapy, hormonal therapy, or radiation therapy for treatment of the primary breast cancer.\n\nStep 10: Check for bilateral synchronous breast cancer\nThe patient's breast cancer type is not mentioned in the note, so we cannot determine if they have bilateral synchronous breast cancer. The trial includes patients with bilateral synchronous breast cancer if other criteria are met.\n\nStep 11: Check for hormone",
        "label": 1
    },
    "64": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note with inclusion criteria\n\n1. Patient: Female diagnosed with metastatic breast cancer\nPatient Note: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- Match\n\n2. Patient: Initiating treatment for metastatic breast cancer\nPatient Note: The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n- Match\n\n3. Patient: ECOG Performance Status Score of 2 or less\nPatient Note: The information about the patient's ECOG Performance Status Score is not provided.\n- Not relevant\n\n4. Spouse: Being the male spouse or significant other of a female patient diagnosed with metastatic breast cancer\nPatient Note: The information about the spouse is not provided.\n- Not relevant\n\n5. Spouse: Having the patient's consent to be contacted\nPatient Note: The information about the spouse's consent is not provided.\n- Not relevant\n\n6. Patients and Spouses: Ability to read and speak English well enough to understand the consent form and complete the questionnaires\nPatient Note: The information about the patient and spouse's language proficiency is not provided.\n- Not relevant\n\n7. Patients and Spouses: Ability to provide informed consent\nPatient Note: The information about the patient and spouse's ability to provide informed consent is not provided.\n- Not relevant\n\nStep 2: Determine Trial-level eligibility\n\nBased on the comparison of the patient note with the inclusion criteria, the patient meets some of the inclusion criteria but does not have sufficient information to qualify for the trial in terms of ECOG Performance Status Score, spouse's consent, and language proficiency.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "65": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR\n\nInclusion criteria:\n- Histologic, pathologic, or cytologic diagnosis of cancer of the female breast\n- Stage IV breast cancer or locally advanced (stage III) breast cancer not considered amenable to curative therapy\n- Tumors potentially sensitive to endocrine therapy (ER and/or PR positive)\n- HER2 status can be any\n- At least one measurable lesion\n- Prior endocrine treatment in either adjuvant or metastatic setting\n- Prior treatment with a commercially available third-generation aromatase inhibitor\n- Prior chemotherapy and trastuzumab allowed\n- Postmenopausal women\n- ECOG performance status 0-2\n\nStep 2: Determine if patient meets inclusion criteria\n\n- The patient has breast cancer, so she meets the first inclusion criterion.\n- The patient has stage IV breast cancer, so she meets the second inclusion criterion.\n- The patient's tumor is HER2-positive and ER/PR negative, so she meets the third inclusion criterion.\n- The patient has at least one measurable lesion, so she meets the fifth inclusion criterion.\n- The patient has received prior endocrine treatment and prior treatment with a commercially available third-generation aromatase inhibitor, so she meets the sixth and seventh inclusion criteria.\n- The patient has received prior chemotherapy and trastuzumab, so she meets the eighth inclusion criterion.\n- The patient is a postmenopausal woman, so she meets the ninth inclusion criterion.\n- The patient has an ECOG performance status of 0, so she meets the tenth inclusion criterion.\n\nStep 3: Determine if patient meets exclusion criteria\n\n- There are no specific exclusion criteria mentioned in the patient note that would disqualify her from the trial.\n\nStep 4: Determine trial-level eligibility\n\nSince the patient meets all the",
        "label": 0
    },
    "66": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions\n\nStep 2: Compare the patient's characteristics to the inclusion criteria of the clinical trial:\n- Breast cancer with evidence of unresectable locally recurrent, or metastatic disease: Yes (patient has metastatic lesions)\n- Her-2 negative tumors: No (patient has HER2-positive tumor)\n\nStep 3: Determine the patient's eligibility based on the comparison:\nSince the patient does not meet one of the inclusion criteria (HER2-negative tumor), the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "67": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Disease: Breast cancer (metastatic)\n- Treatment: Tumor resection and chemotherapy\n- Life expectancy: Not mentioned\n- Performance status: Not mentioned\n- English speaking: Not mentioned\n- Menopausal status: Postmenopausal\n\nStep 2: Compare the patient's characteristics with the inclusion criteria of the clinical trial.\n\n1. Metastatic or locally advanced breast cancer not amenable to curative surgery: The patient has metastatic breast cancer, which meets this criterion.\n2. Life expectance of greater than 12 months: The patient's life expectancy is not mentioned in the note, so we cannot determine if this criterion is met.\n3. English speaking: The patient's language is not mentioned in the note, so we cannot determine if this criterion is met.\n4. Pre- and postmenopausal: The patient is postmenopausal, which meets this criterion.\n5. Performance status 0-1: The patient's performance status is not mentioned in the note, so we cannot determine if this criterion is met.\n\nStep 3: Determine the trial-level eligibility based on the comparison.\n\nSince we cannot determine if the patient meets the life expectancy and performance status criteria, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "68": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nPatient age: 45 years old\nInclusion criterion: Age > 18 years\nThe patient meets the age inclusion criterion.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nPatient gender: Female (postmenopausal)\nInclusion criterion: Premenopausal or postmenopausal women\nThe patient meets the gender inclusion criterion.\n\nStep 3: Compare the patient's cancer type with the inclusion criteria.\nPatient cancer type: Breast cancer\nInclusion criterion: Histologically or cytologically confirmed breast adenocarcinoma\nThe patient meets the cancer type inclusion criterion.\n\nStep 4: Compare the patient's tumor size with the inclusion criteria.\nPatient tumor size: 3 cm invasive ductal breast carcinoma\nInclusion criterion: Tumors measuring > 2 cm (for premenopausal and postmenopausal women)\nThe patient meets the tumor size inclusion criterion.\n\nStep 5: Compare the patient's hormone receptor status with the inclusion criteria.\nPatient hormone receptor status: ER/PR negative\nInclusion criterion: ER/PR negative (for high-risk tumors)\nThe patient meets the hormone receptor inclusion criterion.\n\nStep 6: Compare the patient's HER2 status with the inclusion criteria.\nPatient HER2 status: HER2-positive\nInclusion criterion: HER2 (3+) (before 15.05.2008); HER2 (3+) were not included (after 15.05.2008)\nThe patient does not meet the HER2 inclusion criterion.\n\nStep 7: Compare the patient's lymph node status with the inclusion criteria.\nPatient lymph node status: 5 positive lymph nodes\nInclusion criterion: Absence of lymph node involvement after eclosion and hormone (E&H) staining and light microscopy evaluation\nThe patient does not meet the lymph node inclusion crit",
        "label": 0
    },
    "69": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note and compare it to the inclusion criteria.\n\nPatient characteristics:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma\n- HER2-positive, ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions\n- No smoking, no alcohol consumption\n- No children, not sexually active\n- Candidate for tumor resection\n\nInclusion criteria:\n- Histologically-confirmed unilateral invasive ductal or lobular breast adenocarcinoma\n- Within 60 days after surgical excision of the primary tumor\n- At least 10 axillary lymph nodes removed\n- Tumor involvement of at least one axillary lymph node\n- Absence of clinical or radiological evidence of local or metastatic disease\n- Premenopausal or postmenopausal women aged 18-75 years old\n- Adequate bone marrow function\n- Adequate liver and renal function\n- Adequate cardiac function\n- Written informed consent\n\nStep 2: Determine if the patient meets the inclusion criteria.\n\n- Histologically-confirmed breast cancer: Yes\n- Within 60 days after surgical excision of the primary tumor: Unknown (insufficient information)\n- At least 10 axillary lymph nodes removed: Unknown (insufficient information)\n- Tumor involvement of at least one axillary lymph node: Yes\n- Absence of clinical or radiological evidence of local or metastatic disease: No (metastatic lesions)\n- Age: Yes (45 years old, within the 18-75 years old range)\n- Adequate bone marrow function: Unknown (insufficient information)\n- Adequate liver and renal function: Unknown (insufficient information)\n- Adequate cardiac function: Unknown (insufficient information)\n- Written informed consent: Unknown (insufficient information)\n\nStep 3: Determine the patient's eligibility based on the information available.\n\nSince there is insufficient information to determine if the patient meets the criteria",
        "label": 1
    },
    "70": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nThe patient is a 45-year-old woman. This meets the inclusion criteria of women \u2265 18 years.\n\nStep 2: Identify the patient's disease type and stage.\nThe patient has cytologically confirmed breast cancer, and a core biopsy revealed a 3 cm invasive ductal breast carcinoma. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. This meets the inclusion criteria of locally advanced (stage IIIb) or metastatic (stage IV) and not curable adenocarcinoma of the breast.\n\nStep 3: Identify the patient's HER-2/neu expression and ER/PR status.\nThe patient's tumor is HER2-positive and ER/PR negative. This meets the inclusion criteria of HER-2/neu expression 1+ or 2+ / FISH negative and Estrogen Receptors (ERs) and/or Progesterone Receptors (PRs) positive.\n\nStep 4: Check if the patient has received prior endocrine therapy and if there is disease progression during or after endocrine therapy.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This indicates that she has not received prior endocrine therapy. However, the patient has metastatic lesions, which implies disease progression. This meets the inclusion criteria of prior adequate endocrine therapy for advanced or metastatic disease and disease progression during or after endocrine therapy.\n\nStep 5: Check if the patient has any exclusion criteria.\nThere are no exclusion criteria mentioned in the patient note that would disqualify her from participating in the trial.\n\nStep 6: Determine the trial-level eligibility.\nAs the patient meets all the inclusion criteria and does not have any exclusion criteria, she is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "71": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Disease: HER2-positive, ER/PR negative breast cancer\n- Stage: Not specified, but metastatic lesions are present\n- Menopausal status: Postmenopausal\n- Prior treatment: None\n- ECOG Performance Status: Not specified\n- Laboratory values: Not specified\n- Cardiac function: Not specified\n- Metastatic disease: Present\n- Bilateral mammography: Not specified\n- Time since surgery: Not specified\n- Pregnancy status: Not specified\n- Tumor specimen for FISH analysis: Not specified\n\nStep 2: Compare the patient's characteristics to the inclusion criteria.\n\nAge: The patient is within the acceptable age range (45 years old).\n\nGender: The patient is a woman.\n\nDisease: The patient has HER2-positive, ER/PR negative breast cancer.\n\nStage: The patient has metastatic lesions, which is not specified in the inclusion criteria.\n\nMenopausal status: The patient is postmenopausal.\n\nPrior treatment: The patient has not had prior chemotherapy.\n\nECOG Performance Status: Not specified.\n\nLaboratory values: Not specified.\n\nCardiac function: Not specified.\n\nMetastatic disease: The patient has metastatic disease, which is an exclusion criterion.\n\nBilateral mammography: Not specified.\n\nTime since surgery: Not specified.\n\nPregnancy status: Not specified.\n\nTumor specimen for FISH analysis: Not specified.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\nThe patient meets some inclusion criteria, but she has metastatic disease, which is an exclusion criterion. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "72": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is a 45-year-old, and the inclusion criteria state that females age 18 years or older are eligible. The patient meets this criterion.\n\nStep 2: Compare the patient's ability to provide informed consent with the inclusion criteria.\nThe patient can provide written informed consent, and the inclusion criteria state that the ability to provide written informed consent is required. The patient meets this criterion.\n\nStep 3: Compare the patient's cancer diagnosis with the inclusion criteria.\nThe patient has histologically confirmed infiltrating (invasive) breast cancer, which matches the inclusion criteria.\n\nStep 4: Compare the clinical stage of the patient's cancer with the inclusion criteria.\nThe patient has clinical stage IIB - IIIC breast cancer, which matches the inclusion criteria.\n\nStep 5: Compare the size of the patient's primary tumor with the inclusion criteria.\nThe patient's primary tumor is 3 cm, which is greater than or equal to 2 cm, as required by the inclusion criteria.\n\nStep 6: Compare the patient's receptor status with the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative, which matches the inclusion criteria.\n\nStep 7: Compare the patient's cardiac status with the inclusion criteria.\nThere is no information provided about the patient's cardiac status, so we cannot determine if they meet this criterion.\n\nStep 8: Compare the patient's ambulatory status and ECOG Performance Status with the inclusion criteria.\nThere is no information provided about the patient's ambulatory status or ECOG Performance Status, so we cannot determine if they meet these criteria.\n\nStep 9: Compare the patient's life expectancy with the inclusion criteria.\nThere is no information provided about the patient's life expectancy, so we cannot determine if they meet this criterion.\n\nSince we cannot determine if the patient meets all the inclusion criteria, the trial-level eligibility is: 1) Not relevant.",
        "label": 1
    },
    "73": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the age range of \u2265 18 years.\n\nStep 2: Compare the patient's disease type to the inclusion criteria.\nThe patient has breast cancer, not lung cancer. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nStep 3: Compare the patient's tumor location to the inclusion criteria.\nThe patient's tumor is in the breast, not in the lung. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nStep 4: Compare the patient's tumor stage to the inclusion criteria.\nThe patient has stage IA non-small cell lung cancer, not stage IA breast cancer. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nStep 5: Compare the patient's performance status to the inclusion criteria.\nThe patient's ECOG performance status is not mentioned in the patient note. Therefore, we cannot determine if the patient meets this criterion.\n\nStep 6: Compare the patient's prior malignancies and treatment history to the inclusion criteria.\nThe patient has a history of breast cancer, not non-melanoma skin cancer, superficial bladder cancer, or cervical intraepithelial neoplasia. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nStep 7: Compare the patient's prior chemotherapy or radiation therapy to the inclusion criteria.\nThe patient's prior chemotherapy or radiation therapy is not mentioned in the patient note. Therefore, we cannot determine if the patient meets this criterion.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "74": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria\nThe patient is 45 years old, which is within the age range of 18 years or older required for the trial.\n\nStep 2: Compare patient's gender with the inclusion criteria\nThe patient is a woman, which is acceptable for the trial as it doesn't specify a gender requirement.\n\nStep 3: Compare patient's disease type and stage with the inclusion criteria\nThe patient has invasive ductal breast carcinoma, which is a type of breast cancer. The trial includes patients with histologically or cytologically confirmed invasive breast carcinoma. The patient's cancer is in stage IIA, which is an early stage of breast cancer as per the trial inclusion criteria.\n\nStep 4: Compare patient's HER2 status with the inclusion criteria\nThe patient's tumor is HER2-positive, which matches the trial's inclusion criteria of 3+ HER2 overexpression by IHC or 2+ HER2 overexpression and FISH positivity.\n\nStep 5: Compare patient's measurable disease with the inclusion criteria\nThe patient has a palpable lesion with both diameters greater than or equal to 1 cm, which is measurable disease as per the trial inclusion criteria.\n\nStep 6: Compare patient's ECOG performance status with the inclusion criteria\nThe patient's ECOG performance status is not mentioned in the patient note. Therefore, we cannot determine if she meets this criterion.\n\nStep 7: Compare patient's left ventricular ejection fraction (LVEF) with the inclusion criteria\nThe patient's LVEF is not mentioned in the patient note. Therefore, we cannot determine if she meets this criterion.\n\nStep 8: Compare patient's contraceptive use and amenorrheic status with the inclusion criteria\nThe patient is postmenopausal and amenorrheic for at least 12 months, which fulfills the trial's requirement for women of childbearing potential. The trial doesn't specify any contraceptive use requirement.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "75": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria\nThe patient is 45 years old, which meets the inclusion criteria for patients being 18 years of age or older.\n\nStep 2: Compare the patient's gender with the inclusion criteria\nThe patient is female, which meets the inclusion criteria for patients being female.\n\nStep 3: Compare the patient's tumor size with the inclusion criteria\nThe patient has a 3 cm invasive ductal breast carcinoma, which meets the inclusion criteria for patients with a clinical T1, T2, or T3 tumor size.\n\nStep 4: Compare the patient's histopathologic tissue diagnosis with the inclusion criteria\nThe patient has a histopathologic tissue diagnosis of breast cancer by a core-type of breast biopsy, which meets the inclusion criteria.\n\nStep 5: Compare the patient's axillary lymph node involvement with the inclusion criteria\nThe patient has 5 positive lymph nodes, which meets the inclusion criteria for patients with biopsy-proven involvement of the axillary lymph nodes at initial presentation.\n\nStep 6: Compare the patient's treatment history with the inclusion criteria\nThe patient has undergone preoperative neoadjuvant systemic chemotherapy, which meets the inclusion criteria.\n\nStep 7: Compare the patient's eligibility for surgery with the inclusion criteria\nThe patient is a candidate for tumor resection, which meets the inclusion criteria for patients who may be candidates for either lumpectomy or mastectomy.\n\nStep 8: Compare the patient's medical history with the inclusion criteria\nThe patient has no history of previously treated metachronous contralateral breast cancer or synchronous bilateral breast cancer, which meets the inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "76": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria\nThe patient is 45 years old, which is within the age range of 18 years or older.\n\nStep 2: Compare patient's gender to the inclusion criteria\nThe patient is a woman, which is consistent with the inclusion criteria.\n\nStep 3: Compare patient's disease status to the inclusion criteria\nThe patient has cytologically confirmed breast cancer, which is consistent with the inclusion criteria. The tumor is HER2-positive and ER/PR negative, which is also consistent with the inclusion criteria.\n\nStep 4: Compare patient's disease stage to the inclusion criteria\nThe patient has metastatic breast cancer, which is consistent with the inclusion criteria.\n\nStep 5: Compare patient's previous treatment history to the inclusion criteria\nThe patient has not received prior chemotherapy for metastatic breast cancer, which is consistent with the inclusion criteria.\n\nStep 6: Compare patient's organ and marrow function to the inclusion criteria\nThe patient's absolute neutrophil count, platelets, total bilirubin, AST(SGOT)/ALT(SGPT), creatinine, and PT INR are all within normal institutional limits, which is consistent with the inclusion criteria.\n\nStep 7: Compare patient's tissue availability to the inclusion criteria\nTissue from the primary tumor is available for correlative studies, which is consistent with the inclusion criteria.\n\nStep 8: Compare patient's ability to understand and willingness to sign informed consent to the inclusion criteria\nThe patient is able to understand and willing to sign a written informed consent document, which is consistent with the inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "77": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze patient note\nThe patient is a 45-year-old postmenopausal woman with breast cancer. She is not eligible for the clinical trial as the trial is for epilepsy patients, not for cancer patients.\n\nStep 2: Analyze inclusion criteria\n1. Medically-refractory epilepsy (the patient has breast cancer, not epilepsy)\n2. At least 3 seizures/month in the 3-month period prior to randomization (not applicable, as the patient has cancer)\n3. Ages between 10 and 75 years (the patient is 45, within the age range)\n4. Pre-menopausal women must be utilizing two reliable forms of birth control or abstinence (not applicable, as the patient is postmenopausal)\n5. Ability to understand the concept of a clinical trial (not applicable, as the patient has cancer)\n\nStep 3: Determine trial-level eligibility\nSince the patient has breast cancer and not epilepsy, she does not meet the inclusion criteria. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "78": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria do not specify a minimum age. Therefore, this factor is not relevant.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, and the inclusion criteria specify that only females are eligible. Therefore, this factor is relevant and the patient meets the criteria.\n\nStep 3: Compare the patient's breast cancer subtype to the inclusion criteria.\nThe patient has invasive ductal breast cancer, which is an allowed subtype. Therefore, this factor is relevant and the patient meets the criteria.\n\nStep 4: Compare the patient's stage of breast cancer to the inclusion criteria.\nThe patient has stage II disease, which is within the allowed range of stage I or II. Therefore, this factor is relevant and the patient meets the criteria.\n\nStep 5: Compare the patient's tumor size to the inclusion criteria.\nThe patient's tumor is 3 cm, which is within the allowed range of \u2264 3 cm. Therefore, this factor is relevant and the patient meets the criteria.\n\nStep 6: Compare the patient's number of positive lymph nodes to the inclusion criteria.\nThe patient has 5 positive lymph nodes, which is more than the allowed maximum of 3. Therefore, this factor is relevant and the patient is excluded.\n\nStep 7: Compare the patient's prior surgeries to the inclusion criteria.\nThe patient has undergone a lumpectomy and axillary lymph node sampling, which is required by the inclusion criteria. Therefore, this factor is relevant and the patient meets the criteria.\n\nStep 8: Compare the patient's hormone receptor status to the inclusion criteria.\nThe patient's hormone receptor status is not specified, but the inclusion criteria state that hormone receptor status is not specified. Therefore, this factor is not relevant and the patient meets the criteria.\n\nStep 9: Compare the patient's other medical conditions and treatments to the inclusion criteria.\nThe patient does not have any of the excluded medical conditions or treatments. Therefore, this factor is not relevant and the patient meets the criteria.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "79": {
        "output": "GPT4 Correct Assistant: Step 1: Check the patient's age.\nThe patient is 45 years old, which falls within the age range of 18 years and older for the trial.\n\nStep 2: Check the patient's gender.\nThe patient is a woman, which matches the trial's requirement for female participants.\n\nStep 3: Check the patient's diagnosis.\nThe patient has histologically confirmed breast cancer, which matches the trial's requirement for histologically confirmed breast cancer.\n\nStep 4: Check the stage of the patient's cancer.\nThe patient has node-positive stage IIA breast cancer, which matches the trial's inclusion criteria for node-positive stage IIA and any stage IIB, III breast cancer.\n\nStep 5: Check the patient's hormonal and chemotherapy history.\nThe patient has not received any prior hormonal, chemotherapy, or radiotherapy, which matches the trial's requirement for no prior hormonal, chemotherapy, or radiotherapy.\n\nStep 6: Check if the patient has undergone any breast operations other than biopsy.\nThe patient has not undergone any breast operations other than biopsy, which matches the trial's requirement for no breast operations other than biopsy.\n\nStep 7: Check the patient's performance status.\nThe patient has a good performance status (ECOG 0-1), which matches the trial's requirement for a good performance status.\n\nStep 8: Check the patient's hematopoietic function.\nThe patient's absolute granulocyte count is \u00b31500/mm3, platelet \u00b3100,000/mm3, and hemoglobin \u00b310 g/mm3, which match the trial's requirement for adequate hematopoietic function.\n\nStep 9: Check the patient's renal function.\nThe patient's serum creatinine is \u00b91.5 mg/dl, which matches the trial's requirement for adequate renal function.\n\nStep 10: Check the patient's hepatic function.\nThe patient's total bilirubin is \u00b91.5 mg/dl, AST/ALT is \u00b9two times normal, and alkaline phosphatase",
        "label": 2
    },
    "80": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the age range of \u2265 18 years.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, which matches the inclusion criteria for women.\n\nStep 3: Compare the patient's diagnosis to the inclusion criteria.\nThe patient has cytologically confirmed breast cancer, which matches the inclusion criteria for histologically/cytologically confirmed locally advanced or metastatic breast cancer.\n\nStep 4: Compare the patient's tumor characteristics to the inclusion criteria.\nThe patient's tumor is HER2-positive, which matches the inclusion criteria for primary tumor or metastases being HER2-ICH3+ or FISH+.\n\nStep 5: Compare the patient's disease status to the inclusion criteria.\nThe patient has measurable or non-measurable disease, which matches the inclusion criteria for measurable or non-measurable disease.\n\nStep 6: Compare the patient's previous treatment history to the inclusion criteria.\nThe patient has not received treatment with the combination of trastuzumab and vinorelbine previously, which matches the inclusion criteria.\n\nStep 7: Compare the patient's expected lifetime to the inclusion criteria.\nThe patient has an expected lifetime of more than 12 weeks, which matches the inclusion criteria.\n\nStep 8: Compare the patient's performance status to the inclusion criteria.\nThe patient's performance status is \u2264 2 according to the WHO scale, which matches the inclusion criteria.\n\nStep 9: Compare the patient's ability to comply with the protocol to the inclusion criteria.\nThe patient is able to comply with the protocol, which matches the inclusion criteria.\n\nStep 10: Verify informed consent.\nThe patient has provided verbal and written informed consent, which matches the inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "81": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n\n- Age: 45 years old\n- Gender: Female\n- Cancer type: Invasive ductal breast carcinoma\n- HER2 status: Positive\n- ER/PR status: Negative\n- Axillary lymph node status: 5 positive lymph nodes\n- Tumor size: 3 cm\n- Pre-treatment: Candidate for tumor resection and chemotherapy\n\nStep 2: Compare the patient's characteristics with the inclusion criteria of the clinical trial.\n\nInclusion Criteria:\n- Women with ER, PR, and HER2 negative invasive breast cancer\n- Primary tumor size 2 cm or greater\n- Assessment of pre-treatment axillary lymph nodal status\n- Absolute neutrophil count > 1500 mm3 and platelet count > 100,000 mm3\n- Normal myocardial left ventricular function\n- Serum creatinine < 2.0 mg/dl\n- Total bilirubin and AST < 3X upper limits normal\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\n- The patient's breast cancer is HER2 positive, which is not eligible for the trial.\n- The patient's breast cancer is ER/PR negative, which is eligible for the trial.\n- The patient's tumor size is 3 cm, which is eligible for the trial.\n- The patient has 5 positive lymph nodes, which is not eligible for the trial.\n- The patient is a candidate for tumor resection and chemotherapy, which is not specified in the inclusion criteria but does not exclude the patient.\n\nBased on the comparison, the patient meets some inclusion criteria but does not meet others. Therefore, the patient's eligibility for the trial is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "82": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age to the inclusion criteria\nThe patient is 45 years old, which falls within the age range of 18-65 years specified in the inclusion criteria.\n\nStep 2: Compare patient gender to the inclusion criteria\nThe patient is a woman, which is not specified in the inclusion criteria, but since the criteria do not exclude women, this is not a problem.\n\nStep 3: Compare patient cancer type to the inclusion criteria\nThe patient has histologically confirmed breast cancer, which matches the first inclusion criterion.\n\nStep 4: Compare patient tumor size to the inclusion criteria\nThe patient has a 3 cm invasive ductal breast carcinoma, which is greater than the minimum size of 2 cm specified in the inclusion criteria.\n\nStep 5: Compare patient for systemic metastasis to the inclusion criteria\nThe patient has metastatic lesions, which contradicts the inclusion criteria that state there should be no systemic metastasis.\n\nStep 6: Compare patient ECOG/WHO status to the inclusion criteria\nThe patient's ECOG status is not provided, but since it is not specified in the inclusion criteria, this is not a problem.\n\nStep 7: Compare patient laboratory values to the inclusion criteria\nThe patient's laboratory values are not provided, but since they are not specified in the inclusion criteria, this is not a problem.\n\nStep 8: Compare patient heart echo and hepatitis status to the inclusion criteria\nThe patient's heart echo and hepatitis status are not provided, but since they are not specified in the inclusion criteria, this is not a problem.\n\nStep 9: Compare patient consent to the inclusion criteria\nThe patient has given written consent to participate in the treatment optimization protocol, which matches the inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "83": {
        "output": "GPT4 Correct Assistant: Step 1: Check the patient's age\nThe patient is 45 years old. According to the inclusion criteria, postmenopausal women are defined as aged >= 50 years with amenorrhea for at least 12 months or aged < 50 years with 6 months of spontaneous amenorrhea and follicle stimulating hormone (FSH) level within postmenopausal range (> 40 mIU/ml) or having undergone bilateral oophorectomy. Since the patient is 45 years old, she meets this criterion.\n\nStep 2: Check the patient's breast cancer status\nThe patient has cytologically confirmed breast cancer. The inclusion criteria state that patients must have histologically or cytologically confirmed breast cancer. Therefore, the patient meets this criterion.\n\nStep 3: Check the patient's breast cancer stage\nThe patient has metastatic breast cancer (Stage IV according to UICC - Union Internationale Contre Cancer - criteria, Version 6). The inclusion criteria state that patients must have metastatic breast cancer (Stage IV). Therefore, the patient meets this criterion.\n\nStep 4: Check the patient's progesterone receptor status\nThe patient's tumor is HER2-positive and ER/PR negative. The inclusion criteria state that patients must have progesterone receptor-positive tumors. Therefore, the patient does not meet this criterion.\n\nStep 5: Check the patient's eligibility for endocrine therapy\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The inclusion criteria state that patients must be considered candidates for endocrine therapy (no other therapies for breast cancer are required). Therefore, the patient meets this criterion.\n\nStep 6: Check the patient's disease progression status\nThe patient's disease has progressed since her previous cancer treatment. The inclusion criteria state that patients must have disease progression after first-line endocrine therapy for advanced breast cancer (i.e., with tumor remission or stabilization lasting at least 3 months under endocrine therapy). Therefore, the patient meets this criterion.\n\nStep 7: Check the patient's other inclusion criteria\nThe patient meets all other inclusion",
        "label": 0
    },
    "84": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n\n- Age: 45 years old\n- Sex: Female\n- Disease: Breast cancer (invasive ductal carcinoma)\n- Tumor size: 3 cm\n- HER2-positive, ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- Metastatic lesions on CXR\n\nStep 2: Compare the patient's characteristics to the inclusion and exclusion criteria of the clinical trial.\n\nInclusion Criteria:\n- Biopsy-proven DCIS\n- Mammographic and CE-MRI evidence of DCIS measuring greater than or equal to 4 cm\n- Desire to receive breast conserving therapy\n- Clinically and/or histologically negative axillary lymph nodes\n- No imaging or clinical findings suggestive of invasive carcinoma\n\nExclusion Criteria:\n- Invasive carcinoma\n- Tumor size greater than 4 cm\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\nThe patient has invasive ductal breast cancer, which is not eligible for the trial focused on DCIS. Additionally, the tumor size is 3 cm, which is smaller than the required 4 cm. Therefore, the patient does not meet the inclusion criteria and is excluded based on the exclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "85": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\nPatient Note: \n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions\n\nInclusion Criteria:\n- Histologically or cytologically confirmed adenocarcinoma of the breast\n- Metastatic disease\n- Measurable disease\n- No human epidermal growth factor receptor 2 (HER2)/neu overexpression\n- Estrogen receptor- and/or progesterone receptor-positive disease\n\nStep 2: Determine eligibility based on the comparison\n- The patient has cytologically confirmed breast cancer and is postmenopausal.\n- The patient has metastatic disease.\n- The patient has measurable disease.\n- The patient's tumor is HER2-positive, which is an exclusion criterion.\n- The patient's tumor is ER/PR negative, which is not mentioned in the inclusion criteria but could be considered a negative factor for eligibility.\n\nStep 3: Determine the trial-level eligibility\nBased on the comparison, the patient meets some inclusion criteria but also has at least one exclusion criterion. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "86": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age, gender, and cancer type.\n- Age: 45 years old\n- Gender: Female\n- Cancer type: Invasive ductal breast carcinoma, HER2-positive, ER/PR negative\n\nStep 2: Compare the patient's age and gender to the inclusion criteria.\n- Age: 18 years or older (met)\n- Gender: Not specified in inclusion criteria (met)\n\nStep 3: Compare the patient's cancer type to the inclusion criteria.\n- ER-negative, PR-negative, HER2-negative (met)\n\nStep 4: Check the clinical stage of the patient's cancer.\n- Clinical stage T2 or T3, N0-3, M0 (met)\n\nStep 5: Check the patient's performance status.\n- Performance status (PS) of 0 or 1 (met)\n\nStep 6: Check if the patient is using an effective means of contraception.\n- Not specified in patient note (Not relevant)\n\nStep 7: Check if the patient has normal organ function.\n- Not specified in patient note (Not relevant)\n\nStep 8: Determine the trial-level eligibility based on the information provided.\n- Eligible criteria met: Age, gender, cancer type, clinical stage, performance status\n- Not relevant criteria: Contraception, organ function\n- Exclusion criteria: None\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "87": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age\nThe patient is a 45-year-old postmenopausal woman. The inclusion criteria state that the patient must be over 40 years old with a life expectancy of at least 5 years. The patient meets this criterion.\n\nStep 2: Identify the patient's cancer type and stage\nThe patient has cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma. The inclusion criteria state that the patient must have unifocal histologically proven breast cancer, with or without calcifications in mammogram. The patient meets this criterion.\n\nStep 3: Identify the patient's tumor characteristics\nThe tumor is HER2-positive and ER/PR negative. The inclusion criteria do not specify any requirements for these characteristics. Therefore, we cannot determine the patient's eligibility based on this information.\n\nStep 4: Identify the patient's axillary lymph node status\nThe axillary sampling revealed 5 positive lymph nodes. The inclusion criteria state that axillary lymph nodes must be negative by sentinel lymph node (SLN) mapping and biopsy or by formal axillary lymph node dissection. The patient does not meet this criterion.\n\nStep 5: Identify the patient's Karnofsky status\nThe Karnofsky status is not mentioned in the patient note. The inclusion criteria state that the Karnofsky status must be at least 70. We cannot determine the patient's eligibility based on this information.\n\nStep 6: Identify the patient's awareness and consent\nThe patient must be aware of the neoplastic nature of her disease and must be willing to consent after being informed of the potential benefits, side effects, and risks of radiotherapy. The patient note does not provide information about the patient's awareness and consent. We cannot determine the patient's eligibility based on this information.\n\nConclusion:\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial. The patient has a positive axillary lymph node status, and we do not have information about the patient's Karnofsky status and awareness/consent. Therefore, the trial-level eligibility",
        "label": 0
    },
    "88": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with inclusion criteria\nThe patient is 45 years old, and the inclusion criteria do not mention any specific age requirement.\n\nStep 2: Compare patient's gender with inclusion criteria\nThe patient is a woman, and the inclusion criteria do not mention any specific gender requirement.\n\nStep 3: Compare patient's disease type and stage with inclusion criteria\nThe patient has invasive ductal breast carcinoma, which matches the inclusion criteria for invasive ductal, lobular, medullary, papillary, colloid (mucinous), or tubular histologies.\n\nStep 4: Compare patient's tumor size with inclusion criteria\nThe patient has a 3 cm tumor, which matches the inclusion criteria for AJCC stage 0, I, or II (TisN0, T1N0, T2N0 = 3 cm) histologically confirmed carcinoma of the breast.\n\nStep 5: Compare patient's axillary lymph nodes status with inclusion criteria\nThe patient has 5 positive axillary lymph nodes, which is not mentioned in the inclusion criteria. However, the criteria do not exclude patients with positive axillary lymph nodes.\n\nStep 6: Compare patient's treatment history with inclusion criteria\nThe patient has not received any previous treatment, which matches the inclusion criteria.\n\nStep 7: Compare patient's medical conditions with inclusion criteria\nThe patient is not pregnant, which matches the inclusion criteria for premenopausal patients with an intact uterus.\n\nStep 8: Compare patient's eligibility for brachytherapy with inclusion criteria\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which matches the inclusion criteria for patients treated with tylectomy.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "89": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\n1. Disease Characteristics:\n- The patient has breast cancer, which meets the criteria for invasive or intraductal breast cancer.\n- The tumor size is 3 cm, which meets the criteria for \u2264 3.0 cm.\n- The patient has 5 positive lymph nodes, which is more than the allowed 4 positive nodes on adequate axillary lymph node dissection.\n\n2. Patient Characteristics:\n- The patient is a female, which meets the criteria.\n- The patient is postmenopausal, which is not specified in the criteria.\n- The patient has no history of non-breast malignancies, which is not specified in the criteria.\n- The patient is not pregnant or nursing, which meets the criteria.\n\n3. Prior Concurrent Therapy:\n- The patient has not undergone breast implant or reconstructive surgery prior to study entry, which meets the criteria.\n- The patient has not undergone neoadjuvant chemotherapy or hormonal therapy, which meets the criteria.\n\nStep 2: Determine trial-level eligibility\n\nBased on the comparison, the patient meets some inclusion criteria but does not meet others. Specifically, the patient has more than the allowed 4 positive nodes on adequate axillary lymph node dissection. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "90": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is a 45-year-old postmenopausal woman. The inclusion criteria do not specify a required age range.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nThe patient is a woman. The inclusion criteria do not specify a required gender.\n\nStep 3: Compare the patient's disease characteristics with the inclusion criteria.\nThe patient has cytologically confirmed breast cancer, but the inclusion criteria require histologically confirmed primary invasive breast carcinoma. This is a discrepancy.\n\nStep 4: Compare the patient's stage of disease with the inclusion criteria.\nThe patient has stage IIA breast cancer. The inclusion criteria require stage I or stage IIA disease. This is a match.\n\nStep 5: Compare the patient's tumor size with the inclusion criteria.\nThe patient has a 3 cm tumor. The inclusion criteria require a tumor \u2264 5 cm in diameter. This is a match.\n\nStep 6: Compare the patient's surgical margins with the inclusion criteria.\nThe patient has not undergone surgery yet, and thus, pathologically negative surgical margins cannot be determined. This is a discrepancy.\n\nStep 7: Compare the patient's multicentric disease and malignant appearing microcalcifications with the inclusion criteria.\nThe patient does not have multicentric disease and/or diffuse malignant appearing microcalcifications. The inclusion criteria do not specify this requirement.\n\nStep 8: Compare the patient's axillary lymph node involvement with the inclusion criteria.\nThe patient has 5 positive lymph nodes. The inclusion criteria require no axillary lymph node involvement. This is a discrepancy.\n\nStep 9: Compare the patient's evidence of metastatic breast cancer with the inclusion criteria.\nThe patient has metastatic lesions. The inclusion criteria require no evidence of metastatic breast cancer. This is a discrepancy.\n\nStep 10: Compare the patient's hormone receptor status with the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative. The inclusion criteria do not specify hormone receptor status",
        "label": 0
    },
    "91": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 45 years old, and the trial includes patients 18 years of age or older.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nThe patient is a female, and the trial includes postmenopausal females.\n\nStep 3: Compare the patient's cancer type and receptor status with the inclusion criteria.\nThe patient has invasive ductal breast carcinoma that is HER2-positive and ER/PR negative. The trial includes patients with ER and/or PR-positive breast cancer. Since the patient's cancer is not ER or PR positive, she does not meet the inclusion criteria.\n\nStep 4: Compare the patient's disease stage with the inclusion criteria.\nThe patient has metastatic disease, and the trial includes patients with measurable and/or evaluable metastatic disease.\n\nStep 5: Compare the patient's previous treatment history with the inclusion criteria.\nThe patient has had axillary sampling with 5 positive lymph nodes and metastatic lesions on CXR. The trial includes patients who have not had more than 1 prior chemotherapy regimen for metastatic disease. Since the patient has had more than 1 prior chemotherapy regimen, she does not meet the inclusion criteria.\n\nStep 6: Compare the patient's medical history with the inclusion criteria.\nThe patient has no history of central nervous system metastases or unevaluated CNS symptoms suggestive of possible brain metastases. The trial includes patients who do not have a history of central nervous system metastases or unevaluated CNS symptoms.\n\nStep 7: Compare the patient's ability to participate with the inclusion criteria.\nThe patient is able to provide informed consent and comply with protocol requirements. The trial includes patients who can provide informed consent and comply with protocol requirements.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "92": {
        "output": "GPT4 Correct Assistant: Step 1: Determine the patient's age and gender.\nThe patient is a 45-year-old postmenopausal woman. The trial includes women aged 18-75 years old.\n\nStep 2: Determine the type of breast cancer.\nThe patient has invasive ductal breast carcinoma. The trial includes women with histologically-confirmed unilateral invasive ductal or lobular breast adenocarcinoma.\n\nStep 3: Determine the patient's HER2 status.\nThe patient's tumor is HER2-positive. The trial includes women with HER2/c-neu over expression.\n\nStep 4: Determine the patient's axillary lymph node status.\nThe patient has 5 positive lymph nodes. The trial includes women with tumor involvement of at least one axillary lymph node.\n\nStep 5: Determine the patient's metastatic status.\nThe patient has metastatic lesions. The trial includes women with absence of any clinical or radiological evidence of local or metastatic disease.\n\nStep 6: Determine the patient's menopausal status.\nThe patient is postmenopausal. The trial includes premenopausal or postmenopausal women.\n\nStep 7: Determine the patient's bone marrow, liver, renal, and cardiac function.\nThe patient's bone marrow, liver, renal, and cardiac function is not mentioned in the patient note. The trial includes women with adequate bone marrow, liver, renal, and cardiac function.\n\nStep 8: Determine if the patient has given written informed consent.\nThe patient's consent status is not mentioned in the patient note. The trial includes women who have given written informed consent.\n\nBased on the information provided, the patient meets some inclusion criteria but also has some exclusion factors. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "93": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with inclusion criteria\nThe patient is 45 years old, which is within the range of the inclusion criteria for stage I-III breast cancer.\n\nStep 2: Compare patient's gender with inclusion criteria\nThe patient is a woman, which matches the inclusion criteria for women with breast cancer.\n\nStep 3: Compare patient's diagnosis with inclusion criteria\nThe patient has a histologically confirmed diagnosis of breast cancer. The tumor is 3 cm and lymph node positive, which matches the inclusion criteria.\n\nStep 4: Compare time of physical examination and scans with inclusion criteria\nThe patient's physical examination and scans were performed within 90 days prior to registration.\n\nStep 5: Compare patient's medical history with exclusion criteria\nThe patient does not have a clinical diagnosis of congestive heart failure or angina pectoris, which is an exclusion criterion.\n\nStep 6: Compare patient's laboratory values with inclusion criteria\nThe patient's serum creatinine, bilirubin, SGOT, SGPT, ANC, and platelet count are within normal limits within 90 days prior to registration.\n\nStep 7: Compare patient's performance status with inclusion criteria\nThe patient has a performance status of 0-2 by Zubrod criteria, which matches the inclusion criteria.\n\nStep 8: Compare patient's reproductive status with inclusion criteria\nThe patient is postmenopausal, which means she is not of reproductive potential and does not need to use contraception.\n\nStep 9: Compare patient's informed consent with inclusion criteria\nThe patient has given written informed consent, which is required for participation in the trial.\n\nConclusion: The patient meets all the inclusion criteria and does not meet any exclusion criteria. Therefore, the trial-level eligibility is 2) Eligible.",
        "label": 2
    },
    "94": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n- Patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR was remarkable for metastatic lesions.\n\nStep 2: Compare the patient's information with the inclusion criteria of the clinical trial.\n- Inclusion Criteria for Surveillance Arm: Diagnosis of biopsy-prove ADH, ALH, or LCIS within the past 5 years based on core needle biopsy and/or excisional biopsy and confirmed by a Mayo pathologist.\n- Inclusion Criteria for Diagnostic Arm: Recent core needle biopsy of the breast demonstrating ADH, ALH, or LCIS confirmed by Mayo pathologist.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n- The patient has invasive ductal breast carcinoma, not ADH, ALH, or LCIS.\n\nStep 4: Assign the appropriate scale for the assessment of eligibility.\n- Trial-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).",
        "label": 0
    },
    "95": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria.\nThe patient is 45 years old. The trial includes both pre- and postmenopausal women, so the age criteria are met.\n\nStep 2: Compare patient's disease characteristics with the inclusion criteria.\nThe patient has a histologically confirmed invasive ductal breast carcinoma. The trial includes patients with invasive unilateral breast cancer. The patient's tumor is HER2-positive and ER/PR negative, which matches the triple-negative criteria for node-positive patients. The patient has 5 positive lymph nodes, which meets the node-positive criteria. The patient's tumor is stage II or III, which meets the stage criteria.\n\nStep 3: Compare patient's medical conditions and other requirements with the inclusion criteria.\nThe patient is a woman, which meets the gender criteria. The patient's ECOG performance status is 0, which meets the performance status criteria. The patient's peripheral neuropathy is \u2264 grade 1, which meets the peripheral neuropathy criteria. The patient's lab values are within the acceptable ranges for neutrophil count, platelet count, hemoglobin, AST, ALT, alkaline phosphatase, total bilirubin, serum creatinine, and LVEF. The patient is not pregnant or nursing, which meets the pregnancy criteria.\n\nStep 4: Compare patient's prior therapies and other exclusion criteria with the exclusion criteria.\nThe patient has not received prior chemotherapy, hormonal therapy, or radiotherapy, which meets the prior therapy criteria. The patient has no clinically or radiologically detectable metastases, which meets the metastatic lesions criteria. The patient does not have bilateral breast cancer or contralateral ductal carcinoma in situ, which meets the bilateral breast cancer criteria. The patient's tumor is not \u2265 T4a, which meets the tumor size criteria. The patient's tumor is HER2-positive, which is an exclusion criterion. However, the patient's HER2 positivity is not defined as IHC 3+ OR IHC 2+ and FISH or CISH positive, so this exclusion criter",
        "label": 1
    },
    "96": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and there is no specific age requirement in the inclusion criteria. Therefore, this factor is not relevant.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, and there is no specific gender requirement in the inclusion criteria. Therefore, this factor is not relevant.\n\nStep 3: Compare the patient's diagnosis to the inclusion criteria.\nThe patient has breast cancer, not cervical cancer. The inclusion criteria require the patient to have cervical cancer. Therefore, this factor excludes the patient.\n\nStep 4: Compare the patient's treatment history to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The inclusion criteria require patients to be dispositioned to undergo radical hysterectomy or radical trachelectomy and pelvic lymphadenectomy. The patient's treatment history is not relevant to the inclusion criteria.\n\nStep 5: Compare the patient's medical condition to the inclusion criteria.\nThe patient has metastatic lesions, which are not mentioned in the inclusion criteria. However, the presence of metastases is an exclusion criterion in other clinical trials. Therefore, this factor could potentially exclude the patient.\n\nStep 6: Compare the patient's use of medications to the inclusion criteria.\nThe patient is using multivitamins and iron supplements, which are not mentioned in the inclusion criteria. Therefore, this factor is not relevant.\n\nStep 7: Compare the patient's alcohol and smoking history to the inclusion criteria.\nThe patient does not smoke or consume alcohol, which are not mentioned in the inclusion criteria. Therefore, this factor is not relevant.\n\nStep 8: Compare the patient's sexual activity and reproductive history to the inclusion criteria.\nThe patient is not sexually active and has no children, which are not mentioned in the inclusion criteria. Therefore, this factor is not relevant.\n\nStep 9: Compare the patient's informed consent to the inclusion criteria.\nThe patient has signed an approved informed consent, which is an inclusion criterion. Therefore, this factor makes the patient eligible.\n\nTrial-level eligibility:",
        "label": 0
    },
    "97": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's gender and breast cancer type.\nThe patient is a female, and the patient has cytologically confirmed breast cancer. The tumor is HER2-positive and ER/PR negative, which indicates that it is a triple-negative breast cancer.\n\nStep 2: Compare the patient's breast cancer type with the inclusion criteria.\nThe inclusion criteria specify that the patient must have triple-negative (ER, PR, and HER2 negative) locally advanced non-resectable and/or metastatic breast cancer. The patient's breast cancer matches this description.\n\nStep 3: Check if the patient has a history of prior adjuvant or neoadjuvant anthracycline-based chemotherapy.\nThe patient note does not provide information about the patient's prior chemotherapy history.\n\nStep 4: Determine the patient's eligibility based on the available information.\nSince we do not have information about the patient's prior adjuvant or neoadjuvant anthracycline-based chemotherapy, we cannot determine if the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "98": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n- The patient has invasive carcinoma of the breast.\n- The patient is planning to undergo axillary lymph node dissection.\n- The patient has an ECOG performance status of 0.\n\nStep 2: Compare the patient's information with the inclusion criteria of the clinical trial.\n- The patient has invasive carcinoma of the breast.\n- The patient is planning to undergo axillary lymph node dissection.\n- The patient has an ECOG performance status of 0.\n\nStep 3: Determine if the patient meets all the inclusion criteria.\n- The patient meets all the inclusion criteria.\n\nStep 4: Check if there are any exclusion criteria.\n- There are no exclusion criteria mentioned in the clinical trial summary.\n\nStep 5: Determine the trial-level eligibility.\n- Since the patient meets all the inclusion criteria and there are no exclusion criteria, the trial-level eligibility is 2) Eligible.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "99": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Disease: Cytologically confirmed breast cancer\n- Tumor type: Invasive ductal breast carcinoma\n- Tumor location: Left upper outer quadrant\n- Tumor characteristics: HER2-positive and ER/PR negative\n- Metastatic lesions: CXR was remarkable for metastatic lesions\n- Previous treatment: Not specified in the note\n\nStep 2: Compare the patient's information with the inclusion criteria of the clinical trial.\n\n1. Signed study-specific Informed Consent Form(s): Not specified in the note\n2. Age \u2265 18 years: The patient is 45 years old, which meets the age requirement\n3. Histologically documented breast cancer: The patient has cytologically confirmed breast cancer, which is similar to histologically documented breast cancer\n4. HER2-positive disease: The patient's tumor is HER2-positive, which meets the requirement\n5. Metastatic breast cancer: The patient has metastatic lesions, which meets the requirement\n6. Disease progression on the last chemotherapy regimen received in the metastatic setting: Not specified in the note\n7. Prior treatment with an anthracycline, trastuzumab, a taxane, lapatinib, and capecitabine in the neoadjuvant, adjuvant, locally advanced, or metastatic setting and prior treatment with at least two lines of therapy (a line of therapy can be a combination of two agents or single-agent chemotherapy) in the metastatic setting: Not specified in the note\n8. At least two lines of anti-HER2 therapy must have been given in the metastatic setting as monotherapy or combined with chemotherapy or hormonal therapy: Not specified in the note\n9. A minimum of 6 weeks of trastuzumab for the treatment of metastatic disease is required: Not specified in the note\n10. Patients must have had at least 14 days of exposure in the metastatic setting to lapatinib and capecitabine (given together or separately) unless they were intolerant of lapatinib and/or cap",
        "label": 0
    },
    "100": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the trial's age requirement.\nThe patient is a 45-year-old woman, and the trial does not specify an age requirement. Therefore, this factor is not relevant to the patient's eligibility.\n\nStep 2: Compare the patient's gender to the trial's gender requirement.\nThe patient is a woman, and the trial does not specify a gender requirement. Therefore, this factor is not relevant to the patient's eligibility.\n\nStep 3: Compare the patient's cancer type to the trial's cancer type requirement.\nThe patient has breast cancer, and the trial is for breast cancer patients. Therefore, this factor is relevant and the patient meets the requirement.\n\nStep 4: Compare the patient's tumor stage to the trial's tumor stage requirement.\nThe patient has a 3 cm invasive ductal breast carcinoma, and the trial requires histologically proven breast cancer. Therefore, this factor is relevant and the patient meets the requirement.\n\nStep 5: Compare the patient's axillary lymph node status to the trial's axillary lymph node requirement.\nThe patient has 5 positive lymph nodes, and the trial requires at least one axillary lymph node showing evidence of tumor among a minimum of six resected lymph nodes. Therefore, this factor is relevant and the patient meets the requirement.\n\nStep 6: Compare the patient's surgical treatment to the trial's surgical treatment requirement.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The trial requires definitive surgical treatment (mastectomy or breast conserving surgery with axillary lymph node dissection) for operable breast cancer. Therefore, this factor is relevant and the patient meets the requirement.\n\nStep 7: Compare the patient's treatment history to the trial's treatment history requirement.\nThe patient has not received prior systemic anticancer therapy for breast cancer, and the trial excludes patients who have received prior systemic anticancer therapy for breast cancer. Therefore, this factor is relevant and the patient meets the requirement.\n\nStep 8: Compare the patient's previous anthracycline and taxoid therapy to",
        "label": 2
    },
    "101": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is a 45-year-old woman, and the inclusion criteria state that women must be 18 years old or older. The patient meets this criterion.\n\nStep 2: Compare the patient's diagnosis to the inclusion criteria.\nThe patient has been diagnosed with cytologically confirmed breast cancer, and the inclusion criteria state that women must have a newly diagnosed infiltrative breast cancer. The patient meets this criterion.\n\nStep 3: Compare the patient's willingness to participate to the inclusion criteria.\nThe patient agrees to take part in the study, and the inclusion criteria state that women must agree to participate. The patient meets this criterion.\n\nSince the patient meets all the inclusion criteria, we can proceed to the exclusion criteria.\n\nStep 4: Compare the patient's medical history to the exclusion criteria.\nThere are no exclusion criteria listed in the clinical trial summary.\n\nStep 5: Determine the trial-level eligibility.\nAs the patient meets all the inclusion criteria and none of the exclusion criteria apply, the trial-level eligibility is 2) Eligible.",
        "label": 2
    },
    "102": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and breast cancer diagnosis.\n\nPatient's age: 45 years old\nBreast cancer diagnosis: cytologically confirmed breast cancer, 3 cm invasive ductal breast carcinoma, HER2-positive and ER/PR negative\n\nStep 2: Compare the patient's age and breast cancer diagnosis with the inclusion criteria.\n\nInclusion criteria 1: Women with histologically confirmed invasive primary breast cancer grades I to III.\nInclusion criteria 2: Age up to and including 75 years old.\n\nThe patient meets both inclusion criteria.\n\nStep 3: Check for any exclusion criteria.\n\nThere are no exclusion criteria mentioned in the clinical trial description.\n\nStep 4: Determine the patient's eligibility based on the inclusion and exclusion criteria.\n\nSince the patient meets the inclusion criteria and there are no exclusion criteria, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "103": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n- The patient is a 45-year-old postmenopausal woman.\n- She has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- The patient is scheduled for tumor resection.\n\nStep 2: Compare the patient's information to the inclusion criteria of the clinical trial.\n\nInclusion Criteria:\n- Females with Stage II invasive breast cancer and documented axillary metastases by core biopsy, clinical examination, or fine-needle aspiration who are scheduled to undergo an ALND.\n- Females > 21 years of age\n\nThe patient is a female, has Stage II invasive breast cancer, and has documented axillary metastases. She is also over 21 years of age. She is scheduled to undergo an ALND (axillary lymph node dissection).\n\nStep 3: Determine the trial-level eligibility.\n\nBased on the comparison of the patient's information to the inclusion criteria, the patient meets all the requirements for the clinical trial. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "104": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n\n- Patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer\n- Core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- The tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Patient is using multivitamins and iron supplements\n- Patient does not smoke or consume alcohol\n- Patient is not sexually active and has no children\n- Patient is a candidate for tumor resection and agrees to do so prior to chemotherapy\n\nStep 2: Compare the patient's information to the inclusion criteria of the clinical trial.\n\nInclusion Criteria: Patients having a needle biopsy of a breast mass\n\n- Patient has cytologically confirmed breast cancer (meets inclusion criteria)\n- Patient has had a core biopsy (meets inclusion criteria)\n\nStep 3: Determine if the patient meets any exclusion criteria (if applicable).\n\nExclusion Criteria: (not provided)\n\nStep 4: Assess the patient's eligibility based on the information available.\n\n- Patient meets inclusion criteria\n- No exclusion criteria provided\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "105": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Diagnosis: Cytologically confirmed breast cancer\n- Tumor type: Invasive ductal breast carcinoma\n- Tumor location: Left upper outer quadrant\n- Tumor size: 3 cm\n- HER2 status: Positive\n- ER/PR status: Negative\n- Axillary sampling: 5 positive lymph nodes\n- CXR: Metastatic lesions\n- Medications: Multivitamins and iron supplements\n- Smoking: No\n- Alcohol: No\n- Sexual activity: Not sexually active\n- Children: No children\n- Treatment plan: Candidate for tumor resection before chemotherapy\n\nStep 2: Compare the patient's characteristics to the inclusion and exclusion criteria of the clinical trial.\n\nInclusion Criteria:\n- Clinical diagnosis of Breast Cancer\n\nExclusion Criteria:\nThere are no exclusion criteria listed in the trial description.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\nSince the patient has a clinical diagnosis of breast cancer and there are no exclusion criteria listed, the patient meets the inclusion criteria and the exclusion criteria do not apply.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "106": {
        "output": "GPT4 Correct Assistant: Step 1: Determine the patient's age\nThe patient is a 45-year-old postmenopausal woman.\n\nStep 2: Determine the patient's gender\nThe patient is a woman.\n\nStep 3: Determine the patient's disease type and stage\nThe patient has cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions.\n\nStep 4: Determine the patient's hormone receptor status\nThe patient's tumor is hormone receptor-positive (ER/PR negative).\n\nStep 5: Determine the patient's eligibility for the clinical trial\nInclusion Criteria: Postmenopausal women with hormone receptor-positive locally advanced or metastatic breast cancer\nExclusion Criteria: Not provided\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "107": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with inclusion criteria\nThe patient is 45 years old. The inclusion criteria state that the patient should have a unifocal infiltrative breast cancer diagnosed preoperatively by core biopsy or cytology. There is no mention of age in the inclusion criteria.\n\nStep 2: Compare patient's gender with inclusion criteria\nThe patient is a woman. The inclusion criteria state that the patient should have a unifocal infiltrative breast cancer diagnosed preoperatively by core biopsy or cytology. There is no mention of gender in the inclusion criteria.\n\nStep 3: Compare patient's cancer type with inclusion criteria\nThe patient has a 3 cm invasive ductal breast carcinoma. The inclusion criteria state that the patient should have a unifocal infiltrative breast cancer diagnosed preoperatively by core biopsy or cytology. The patient's cancer type does not match the inclusion criteria.\n\nStep 4: Compare patient's treatment history with inclusion criteria\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The inclusion criteria state that the patient should have a unifocal infiltrative breast cancer diagnosed preoperatively by core biopsy or cytology. There is no mention of treatment history in the inclusion criteria.\n\nStep 5: Compare patient's other medical conditions with inclusion criteria\nThe patient has metastatic lesions. The inclusion criteria state that the patient should have a unifocal infiltrative breast cancer diagnosed preoperatively by core biopsy or cytology. The patient's medical condition does not match the inclusion criteria.\n\nConclusion: The patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "108": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nThe patient is a 45-year-old postmenopausal woman. The trial includes female patients aged 18 years or older.\n\nStep 2: Identify the type of cancer and its stage.\nThe patient has a 3 cm invasive ductal breast carcinoma that is HER2-positive and ER/PR negative. The trial includes patients with early-stage breast cancer, which can be node-positive or node-negative with a primary tumor larger than 1 cm.\n\nStep 3: Check if the patient has undergone the required surgery.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The trial requires patients to have undergone either breast conservation surgery (lumpectomy) or total mastectomy.\n\nStep 4: Check if the patient has the required surgical margins.\nThe patient's surgical margins are not mentioned in the note. The trial requires surgical margins to be histologically free of invasive adenocarcinoma and ductal carcinoma in situ.\n\nStep 5: Check if the patient has completed axillary lymph node sampling.\nThe patient has axillary sampling that revealed 5 positive lymph nodes. The trial requires patients to have undergone sentinel node biopsy and/or either lymph node sampling procedure or axillary dissection.\n\nStep 6: Check if the patient has a triple-negative breast cancer.\nThe patient's tumor is HER2-positive and ER/PR negative, which makes it a triple-negative breast cancer. The trial includes patients with synchronous bilateral cancers that are of triple-negative phenotype.\n\nStep 7: Check if the patient has the required hematologic, liver, renal, and cardiac function.\nThe patient's hematologic, liver, renal, and cardiac function is not mentioned in the note. The trial requires adequate hematologic, liver, renal, and cardiac function.\n\nStep 8: Check if the patient has a complete staging work-up and recovery from recent surgery.\nThe patient's staging work-up and recovery from recent surgery is not mentioned in",
        "label": 0
    },
    "109": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the age range for the trial.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, which matches the gender requirement for the trial.\n\nStep 3: Compare the patient's disease characteristics to the inclusion criteria.\nThe patient has invasive ductal breast carcinoma, not ductal carcinoma in situ (DCIS) or atypical ductal hyperplasia (ADH). Therefore, the patient does not meet the disease characteristics criteria.\n\nStep 4: Compare the patient's prior therapy to the inclusion criteria.\nThe patient has undergone a core biopsy and has not had prior surgery, radiotherapy, or cytotoxic regimens to the ipsilateral breast. This matches the prior concurrent therapy criteria.\n\nStep 5: Compare the patient's other characteristics to the inclusion criteria.\nThe patient is not pregnant or nursing, has no contraindications to MRI, and has not had any ferromagnetic devices implanted. This matches the patient characteristics criteria.\n\nConclusion:\nSince the patient does not meet the disease characteristics criteria, they are not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "110": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\n1. Histologically or cytologically confirmed metastatic carcinoma of the breast: The patient note states that the patient has cytologically confirmed breast cancer with metastatic lesions in the chest X-ray. This criterion is met.\n\n2. Hormone receptor (estrogen receptor [ER] and/or progesterone receptor [PR]) positive disease: The patient note states that the tumor is HER2-positive and ER/PR negative. This criterion is not met.\n\n3. Postmenopausal: The patient is a 45-year-old postmenopausal woman. This criterion is met.\n\n4. Measurable or non-measurable (but evaluable) disease: The patient note does not provide information about the size or evaluability of the tumor. This criterion is not relevant.\n\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1: The patient note does not provide information about the patient's performance status. This criterion is not relevant.\n\n6. Neutrophil count >= 1.5 X 10^9 cells/L: The patient note does not provide information about the patient's neutrophil count. This criterion is not relevant.\n\n7. Platelet count >= 100 X 10^9 cells/L: The patient note does not provide information about the patient's platelet count. This criterion is not relevant.\n\n8. Serum creatinine =< 1.5 times upper limit of normal (ULN): The patient note does not provide information about the patient's serum creatinine level. This criterion is not relevant.\n\n9. Total serum bilirubin =< 1.5 times ULN: The patient note does not provide information about the patient's total serum bilirubin level. This criterion is not relevant.\n\n10. Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) levels =< 2.5 x ULN in patients without liver metastases or =< 5 times",
        "label": 0
    },
    "111": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 45 years old, which meets the inclusion criteria of being 18 years of age or older.\n\nStep 2: Compare the patient's informed consent with the inclusion criteria.\nThe patient has signed an informed consent, which meets the inclusion criteria.\n\nStep 3: Compare the patient's health condition with the inclusion criteria.\nThe patient's health condition, as described in the note, is in the opinion of the attending physician that with the administration of mifepristone, benefits may outweigh risks. This meets the inclusion criteria.\n\nStep 4: Determine if any exclusion criteria apply.\nThere are no exclusion criteria mentioned in the clinical trial summary.\n\nStep 5: Assess the patient's eligibility.\nThe patient meets all inclusion criteria and no exclusion criteria apply.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "112": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Diagnosis: Invasive ductal breast carcinoma (HER2-positive, ER/PR negative)\n- Treatment: Candidate for tumor resection and chemotherapy\n\nStep 2: Compare the patient's characteristics with the inclusion and exclusion criteria of the clinical trial.\n\nInclusion Criteria:\n- Diagnostic mammogram: Not mentioned in the patient note\n- English speaking: Not mentioned in the patient note\n- Breast cancer, ductal carcinoma in situ, or atypical ductal hyperplasia: Patient has invasive ductal breast carcinoma\n\nExclusion Criteria:\n- Pregnancy: Not mentioned in the patient note\n- No biopsy referral after diagnostic mammogram: Not mentioned in the patient note\n- Patient reported breastfeeding: Not mentioned in the patient note\n- Significant active medical illness: Not mentioned in the patient note\n- History of or active liver disease: Not mentioned in the patient note\n- Patient reported allergy or sensitivity to cruciferous vegetables: Not mentioned in the patient note\n- Use of oral antibiotics within three months prior to randomization: Not mentioned in the patient note\n- Oral steroid therapy at enrollment: Not mentioned in the patient note\n- Current therapy with valproate acid or SAHA: Not mentioned in the patient note\n- Current use of nutrient supplements or herbal remedies containing sulforaphane: Patient is using multivitamins and iron supplements\n- Radiation for currently-diagnosed disease prior to or during study supplementation: Patient is a candidate for tumor resection and agrees to do so prior to chemotherapy\n- Chemotherapy for currently-diagnosed disease prior to or during study supplementation: Patient is a candidate for tumor resection and agrees to do so prior to chemotherapy\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\nThe patient meets the inclusion criteria for breast cancer, ductal carcinoma in situ, or atypical ductal hyperplasia. She does not meet any of the exclusion criteria. Therefore, the patient is eligible for the",
        "label": 0
    },
    "113": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the age range for the trial.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, which is within the gender range for the trial.\n\nStep 3: Compare the patient's diagnosis to the inclusion criteria.\nThe patient has breast cancer, not bladder cancer.\n\nStep 4: Compare the patient's residence to the inclusion criteria.\nThe patient is not a Texas resident.\n\nStep 5: Compare the patient's language understanding to the inclusion criteria.\nThe patient understands English, which is within the language range for the trial.\n\nStep 6: Compare the patient's consent to the inclusion criteria.\nThe patient consents to participate in the study.\n\nStep 7: Determine the trial-level eligibility based on the comparison.\nSince the patient has a different cancer type and is not a Texas resident, the patient does not meet the inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "114": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the trial's age requirements.\nThe patient is 45 years old, which falls within the age range for the trial.\n\nStep 2: Compare patient's gender with the trial's gender requirements.\nThe patient is a woman, which matches the trial's requirement for female participants.\n\nStep 3: Compare patient's breast cancer type with the trial's requirements.\nThe patient has invasive ductal breast cancer, which matches the trial's requirement for invasive breast cancer.\n\nStep 4: Compare patient's hormone receptor status with the trial's requirements.\nThe patient's tumor is ER/PR negative, which matches the trial's requirement for hormone receptor-poor status.\n\nStep 5: Compare patient's HER2 status with the trial's requirements.\nThe patient's tumor is HER2-positive, which matches the trial's requirement for HER2-positive status.\n\nStep 6: Compare patient's clinical stage with the trial's requirements.\nThe patient has clinical stage III breast cancer, which matches the trial's requirement for clinical stage II-III breast cancer.\n\nStep 7: Compare patient's tumor size with the trial's requirements.\nThe patient's tumor is 3 cm, which is greater than the trial's requirement for a tumor size of at least 1 cm.\n\nStep 8: Compare patient's medical history with the trial's exclusion criteria.\nThe patient has metastatic lesions, which is an exclusion criterion for the trial.\n\nStep 9: Compare patient's use of supplements with the trial's requirements.\nThe patient is using multivitamins and iron supplements, which does not conflict with the trial's requirements.\n\nStep 10: Compare patient's eligibility for tumor resection with the trial's requirements.\nThe patient is a candidate for tumor resection, which matches the trial's requirement for participants who plan to undergo surgical resection after neoadjuvant therapy.\n\nStep 11: Compare patient's agreement to undergo pretreatment research biopsies with the trial'",
        "label": 1
    },
    "115": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's key characteristics from the patient note.\n\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR was remarkable for metastatic lesions\n\nStep 2: Compare the patient's characteristics to the inclusion criteria of the clinical trial.\n\nInclusion Criteria:\n1. Histologically or cytologically confirmed metastatic breast carcinoma that is HER2 positive\n2. Measurable disease as defined by the RECIST criteria\n3. Life expectancy greater than or equal to 6 months\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nStep 3: Determine if the patient meets the inclusion criteria.\n\n1. The patient has cytologically confirmed metastatic breast carcinoma that is HER2 positive.\n2. The patient has measurable disease.\n3. The patient's life expectancy is greater than or equal to 6 months (not explicitly stated, but implied by the trial's inclusion of patients with a life expectancy greater than or equal to 6 months).\n4. The patient's ECOG performance status is not provided, but it is not mentioned as an exclusion criterion.\n\nStep 4: Determine if the patient meets any exclusion criteria (if provided).\n\nExclusion Criteria (not provided in the given information).\n\nStep 5: Determine the patient's trial-level eligibility based on the comparison of their characteristics to the inclusion and exclusion criteria.\n\nSince the patient meets all the inclusion criteria and there are no exclusion criteria provided, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "116": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria\nThe patient is 45 years old, which is within the age range of 18 years or older.\n\nStep 2: Compare the patient's gender to the inclusion criteria\nThe patient is a female, which matches the inclusion criteria for both male and female.\n\nStep 3: Compare the patient's diagnosis to the inclusion criteria\nThe patient has been diagnosed with breast cancer, which matches the inclusion criteria.\n\nStep 4: Compare the patient's scheduled procedure to the inclusion criteria\nThe patient is scheduled for sentinel lymph node dissection, which matches the inclusion criteria.\n\nStep 5: Compare the patient's consent to the inclusion criteria\nThe patient is able and willing to give consent to participate in the study, which matches the inclusion criteria.\n\nSince the patient meets all the inclusion criteria, we can proceed to check for exclusion criteria.\n\nStep 6: Compare the patient's exclusion criteria to the trial's exclusion criteria\nThere are no specific exclusion criteria mentioned in the patient note.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "117": {
        "output": "GPT4 Correct Assistant: Step 1: Age\nThe patient is 45 years old. The inclusion criteria state that participants must be \u2265 18 years old. Since 45 is greater than 18, the patient meets the age requirement.\n\nStep 2: Performance Status\nThe patient's ECOG/Zubrod Performance Status is not mentioned in the patient note. Therefore, we cannot determine if the patient meets this criterion.\n\nStep 3: Gender\nThe patient is female. The inclusion criteria state that participants must be female. Since the patient is female, she meets this criterion.\n\nStep 4: Histologic Diagnosis\nThe patient has a histologic diagnosis of invasive breast cancer. The inclusion criteria state that participants must have a histologic diagnosis of invasive breast cancer. Since the patient meets this criterion, she is eligible.\n\nStep 5: Clinical Stage\nThe patient's clinical stage is not mentioned in the patient note. Therefore, we cannot determine if the patient meets this criterion.\n\nStep 6: Biopsy\nThe patient has a core needle biopsy revealing a 3 cm invasive ductal breast carcinoma. The inclusion criteria state that participants must have a FNA biopsy or core needle biopsy of an axillary node documenting nodal disease at time of diagnosis and prior to preoperative chemotherapy. Since the patient has a core needle biopsy, she meets this criterion.\n\nStep 7: Preoperative Chemotherapy\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The inclusion criteria state that participants must have preoperative chemotherapy completed or planned. Since the patient will have chemotherapy, she meets this criterion.\n\nStep 8: Prior Axillary Surgery\nThe patient is not mentioned to have had any prior axillary surgery. The inclusion criteria state that participants must not have had prior ipsilateral axillary surgery, such as excisional biopsy of lymph node(s) or treatment of hidradenitis. Since the patient has not had any prior axillary surgery, she meets this criterion.\n\nStep 9: Prior SLN Surgery/Excisional Lymph Node Biopsy\nThe patient is not mentioned to have had",
        "label": 1
    },
    "118": {
        "output": "GPT4 Correct Assistant: Step 1: Check the patient's age.\nThe patient is 45 years old, which is within the required age range of \u2265 18 years old.\n\nStep 2: Check the patient's tumor type and size.\nThe patient has invasive ductal breast carcinoma with a 3 cm tumor size, which meets the criteria for pathological stage 0, I, or II breast cancer.\n\nStep 3: Check the patient's hormone receptor status.\nThe patient's tumor is HER2-positive and ER/PR negative, which matches the inclusion criteria of negative ER and PR analysis.\n\nStep 4: Check the patient's axillary staging.\nThe patient has 5 positive lymph nodes, which means she does not meet the inclusion criteria of having 1-3 histologically positive axillary nodes or negative ER and PR analysis if older than 49 years.\n\nStep 5: Check the patient's life expectancy.\nThe patient's life expectancy is not mentioned in the note, but since she has breast cancer, it might be less than 10 years. However, without knowing her life expectancy, we cannot determine her eligibility.\n\nStep 6: Check the patient's surgical treatment and lumpectomy cavity.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. However, we do not have information about the lumpectomy cavity or whole breast reference volume based on the postoperative CT scan.\n\nConclusion: Based on the available information, the patient meets some of the inclusion criteria but does not have sufficient information to qualify for the trial. Therefore, the trial-level eligibility is 1) Not relevant.",
        "label": 0
    },
    "119": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age to the inclusion criteria.\nThe patient is 45 years old, which is greater than 18 years old. This meets the age requirement.\n\nStep 2: Compare patient gender to the inclusion criteria.\nThe patient is a woman, which matches the requirement for being postmenopausal or surgically sterilized.\n\nStep 3: Compare patient's condition to the inclusion criteria.\nThe patient has a 3 cm invasive ductal breast carcinoma, which is larger than 15 mm in diameter. This meets the requirement for having a lesion on mammogram, ultrasound, or breast MRI that measured > 15 mm in diameter and is known to be malignant, scheduled for surgery.\n\nStep 4: Compare patient's pregnancy status to the inclusion criteria.\nThe patient is postmenopausal, which meets the requirement for having a negative pregnancy test or being postmenopausal or surgically sterilized.\n\nBased on the comparison of the patient note and the inclusion criteria of the clinical trial, the patient meets all the requirements. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "120": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the range of the inclusion criteria for stage I or II breast cancer.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, which matches the inclusion criteria for both patients with breast cancer and those at high risk of developing breast cancer.\n\nStep 3: Compare the patient's breast cancer stage to the inclusion criteria.\nThe patient has a 3 cm invasive ductal breast carcinoma, which is a stage II breast cancer. This matches the inclusion criteria for stage II breast cancer.\n\nStep 4: Compare the patient's hormone receptor status to the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative. This does not match the inclusion criteria for hormone receptor status not specified.\n\nStep 5: Compare the patient's previous treatment history to the inclusion criteria.\nThe patient has already had a core biopsy, which is a form of treatment. This does not match the inclusion criteria for no prior chemotherapy for breast cancer or any other cancer.\n\nStep 6: Compare the patient's medical conditions to the inclusion criteria.\nThe patient has metastatic lesions, which is an advanced stage of breast cancer. This does not match the inclusion criteria for no advanced breast cancer.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "121": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which falls within the range of Stage I-IV infiltrating ductal or infiltrating lobular carcinoma.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, which matches the inclusion criteria for women with breast cancer.\n\nStep 3: Compare the patient's disease to the inclusion criteria.\nThe patient has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. This matches the inclusion criteria for Stage I-IV infiltrating ductal or infiltrating lobular carcinoma.\n\nStep 4: Compare the patient's HER2 status to the inclusion criteria.\nThe patient's tumor is HER2-positive, which matches the inclusion criteria for breast cancer.\n\nStep 5: Compare the patient's ER/PR status to the inclusion criteria.\nThe patient's tumor is ER/PR negative, which matches the inclusion criteria for breast cancer.\n\nStep 6: Compare the patient's axillary sampling results to the inclusion criteria.\nThe patient has 5 positive lymph nodes, which matches the inclusion criteria for Stage I-IV infiltrating ductal or infiltrating lobular carcinoma.\n\nStep 7: Compare the patient's CXR results to the inclusion criteria.\nThe patient has metastatic lesions, which matches the inclusion criteria for Stage I-IV infiltrating ductal or infiltrating lobular carcinoma.\n\nStep 8: Compare the patient's prior treatment history to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This matches the inclusion criteria for patients with Stage I-III disease who have not started systemic treatment.\n\nStep 9: Compare the patient's Karnofsky performance status to the inclusion criteria.\nThe patient's Karnofsky performance status is not mentioned in the patient note, but it is not required for this trial.\n\nStep 10: Compare the patient's pregnancy status to the inclusion criteria.\nThe patient is not pregnant, which matches the",
        "label": 2
    },
    "122": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note with inclusion criteria\n- DISEASE CHARACTERISTICS: The patient has breast cancer and has undergone a core biopsy, which matches the inclusion criteria.\n- PATIENT CHARACTERISTICS: Not specified\n- PRIOR CONCURRENT THERAPY: Not specified\n\nStep 2: Determine eligibility based on the comparison\nSince the patient note matches the inclusion criteria for disease characteristics, and there are no exclusion criteria or specific patient characteristics mentioned, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "123": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age to inclusion criteria\nThe patient is 45 years old. The trial includes patients who are postmenopausal, which is not explicitly defined by age but typically occurs around 51 years old. The patient may not be considered postmenopausal at 45 years old.\n\nStep 2: Compare patient gender to inclusion criteria\nThe patient is a female, which matches the inclusion criteria.\n\nStep 3: Compare patient breast cancer diagnosis to inclusion criteria\nThe patient has invasive ductal breast carcinoma, which matches the inclusion criteria.\n\nStep 4: Compare patient hormone receptor status to inclusion criteria\nThe patient's tumor is ER/PR negative and HER2-positive, which matches the inclusion criteria for hormone receptor-positive tumors.\n\nStep 5: Compare patient lymph node status to inclusion criteria\nThe patient has 5 positive lymph nodes, which matches the inclusion criteria for positive lymph node involvement.\n\nStep 6: Compare patient treatment history to inclusion criteria\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This matches the inclusion criteria for patients who have not yet received chemotherapy.\n\nStep 7: Compare patient performance status to inclusion criteria\nThe patient's WHO performance status is not provided, so we cannot determine if they meet the inclusion criteria.\n\nStep 8: Compare patient laboratory values to inclusion criteria\nThe patient's laboratory values are not provided, so we cannot determine if they meet the inclusion criteria.\n\nStep 9: Repeat trial-level eligibility\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "124": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n- The patient has histologically confirmed breast cancer, which matches the inclusion criteria.\n- The patient's tumor is invasive ductal breast carcinoma, which matches the inclusion criteria for invasive ductal carcinoma.\n- The patient's tumor is HER2-positive and ER/PR negative, which matches the inclusion criteria for any subtype of breast cancer.\n- The patient has pathological stage IIA disease, which matches the inclusion criteria for stage 0-IIIA disease.\n- The patient's tumor size is 3 cm, which is less than or equal to the 5 cm maximum allowed by the inclusion criteria.\n- The patient has undergone lumpectomy, which matches the inclusion criteria for having undergone lumpectomy or mastectomy.\n- The patient has no distant metastases, which matches the inclusion criteria for no distant metastases.\n\nStep 2: Compare patient note and exclusion criteria\n- The patient has metastatic lesions on CXR, which is an exclusion criterion for distant metastases.\n\nStep 3: Determine trial-level eligibility\n- Since the patient meets the inclusion criteria but also meets an exclusion criterion, the trial-level eligibility is 0) Excluded.",
        "label": 1
    },
    "125": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nPatient's age: 45 years\nInclusion criteria: Women aged \u2265 18 years and < 70 years\nThe patient is within the age range, so this criterion is met.\n\nStep 2: Compare the patient's performance status with the inclusion criteria.\nPatient's KPS: Not mentioned in the patient note\nInclusion criteria: Karnofsky performance status (KPS) \u2265 70\nThe patient's performance status is not mentioned in the patient note, so we cannot determine if this criterion is met.\n\nStep 3: Compare the patient's disease stage with the inclusion criteria.\nInclusion criteria: At least one measurable disease according to the RECIST, histologically confirmed invasive breast cancer (excluding inflammatory breast cancer), T2N1 or locally advanced breast cancer (T3-T4N0-3 or T0-4N2-3)\nPatient's disease stage: 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, HER2-positive and ER/PR negative, 5 positive lymph nodes, metastatic lesions\nThe patient has a locally advanced breast cancer, so this criterion is met.\n\nStep 4: Compare the patient's tumor type with the inclusion criteria.\nInclusion criteria: Biopsy specimens are available for ER, PgR and Her2 detection, patients should be with triple negative or Her2 positive breast cancer, Her2 positivity is defined as FISH/CISH Her2 positive or IHC Her2 3+, Triple-negative disease defined as negativity for ER, PgR and Her2\nPatient's tumor type: HER2-positive and ER/PR negative\nThe patient has a Her2 positive breast cancer, so this criterion is met.\n\nStep 5: Compare the patient's bone marrow function with the inclusion criteria.\nInclusion criteria: Adequate bone marrow function: Neutrophil \u2265 1.5*109/L; Hb \u2265 100g/L; PLT \u2265 100*109",
        "label": 2
    },
    "126": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the allowed age range for the trial.\n\nStep 2: Compare the patient's breast cancer type to the inclusion criteria.\nThe patient has HER2-positive breast cancer, which is not allowed in the trial.\n\nStep 3: Compare the patient's disease stage to the inclusion criteria.\nThe patient has metastatic lesions, which is not allowed in the trial.\n\nStep 4: Compare the patient's residual disease status to the inclusion criteria.\nThe patient has residual invasive disease on pathologic review following neoadjuvant chemotherapy, which is allowed in the trial.\n\nStep 5: Compare the patient's hormone receptor status to the inclusion criteria.\nThe patient's breast cancer is ER/PR negative, which is allowed in the trial.\n\nStep 6: Compare the patient's previous treatment history to the inclusion criteria.\nThe patient is using multivitamins and iron supplements but has not received bevacizumab or other inhibitors of angiogenesis, which is allowed in the trial.\n\nStep 7: Compare the patient's eligibility for tumor resection to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which is allowed in the trial.\n\nTrial-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).",
        "label": 0
    },
    "127": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n- The patient has breast cancer.\n- The patient is a candidate for tumor resection.\n- The patient agrees to do so prior to chemotherapy.\n\nStep 2: Compare the patient information with the inclusion criteria of the clinical trial.\n- The clinical trial is for patients with PTBD with at least 14 French in diameter.\n- There is no information in the patient note about the patient having PTBD or the diameter of the drainage.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n- The patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "128": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\n1. Patient's cancer type: The patient note states that the patient has invasive ductal breast carcinoma, which matches the inclusion criteria of histologically confirmed ductal carcinoma in-situ, invasive ductal, medullary, papillary, colloid (mucinous), or tubular histologies.\n2. Lesion size: The patient note states that the lesion size is 3 cm, which matches the inclusion criteria of lesion size \u2264 3 cm.\n3. Type of recurrence: The patient note does not specify if the recurrence is unifocal, so we cannot determine if this criterion is met.\n4. Resection margins: The patient note does not provide information about resection margins, so we cannot determine if this criterion is met.\n5. Hormonal therapy: The patient note states that the patient is using multivitamins and iron supplements, but does not mention hormonal therapy. We cannot determine if this criterion is met.\n6. Chemotherapy: The patient note states that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which matches the inclusion criteria of chemotherapy beginning no earlier than two weeks following completion of radiation.\n7. Informed consent: The patient note does not mention if the patient has signed study-specific informed consent, so we cannot determine if this criterion is met.\n\nStep 2: Determine trial-level eligibility\n\nBased on the information provided in the patient note, we can only determine that the patient meets some of the inclusion criteria. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "129": {
        "output": "GPT4 Correct Assistant: Let's compare the patient note and the inclusion criteria of the clinical trial step by step.\n\n1. Age: The patient is 45 years old, which is at least 18 years old. Included.\n2. Gender: The patient is a woman, which is eligible. Included.\n3. Diagnosis: The patient has invasive ductal breast carcinoma, which is a form of invasive breast cancer. Included.\n4. Stage: The patient has stage IV disease, which is metastatic breast cancer. Included.\n5. HER2 status: The patient's tumor is HER2-positive, which is required. Included.\n6. ER/PR status: The patient's tumor is ER/PR negative, which is not a requirement for the trial. Included.\n7. Prior therapy: The patient has had axillary sampling and a core biopsy, which is a form of prior therapy. Included.\n8. Prior lapatinib use: The patient has not used lapatinib before, which is eligible. Included.\n9. Chemotherapy: The patient has not received chemotherapy for at least 28 days, which is required. Included.\n10. Trastuzumab use: The patient has not received trastuzumab in the last three weeks, which is required. Included.\n11. ER+/PR+ metastatic patients: The patient is not ER+/PR+ with visceral disease, which is not a requirement for the trial. Included.\n12. HER2 overexpression/amplification: The patient's tumor shows overexpression of the HER2 protein, which is required. Included.\n13. Measurable lesion: The patient has at least one measurable lesion, which is required. Included.\n14. ECOG status: The patient has an ECOG status of 0 or 1, which is required. Included.\n15. Bone marrow reserve: The patient has adequate bone marrow reserve, which is required. Included.\n16. Renal function: The patient has adequate renal function, which is required. Included.\n17. Hepatic function: The patient has adequate hepatic function, which is required.",
        "label": 0
    },
    "130": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\n1.1. Disease Characteristics:\n- The patient has histologically proven primary invasive breast cancer, which is suitable for neoadjuvant treatment.\n- The patient's tumor is T2 or greater (\u2265 20 mm by ultrasound) or any T stage with nodal disease \u2265 20 mm diameter on ultrasound assessment.\n- The patient has no evidence of distant metastatic disease as disclosed by bone scan, liver, and chest imaging.\n- The patient has a definite indication for neoadjuvant and adjuvant chemotherapy.\n- The patient's primary tumor is amenable to biopsy.\n- The patient does not have inoperable disease that is judged very unlikely to be rendered operable by neoadjuvant treatment.\n- The patient does not have inflammatory breast cancer.\n- The patient does not have bilateral invasive breast cancer.\n- The patient's tumor is HER-2 positive, but this is not an exclusion criterion in the feasibility (pilot) study.\n- The patient's tumor is ER/PR negative.\n\n1.2. Patient Characteristics:\n- The patient is postmenopausal.\n- The patient meets one of the criteria for postmenopausal status: Over 12 months since last menstrual period, postmenopausal gonadotrophin levels (luteinizing hormone or follicle-stimulating hormone levels above local criteria), or postmenopausal estradiol levels below local criteria.\n- The patient has a WHO performance status of 0 or 1.\n- The patient has WBC \u2265 3.0 \u00d7 10^9/L, ANC \u2265 1.5 \u00d7 10^9/L, Platelets \u2265 100 \u00d7 10^9/L, Hemoglobin > 9 g/dL, AST/ALT \u2264 1.5 times ULN, Serum bilirubin \u2264 1.5 times ULN, Alkaline phosphatase \u2264 1.5 times ULN, Serum creatinine \u2264",
        "label": 1
    },
    "131": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age, gender, and disease type.\n- The patient is a 45-year-old postmenopausal woman with breast cancer.\n\nStep 2: Identify the patient's disease characteristics.\n- The patient has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR was remarkable for metastatic lesions.\n\nStep 3: Compare the patient's disease characteristics to the inclusion criteria.\n- The patient has operable breast cancer with pathologically positive axillary lymph nodes (inclusion criteria).\n\nStep 4: Identify any exclusion criteria.\n- There are no exclusion criteria mentioned in the patient note.\n\nStep 5: Determine the patient's eligibility based on the inclusion and exclusion criteria.\n- The patient meets the inclusion criteria and does not meet any exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "132": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- Invasive ductal breast carcinoma\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions\n\nInclusion Criteria:\n- Histologically or cytologically confirmed invasive breast cancer\n- Complete resection of primary tumor\n- Stage I-III (T1-3, N0-3, M0) disease\n- Enrolled in clinical trial CAN-NCIC-MA27\n- No locally recurrent or metastatic breast cancer\n- Hormone receptor status: Estrogen receptor- or progesterone receptor-positive disease\n- Postmenopausal status\n\nStep 2: Determine the patient's eligibility based on the comparison\n\n- The patient has cytologically confirmed invasive breast cancer, which meets the first inclusion criterion.\n- The patient has Stage III disease, which meets the third inclusion criterion.\n- The patient is enrolled in clinical trial CAN-NCIC-MA27, which meets the fourth inclusion criterion.\n- The patient has metastatic lesions, which excludes her from the second inclusion criterion (no locally recurrent or metastatic breast cancer).\n- The patient is postmenopausal, which meets the fifth inclusion criterion.\n- The patient is HER2-positive and ER/PR negative, which does not meet the sixth inclusion criterion (hormone receptor status: Estrogen receptor- or progesterone receptor-positive disease).\n\nStep 3: Assign the patient's eligibility based on the assessment\n\nSince the patient does not meet the inclusion criteria for hormone receptor status, she is excluded from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "133": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nPatient's age: 45 years\nInclusion criteria: Age between 40 and 75 years\nThe patient's age is within the range of 40 to 75 years, so this criterion is met.\n\nStep 2: Compare the patient's tumor size to the inclusion criteria.\nPatient's tumor size: 3 cm invasive ductal breast carcinoma\nInclusion criteria: Clinical, mammographic or ultrasonographic diagnosis of a unicentric carcinoma with an ultrasonographic diameter of equal or less than 2.0 cm\nThe patient's tumor size is greater than 2.0 cm, so this criterion is not met.\n\nStep 3: Compare the patient's axillary lymph nodes to the inclusion criteria.\nPatient's axillary lymph nodes: 5 positive lymph nodes\nInclusion criteria: Axillary lymph nodes that cannot be palpated or that are not clinically suspicious for metastasis\nThe patient has palpable lymph nodes with metastasis, so this criterion is not met.\n\nStep 4: Check for any exclusion criteria.\nThe patient note does not mention any exclusion criteria that apply to this patient.\n\nStep 5: Determine the trial-level eligibility.\nSince the patient does not meet the inclusion criteria, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "134": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the range for the trial (no specific age range mentioned in the inclusion criteria).\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, which matches the inclusion criteria for the trial.\n\nStep 3: Compare the patient's breast cancer type to the inclusion criteria.\nThe patient has invasive ductal breast carcinoma, which is a type of breast cancer. The inclusion criteria state that the trial is for women with newly diagnosed biopsy-proven breast cancer.\n\nStep 4: Compare the patient's tumor size to the inclusion criteria.\nThe patient's tumor is 3 cm, which is greater than 1 centimeter as required by the inclusion criteria.\n\nStep 5: Compare the patient's menstrual status to the inclusion criteria.\nThe patient is postmenopausal, which matches the inclusion criteria for the trial.\n\nStep 6: Compare the patient's tumor tissue to the inclusion criteria.\nThe patient has sufficient tumor tissue from the diagnostic core biopsy, which meets the inclusion criteria.\n\nStep 7: Compare the patient's prior treatment to the inclusion criteria.\nThe patient has not received any treatment for breast cancer in the affected breast, which meets the inclusion criteria.\n\nStep 8: Compare the patient's performance status to the inclusion criteria.\nThe patient's Karnofsky performance status is greater than 70%, which meets the inclusion criteria.\n\nStep 9: Compare the patient's organ function to the inclusion criteria.\nThe patient has adequate organ function for receiving the study drug within 14 days of the first dose, which meets the inclusion criteria.\n\nStep 10: Compare the patient's contraception status to the inclusion criteria.\nThe patient is a woman of childbearing potential and is using an effective method of contraception, which meets the inclusion criteria.\n\nStep 11: Compare the patient's eligibility to the exclusion criteria.\nThe patient does not have any of the exclusion criteria mentioned in the trial (e.g., pregnant, lactating, positive HIV status, diabetes, gastrointest",
        "label": 2
    },
    "135": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria\nPatient's age: 45 years\nInclusion criteria: Female patients, age \u226665 years\nThe patient is within the age range, so she meets this criterion.\n\nStep 2: Compare patient's gender to the inclusion criteria\nPatient's gender: Female\nInclusion criteria: Female patients\nThe patient is female, so she meets this criterion.\n\nStep 3: Compare patient's cancer type and stage to the inclusion criteria\nPatient's cancer: HER2-positive and ER/PR negative breast cancer\nInclusion criteria: Biopsy proven lymph node positive, estrogen receptor-positive primary breast cancer\nThe patient has breast cancer, but it is HER2-positive and ER/PR negative, which does not match the inclusion criteria. Therefore, the patient is excluded based on this criterion.\n\nStep 4: Compare patient's treatment history to the inclusion criteria\nPatient's treatment history: The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nInclusion criteria: Must have completed a 4-cycle neo-adjuvant chemotherapy with a standard regimen (containing anthracycline or paclitaxel)\nThe patient has not completed the required neo-adjuvant chemotherapy, so she does not meet this criterion.\n\nStep 5: Compare patient's medical conditions and function to the inclusion criteria\nThe patient note does not provide information on the patient's cardiovascular function, hematologic function, hepatic function, renal function, or history of other malignancies. Therefore, we cannot determine if the patient meets or does not meet these criteria.\n\nStep 6: Repeat Trial-level eligibility\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "136": {
        "output": "GPT4 Correct Assistant: Step 1: Compare age\nPatient age: 45 years\nInclusion criteria: Age 18-55\nThe patient is outside the age range for the clinical trial.\n\nStep 2: Compare gender and childbearing potential\nPatient: Postmenopausal woman\nInclusion criteria: Females of childbearing potential (including peri-menopausal women who have had a menstrual period within 1 year)\nThe patient does not meet the gender and childbearing potential criteria.\n\nStep 3: Compare medical condition\nPatient: Breast cancer\nInclusion criteria: Subjects in good health as determined by the Investigator\nThe patient has a medical condition (breast cancer) and does not meet the good health criteria.\n\nStep 4: Compare other factors\nThe patient is not using physical therapy, hard physical work, exercise, or sauna during the study observation period, which is in line with the inclusion criteria. However, the other factors (age, gender, and medical condition) have already determined the patient's ineligibility.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "137": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the age range of 18 years and older.\n\nStep 2: Compare the patient's HIV status and viral load to the inclusion criteria.\nThe patient does not have HIV, hepatitis B, or C co-infection, and does not have a plasma viral load at screening visit below 50 copies per mL for at least 6 months. Therefore, the patient does not meet the inclusion criteria related to HIV and viral load.\n\nStep 3: Compare the patient's liver condition to the inclusion criteria.\nThe patient does not have end stage liver disease, severe liver failure, or a MELD score of 15 or higher. Therefore, the patient does not meet the inclusion criteria related to liver condition.\n\nStep 4: Compare the patient's eligibility for liver transplant to the inclusion criteria.\nThe patient does not have liver transplant waiting list eligibility or immediate post-transplantation eligibility. Therefore, the patient does not meet the inclusion criteria related to liver transplant.\n\nStep 5: Compare the patient's alcohol and drug use to the inclusion criteria.\nThe patient does not meet the criteria for abstinence from alcohol intake for at least 6 months (WHO norm) or withdrawal from intravenous drug use for at least 6 months (methadone substitution is permitted). Therefore, the patient does not meet the inclusion criteria related to alcohol and drug use.\n\nStep 6: Compare the patient's HIV resistance profile and treatment history to the inclusion criteria.\nThe patient does not have a profile of mutations associated with resistance to raltegravir and is sensitive to at least two fully active* agents selected among nucleoside/nucleotide reverse transcriptase analogs NRTI (abacavir, lamivudine, emtricitabine, tenofovir) or enfuvirtide. Therefore, the patient does not meet the inclusion criteria related to HIV resistance profile and treatment history.\n\nStep 7: Compare the patient's pregnancy status to the inclusion criteria.\nThe patient is a postmenopausal woman, which means she is not of child-bearing potential. Therefore, she",
        "label": 0
    },
    "138": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nThe patient is a 45-year-old postmenopausal woman.\n\nStep 2: Identify the patient's medical condition.\nThe patient has cytologically confirmed breast cancer, which is HER2-positive and ER/PR negative.\n\nStep 3: Compare the patient's medical condition to the inclusion criteria of the clinical trial.\nThe clinical trial is focused on assessing vaccine responses to influenza A(H1N1) vaccines in high-risk patients. The patient's medical condition (breast cancer) is not related to influenza A(H1N1).\n\nStep 4: Determine if the patient meets any exclusion criteria.\nThere are no specific exclusion criteria mentioned in the clinical trial summary.\n\nStep 5: Assess the patient's eligibility based on the information provided.\nThe patient does not have sufficient information to qualify for the trial (not relevant).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "139": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age.\nIn the patient note, it is mentioned that the patient is a 45-year-old woman.\n\nStep 2: Check if the patient's age is within the inclusion criteria.\nThe inclusion criteria state that the patient must be aged between 18 and 59 years. The patient's age (45 years) falls within this range.\n\nStep 3: Identify the patient's diagnosis.\nThe patient has cytologically confirmed breast cancer, not a psychotic disorder.\n\nStep 4: Check if the patient's diagnosis matches the inclusion criteria.\nThe inclusion criteria state that the patient must meet DSM-IV diagnostic criteria for first episode of schizophrenia, schizophreniform disorder, schizoaffective disorder, or psychotic disorder NOS. The patient's diagnosis (breast cancer) does not match any of these diagnostic criteria.\n\nStep 5: Determine the patient's eligibility based on the comparison of patient note and inclusion criteria.\nSince the patient's diagnosis does not match the inclusion criteria, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "140": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's disease and its characteristics.\nThe patient has cytologically confirmed breast cancer, which is not the same as metastatic melanoma, the disease being studied in the clinical trial.\n\nStep 2: Compare the patient's disease characteristics to the inclusion criteria.\nSince the patient has breast cancer and not metastatic melanoma, they do not meet the disease characteristics inclusion criteria.\n\nStep 3: Identify any other relevant inclusion criteria.\nThe patient is 45 years old, postmenopausal, and HER2-positive and ER/PR negative, but these characteristics are not mentioned in the inclusion criteria.\n\nStep 4: Compare the patient's other characteristics to the inclusion criteria.\nThe patient's characteristics do not match any of the inclusion criteria mentioned in the clinical trial.\n\nStep 5: Determine the patient's eligibility based on the comparison.\nSince the patient does not meet the disease characteristics inclusion criteria, they are not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "141": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age.\nThe patient is 45 years old.\n\nStep 2: Identify the patient's gender.\nThe patient is a woman.\n\nStep 3: Identify the patient's medical condition.\nThe patient has cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative, and axillary sampling revealed 5 positive lymph nodes.\n\nStep 4: Compare the patient's medical condition to the inclusion criteria.\nInclusion Criteria: Known or suspected malignancy involving the breast as determined by biopsy, physical examination or noninvasive imaging studies including plain films, CT, MR, ultrasound or nuclear medicine imaging.\n\nThe patient's medical condition meets the inclusion criteria.\n\nStep 5: Check if the patient meets any exclusion criteria.\nThere are no exclusion criteria listed in the provided information.\n\nStep 6: Determine the trial-level eligibility based on the comparison of the patient's medical condition and the inclusion/exclusion criteria.\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "142": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Disease: Cytologically confirmed breast cancer\n- Tumor type: 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- Hormone receptor status: HER2-positive and ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- Other medical conditions: None mentioned\n\nStep 2: Compare the patient's characteristics with the inclusion criteria of the clinical trial.\n- Inclusion Criteria: Postmenopausal women with breast cancer eligible for hormonal therapy.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n- The patient is a postmenopausal woman with breast cancer, and she is eligible for hormonal therapy.\n\nStep 4: Assess the patient's eligibility using the three-point scale.\n- Trial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "143": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state that subjects must be female subjects with age \u2265 18 years. The patient meets this criterion.\n\nStep 2: Compare the patient's breast cancer stage to the inclusion criteria.\nThe patient has cytologically confirmed stage II or III breast cancer, which meets the inclusion criteria of histologically confirmed, American Joint Committee on Cancer (AJCC) stage II or III breast cancer.\n\nStep 3: Compare the patient's risk of breast cancer recurrence to the inclusion criteria.\nThe patient has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, which is a T2 tumor (2 cm to 5 cm in diameter). This meets the criterion of tumor size > 5 cm (T3) or locally advanced disease (T4). Additionally, the patient has 5 positive lymph nodes, which meets the criterion of node-positive disease. The patient is HER2-positive and ER/PR negative, but these criteria are not mentioned in the inclusion criteria, so we will not consider them.\n\nStep 4: Compare the patient's treatment history to the inclusion criteria.\nThe patient is scheduled for tumor resection and agrees to do so prior to chemotherapy, which matches the criteria for subjects who have undergone or are scheduled to receive standard of care systemic adjuvant or neoadjuvant chemotherapy and/or endocrine therapy and/or HER-2 targeted therapy.\n\nStep 5: Compare the patient's other characteristics to the inclusion criteria.\nThe patient is not pregnant, has serum calcium or albumin-adjusted serum calcium \u2265 2.0 mmol/L (8.0 mg/dL) and \u2264 2.9 mmol/L (11.5 mg/dL), and has an ECOG performance status of 0 or 1. The patient has not received prior neoadjuvant treatment, and subjects with node positive disease must have undergone treatment of axillary LN with curative intent.\n\nBased on the comparison of the patient's characteristics to the inclusion criteria, the patient meets all the necessary criteria for",
        "label": 2
    },
    "144": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the range specified in the inclusion criteria (age not specified).\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, which matches the inclusion criteria (gender not specified).\n\nStep 3: Compare the patient's cancer type and stage to the inclusion criteria.\nThe patient has invasive ductal breast carcinoma, which is included in the list of eligible cancer types (invasive ductal breast carcinoma, medullary ductal breast carcinoma, tubular ductal breast carcinoma, mucinous ductal breast carcinoma, lobular breast carcinoma, and ductal carcinoma in situ). The tumor size is 3 cm, which is within the specified range (tumor size \u2264 3 cm in greatest dimension on pathologic specimen).\n\nStep 4: Compare the patient's lymph node status to the inclusion criteria.\nThe patient has 5 positive lymph nodes, which is more than the specified maximum of 3 positive lymph nodes (0-3 positive lymph nodes without extracapsular extension).\n\nStep 5: Compare the patient's other medical conditions and treatments to the inclusion criteria.\nThe patient is not pregnant or nursing and has no other invasive malignancies within the past 3 years. She is not taking any contraindicated medications, such as trastuzumab.\n\nTrial-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).",
        "label": 0
    },
    "145": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n- Age: Patient is 45 years old, which is within the range of 18 years or older.\n- Gender: Patient is a woman, which matches the inclusion criteria for both men and women.\n- Cancer type and stage: Patient has HER2-negative metastatic breast cancer, which matches the inclusion criteria of adenocarcinoma of the breast with clinical evidence of metastatic breast cancer.\n- Pre-treatment requirements:\n  - Patient has received 2-3 prior chemotherapy treatment regimens, which matches the inclusion criteria.\n  - Patient has not received (neo)adjuvant chemotherapy, so she has received at least 2 prior chemotherapy regimens in the metastatic setting, which matches the inclusion criteria.\n- Other criteria: Patient has measurable disease, negative pregnancy test, adequate laboratory values, ECOG Performance Status of 0, 1, or 2, life expectancy of more than 3 months, and ability to complete questionnaires.\n\nStep 2: Compare patient note and exclusion criteria\n- Pregnancy and lactation: Patient is not pregnant and not nursing, which matches the exclusion criteria.\n- Other cancers: Patient has no stage III or IV invasive cancer other than breast cancer within 3 years, which matches the exclusion criteria.\n- HER2-positive breast cancer: Patient has HER2-negative breast cancer, which matches the exclusion criteria.\n- Treatment history: Patient has not received lifetime cumulative treatment with doxorubicin equivalent to >400 mg/m2, which matches the exclusion criteria.\n- Major surgery, chemotherapy, or immunologic therapy: Patient has not received major surgery, chemotherapy, or immunologic therapy within 3 weeks prior to registration, which matches the exclusion criteria.\n- Radiotherapy: Patient has not received radiotherapy within 4 weeks prior to registration, which matches the exclusion criteria.\n- Brain metastasis: Patient does not have active brain metastasis or leptomeningeal involvement, which matches the exclusion criteria.\n- Uncontrolled hypertension: Patient does not have uncontrolled hypertension, which matches",
        "label": 0
    },
    "146": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\n1. Patient has multicentric carcinoma: Not mentioned in patient note\n2. Histologically confirmed ductal carcinoma in-situ, invasive ductal, invasive lobular, medullary, papillary, colloid (mucinous), or tubular histologies: Patient has invasive ductal carcinoma\n3. Maximum of two radiographically detected malignant lesions: Patient has one malignant lesion\n4. Clinical Stage I-II breast carcinoma, with lesion size \u2264 5 cm: Patient has Stage II breast carcinoma with a 3 cm lesion\n5. Axillary lymph node evaluation: Patient has 5 positive lymph nodes\n6. Negative resection margins with at least a 2 mm margin from invasive and in-situ cancer: Not mentioned in patient note\n7. Negative posterior margin \u2264 2 mm from DCIS: Not mentioned in patient note\n8. Eligible regardless of estrogen receptor, progesterone receptor, or Her-2/neu amplification: Patient is HER2-positive and ER/PR negative\n9. Hormonal therapy allowed: Patient is using multivitamins and iron supplements\n10. Chemotherapy and radiation therapy timing: Not mentioned in patient note\n11. Informed consent: Not mentioned in patient note\n\nExclusion criteria:\n\n1. Extensive intraductal component by the Harvard definition: Not mentioned in patient note\n2. Palpable or radiographically suspicious contralateral axillary, ipsilateral or contralateral supraclavicular, infraclavicular, or internal mammary lymph nodes: Not mentioned in patient note\n3. Patients receiving neoadjuvant chemotherapy: Not mentioned in patient note\n4. Distant metastatic disease detected by radiographic imaging: Patient has metastatic lesions\n5. Known BRCA 1/BRCA 2 mutations or predicted risk of carrying the mutation: Not mentioned in patient note\n6. Diffuse calcifications throughout the breast: Not mentioned in patient note\n7. Skin involvement or inflammatory breast cancer: Not mentioned",
        "label": 1
    },
    "147": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\n1.1 Patient characteristics:\n- Age: 45 years old\n- Gender: Female\n- Disease: Breast cancer (cytologically confirmed, HER2-positive, ER/PR negative)\n- Metastatic disease: Yes (5 positive lymph nodes, metastatic lesions on CXR)\n- Tumor status: Unresected (patient is a candidate for tumor resection)\n- Hormone receptor status: ER/PR negative (phase II requirement)\n\n1.2 Trial inclusion criteria:\n- Histologically confirmed breast cancer (metastatic)\n- Triple-negative disease (phase II)\n- ER and PR negative (phase II)\n- HER2 negative\n- ECOG performance status 0-2 (phase II)\n- Postmenopausal (defined as \u2265 45 years of age with last menstrual period \u2265 12 months prior and estradiol and follicle-stimulating hormone levels in postmenopausal range)\n- Life expectancy \u2265 12 weeks\n- ANC \u2265 1,500/mm^3\n- Platelet count \u2265 100,000/mm^3\n- Total bilirubin normal\n- ALT and AST \u2264 3 times ULN (\u2264 5 times ULN if due to liver metastasis)\n- Serum creatinine \u2264 1.5 times ULN\n- TSH normal (thyroid hormone supplements allowed for patients with hypothyroidism)\n- Not pregnant or nursing\n- Fertile patients must use effective contraception\n- Willing to return to Mayo Clinic or NCCTG institution (phase II)\n- Willing to provide blood samples for correlative research purposes\n- No uncontrolled or intercurrent illness\n- No known seizure disorder\n- No co-morbid systemic illnesses or other severe concurrent disease\n- No immunocompromised patients, including patients known to be HIV positive\n- No malignancy within the past 5 years except for nonmelanoma skin cancer or carcinoma in situ of the cervix\n- No history of myocardial",
        "label": 2
    },
    "148": {
        "output": "GPT4 Correct Assistant: Let's compare the patient note with the inclusion criteria of the clinical trial step by step:\n\n1. Histologically confirmed breast cancer: The patient note confirms that the patient has breast cancer.\n2. T1c N1-2 or T2 N0-2 disease: The patient note states that the patient has a 3 cm invasive ductal breast carcinoma, which falls under T1c category. There is no information about the N stage.\n3. HER2-positive tumors with 3+ intensity on immunohistochemical staining for HER2 or amplification of the HER2 gene on fluorescence in situ hybridization (FISH): The patient note confirms that the patient's tumor is HER2-positive.\n4. No prior systemic treatment regimens for breast cancer: The patient note states that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n5. Adequate hematologic function: The patient note does not provide information about the patient's ANC, platelet count, or hemoglobin levels.\n6. Serum creatinine concentration < 1.5 times the upper limit of normal (ULN) and/or creatinine clearance >60 ml/min: The patient note does not provide information about the patient's creatinine concentration or creatinine clearance.\n7. Bilirubin level < 1.5 X ULN: The patient note does not provide information about the patient's bilirubin level.\n8. Normal cardiac function with a left ventricular ejection fraction of at least 50% (as assessed by quantitative echocardiogram or MUGA scan): The patient note does not provide information about the patient's cardiac function.\n9. Karnofsky performance status 80%: The patient note does not provide information about the patient's performance status.\n10. Age 18 years: The patient note confirms that the patient is 45 years old.\n11. If the patient is of childbearing potential, she agrees to: comply with effective contraceptive measures, has been using adequate contraception since the last menses, will use adequate contraception during the study,",
        "label": 1
    },
    "149": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 45 years old, and the trial includes patients who are 18 years of age or older. The patient meets this criterion.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nThe patient is a woman, and the trial includes women and men. The patient meets this criterion.\n\nStep 3: Compare the patient's cancer type and stage with the inclusion criteria.\nThe patient has metastatic invasive breast cancer, which matches the trial's inclusion criteria.\n\nStep 4: Compare the patient's HER2 status with the inclusion criteria.\nThe patient's tumor is HER2-positive, which matches the trial's inclusion criteria.\n\nStep 5: Compare the patient's measurable disease with the inclusion criteria.\nThe patient has measurable disease, which matches the trial's inclusion criteria.\n\nStep 6: Compare the patient's prior treatment history with the inclusion criteria.\nThe patient has received at least one prior chemotherapy regimen for metastatic breast cancer, which matches the trial's inclusion criteria.\n\nStep 7: Compare the patient's life expectancy with the inclusion criteria.\nThe patient has a life expectancy of greater than 3 months, which matches the trial's inclusion criteria.\n\nStep 8: Compare the patient's ECOG Performance Status with the inclusion criteria.\nThe patient's ECOG Performance Status is not provided, so we cannot determine if they meet this criterion.\n\nStep 9: Compare the patient's organ and marrow function with the inclusion criteria.\nThe patient's organ and marrow function is not provided, so we cannot determine if they meet this criterion.\n\nStep 10: Compare the patient's contraception agreement with the inclusion criteria.\nThe patient's contraception agreement is not provided, so we cannot determine if they meet this criterion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "150": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR was remarkable for metastatic lesions\n\nStep 2: Compare the patient's information with the inclusion criteria of the clinical trial\n- Inclusion Criteria: Patients with metastatic breast cancer in first line treatment who have completed treatment with Avastin\n\nStep 3: Determine the patient's eligibility based on the comparison\n- The patient has metastatic breast cancer, but there is no information about whether she has completed treatment with Avastin or not.\n\nStep 4: Output the scale for the assessment of eligibility\n- Trial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "151": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's demographic information\n- The patient is a 45-year-old postmenopausal woman.\n- The patient is a Hispanic/Latino woman.\n\nStep 2: Identify the patient's medical condition and history\n- The patient has cytologically confirmed breast cancer.\n- The patient is 18 years old or older.\n\nStep 3: Compare the patient's information with the inclusion and exclusion criteria\n\nInclusion Criteria:\n1. Self-identified as Hispanic/Latino origin (met)\n2. Histologically or cytologically confirmed diagnosis of breast cancer (met)\n3. Age greater than or equal to 18 years (met)\n4. Ability to understand and willingness to sign a written informed consent document (not mentioned)\n5. Willing and able to provide a saliva sample, answer questionnaire data online or complete a paper questionnaire, and request a copy of their pathology report (not mentioned)\n\nExclusion Criteria:\n- Males (not applicable)\n- Subjects under the age of 18 (not applicable)\n\nStep 4: Determine the patient's eligibility\nThe patient meets all the inclusion criteria and none of the exclusion criteria. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "152": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria for eligibility\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions in CXR\n\nInclusion Criteria:\n- Histologically confirmed node positive (1-3 nodes) invasive breast carcinoma\n- Positive estrogen and/or progesterone receptor status, and negative HER-2 status\n- HER-2 test result negativity must be assessed according to ASCO/CAP guidelines\n- Patients with multifocal, multicentric, and synchronous bilateral breast cancers are allowed\n- Patients with at least one, but no more than three known positive lymph nodes (pN1a, pN1b, or pN1c); patients with micrometastases as the only nodal involvement (pN1mi) are not eligible\n- Patients must have undergone axillary staging by sentinel node biopsy or axillary lymph nodes dissection (ALND)\n- Patients with a prior diagnosis of contralateral ductal carcinoma in situ (DCIS) are eligible if they underwent a mastectomy or lumpectomy with whole breast radiation\n- Patients must have had either breast-conserving surgery with planned radiation therapy or total mastectomy (with or without planned postmastectomy radiation)\n- Patients must be females \u2265 18 years of age\n- Patients must have a complete history and physical examination within 28 days prior to registration\n- Patients must have a performance status of 0-2 by Zubrod criteria\n- Patients must be able to receive taxane and/or anthracycline based chemotherapy\n- Patients must not have received an aromatase inhibitor (AI) or a selective estrogen receptor modulator (SERM) such as tamoxifen or raloxifene within 5 years prior to registration\n- No other prior malignancy is allowed except for adequately treated basal cell (or",
        "label": 0
    },
    "153": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is a 45-year-old postmenopausal woman, which is within the acceptable age range for this trial.\n\nStep 2: Compare the patient's breast cancer type with the inclusion criteria.\nThe patient has a HER2-positive and ER/PR-negative invasive ductal breast carcinoma, which matches the tumor type described in the inclusion criteria.\n\nStep 3: Compare the patient's axillary lymph nodes with the inclusion criteria.\nThe patient has 5 positive lymph nodes, which is within the acceptable range of 1 to 3 positive lymph nodes for this trial.\n\nStep 4: Compare the patient's metastatic lesions with the inclusion criteria.\nThe patient has metastatic lesions, which may exclude her from this trial. However, the inclusion criteria do not specifically mention exclusion for metastatic lesions.\n\nStep 5: Compare the patient's use of multivitamins and iron supplements with the inclusion criteria.\nThe patient is taking multivitamins and iron supplements, but there is no mention of this in the inclusion criteria. Therefore, this does not affect her eligibility.\n\nStep 6: Compare the patient's medical history with the inclusion criteria.\nThe patient has no children and is not sexually active, which matches the inclusion criteria. She is also a candidate for tumor resection and agrees to do so prior to chemotherapy, which is within the acceptable treatment plan for this trial.\n\nStep 7: Compare the patient's ability to consent with the inclusion criteria.\nThe patient has signed an Institutional Review Board (IRB)-approved consent form, which is within the acceptable consent requirements for this trial.\n\nStep 8: Compare the patient's performance status with the inclusion criteria.\nThe patient has an ECOG performance status of 0 or 1, which is within the acceptable performance status range for this trial.\n\nStep 9: Compare the patient's tumor samples with the inclusion criteria.\nThe patient's tumor samples have been submitted and are available for review, which is within the acceptable requirements for this trial.\n\nStep 10: Compare the patient'",
        "label": 1
    },
    "154": {
        "output": "GPT4 Correct Assistant: Step 1: Compare age\nPatient age: 45 years\nInclusion criteria: Age \u2265 18\nThe patient meets the age requirement.\n\nStep 2: Compare stage of cancer\nPatient note: Stage IV HER2-positive breast cancer\nInclusion criteria: Stage IV HER2 (+) breast cancer\nThe patient meets the stage requirement.\n\nStep 3: Compare HER2 status\nPatient note: HER2-positive breast cancer\nInclusion criteria: Histologically documented HER2 (+) breast cancer\nThe patient meets the HER2 status requirement.\n\nStep 4: Compare ECOG performance status\nPatient note: Not mentioned\nInclusion criteria: ECOG performance 0 - 1\nThe patient's ECOG performance status is not mentioned, so we cannot determine if they meet this requirement.\n\nStep 5: Compare prior treatment in the metastatic setting\nPatient note: Not mentioned\nInclusion criteria: 0-1 prior treatment in the metastatic setting\nThe patient's prior treatment history in the metastatic setting is not mentioned, so we cannot determine if they meet this requirement.\n\nStep 6: Compare measurable or non-measurable disease\nPatient note: Not mentioned\nInclusion criteria: Measurable or non-measurable disease\nThe patient's disease status is not mentioned, so we cannot determine if they meet this requirement.\n\nStep 7: Compare LVEF\nPatient note: Not mentioned\nInclusion criteria: LVEF \u2265 50%\nThe patient's LVEF is not mentioned, so we cannot determine if they meet this requirement.\n\nStep 8: Compare hematologic parameters\nPatient note: Not mentioned\nInclusion criteria: Hematologic parameters (WBC, ANC, platelets, hemoglobin)\nThe patient's hematologic parameters are not mentioned, so we cannot determine if they meet this requirement.\n\nStep 9: Compare non-hematologic parameters\nPatient note: Not mentioned\nInclusion criteria: Non-hematologic parameters (bilirubin, AST/ALT, alkaline phosphatase, creatinine)\nThe patient's non-hematologic parameters are",
        "label": 2
    },
    "155": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria.\nPatient's age: 45 years\nInclusion criteria: The patient must be greater than or equal to 18 years old\nThe patient meets the age criteria.\n\nStep 2: Compare patient's gender with the inclusion criteria.\nPatient's gender: Female\nInclusion criteria: The patient must be female\nThe patient meets the gender criteria.\n\nStep 3: Compare patient's diagnosis with the inclusion criteria.\nPatient's diagnosis: Invasive ductal breast carcinoma\nInclusion criteria: The diagnosis of invasive carcinoma of the breast must have been made by core needle biopsy\nThe patient meets the diagnosis criteria.\n\nStep 4: Compare patient's tumor size with the inclusion criteria.\nPatient's tumor size: 3 cm\nInclusion criteria: The primary breast tumor must be >= 2 cm by physical exam or imaging\nThe patient meets the tumor size criteria.\n\nStep 5: Compare patient's ECOG performance status with the inclusion criteria.\nPatient's ECOG performance status: Not mentioned in the patient note\nInclusion criteria: The patient must have an Eastern Cooperative Oncology Group Score (ECOG) performance status of 0 or 1\nThe patient's ECOG performance status is not mentioned, so we cannot determine if they meet this criterion.\n\nStep 6: Compare patient's HER2 status with the inclusion criteria.\nPatient's HER2 status: HER2-positive\nInclusion criteria: The tumor must have been determined to be HER2-negative as follows:\nThe patient does not meet the HER2 criteria.\n\nStep 7: Compare patient's ER/PR status with the inclusion criteria.\nPatient's ER/PR status: ER/PR negative\nInclusion criteria: The tumor must have been determined to be ER+ and/or progesterone positive (PgR+) defined as > 10% tumor staining by immunohistochemistry\nThe patient does not meet the ER/PR criteria.\n\nStep 8: Compare patient's lymph node status with the inclusion criteria.\nPatient",
        "label": 0
    },
    "156": {
        "output": "GPT4 Correct Assistant: Let's compare the patient note and the inclusion criteria of the clinical trial step by step.\n\n1. Age: The patient is 45 years old, which meets the requirement of being \u2265 18 years of age.\n2. Gender and Menopausal Status: The patient is a postmenopausal woman, which meets the requirement of being a postmenopausal woman.\n3. Cancer Type and Stage: The patient has cytologically confirmed breast cancer, which is stage IV. This meets the requirement of having histologically or cytologically confirmed invasive breast cancer that is stage IV or metastatic.\n4. Hormone Receptor Status: The patient's tumor is ER/PR negative, but the trial requires the tumor to be positive for estrogen receptor. This exclusion criterion is not met.\n5. Number of Prior Lines of Therapy: The patient has had at least one line of systemic therapy for metastatic disease, which is allowed in the trial.\n6. Performance Status: The patient has an ECOG performance status \u2264 2, which meets the requirement.\n7. Pregnancy Test: The patient is not of childbearing potential, so a negative serum pregnancy test is not required.\n8. Organ Function: The patient's organ function is not mentioned in the note, so we cannot determine if they meet the requirements.\n9. Consent: The patient is willing to sign the consent form, which meets the requirement.\n\nBased on the comparison, the patient does not meet the inclusion criteria due to the tumor being ER/PR negative. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).",
        "label": 0
    },
    "157": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nPatient age: 45 years old\nPatient gender: Female\n\nStep 2: Check if the patient has a primary invasive breast cancer.\nPatient note: \"cytologically confirmed breast cancer\"\n\nStep 3: Check if the patient meets the tumor size criteria.\nPatient note: \"3 cm invasive ductal breast carcinoma\"\nTumor size: 3 cm\n\nStep 4: Check if the patient's tumor is HER2-positive and ER/PR negative.\nPatient note: \"The tumor is HER2-positive and ER/PR negative\"\n\nStep 5: Check if the patient has lymph node involvement.\nPatient note: \"Axillary sampling revealed 5 positive lymph nodes\"\n\nStep 6: Check if the patient is premenopausal.\nPatient note: \"postmenopausal woman\"\n\nStep 7: Check if the patient meets the other inclusion criteria.\n- Informed consent: Not mentioned in the patient note\n- Standard surgery: Not mentioned in the patient note\n- Adjuvant endocrine therapy: Not mentioned in the patient note\n- Date of randomization: Not mentioned in the patient note\n- Neo-chemotherapy: Not mentioned in the patient note\n- Hormone receptor positive: Patient is ER/PR negative\n- ECOG performance status: Not mentioned in the patient note\n- Leucocyte count: Not mentioned in the patient note\n- Platelet count: Not mentioned in the patient note\n- AST/SGOT or ALT/AGPT: Not mentioned in the patient note\n- Serum creatinine: Not mentioned in the patient note\n- Ability to swallow pills: Not mentioned in the patient note\n- Pregnancy test: Not mentioned in the patient note\n\nBased on the information provided in the patient note and the inclusion criteria of the clinical trial, the patient does not meet all the requirements for participation in the trial. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "158": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with inclusion criteria\nThe patient is 45 years old, which is within the range of the inclusion criteria for high-risk urothelial carcinoma.\n\nStep 2: Compare patient's gender with inclusion criteria\nThe patient is a woman, which is consistent with the inclusion criteria for high-risk urothelial carcinoma.\n\nStep 3: Compare patient's disease type with inclusion criteria\nThe patient has breast cancer, not urothelial carcinoma. Therefore, the patient does not meet the inclusion criteria.\n\nStep 4: Compare patient's tumor characteristics with inclusion criteria\nThe patient has a HER2-positive and ER/PR negative tumor, which is not relevant to the inclusion criteria for high-risk urothelial carcinoma.\n\nStep 5: Compare patient's lymph node status with inclusion criteria\nThe patient has 5 positive lymph nodes, which is consistent with the inclusion criteria for high-risk urothelial carcinoma.\n\nStep 6: Compare patient's surgical history with inclusion criteria\nThe patient is a candidate for tumor resection, which is consistent with the inclusion criteria for high-risk urothelial carcinoma.\n\nStep 7: Compare patient's HER2 status with inclusion criteria\nThe patient is HER2-positive, which is consistent with the inclusion criteria for high-risk urothelial carcinoma.\n\nStep 8: Compare patient's neoadjuvant chemotherapy history with inclusion criteria\nThe patient has not received neoadjuvant chemotherapy, which is consistent with the inclusion criteria for high-risk urothelial carcinoma.\n\nStep 9: Compare patient's left ventricular ejection fraction with inclusion criteria\nThere is no information about the patient's left ventricular ejection fraction. Therefore, this criterion is not relevant.\n\nStep 10: Compare patient's pregnancy status and birth control with inclusion criteria\nThe patient is postmenopausal and not sexually active. Therefore, these criteria are not relevant.\n\nStep 11: Compare patient's hematologic, renal,",
        "label": 0
    },
    "159": {
        "output": "GPT4 Correct Assistant: 1. The patient is a 45-year-old postmenopausal woman. The trial includes premenopausal patients only, so this is a potential exclusion criterion.\n2. The patient has cytologically confirmed invasive breast cancer, which meets the inclusion criterion.\n3. The patient's tumor is HER2-positive, but the trial only includes HER2-negative patients, so this is an exclusion criterion.\n4. The patient's tumor is ER/PR negative, which is not specified in the inclusion or exclusion criteria.\n5. The patient has 5 positive lymph nodes, which is not specified in the inclusion or exclusion criteria.\n6. The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which is not specified in the inclusion or exclusion criteria.\n7. The patient is not sexually active and has no children, which is not specified in the inclusion or exclusion criteria.\n\nBased on the information provided, the patient meets some inclusion criteria but also has some characteristics that could be exclusion criteria. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "160": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria require participants to be 21 years of age or older. The patient meets this criterion.\n\nStep 2: Compare the patient's diagnosis to the inclusion criteria.\nThe patient has invasive ductal breast carcinoma, while the inclusion criteria require participants to have ductal carcinoma in situ (DCIS). The patient does not meet this criterion.\n\nStep 3: Compare the patient's performance status to the inclusion criteria.\nThe patient's performance status is not mentioned in the patient note. We cannot determine if the patient meets this criterion.\n\nStep 4: Compare the patient's medical history to the inclusion criteria.\nThe patient has no history of diabetes, and the inclusion criteria require participants to have no history of diabetes. The patient meets this criterion.\n\nStep 5: Compare the patient's accessibility for follow-up to the inclusion criteria.\nThe patient's accessibility for follow-up is not mentioned in the patient note. We cannot determine if the patient meets this criterion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "161": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's diagnosis\nThe patient note states that the patient has cytologically confirmed breast cancer. This meets the first inclusion criteria of having a diagnosis of invasive breast cancer or DCIS.\n\nStep 2: Determine if the patient is appropriate for genetic testing\nThe patient note does not provide information about the patient's family history or ethnicity, which are factors that could make her appropriate for genetic testing. Therefore, we cannot determine if she meets this inclusion criteria.\n\nStep 3: Check the patient's age\nThe patient is 45 years old. This meets the age criteria for non-Ashkenazi Jewish patients (age \u2264 45).\n\nStep 4: Check if the patient has completed definitive surgical treatment\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This means she has not yet completed definitive surgical treatment. This meets the criteria for patients planning mastectomy for treatment or breast conservation for treatment.\n\nStep 5: Determine if the patient meets any exclusion criteria\nThe patient note does not provide information about the patient's alcohol or smoking history, which could be relevant for exclusion criteria. Therefore, we cannot determine if she meets any exclusion criteria.\n\nConclusion:\nBased on the information provided, we can only determine that the patient meets some inclusion criteria (diagnosis of breast cancer, age \u2264 45, and not having completed definitive surgical treatment). We cannot determine if she meets the criteria for appropriateness for genetic testing or if she meets any exclusion criteria. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "162": {
        "output": "GPT4 Correct Assistant: 1) The patient is a 45-year-old postmenopausal woman, which does not conflict with any of the inclusion or exclusion criteria.\n\n2) The patient has cytologically confirmed breast cancer, which is an inclusion criterion.\n\n3) A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, which meets the inclusion criterion of unifocal primary invasive ductal breast carcinoma diagnosed by core needle biopsy.\n\n4) The tumor is HER2-positive and ER/PR negative, which does not conflict with any of the inclusion or exclusion criteria.\n\n5) Axillary sampling revealed 5 positive lymph nodes, which does not conflict with any of the inclusion or exclusion criteria.\n\n6) The patient has metastatic lesions on CXR, which does not conflict with any of the inclusion or exclusion criteria.\n\n7) The patient is using multivitamins and iron supplements, which does not conflict with any of the inclusion or exclusion criteria.\n\n8) The patient does not smoke or consume alcohol, which does not conflict with any of the inclusion or exclusion criteria.\n\n9) The patient is not sexually active and has no children, which does not conflict with any of the inclusion or exclusion criteria.\n\n10) The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which does not conflict with any of the inclusion or exclusion criteria.\n\n11) Neoadjuvant chemotherapy or hormonal therapy for the index tumor is required, and the patient is eligible for this treatment.\n\n12) The patient's residual tumor size is 3 cm, which is greater than the 2.0 cm maximum diameter allowed by the inclusion criteria.\n\n13) The patient's tumor has not been assessed for tumor enhancement on pre-registration MRI and tumor components, which are required for eligibility.\n\n14) The patient's breast size has not been assessed for adequacy for safe cryoablation, which is required for eligibility.\n\n15) The patient has not been assessed for prior in-situ or invasive breast carcinomas, which",
        "label": 2
    },
    "163": {
        "output": "GPT4 Correct Assistant: Step 1: Age\nThe patient is 45 years old, which is within the age range of 18-84 years for the trial.\n\nStep 2: Gender\nThe patient is female, which matches the inclusion criteria.\n\nStep 3: Cancer type and stage\nThe patient has breast cancer, and the biopsy revealed a 3 cm invasive ductal breast carcinoma. The trial includes patients with breast cancer, so this criterion is met.\n\nStep 4: Previous treatment\nThe patient has not received any treatment yet, so she has not met the criteria for previous treatment with a minimum of 4 cycles of neoadjuvant anthracycline and/or taxane containing chemotherapy.\n\nStep 5: Pathologic CR (pCR)\nThe patient has not undergone surgery yet, so she has not achieved or failed to achieve a pathologic complete response (pCR) following neoadjuvant treatment.\n\nStep 6: Performance status\nThe patient's ECOG performance status score is not mentioned in the note.\n\nStep 7: Toxic effects of prior therapy\nThe patient has not received any prior therapy, so this criterion is not applicable.\n\nStep 8: Peripheral neuropathy\nThe patient's peripheral neuropathy status is not mentioned in the note.\n\nStep 9: Left ventricular ejection fraction (LVEF)\nThe patient's LVEF is not mentioned in the note.\n\nStep 10: Hematologic, hepatic, and renal function\nThe patient's hematologic, hepatic, and renal function is not mentioned in the note.\n\nStep 11: Complete staging work-up\nThe patient's staging work-up is not mentioned in the note.\n\nStep 12: Contraceptive measures and pregnancy test\nThe patient's contraceptive measures and pregnancy test results are not mentioned in the note.\n\nStep 13: Willingness and ability to comply with trial and follow-up procedures\nThe patient's willingness and ability to comply with trial and follow-up procedures are not mentioned in the note.\n\nStep 14: Understanding of the investigative nature of the trial",
        "label": 0
    },
    "164": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and menopausal status.\nThe patient is a 45-year-old postmenopausal woman.\n\nStep 2: Identify the type and stage of the patient's cancer.\nThe patient has cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n\nStep 3: Determine the patient's hormone receptor status.\nThe tumor is HER2-positive and ER/PR negative.\n\nStep 4: Check if the patient has a planned lumpectomy or mastectomy before systemic therapy.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nStep 5: Check if the patient can provide informed consent.\nThe patient's note does not mention informed consent, but it is assumed that the patient can provide informed consent as they are participating in the trial.\n\nStep 6: Compare the patient's information with the inclusion criteria.\n1. Postmenopausal women - The patient is postmenopausal.\n2. Diagnosis of early stage, invasive ductal carcinoma (for which a lumpectomy or mastectomy is planned prior to systemic therapy) - The patient has invasive ductal breast carcinoma and is planning for tumor resection before chemotherapy.\n3. Estrogen receptor (ER)/progesterone receptor (PR) positive tumor - The patient's tumor is HER2-positive and ER/PR negative, which is not a match for the inclusion criteria.\n4. Ability to provide informed consent - The patient can provide informed consent.\n\nStep 7: Determine the trial-level eligibility.\nSince the patient's tumor is HER2-positive and ER/PR negative, the patient does not meet the inclusion criteria for this trial. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "165": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state that the patient must be at least 18 years old. The patient meets this criterion.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, and the inclusion criteria do not specify a gender requirement. The patient meets this criterion.\n\nStep 3: Compare the patient's diagnosis to the inclusion criteria.\nThe patient has cytologically confirmed breast cancer, and the inclusion criteria state that the patient must have histologically confirmed HER2-positive invasive carcinoma of the breast. The patient meets this criterion.\n\nStep 4: Compare the patient's HER2 status to the inclusion criteria.\nThe patient's tumor is HER2-positive, and the inclusion criteria state that the patient must have HER2-positive (defined as FISH amplification ratio more than 2.2) invasive carcinoma of the breast. The patient meets this criterion.\n\nStep 5: Compare the patient's metastatic status to the inclusion criteria.\nThe patient has metastatic lesions, and the inclusion criteria state that patients with FDG-PET positive metastatic lesions are eligible. The patient meets this criterion.\n\nStep 6: Compare the patient's performance status to the inclusion criteria.\nThe patient's ECOG performance status is not provided, and the inclusion criteria state that patients with an ECOG performance status of 0 to 1 are eligible. The patient does not have sufficient information to qualify for the trial.\n\nStep 7: Compare the patient's contraception requirement to the inclusion criteria.\nThe patient is postmenopausal and does not have children, and the inclusion criteria state that for women of childbearing potential, a pregnancy test will be done, and an agreement to use a highly-effective non-hormonal form of contraception is required. The patient does not have sufficient information to qualify for the trial.\n\nStep 8: Compare the patient's willingness to participate to the inclusion criteria.\nThe patient's willingness to participate is not provided, and the inclusion criteria state that patients must agree to",
        "label": 0
    },
    "166": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions on CXR\n\nInclusion criteria:\n- Women or men with histologic evidence of invasive breast cancer (ductal, lobular, or mixed disease)\n- Surgical resection including breast conserving surgery or modified radical mastectomy or simple mastectomy, within the last four months\n- Axillary lymph nodes assessed for tumor by sentinel node biopsy, axillary node dissection, or both\n- Axillary lymph node assessment negative for cancer, or positive only for micrometastases (i.e., cancer <2mm by H&E stain)\n- Tumor is estrogen receptor (ER) positive\n- Receiving or to receive adjuvant endocrine therapy (i.e., tamoxifen or aromatase inhibitor)\n- Being considered for adjuvant chemotherapy\n\nStep 2: Assess eligibility based on the comparison\n\n- The patient has histologic evidence of invasive breast cancer, so she meets the first inclusion criterion.\n- The patient had a core biopsy, but it's not clear if it was within the last four months or if it was a surgical resection. This information is not sufficient to determine eligibility.\n- The patient has 5 positive lymph nodes, so she does not meet the axillary lymph node assessment criteria.\n- The patient's tumor is HER2-positive and ER/PR negative, which is not consistent with the requirement that the tumor be ER positive.\n- The patient is not receiving or to receive adjuvant endocrine therapy, so she does not meet this criterion.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, but this does not meet the criteria for being considered for adjuvant chemotherapy.\n\nStep 3: Det",
        "label": 0
    },
    "167": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state \"Age \u226518 years\". The patient meets this criterion.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, and the inclusion criteria do not specify a required gender. The patient meets this criterion.\n\nStep 3: Compare the patient's cancer type to the inclusion criteria.\nThe patient has breast cancer, not colorectal cancer. The patient does not meet this criterion.\n\nStep 4: Compare the patient's cancer stage to the inclusion criteria.\nThe patient has metastatic breast cancer, not metastatic colorectal cancer. The patient does not meet this criterion.\n\nStep 5: Compare the patient's cancer treatment history to the inclusion criteria.\nThe patient has not received chemotherapy for metastatic colorectal cancer, and the patient has not received prior adjuvant chemotherapy for the primary tumor with fluoropyrimidine and oxaliplatin. The patient does not meet this criterion.\n\nStep 6: Compare the patient's measurable disease to the inclusion criteria.\nThe patient has breast cancer, not metastatic colorectal cancer. The patient does not meet this criterion.\n\nStep 7: Compare the patient's life expectancy to the inclusion criteria.\nThe patient has a life expectancy of 3 months or more, as required by the inclusion criteria.\n\nStep 8: Compare the patient's hematologic function to the inclusion criteria.\nThe patient's hematologic function is not mentioned in the patient note, so we cannot determine if the patient meets this criterion.\n\nStep 9: Compare the patient's hepatic transaminases and alkaline phosphatases to the inclusion criteria.\nThe patient's hepatic transaminases and alkaline phosphatases are not mentioned in the patient note, so we cannot determine if the patient meets this criterion.\n\nStep 10: Compare the patient's renal function to the inclusion criteria.\nThe patient's renal function is not mentioned in the patient note,",
        "label": 0
    },
    "168": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria\nThe patient is 45 years old, which is less than 85, so she meets the age inclusion criteria.\n\nStep 2: Compare the patient's surgery to the inclusion criteria\nThe patient is not undergoing elective bilateral staged total knee arthroplasty (BTKA), so she does not meet the surgery inclusion criteria.\n\nStep 3: Compare the patient's American Society of Anesthesiologists physical status to the inclusion criteria\nThe patient's physical status is not mentioned in the note, so we cannot determine if she meets the physical status inclusion criteria.\n\nStep 4: Compare the patient's medical history to the exclusion criteria\nThe patient has breast cancer, which is not mentioned in the exclusion criteria. However, the trial is focused on pain management after knee surgery, and the patient's condition is unrelated to knee surgery, so it is unlikely that she would be eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "169": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nPatient age: 45 years\nInclusion criteria: Age \u2265 18 years\nThe patient meets the age inclusion criteria.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nPatient gender: Female\nInclusion criteria: No specific gender criteria\nThe patient meets the gender inclusion criteria.\n\nStep 3: Compare the patient's cancer type with the inclusion criteria.\nPatient cancer: Breast cancer\nInclusion criteria: Muscle invasive urothelial cancer\nThe patient does not meet the cancer type inclusion criteria.\n\nStep 4: Compare the patient's cancer stage with the inclusion criteria.\nPatient stage: Invasive ductal breast carcinoma, 5 positive lymph nodes, metastatic lesions\nInclusion criteria: pT2-pT3 stage without lymphatic impairment (N0) and without detectable metastases (M0)\nThe patient does not meet the cancer stage inclusion criteria.\n\nStep 5: Compare the patient's previous treatment history with the inclusion criteria.\nPatient history: Multivitamins and iron supplements, tumor resection planned prior to chemotherapy\nInclusion criteria: No radiotherapy or chemotherapy history except for in situ bladder lesions, no carcinological history except for non-melanoma skin tumors, in situ uterine cervix cancer\nThe patient does not meet the previous treatment history inclusion criteria.\n\nStep 6: Compare the patient's medical conditions with the inclusion criteria.\nPatient conditions: HER2-positive and ER/PR negative breast cancer\nInclusion criteria: No specific medical condition criteria\nThe patient meets the medical condition inclusion criteria.\n\nStep 7: Compare the patient's biological criteria with the inclusion criteria.\nPatient biological criteria: Not applicable\nInclusion criteria: Neutrophils \u2265 1500/mm3, Platelets \u2265 100,000/mm3, Hemoglobin \u2265 10 g/dl, Creatinine clearance > 60 ml/min\nThe patient's information is not sufficient to determine eligibility based on biological criteria.",
        "label": 0
    },
    "170": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria\nPatient's age: 45 years old\nInclusion criteria: Age \u2265 18 years\nThe patient meets the age requirement.\n\nStep 2: Compare patient's tumor size with the inclusion criteria\nPatient's tumor size: 3 cm invasive ductal breast carcinoma\nInclusion criteria: Lymphnode negative and a clinical tumor classification of T2 (\u22653.5cm)-T4 or with 1-3 positive lymph nodes and a clinical tumor classification of T2-T4 DCIS or LCIS are allowed in addition to invasive cancer at T2 or T3 level.\nThe patient's tumor size meets the requirement.\n\nStep 3: Compare patient's lymph node status with the inclusion criteria\nPatient's lymph node status: 5 positive lymph nodes\nInclusion criteria: Lymphnode negative and a clinical tumor classification of T2 (\u22653.5cm)-T4 or with 1-3 positive lymph nodes and a clinical tumor classification of T2-T4 DCIS or LCIS are allowed in addition to invasive cancer at T2 or T3 level.\nThe patient does not meet the lymph node requirement.\n\nStep 4: Compare patient's cancer type with the inclusion criteria\nPatient's cancer type: Invasive ductal breast carcinoma (HER2-positive and ER/PR negative)\nInclusion criteria: Women with histologically proven invasive breast cancer and no distant metastases.\nThe patient meets the cancer type requirement.\n\nStep 5: Compare patient's laboratory values with the inclusion criteria\nThe patient's laboratory values are not provided in the patient note.\n\nStep 6: Assess informed consent\nPatient has signed informed consent.\n\nTrial-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).",
        "label": 1
    },
    "171": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. She has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nStep 2: Compare the patient's characteristics to the inclusion criteria of the clinical trial\nInclusion Criteria:\n1. Patients aged over 18 years old with invasive breast cancer with an indication of SN procedure as recommended by Saint-Paul de VENCE in 2005 amended in 2009\n2. T1-2 breast cancer\n3. Patients having social security coverage.\n\nStep 3: Determine the patient's eligibility based on the inclusion criteria\n1. The patient is 45 years old, which meets the age requirement.\n2. The patient has invasive breast cancer with 5 positive lymph nodes, which meets the breast cancer requirement.\n3. The patient is not specified as having T1-2 breast cancer, but her tumor is 3 cm in size, which is within the T1-2 range.\n4. The patient is not specified as having social security coverage, but this is not an exclusion criterion.\n\nStep 4: Assess the patient's eligibility using the three-point scale\nThe patient meets the inclusion criteria and does not meet any exclusion criteria. Therefore, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "172": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old. The inclusion criteria state that the patient must be between 18 and 80 years old. The patient is within the age range.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman. The inclusion criteria do not specify a gender requirement.\n\nStep 3: Compare the patient's disease type to the inclusion criteria.\nThe patient has breast cancer. The inclusion criteria state that the patient must have histologically proven breast cancer, regardless of histological type or molecular subtype. The patient meets this criterion.\n\nStep 4: Compare the patient's disease stage to the inclusion criteria.\nThe patient has localized breast cancer with axillary lymph node involvement. The inclusion criteria state that the patient must have localized breast cancer with or without axillary or subclavicular lymph node involvement. The patient meets this criterion.\n\nStep 5: Compare the patient's metastatic status to the inclusion criteria.\nThe patient has metastatic lesions. The inclusion criteria state that the patient must have no bone or visceral metastasis on further evaluation. The patient does not meet this criterion.\n\nStep 6: Compare the patient's treatment history to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The inclusion criteria state that the patient must be treated with neoadjuvant chemotherapy. The patient meets this criterion.\n\nStep 7: Compare the patient's ability to receive adjuvant therapy to the inclusion criteria.\nThe patient is amenable to receiving adjuvant therapy. The inclusion criteria state that the patient must be amenable to receiving adjuvant therapy. The patient meets this criterion.\n\nStep 8: Compare the patient's planned surgery to the inclusion criteria.\nThe patient plans to have breast surgery after neoadjuvant chemotherapy. The inclusion criteria state that the patient must have breast surgery planned after neoadjuvant chemotherapy. The patient meets this criterion.\n\nStep 9: Compare the patient's legal capacity and ability to attend medical follow-up to the exclusion criteria.\nThe patient",
        "label": 1
    },
    "173": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and menopausal status\nThe patient is a 45-year-old postmenopausal woman. The trial includes postmenopausal women, so this criterion is met.\n\nStep 2: Identify the patient's breast cancer status\nThe patient has cytologically confirmed breast cancer with a 3 cm invasive ductal carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. The trial includes patients with HER2- and HR+ locally advanced or metastatic breast cancer. Since the patient's tumor is HER2-positive and ER/PR negative, this criterion is met.\n\nStep 3: Determine if the patient has progressed on or after endocrine treatment\nThe patient's note does not provide information about her previous treatment history, specifically whether she has progressed on or after endocrine treatment. Therefore, we cannot determine if this criterion is met.\n\nStep 4: Determine if the patient has measureable disease as per RECIST\nThe patient's note does not provide information about the measurability of her disease as per RECIST. Therefore, we cannot determine if this criterion is met.\n\nStep 5: Determine the patient's ECOG performance status\nThe patient's note does not provide information about her ECOG performance status. Therefore, we cannot determine if this criterion is met.\n\nConclusion:\nSince we cannot determine if the patient has progressed on or after endocrine treatment, has measureable disease as per RECIST, or has an ECOG performance status of 0, 1, or 2, we cannot definitively determine her eligibility for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "174": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age to inclusion criteria\nThe patient is 45 years old, which is within the age range of 18 years and above, as specified in the inclusion criteria.\n\nStep 2: Compare patient gender to inclusion criteria\nThe patient is a female, which is included in the inclusion criteria that accept both male and female patients.\n\nStep 3: Compare patient breast cancer stage to inclusion criteria\nThe patient has stage IV breast cancer, which meets the criteria for inclusion as it is one of the stages (I-IV) specified in the inclusion criteria.\n\nStep 4: Compare patient treatment history to inclusion criteria\nThe patient has not received any prior therapy (other than surgery) for her current disease, which meets the criteria specified in the inclusion criteria.\n\nStep 5: Compare patient informed consent to inclusion criteria\nThe patient has given written informed consent, which meets the criteria specified in the inclusion criteria.\n\nAll inclusion criteria are met, and no exclusion criteria are mentioned in the given information. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "175": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age to inclusion criteria\nThe patient is 45 years old, which meets the age requirement of \u2265 40 years per NCCN recommendations for breast conservation.\n\nStep 2: Compare patient life expectancy to inclusion criteria\nThe patient's life expectancy is not mentioned, but given her diagnosis, it is assumed to be at least 5 years.\n\nStep 3: Compare patient gender to inclusion criteria\nThe patient is female, which meets the inclusion criteria of being female.\n\nStep 4: Compare patient foci of breast cancer to inclusion criteria\nThe patient has two foci of breast cancer: a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant and HER2-positive and ER/PR negative status. This meets the criteria of having at least one focus of invasive breast carcinoma with another focus of either invasive breast carcinoma or ductal carcinoma in situ (DCIS).\n\nStep 5: Compare number of quadrants with biopsy-proven breast cancer to inclusion criteria\nThe patient has no more than 2 quadrants with biopsy-proven breast cancer, which meets the inclusion criteria.\n\nStep 6: Compare patient eligibility for study after surgery and prior to radiation therapy to inclusion criteria\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which meets the inclusion criteria for registration after surgery and prior to radiation therapy.\n\nStep 7: Compare patient mammogram imaging to inclusion criteria\nThe patient's mammogram imaging is not mentioned, but it is not a requirement for eligibility.\n\nStep 8: Compare patient staging of cancer to inclusion criteria\nThe patient's staging of cancer is not mentioned, but it is assumed to be cN0 or cN1 disease, which meets the inclusion criteria.\n\nStep 9: Compare patient ECOG performance status to inclusion criteria\nThe patient's ECOG performance status is not mentioned, but it is assumed to be 0, 1, or 2, which meets the inclusion criteria.\n\nStep 10: Compare patient ability to complete questionnaires and provide informed consent to inclusion criteria\nThe patient's ability to complete questionnaires and provide informed consent is not mentioned,",
        "label": 0
    },
    "176": {
        "output": "GPT4 Correct Assistant: Step 1: Patient's age\nThe patient is 45 years old, which falls within the age range of 18-75 years specified in the inclusion criteria.\n\nStep 2: Gender\nThe patient is a female, which matches the inclusion criteria.\n\nStep 3: Pathologically confirmed diagnosis of primary invasive operable breast cancer, stage IIa-IIIc\nThe patient has stage II breast cancer, which is within the specified stage range of IIa-IIIc.\n\nStep 4: Triple negative phenotype\nThe patient's tumor is HER2-positive and ER/PR negative, which is considered a triple negative phenotype.\n\nStep 5: Adequate performance status\nThe patient's ECOG performance status is not mentioned in the patient note.\n\nStep 6: Adequate renal and liver function and bone marrow reserve\nThe patient's renal, liver function, and bone marrow reserve are not mentioned in the patient note.\n\nStep 7: Informed consent\nThe patient's informed consent is not mentioned in the patient note.\n\nSince the patient's ECOG performance status, renal and liver function, bone marrow reserve, and informed consent are not mentioned, we cannot definitively determine if the patient meets all the inclusion criteria. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "177": {
        "output": "GPT4 Correct Assistant: Step 1: Check the patient's age.\nPatient's age: 45 years old\nInclusion criteria: Age \u2265 18 years\nThe patient meets the age requirement.\n\nStep 2: Check the patient's gender.\nPatient's gender: Female\nInclusion criteria: No specific gender requirement\nThe patient meets the gender requirement.\n\nStep 3: Check the patient's cancer type and stage.\nPatient's cancer: Invasive ductal breast carcinoma, HER2-positive, ER/PR negative\nInclusion criteria: Histologically confirmed HER2 positive invasive carcinoma of the breast\nThe patient meets the cancer type and stage requirement.\n\nStep 4: Check the patient's metastatic lesions.\nPatient's metastatic lesions: CXR was remarkable for metastatic lesions, 5 positive lymph nodes\nInclusion criteria: Documented progressive disease and present with at least 2 non-bone target metastatic lesions, unequivocally of neoplastic origin\nThe patient meets the metastatic lesions requirement.\n\nStep 5: Check the patient's performance status.\nPatient's ECOG performance status: Not mentioned\nInclusion criteria: ECOG performance status (PS) 0 to 1\nThe patient does not have sufficient information to qualify for the trial based on performance status.\n\nStep 6: Check the patient's cardiac history and LVEF.\nPatient's cardiac history: No significant cardiac history, current LVEF \u2265 50%\nInclusion criteria: No significant cardiac history and current LVEF \u2265 50%\nThe patient meets the cardiac history requirement.\n\nStep 7: Check the patient's organ function.\nPatient's organ function: Not mentioned\nInclusion criteria: Adequate organ function, evidenced by the following laboratory results\nThe patient does not have sufficient information to qualify for the trial based on organ function.\n\nStep 8: Check the patient's contraception and pregnancy status.\nPatient's contraception and pregnancy status: Not mentioned\nInclusion criteria: For women of childbearing potential, a serum pregnancy test will be done (and it must be negative) and",
        "label": 2
    },
    "178": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with inclusion criteria\nThe patient is 45 years old, which falls within the age range of 18 to 70 years old for the trial.\n\nStep 2: Compare patient's cancer type and stage with inclusion criteria\nThe patient has invasive ductal breast carcinoma, which is an invasive breast cancer confirmed by core biopsy. The tumor is 3 cm and has 5 positive lymph nodes, which meets the criteria of tumor \u22652 cm and/or lymph node positive.\n\nStep 3: Compare patient's hormone receptor status with inclusion criteria\nThe patient's tumor is HER2-positive and ER/PR negative, which does not match the inclusion criteria of ER/PR positive and HER2 negative.\n\nStep 4: Compare other patient characteristics with inclusion criteria\nThe patient has no previous treatment for breast cancer, has normal liver, kidney, and blood tests, and has a performance status of ECOG 0-2.\n\nStep 5: Determine trial-level eligibility\nThe patient does not meet the inclusion criteria for hormone receptor status, so the trial-level eligibility is 0) Excluded.",
        "label": 0
    },
    "179": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria require participants to be at least 18 years old. The patient meets this criterion.\n\nStep 2: Compare the patient's cancer type with the inclusion criteria.\nThe patient has breast cancer, not bladder cancer. The inclusion criteria require participants to have primary transitional cell carcinoma of the bladder. The patient does not meet this criterion.\n\nStep 3: Compare the patient's disease stage with the inclusion criteria.\nThe patient's cancer is stage T2 to T4, but the inclusion criteria require T2 to T4 disease, N0 M0. The patient does not meet this criterion.\n\nStep 4: Compare the patient's ECOG Performance status with the inclusion and exclusion criteria.\nThe patient's ECOG Performance status is not provided. We cannot determine if the patient meets or does not meet this criterion.\n\nStep 5: Compare the patient's GFR with the inclusion criteria.\nThe patient's GFR is not provided. We cannot determine if the patient meets this criterion.\n\nStep 6: Compare the patient's medical history with the exclusion criteria.\nThe patient has metastatic lesions, which are a form of metastatic disease. This matches the exclusion criterion of lymph node involvement or metastatic disease. The patient meets this criterion.\n\nStep 7: Compare the patient's prior treatment history with the exclusion criteria.\nThe patient's prior treatment history is not provided. We cannot determine if the patient meets or does not meet this criterion.\n\nStep 8: Compare the patient's other medical conditions with the exclusion criteria.\nThe patient's other medical conditions are not provided. We cannot determine if the patient meets or does not meet this criterion.\n\nStep 9: Compare the patient's organ function with the exclusion criteria.\nThe patient's organ function is not provided. We cannot determine if the patient meets or does not meet this criterion.\n\nStep 10: Compare the patient's infection status with the exclusion criteria.\nThe patient's infection status is not",
        "label": 0
    },
    "180": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions on CXR\n\nInclusion criteria:\n- Women or men > age 18\n- Ability to give informed consent\n- Archived tumor tissue must be available for genetic analysis\n- Patients with early-stage breast cancer\n- Histologic documentation of invasive breast cancer by core needle or incisional biopsy\n- Invasive cancer must be either:\n  - Triple-negative with both estrogen and progesterone receptor staining present in fewer than 10% of invasive cancer cells by IHC, and HER2-negative defined as IHC 0-1+, or with a FISH ratio of <1.8 if IHC is 2+ or if IHC has not been done.\n  - HER2-positive with IHC 3+ or a FISH ratio of >2.2.\n- Clinical Stage II-III invasive breast cancer with the intent to treat with:\n  - Pretreatment mammography, ultrasound, and breast MRI for staging\n  - Pretreatment axillary staging\n  - Neoadjuvant treatment with DNA-damaging chemotherapy (with or without HER2- directed therapy)\n  - Post-chemotherapy breast MRI\n  - Surgical resection of the primary tumor with an axillary dissection for one or more positive nodes after neoadjuvant chemotherapy\n- Patients with multicentric or bilateral disease are eligible if the target lesion(s) meet the other eligibility criteria.\n- No prior chemotherapy, endocrine therapy, or radiotherapy with therapeutic intent for treatment of a prior malignancy is allowed.\n- Patients with locally advanced or metastatic breast cancer\n- ER/PR/HER2 status may be determined using any breast tumor specimen acquired at any point during a given patient's disease history (i.e., archived tumor). The invasive",
        "label": 2
    },
    "181": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n\n- Age: 45 years old\n- Gender: Female\n- Condition: Postmenopausal woman with cytologically confirmed breast cancer\n- Tumor type: Invasive ductal breast carcinoma, HER2-positive, ER/PR negative\n- Stage: Not specified\n- Treatment history: Candidate for tumor resection before chemotherapy\n- Other medical conditions: Metastatic lesions\n- Medications: Multivitamins and iron supplements\n\nStep 2: Compare the patient's characteristics to the inclusion criteria of the clinical trial.\n\nInclusion Criteria: Patients with breast cancer\n\nThe patient has breast cancer, so she meets the inclusion criteria.\n\nStep 3: Determine if the patient meets any exclusion criteria (if applicable).\n\nExclusion Criteria: Not specified\n\nSince there are no exclusion criteria specified in the clinical trial description, the patient does not meet any exclusion criteria.\n\nStep 4: Assess the patient's eligibility based on the inclusion and exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "182": {
        "output": "GPT4 Correct Assistant: Step 1: Check the patient's age.\nThe patient is 45 years old, which is greater than or equal to 18 years.\n\nStep 2: Check the patient's condition.\nThe patient is in good condition (WHO lower 2).\n\nStep 3: Check the type of cancer.\nThe patient has invasive ductal breast cancer, which is a type of invasive non-lobular breast cancer.\n\nStep 4: Check the tumor stage.\nThe tumor is T2-T3, regardless of nodal status.\n\nStep 5: Check if the patient is receiving effective contraception.\nThe patient is not sexually active and has no children, so she is not receiving effective contraception.\n\nStep 6: Check if the patient has signed informed consent.\nThe patient has agreed to tumor resection before chemotherapy, which implies she has signed informed consent.\n\nBased on the comparison of the patient note and the inclusion criteria, the patient meets all the inclusion criteria for the clinical trial. The patient does not meet any exclusion criteria, as there are no exclusion criteria mentioned in the provided information. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "183": {
        "output": "GPT4 Correct Assistant: Step 1: Check if the patient has histological confirmation of primary breast cancer, stage II or III.\nThe patient note states that she has cytologically confirmed breast cancer, which is not the same as histological confirmation. Therefore, the patient does not meet this inclusion criterion.\n\nStep 2: Check if the patient has a prior diagnosis of HER-2 positive primary breast cancer.\nThe patient note states that the tumor is HER2-positive, so the patient meets this inclusion criterion.\n\nStep 3: Check if the patient has completed surgery +/- radiation at least 30 days prior to registration.\nThe patient note states that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which implies that she has completed surgery. Therefore, the patient meets this inclusion criterion.\n\nStep 4: Check if the patient has received either neoadjuvant and/or adjuvant chemotherapy for treatment of breast cancer.\nThe patient note does not provide information about the patient's chemotherapy history. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nStep 5: Check if the patient has received either neoadjuvant and/or adjuvant trastuzumab for treatment of breast cancer.\nThe patient note does not provide information about the patient's trastuzumab history. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nStep 6: Check if all chemotherapy, trastuzumab, and/or corticosteroids must be completed at least 90 days prior to registration.\nThe patient note does not provide information about the patient's chemotherapy, trastuzumab, and/or corticosteroids history. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nStep 7: Check if the patient is clinically without any evidence of disease recurrence/progression.\nThe patient note states that the patient has metastatic lesions, which indicates evidence of disease recurrence/progression. Therefore, the patient does not meet this inclusion criterion.\n\nStep 8: Check if the patient meets the other inclusion criteria.\nThe patient note does not provide information about the patient's absolute neutrophil count, platelet count, hemoglobin, creatin",
        "label": 0
    },
    "184": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nPatient's age: 45 years\nInclusion criteria: Age \u2265 18 years\nThe patient meets the age requirement.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nPatient's gender: Female\nInclusion criteria: Only female patients are eligible\nThe patient meets the gender requirement.\n\nStep 3: Compare the patient's cancer type with the inclusion criteria.\nPatient's cancer: Invasive ductal breast carcinoma\nInclusion criteria: Diagnosis of invasive ductal or lobular breast cancer plus or minus DCIS. Inflammatory carcinoma will also be eligible.\nThe patient meets the cancer type requirement.\n\nStep 4: Compare the patient's tumor size with the inclusion criteria.\nPatient's tumor size: 3 cm\nInclusion criteria: Tumor \u2265 1.0 cm by MRI and/or sonographic or clinical exam measurements. If the tumor is <1.0 but the patient has biopsy proven lymph node metastasis, she will also be considered eligible.\nThe patient meets the tumor size requirement.\n\nStep 5: Compare the patient's performance status with the inclusion criteria.\nPatient's performance status: Not mentioned\nInclusion criteria: Performance status ECOG \u2264 2 or Karnofsky \u2265 50%\nThe patient's performance status is not mentioned, so this criterion is not relevant.\n\nStep 6: Compare the patient's peripheral neuropathy with the inclusion criteria.\nPatient's peripheral neuropathy: Not mentioned\nInclusion criteria: Peripheral neuropathy \u2264 grade 1\nThe patient's peripheral neuropathy is not mentioned, so this criterion is not relevant.\n\nStep 7: Compare the patient's hematologic values with the inclusion criteria.\nPatient's hematologic values: Not mentioned\nInclusion criteria: Hematologic (minimal values): Absolute Neutrophil count \u2265 1,500/mm\u00b3; Hemoglobin \u2265 8.0 g/",
        "label": 0
    },
    "185": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria\nPatient's age: 45 years old\nInclusion criteria: Patients who are 65 years old and blew\n\nThe patient is younger than the specified age range, so she does not meet the age inclusion criteria.\n\nStep 2: Compare patient's gender to the inclusion criteria\nPatient's gender: Female\nInclusion criteria: No specific gender requirement\n\nThe patient meets the gender inclusion criteria.\n\nStep 3: Compare patient's diagnosis to the inclusion criteria\nPatient's diagnosis: Breast cancer, not gastric adenocarcinoma\nInclusion criteria: Diagnosed with gastric adenocarcinoma\n\nThe patient does not have gastric adenocarcinoma, so she does not meet the diagnosis inclusion criteria.\n\nStep 4: Compare patient's medical history to the inclusion criteria\nPatient's medical history: Breast cancer, no complication by gastric cancer, no synchronous metastatic lesions\nInclusion criteria: No complication by gastric cancer, no synchronous metastatic lesions\n\nThe patient does not have a complication by gastric cancer or synchronous metastatic lesions, so she meets these inclusion criteria.\n\nStep 5: Compare patient's treatment to the inclusion criteria\nPatient's treatment: Candidate for tumor resection prior to chemotherapy\nInclusion criteria: Expected to undergo distal subtotal gastrectomy\n\nThe patient is expected to undergo a different surgery (tumor resection) rather than distal subtotal gastrectomy, so she does not meet this inclusion criteria.\n\nStep 6: Compare patient's other factors to the inclusion criteria\nPatient's other factors: Laparoscopic or robotic surgery is not mentioned, informed consent is not mentioned\nInclusion criteria: Laparoscopic or robotic surgery, informed consent\n\nThe patient's note does not provide information about the type of surgery or whether informed consent has been given, so we cannot determine if she meets these criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "186": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nPatient age: 45 years old\nInclusion criteria: Patient must be > 50 years old\n\nStep 2: Compare the patient's life expectancy and Karnofsky performance status to the inclusion criteria.\nPatient life expectancy and Karnofsky performance status information is not provided in the patient note.\n\nStep 3: Compare the patient's breast cancer stage and type to the inclusion criteria.\nPatient has stage I breast cancer (T1cN1M0)\nInclusion criteria: Patient must have stage 0 or I breast cancer\n\nStep 4: Compare the patient's tumor characteristics to the inclusion criteria.\nPatient has a 3 cm invasive ductal breast carcinoma that is HER2-positive and ER/PR negative.\nInclusion criteria: On histological examination, the tumor must be DCIS or invasive adenocarcinoma of the breast.\n\nStep 5: Compare the patient's surgical treatment to the inclusion criteria.\nPatient has undergone a core biopsy and is a candidate for tumor resection.\nInclusion criteria: Surgical treatment of the breast must have been lumpectomy.\n\nStep 6: Compare the patient's axillary staging to the inclusion criteria.\nPatient has 5 positive lymph nodes.\nInclusion criteria: Patients with invasive breast cancer are required to have axillary staging which can include sentinel node biopsy alone (if negative), sentinel node biopsy followed by axillary dissection or sampling with a minimum total of 6 axillary nodes or axillary dissection alone (with a minimum of 6 axillary nodes). Axillary staging is NOT required for patients with DCIS.\n\nStep 7: Compare the patient's simulation timeline to the inclusion criteria.\nPatient's simulation timeline information is not provided in the patient note.\n\nStep 8: Compare the patient's history of non-ipsilateral breast malignancies to the inclusion criteria.\nPatient's history of non-ipsilateral breast malignancies information is not provided in the patient note.\n\nStep 9",
        "label": 0
    },
    "187": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender\nPatient age: 45 years old\nPatient gender: Female\nTrial gender requirement: Premenopausal woman\n\nStep 2: Check if the patient has breast cancer and if it's invasive ductal carcinoma\nPatient has invasive ductal breast carcinoma\nTrial requirement: Pathological confirmation of invasive ductal carcinoma\n\nStep 3: Check if the patient is at the clinical stage T2-4N0-2M0\nTumor stage: T2-4N0-2M0\nTrial requirement: Tumor stage(TNM): T2-4bN0-3M0\n\nStep 4: Check if the patient is estrogen receptor positive\nPatient's cancer is ER/PR negative\nTrial requirement: Estrogen receptor is positive\n\nStep 5: Check if the patient has not received previous treatment with bisphosphonate\nPatient has not received bisphosphonate treatment\nTrial requirement: Not previously received treatment with bisphosphonate\n\nStep 6: Check if the patient meets the laboratory criteria\nPLT \u2265 100*109/L: Not mentioned\nWBC \u2265 4000/mm3: Not mentioned\nHGB \u2265 10g/dl: Not mentioned\nGOT, GPT, ALP \u2264 2*ULN: Not mentioned\nTBIL, DBIL, CCr \u2264 1.5*ULN: Not mentioned\n\nStep 7: Determine the trial-level eligibility\nSince the patient does not meet all the inclusion criteria, the trial-level eligibility is 0) Excluded.",
        "label": 0
    },
    "188": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n\n- Age: 45 years old\n- Gender: Female\n- Disease: Breast cancer (invasive ductal carcinoma)\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions on CXR\n\nStep 2: Compare the patient's characteristics with the inclusion and exclusion criteria of the clinical trial.\n\nInclusion Criteria:\n\n1. Patient has signed and received a copy of the Informed Consent Form\n2. Patient may have up to 3 target supratentorial metastatic lesions previously treated with stereotactic radiosurgery, with radiological evidence of progression, pseudoprogression or radionecrosis.\n3. Subject may have additional non-target lesions present as long as they are not expected (in Investigator's judgment) to contribute to symptomatology during the course of the study or confound interpretation of radiological and clinical measures.\n4. Karnofsky Performance Status (KPS) \u2265 60.\n\nExclusion Criteria:\n\n1. Females who are pregnant, breast feeding, or plan to become pregnant in the 6 months following index procedure.\n2. Leptomeningeal metastases.\n3. Uncontrolled infectious process.\n4. Uncontrolled hypertension (systolic >180 mm Hg), angina pectoris, or cardiac dysrhythmia, or recent (within 6 weeks) history of intracranial hemorrhage.\n5. Serious infection, immunosuppression or concurrent medical condition (chronic or acute in nature) that may prevent safe participation or ability to meet follow-up requirements.\n6. Abnormal absolute neutrophil count (ANC<1000/mm), platelets (<100,000/mm) or the administration of antiplatelet agents (aspirin, plavix etc) or anticoagulation within 7 days prior to treatment.\n7. Inadequate bone marrow, liver and renal function (e.g., total bilirubin > 1.5",
        "label": 0
    },
    "189": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's cancer type to the inclusion criteria.\nThe patient has breast cancer, not melanoma or Merkel cell carcinoma. Therefore, the patient does not meet the inclusion criteria for this trial.\n\nStep 2: Compare the patient's disease stage to the inclusion criteria.\nThe patient has stage IV breast cancer, which is similar to the stage III/IV requirement for the trial. However, the trial is specifically for melanoma or Merkel cell carcinoma, so the patient does not meet the inclusion criteria.\n\nStep 3: Compare the patient's previous treatment history to the exclusion criteria.\nThe patient has not been previously treated with somatostatin analogs or radiolabeled somatostatin analogs, so they do not meet the exclusion criteria related to previous treatment.\n\nStep 4: Compare the patient's other medical conditions to the exclusion criteria.\nThe patient does not have any of the medical conditions listed in the exclusion criteria, such as primary uveal melanoma, symptomatic CNS metastases, or a history of immunodeficiency.\n\nStep 5: Determine the patient's eligibility based on the comparison.\nSince the patient does not meet the inclusion criteria for the trial (due to having breast cancer instead of melanoma or Merkel cell carcinoma), they are not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "190": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's diagnosis from the patient note.\nThe patient has cytologically confirmed breast cancer.\n\nStep 2: Compare the patient's diagnosis with the inclusion criteria of the clinical trial.\nThe clinical trial includes patients with histological confirmation of malignancy, including breast cancer.\n\nStep 3: Check if the patient meets other inclusion criteria.\n- The patient has radiological documentation of metastatic disease to the thoracic or lumbar spine.\n- The patient has one to three spinal metastases to the thoracic or lumbar spine.\n- The spinal metastatic lesions are limited to one vertebral body level or \u2264 6cm in greatest dimension.\n- The tumors do not directly abut the spinal cord, and have at least 5mm separation from the spinal cord.\n- The patient is \u2265 18 years of age.\n- The patient is ECOG status 0-2.\n\nStep 4: Determine if the patient meets any exclusion criteria.\nThere are no specific exclusion criteria mentioned in the patient note that would disqualify the patient from participating in the clinical trial.\n\nStep 5: Assess the patient's eligibility for the clinical trial.\nThe patient meets the inclusion criteria and does not meet any exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "191": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age with inclusion criteria\nThe patient is 45 years old, which falls within the age range of 20 to 70 years specified in the inclusion criteria.\n\nStep 2: Compare patient gender with inclusion criteria\nThe patient is a woman, which is not specified in the inclusion criteria, but since the trial is open-label and not limited to a specific gender, this is not an exclusion criterion.\n\nStep 3: Compare patient cancer type with inclusion criteria\nThe patient has cytologically confirmed breast cancer, which matches the inclusion criteria.\n\nStep 4: Compare tumor size with inclusion criteria\nThe patient has a 3 cm invasive ductal breast carcinoma, which is smaller than the 5 cm size specified in the inclusion criteria. However, the patient also has cytologically proven axillary node metastasis, which meets another inclusion criterion.\n\nStep 5: Compare patient's metastatic status with inclusion criteria\nThe patient has metastatic lesions as seen on CXR, which is not specified in the inclusion criteria. However, this is not an exclusion criterion since the trial is for patients with breast cancer of at least 5 cm in size or cytologically proven axillary node metastasis.\n\nStep 6: Compare patient's previous treatment history with inclusion criteria\nThe patient has not received any previous treatment, which matches the inclusion criteria.\n\nStep 7: Compare patient's performance status with inclusion criteria\nThe patient has a general performance status with ECOG 0-2, which matches the inclusion criteria.\n\nStep 8: Compare patient's hematopoietic function with inclusion criteria\nThe patient has sufficient hematopoietic function, as the absolute neutrophil count, platelet count, and hemoglobin levels are within the specified ranges in the inclusion criteria.\n\nStep 9: Compare patient's renal function with inclusion criteria\nThe patient has sufficient renal function, as the serum creatinine level is within the specified range in the inclusion criteria.\n\nStep 10: Compare patient's liver function with inclusion criteria\nThe patient has sufficient liver function, as the total serum bilirubin, serum AST, ALT, and serum alkal",
        "label": 1
    },
    "192": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note with inclusion criteria\n- Patient has histologically confirmed invasive carcinoma of the female breast\n- Patient is a candidate for chemotherapy by the treating oncologist\n- Patient has HER2 positive, ER/PR negative tumor\n- Patient is 45 years old (Age >18 years)\n- Patient has ECOG performance status \u2264 1\n- Patient is not pregnant or nursing\n- Patient is willing and able to sign informed consent\n\nStep 2: Check exclusion criteria\n- Patient has 5 positive lymph nodes (Possible exclusion: Patients with N2 or N3 disease are NOT explicitly excluded, but must be reviewed with the PI or study chair before enrollment)\n- Patient is using multivitamins and iron supplements (No mention of this in inclusion or exclusion criteria)\n\nStep 3: Determine eligibility\nSince the patient meets the inclusion criteria and the exclusion criteria do not apply, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "193": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions in CXR\n\nInclusion Criteria:\n- Histologically confirmed diagnosis of invasive breast carcinoma with positive ER and/or PR status, and negative HER2\n- ER and PR positivity must be assessed according to ASCO/CAP guidelines\n- HER2 test result negativity must be assessed as per ASCO/CAP 2013 guidelines using IHC, ISH, or both\n- Patients must not have metastatic breast cancer (stage IV disease)\n- Patients must be high risk by belonging to one of the following risk groups\n- Patients must have completed either breast-conserving surgery or total mastectomy with negative margins and appropriate axillary staging\n- Patients must have undergone axillary staging by sentinel-node biopsy or axillary lymph node dissection (ALND)\n- Patients must meet certain blood count, liver function, and kidney function criteria\n- Patients must not have any grade III/IV cardiac disease, uncontrolled diabetes, or known uncontrolled pulmonary disease\n- Patients must not have prior exposure to mTOR inhibitors or investigational drugs within the preceding 28 days\n\nStep 2: Evaluate patient note against inclusion criteria\n\n- The patient has a histologically confirmed diagnosis of invasive breast carcinoma (meets criteria)\n- The patient is HER2-positive and ER/PR negative (meets criteria)\n- The patient has metastatic breast cancer (excluded)\n- The patient has completed breast-conserving surgery or total mastectomy with negative margins and appropriate axillary staging (meets criteria)\n- The patient has undergone axillary staging by sentinel-node biopsy or axillary lymph node dissection (meets criteria)\n- The patient meets certain blood count, liver function, and kidney function",
        "label": 0
    },
    "194": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Disease: Invasive ductal breast carcinoma (HER2-positive, ER/PR negative)\n- Stage: Not specified, but metastatic lesions are present\n- ECOG Performance status: Not specified\n- Measurable disease: Not specified\n- Hormonal receptor status: ER/PR negative\n- Hematological function: Not specified\n- Hepatic function: Not specified\n- Renal function: Not specified\n- Pregnancy test: Not specified\n- Consent and compliance: Not specified\n\nStep 2: Compare the patient's information with the inclusion criteria.\n\n1. Pathologically confirmed diagnosis of invasive breast cancer: Yes\n2. Stage IV disease: Not specified, but metastatic lesions are present (partial match)\n3. Documented HER2 and hormonal receptor status per protocol, ER/PR+ patients must be refractory to at least one prior hormonal treatment: No (patient is ER/PR negative)\n4. ECOG Performance status 0-1: Not specified\n5. Measurable disease per RECIST (1.1): Not specified\n6. Adequate hematological function per protocol: Not specified\n7. Adequate hepatic function per protocol: Not specified\n8. Adequate renal function per protocol: Not specified\n9. Negative serum pregnancy test at study entry for patients of childbearing potential: Not specified\n10. Ability to understand and sign written consent and to comply with the study protocol: Not specified\n\nStep 3: Determine the trial-level eligibility.\n\nBased on the comparison, the patient meets some inclusion criteria (1, 2, and 9), but does not meet others (3, 4, 5, 6, 7, 8, and 10). Since the patient does not meet all the inclusion criteria, she is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "195": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria\nThe patient is 45 years old, which meets the inclusion criteria of age > 40 years.\n\nStep 2: Compare the patient's tumor type to the inclusion criteria\nThe patient has a 3 cm invasive ductal breast carcinoma, which meets the inclusion criteria of histological proven invasive breast carcinoma ductal, lobular, and/or Ductal Carcinoma in situ.\n\nStep 3: Compare the patient's Karnofsky performance status to the inclusion criteria\nThe patient's Karnofsky performance status is not mentioned in the patient note. Therefore, we cannot determine if they meet the inclusion criteria of Karnofsky performance status > 70%.\n\nStep 4: Compare the patient's tumor size and nodal status to the inclusion criteria\nThe patient has a 3 cm tumor and 5 positive lymph nodes, which does not meet the inclusion criteria of a single discrete tumor or focal microcalcifications that can be imaged on a specimen radiograph or multifocal disease within the same quadrant with a maximum dimension of equal to or less than 2.5 cm and preoperatively N0.\n\nStep 5: Compare the patient's hormonal receptor and HER-2 status to the inclusion criteria\nThe patient has a HER2-positive and ER/PR negative tumor, which does not meet the inclusion criteria of any hormonal receptor and HER-2 status.\n\nStep 6: Compare the patient's informed consent to the inclusion criteria\nThe patient has provided informed consent, which meets the inclusion criteria of informed consent.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "196": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nThe patient is a 45-year-old postmenopausal woman.\n\nStep 2: Identify the patient's disease.\nThe patient has cytologically confirmed breast cancer.\n\nStep 3: Check if the patient's disease matches the clinical trial's inclusion criteria.\nThe patient has metastatic breast cancer, which matches the clinical trial's inclusion criteria.\n\nStep 4: Check if the patient's age matches the clinical trial's inclusion criteria.\nThe patient is 45 years old, which is within the age range of 18 years or older for the clinical trial.\n\nStep 5: Check if there are any exclusion criteria that would disqualify the patient.\nThere are no exclusion criteria mentioned in the clinical trial summary.\n\nConclusion: Based on the information provided, the patient meets the inclusion criteria and does not meet any exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "197": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state that patients must be at least 18 years old. Since the patient is within the age range, this criterion is met.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nThe patient is a woman, and the inclusion criteria state that both men and women are eligible. Since the patient is within the gender range, this criterion is met.\n\nStep 3: Compare the patient's diagnosis with the inclusion criteria.\nThe patient has breast cancer, not melanoma, which is the disease specified in the inclusion criteria. Therefore, this criterion is not met.\n\nStep 4: Compare the patient's medical history with the inclusion criteria.\nThe patient has a history of breast cancer, but the inclusion criteria specify that prior therapy with ipilimumab is not permitted. Although the patient has not received ipilimumab, she has received other treatments for her cancer. Therefore, this criterion is not met.\n\nStep 5: Compare the patient's organ and marrow function with the inclusion criteria.\nThe patient's laboratory tests have not been provided, so we cannot determine if she meets the criteria for adequate organ and marrow function. Therefore, this criterion is not relevant.\n\nStep 6: Compare the patient's performance status and life expectancy with the inclusion criteria.\nThe patient's performance status and life expectancy have not been provided, so we cannot determine if she meets the criteria for performance status and life expectancy. Therefore, these criteria are not relevant.\n\nStep 7: Compare the patient's contraception use with the inclusion criteria.\nThe patient's contraception use has not been provided, so we cannot determine if she meets the criteria for women of childbearing potential. Therefore, this criterion is not relevant.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "198": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state that subjects must be at least 18 years of age. The patient meets this criterion.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, and the inclusion criteria state that both men and women are eligible. The patient meets this criterion.\n\nStep 3: Compare the patient's medical condition to the inclusion criteria.\nThe patient has breast cancer, not melanoma, which is the type of cancer specified in the inclusion criteria. The patient does not meet this criterion.\n\nStep 4: Compare the patient's treatment history to the inclusion criteria.\nThe patient has already undergone a core biopsy and has metastatic lesions, which indicates that she has received previous treatment. The inclusion criteria state that subjects must be previously untreated. The patient does not meet this criterion.\n\nStep 5: Compare the patient's laboratory values to the inclusion criteria.\nThe patient's laboratory values are not provided in the patient note. We cannot determine if the patient meets the laboratory value criteria.\n\nStep 6: Compare the patient's life expectancy to the inclusion criteria.\nThe patient's life expectancy is not provided in the patient note. We cannot determine if the patient meets the life expectancy criterion.\n\nStep 7: Compare the patient's performance status to the inclusion criteria.\nThe patient's ECOG performance status is not provided in the patient note. We cannot determine if the patient meets the performance status criterion.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "199": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria require the patient to be at least 50 years old and postmenopausal with no menses for at least one year prior to study enrollment. Since the patient is younger than 50 years old, she does not meet this criterion.\n\nStep 2: Compare the patient's cancer type and size with the inclusion criteria.\nThe patient has a 3 cm invasive ductal breast carcinoma, which meets the criterion for clinical size (<= 3 cm). However, the patient's cancer is HER2-positive, which is excluded in the inclusion criteria.\n\nStep 3: Compare the patient's hormone receptor status and HER2 status with the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative, which does not meet the criterion for either Estrogen or progesterone receptor positive or Estrogen and progesterone receptor negative and clinical tumor size <= 1.0 cm.\n\nConclusion: Based on the comparison of the patient note and the inclusion criteria of the clinical trial, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "200": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note to inclusion criteria\n- Age: Patient is 45 years old. Inclusion criteria: At least 18 years old.\n- Gender: Patient is a woman. Inclusion criteria: Not specified.\n- Disease: Patient has HER2-positive and ER/PR negative breast cancer. Inclusion criteria: HER2-negative primary invasive ductal or invasive lobular breast carcinoma.\n- Stage: Patient has stage II-III breast cancer. Inclusion criteria: Clinical stage II or III or pathologic stage IIA to IIIC.\n- Treatment: Patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. Inclusion criteria: Planning to receive best practice adjuvant or neoadjuvant chemotherapy according to institutional guidelines.\n- Informed consent: Patient is able to understand and willing to sign a written informed consent document. Inclusion criteria: Patient (or legally authorized representative) must be able to understand and willing to sign a written informed consent document.\n\nStep 2: Compare patient note to exclusion criteria\n- Prior chemotherapy: Patient has not received chemotherapy for this cancer. Exclusion criteria: Prior chemotherapy for this cancer (excluding initiation of best practice chemotherapy to be given as standard of care as described in this protocol).\n- Previous treatment with trastuzumab or Her2 targeted therapy: Patient has not received trastuzumab or Her2 targeted therapy. Exclusion criteria: Previous treatment with trastuzumab or any other Her2 targeted therapy.\n- Uncontrolled intercurrent illness: Patient does not have an uncontrolled intercurrent illness. Exclusion criteria: Presence of an uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n- Bone marrow ERBB2 overexpressing DTCs: Patient does not have bone marrow ERBB2 overexpressing DTCs. Registration Inclusion Criteria: Presence of bone marrow ERBB2 overexpressing DTCs at the time of diagnosis.\n- Distant metastasis: Patient does",
        "label": 0
    },
    "201": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nPatient's age: 45 years old\nInclusion criteria: Subject must be at least 18 years of age.\n\nThe patient meets the age inclusion criteria.\n\nStep 2: Compare the patient's ability to understand and consent to the treatment to the inclusion criteria.\nInclusion criteria: Subject is able to verbally confirm understandings of risks, benefits of treatment of either multivessel stenting or staged PCI using the zotarolimus-eluting stent (Resolute Integrity\u2122 Stent, Medtronic) and he or she or his or her legally authorized representative provides written informed consent prior to any study related procedure.\n\nThe patient note does not provide enough information to determine if the patient meets this criterion.\n\nStep 3: Compare the patient's medical condition to the inclusion criteria.\nInclusion criteria: Subject must have significant stenoses (\u2265 70%) of two or more than two of coronary arteries and requiring primary PCI for acute ST elevation myocardial infarction (STEMI) within 12hrs\nTarget lesion(s) must be located in a native coronary artery with visually estimated diameter of less than 2.5 mm and more than 4.0 mm.\nTarget lesion(s) must be amenable for percutaneous coronary intervention\n\nThe patient note does not provide enough information to determine if the patient meets these criteria.\n\nStep 4: Determine the trial-level eligibility based on the comparison.\nSince there is not enough information to determine if the patient meets the inclusion criteria, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "202": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria\nThe patient is a 45-year-old woman, and the inclusion criteria state \"Female patients aged 18 years or older at diagnosis of, or progression to, metastatic breast cancer.\" Since 45 years is greater than 18 years, the patient meets the age inclusion criteria.\n\nStep 2: Compare patient's gender with the inclusion criteria\nThe patient is a woman, and the inclusion criteria state \"Female patients aged 18 years or older at diagnosis of, or progression to, metastatic breast cancer.\" Since the patient is female, she meets the gender inclusion criteria.\n\nStep 3: Compare patient's diagnosis with the inclusion criteria\nThe patient has been diagnosed with breast cancer and has metastatic disease. The inclusion criteria state \"Patients with a diagnosis of breast cancer with documented metastatic disease and with known date of metastatic disease.\" Since the patient has metastatic breast cancer, she meets the diagnosis inclusion criteria.\n\nStep 4: Compare patient's HER2 status with the inclusion criteria\nThe patient's tumor is HER2-positive, and the inclusion criteria state \"Patients with a histologically confirmed HER2+ breast cancer (HER2 testing procedures per routine institutional practice; no tissue re-sampling will be performed. If conducted at another site, documented results must be available).\" Since the patient's tumor is HER2-positive, she meets the HER2 status inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "203": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 45 years old, which is within the range of 18 years or older. So, this criteria is met.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nThe patient is a female, which matches the criteria for female subjects. So, this criteria is met.\n\nStep 3: Compare the patient's cancer type and stage with the inclusion criteria.\nThe patient has cytologically confirmed breast cancer, which is a type of breast cancer. The cancer is HER2-positive, T1 or T2 or T3, N0 or N1, resectable T4, or resectable N2, and M0 (metastatic). This matches the criteria for clinical stages breast cancer: HER2 positive, T1 or T2 or T3, N0 or N1, resectable T4, or resectable N2, (all M0). So, this criteria is met.\n\nStep 4: Compare the patient's HER2 status with the inclusion criteria.\nThe patient's tumor is HER2-positive, which matches the criteria for documentation of erbB-2 gene amplification by FISH or chromogenic in situ hybridization or documentation of erbB-2-overexpression by IHC. So, this criteria is met.\n\nStep 5: Compare the patient's laboratory values with the inclusion criteria.\nThe patient's laboratory values are within the specified parameters for ANC, platelet count, hemoglobin, serum creatinine, total bilirubin, and AST/ALT. So, this criteria is met.\n\nSince all the inclusion criteria are met, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "204": {
        "output": "GPT4 Correct Assistant: Step 1: Determine if the patient is postmenopausal.\nThe patient note states that the patient is a \"45-year-old postmenopausal woman,\" so she meets this criterion.\n\nStep 2: Determine if the patient has a histological diagnosis of breast invasive ductal carcinoma with receptor profiles obtained.\nThe patient note states that the patient has \"cytologically confirmed breast cancer\" and a \"3 cm invasive ductal breast carcinoma,\" so she meets this criterion.\n\nStep 3: Determine if the patient has an MRI visible breast lesion.\nThe patient note does not provide information about an MRI visible breast lesion.\n\nStep 4: Determine if the patient has unifocal cancer, less than 1.5 cm in maximum diameter, with no evidence of extensive in situ cancer surrounding the main tumor.\nThe patient note states that the tumor is \"3 cm invasive ductal breast carcinoma,\" which is larger than the 1.5 cm maximum diameter allowed. Therefore, she does not meet this criterion.\n\nStep 5: Determine if the patient is clinical stage N0 (no metastatic axillary lymph node on physical examination or imaging work-up).\nThe patient note states that axillary sampling revealed \"5 positive lymph nodes,\" which indicates metastatic axillary lymph nodes. Therefore, she does not meet this criterion.\n\nStep 6: Determine if the patient can give informed consent.\nThe patient note does not provide information about the patient's ability to give informed consent.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "205": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is older than 18 years. This criterion is met.\n\nStep 2: Check if the patient has signed consent and has a health form approved by a professional practitioner.\nWe do not have enough information to determine if the patient has signed consent and has a health form approved by a professional practitioner. This criterion is not relevant.\n\nStep 3: Determine if the patient's condition is relevant to the clinical trial.\nThe clinical trial is focused on ultrasound detection of peripheral IV infiltration. The patient note mentions breast cancer and metastatic lesions, but there is no information about peripheral IV infiltration. This criterion is not relevant.\n\nStep 4: Check for any exclusion criteria.\nWe do not have enough information about any exclusion criteria to determine if the patient is excluded from the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "206": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's gender and age.\nThe patient is a 45-year-old postmenopausal woman.\n\nStep 2: Identify the patient's diagnosis.\nThe patient has cytologically confirmed breast cancer, specifically a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes, and CXR was remarkable for metastatic lesions.\n\nStep 3: Compare the patient's diagnosis to the inclusion criteria.\nThe patient has breast cancer, but the trial is specifically for women with metastatic breast cancer. The patient's diagnosis does not explicitly state that it is metastatic.\n\nStep 4: Determine the patient's eligibility based on the comparison.\nSince the patient's diagnosis does not explicitly state that it is metastatic, there is not enough information to determine if they meet the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "207": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria\nThe patient is 45 years old, which is greater than or equal to 18 years of age, as required by the inclusion criteria.\n\nStep 2: Compare patient's diagnosis to the inclusion criteria\nThe patient has a newly diagnosed invasive ductal breast carcinoma, which matches the inclusion criteria.\n\nStep 3: Compare patient's stage of cancer to the inclusion criteria\nThe patient has Stage I-II breast cancer, which matches the inclusion criteria.\n\nStep 4: Compare patient's surgical and radiation therapy status to the inclusion criteria\nThe patient has not completed their surgical and radiation therapy, which does not match the inclusion criteria.\n\nStep 5: Compare patient's performance status to the inclusion criteria\nThe patient's performance status is not mentioned in the patient note, so we cannot determine if they meet the inclusion criteria.\n\nStep 6: Compare patient's organ function to the inclusion criteria\nThe patient's organ function is not mentioned in the patient note, so we cannot determine if they meet the inclusion criteria.\n\nStep 7: Compare patient's serum calcium-phosphate product to the inclusion criteria\nThe patient's serum calcium-phosphate product is not mentioned in the patient note, so we cannot determine if they meet the inclusion criteria.\n\nStep 8: Compare patient's recovery from prior surgery to the inclusion criteria\nThe patient's recovery from prior surgery is not mentioned in the patient note, so we cannot determine if they meet the inclusion criteria.\n\nStep 9: Compare patient's willingness to use contraception to the inclusion criteria\nThe patient's willingness to use contraception is not mentioned in the patient note, so we cannot determine if they meet the inclusion criteria.\n\nStep 10: Compare patient's use of Vitamin D3 to the inclusion criteria\nThe patient is using multivitamins and iron supplements, but it is not specified if they are using Vitamin D3. Therefore, we cannot determine if they meet the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "208": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state that patients must be \u2265 18 years old. The patient meets this criterion.\n\nStep 2: Compare the patient's cancer type and characteristics to the inclusion criteria.\nThe patient has cytologically confirmed breast cancer, and the inclusion criteria state that patients must have biopsy-proven triple negative invasive ductal or lobular metastatic breast cancer. The patient meets this criterion.\n\nStep 3: Compare the patient's hormone receptor status to the inclusion criteria.\nThe patient's cancer is HER2-positive and ER/PR negative, which matches the inclusion criteria of being triple negative (ER-defined as \u22641% by IHC, PR-defined as \u22641% by IHC, and HER2- by IHC 1+). The patient meets this criterion.\n\nStep 4: Compare the patient's previous treatment history to the inclusion criteria.\nThe patient has not started Ixabepilone treatment more than 5 weeks prior to initiation of SBRT treatment, and has failed an anthracycline, a taxane, and capecitabine as per FDA approved criteria. The patient meets this criterion.\n\nStep 5: Compare the patient's performance status and organ function to the inclusion criteria.\nThe patient's ECOG performance status is not mentioned in the patient note, but the inclusion criteria state that patients must have a performance status of ECOG 0, 1, or 2. The patient's organ function is not mentioned in the patient note, but the inclusion criteria state that patients must have adequate organ and marrow function. The patient's eligibility cannot be determined based on the information provided.\n\nStep 6: Compare the patient's ability to give informed consent to the inclusion criteria.\nThe patient's ability to understand and willingness to sign a written informed consent is not mentioned in the patient note, but the inclusion criteria state that patients must have the ability to understand and the willingness to sign a written informed consent. The patient's eligibility cannot be determined based on the information provided.\n\nTrial-level eligibility: 1) Not",
        "label": 0
    },
    "209": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the inclusion criteria of at least 18 years of age.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is female, which matches the inclusion criteria.\n\nStep 3: Compare the patient's clinical stage to the inclusion criteria.\nThe patient has a 3 cm invasive ductal breast carcinoma with 5 positive lymph nodes and metastatic lesions, which does not meet the inclusion criteria of tumor size less than 5 cm, no palpable nodes, and no evidence of metastatic disease (T1 or T2 N0 M0).\n\nStep 4: Compare the patient's axillary ultrasound results to the inclusion criteria.\nThe patient's axillary ultrasound results are not provided, so we cannot determine if they meet the inclusion criteria.\n\nStep 5: Compare the patient's tissue diagnosis to the inclusion criteria.\nThe patient has a tissue diagnosis of invasive breast carcinoma, which matches the inclusion criteria.\n\nStep 6: Compare the patient's ECOG status to the inclusion criteria.\nThe patient's ECOG status is not provided, so we cannot determine if they meet the inclusion criteria.\n\nStep 7: Compare the patient's history of previous malignancy to the inclusion criteria.\nThe patient's history of previous malignancy is not provided, so we cannot determine if they meet the inclusion criteria.\n\nStep 8: Compare the patient's informed consent and authorization to the inclusion criteria.\nThe patient's informed consent and authorization are not provided, so we cannot determine if they meet the inclusion criteria.\n\nStep 9: Determine if the patient is a candidate for sentinel lymph node biopsy (SLNB).\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, but we do not have enough information to determine if they are a candidate for SLNB.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "210": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the age range in the inclusion criteria.\nPatient's age: 45 years\nInclusion criteria: Age between 18-70 years\nThe patient's age is within the age range in the inclusion criteria.\n\nStep 2: Compare patient's gender with the gender in the inclusion criteria.\nPatient's gender: Female\nInclusion criteria: Female operable breast cancer patients\nThe patient's gender matches the gender in the inclusion criteria.\n\nStep 3: Compare patient's breast cancer status with the inclusion criteria.\nPatient's breast cancer status: Cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\nInclusion criteria: Histologically confirmed adenocarcinoma of the breast with a. histologically involved positive lymph nodes b. or histologic diagnosis for three negative patients; c. or lymph node negative, HER2 positive\nThe patient's breast cancer status matches the breast cancer status in the inclusion criteria.\n\nStep 4: Compare patient's lymph node status with the inclusion criteria.\nPatient's lymph node status: 5 positive lymph nodes\nInclusion criteria: a. histologically involved positive lymph nodes\nThe patient's lymph node status matches the lymph node status in the inclusion criteria.\n\nStep 5: Compare patient's HER2 status with the inclusion criteria.\nPatient's HER2 status: HER2-positive\nInclusion criteria: c. or lymph node negative, HER2 positive\nThe patient's HER2 status matches the HER2 status in the inclusion criteria.\n\nStep 6: Compare patient's Karnofsky points with the inclusion criteria.\nPatient's Karnofsky points: Not mentioned\nInclusion criteria: Karnofsky points greater than or equal to 70\nThe patient's Karnofsky points are not mentioned in the patient note, so we cannot determine if they meet this criterion.\n\nStep 7: Compare patient's reproductive status with the inclusion criteria.\nPatient's reproductive status: Postmenopausal woman, no children",
        "label": 2
    },
    "211": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which falls within the range of an adult. No specific age criteria are mentioned in the inclusion criteria.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a female, which matches the inclusion criteria for breast cancer.\n\nStep 3: Compare the patient's cancer type and stage to the inclusion criteria.\nThe patient has HER2-positive, ER/PR negative invasive ductal breast cancer. This matches the inclusion criteria for HER2-positive Stage I histologically confirmed invasive carcinoma of the breast.\n\nStep 4: Compare the patient's tumor characteristics to the inclusion criteria.\nThe patient's tumor is HER2-positive, confirmed by central testing. This matches the inclusion criteria for HER2-positive breast cancer.\n\nStep 5: Compare the patient's treatment history to the inclusion criteria.\nThe patient has not received any treatment for this breast cancer, which matches the inclusion criteria for less than or equal to 90 days since most recent breast surgery for this breast cancer.\n\nStep 6: Compare the patient's medical history to the inclusion criteria.\nThe patient has a history of multivitamins and iron supplements, but no history of smoking, alcohol consumption, or sexual activity. No specific medical history criteria are mentioned in the inclusion criteria.\n\nStep 7: Compare the patient's eligibility for surgery to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which matches the inclusion criteria for all tumor to be removed by either a modified radical mastectomy or a segmental mastectomy with either a sentinel node biopsy or axillary dissection.\n\nStep 8: Compare the patient's eligibility for contraception to the inclusion criteria.\nThe patient is not sexually active and has no children, which makes her eligible for the study without any contraception requirements.\n\nStep 9: Compare the patient's eligibility for other criteria to the inclusion criteria.\nThe patient has no other information that would disqualify her based on the inclusion criteria.\n\nTrial-level el",
        "label": 0
    },
    "212": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria\nThe patient is 45 years old, which is within the range for the clinical trial.\n\nStep 2: Compare patient's gender to the inclusion criteria\nThe patient is a woman, which matches the gender requirement for the clinical trial.\n\nStep 3: Compare patient's cancer type and stage to the inclusion criteria\nThe patient has invasive ductal breast carcinoma, which matches the ductal histology requirement. The tumor is 3 cm, which is larger than the 1.5 cm requirement.\n\nStep 4: Compare patient's hormone receptor status to the inclusion criteria\nThe patient's tumor is HER2-positive and ER/PR negative, which does not match the requirement of being estrogen receptor positive and her2/neu negative.\n\nStep 5: Compare patient's previous treatment history and other medical conditions to the inclusion criteria\nThe patient has not had prior surgical resection of the primary lesion, which matches the requirement. The patient has metastatic disease, but has elected to have their primary tumor excised, which matches the requirement for subjects with metastatic disease. The patient is able to provide consent.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "213": {
        "output": "GPT4 Correct Assistant: Step 1: Determine the patient's stage of breast cancer.\nThe patient note states that the patient has cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. It also mentions that axillary sampling revealed 5 positive lymph nodes and that the patient has metastatic lesions. This indicates that the patient has stage 4 breast cancer.\n\nStep 2: Determine if the patient has measurable disease in liver or lung.\nThe patient note does not provide information about the location of the metastatic lesions. Therefore, we cannot determine if the patient has measurable disease in the liver or lung.\n\nStep 3: Determine if the patient has received prior therapy.\nThe patient note states that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This indicates that the patient has not yet received chemotherapy.\n\nStep 4: Determine the patient's ECOG performance status.\nThe patient note does not provide information about the patient's ECOG performance status. Therefore, we cannot determine if the patient meets this criterion.\n\nStep 5: Determine if the patient is of childbearing potential and has a negative pregnancy test.\nThe patient note states that the patient is a postmenopausal woman. This indicates that she is not of childbearing potential.\n\nStep 6: Determine if the patient has blood test results within the pre-specified range, no active bleeding, no clinical coagulopathy, and an anticipated lifespan greater than 12 weeks.\nThe patient note does not provide information about the patient's blood test results, bleeding, coagulopathy, or lifespan. Therefore, we cannot determine if the patient meets these criteria.\n\nBased on the information provided in the patient note, we cannot determine if the patient meets all of the inclusion criteria for the clinical trial. Therefore, the trial-level eligibility is 1) Not relevant.",
        "label": 0
    },
    "214": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions\n\nInclusion Criteria:\n- Diagnosis of breast cancer by biopsy\n- Life expectancy of at least 1 year\n- Mass on clinical or radiological examination of >1 cm\n- ER or Her2 status unknown is allowed\n- Patients with inflammatory breast cancer allowed\n- History and physical exam, blood tests, chest imaging, mammogram, ultrasound, bone scan, and MRI performed\n- White blood cell count (WBC) > 3,000, platelet count > 100,000, bilirubin, SGOT, SGPT, alkaline phosphatase, and serum creatinine must all be < 1.2 x ULN, calculated creatinine clearance > 50 ml/min\n- Patients with bone pain eligible if bone scan and/or roentgenological exam fail to disclose metastatic disease, or if metastatic disease is found, definitive local treatment is to be performed\n- Patients with non-breast malignancies eligible if not received prior chemotherapy or extensive radiation therapy, and free from disease for at least two years\n- Negative serum or urine pregnancy test within 7 days prior to initiation of chemotherapy (female patients of childbearing potential)\n\nStep 2: Determine patient eligibility\n\n- The patient has a confirmed diagnosis of breast cancer by biopsy.\n- The patient has a life expectancy of at least 1 year.\n- The patient has a mass on clinical or radiological examination of >1 cm.\n- The patient's ER or Her2 status is unknown, which is allowed in the trial.\n- The patient has inflammatory breast cancer, which is allowed in the trial.\n- The patient has undergone the required tests and examinations.\n- The patient has a WBC > 3,000, platelet count > 100,",
        "label": 1
    },
    "215": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is a 45-year-old postmenopausal woman. The inclusion criteria do not mention any specific age requirement.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nThe patient is a woman. The inclusion criteria do not mention any specific gender requirement.\n\nStep 3: Compare the patient's breast cancer type with the inclusion criteria.\nThe patient has invasive ductal breast cancer. The inclusion criteria do not mention any specific breast cancer type.\n\nStep 4: Compare the patient's HER2 status with the inclusion criteria.\nThe patient has HER2-positive breast cancer. The inclusion criteria state that patients who have a primary tumor that is either HER2-positive or HER2-negative are eligible.\n\nStep 5: Compare the patient's ER/PR status with the inclusion criteria.\nThe patient has ER/PR negative breast cancer. The inclusion criteria state that patients must have had ER analysis performed on the primary breast tumor before neoadjuvant therapy. Since the patient is ER/PR negative, she meets this requirement.\n\nStep 6: Compare the patient's axillary lymph node status with the inclusion criteria.\nThe patient has 5 positive lymph nodes. The inclusion criteria state that patients must have had pathologic confirmation of axillary nodal involvement at presentation (before neoadjuvant therapy) based on either a positive fine needle aspirate (FNA) (demonstrating malignant cells) or positive core needle biopsy (demonstrating invasive adenocarcinoma). Since the patient has axillary lymph node involvement, she meets this requirement.\n\nStep 7: Compare the patient's previous treatment history with the inclusion criteria.\nThe patient has not undergone neoadjuvant chemotherapy. The inclusion criteria state that patients must have completed a minimum of 8 weeks of standard neoadjuvant chemotherapy consisting of an anthracycline and/or taxane-based regimen. Since the patient has not received neoadjuvant chemotherapy, she does not meet this requirement.\n\nStep 8: Compare the patient's eligibility for the clinical trial.",
        "label": 0
    },
    "216": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age\nThe patient is 45 years old.\n\nStep 2: Identify the patient's diagnosis\nThe patient has cytologically confirmed breast cancer.\n\nStep 3: Determine the stage of the patient's cancer\nThe patient has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions.\n\nStep 4: Compare the patient's stage with the clinical trial's inclusion criteria\nThe patient's stage is T3 N1 M0, which is outside the clinical trial's inclusion criteria of clinical stage T0-3 N1.\n\nStep 5: Determine the patient's eligibility\nThe patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "217": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old and the trial includes patients with stage IIA-IIIC breast cancer, so the age criteria are met.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman and the trial includes both men and women, so the gender criteria are met.\n\nStep 3: Compare the patient's disease type and stage to the inclusion criteria.\nThe patient has breast cancer, and the trial includes patients with stage IIA-IIIC breast cancer, so the disease type and stage criteria are met.\n\nStep 4: Compare the patient's tumor characteristics to the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative, and the trial includes patients with these characteristics, so the tumor characteristics criteria are met.\n\nStep 5: Compare the patient's previous treatment history to the inclusion criteria.\nThe patient has not had chemotherapy, irradiation, or definitive therapeutic surgery for this malignancy, and the trial includes patients who have not had these treatments, so the previous treatment history criteria are met.\n\nStep 6: Compare the patient's other medical conditions to the inclusion criteria.\nThe patient is taking multivitamins and iron supplements and does not smoke or consume alcohol, and the trial includes patients with these characteristics, so the other medical conditions criteria are met.\n\nStep 7: Compare the patient's willingness to participate in the trial to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, and the trial includes patients who are willing to participate, so the willingness to participate criteria are met.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "218": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is a 45-year-old postmenopausal woman. The inclusion criteria state \"No inflammatory breast cancer.\" The patient does not have inflammatory breast cancer. The patient meets the age requirement.\n\nStep 2: Compare the patient's cancer type to the inclusion criteria.\nThe patient has cytologically confirmed breast cancer. The inclusion criteria state \"Clinical stage T1-3 N1 M0 breast cancer at diagnosis (prior to the start of neoadjuvant chemotherapy) by American Joint Committee on Cancer (AJCC) staging 7th edition.\" The patient's cancer stage is T1-3 N1 M0. The patient meets the cancer type requirement.\n\nStep 3: Compare the patient's cancer stage to the inclusion criteria.\nThe patient has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The inclusion criteria state \"No other malignancy within 5 years of registration with the exception of basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the cervix.\" The patient does not have any other malignancies. The patient meets the cancer stage requirement.\n\nStep 4: Compare the patient's HER2 status to the inclusion criteria.\nThe patient's tumor is HER2-positive. The inclusion criteria state \"Patients must have had estrogen receptor, progesterone receptor and HER2 status (by immunohistochemistry [IHC] and/or in situ hybridization [ISH]) evaluated on diagnostic core biopsy prior to start of neoadjuvant chemotherapy.\" The patient has had her HER2 status evaluated. The patient meets the HER2 status requirement.\n\nStep 5: Compare the patient's axillary lymph node status to the inclusion criteria.\nThe patient has 5 positive lymph nodes. The inclusion criteria state \"All patients must have had an axillary ultrasound with fine needle aspiration (FNA) or core needle biopsy of axillary lymph nodes documenting axillary metastasis at the time of diagnosis, prior to or at most",
        "label": 0
    },
    "219": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the age requirement.\nThe patient is 45 years old, which meets the requirement of being \u2265 18 years of age.\n\nStep 2: Compare the patient's gender to the gender requirement.\nThe patient is a female, which meets the requirement of being a female.\n\nStep 3: Compare the patient's cancer type to the cancer type requirement.\nThe patient has cytologically confirmed breast cancer, which meets the requirement of having histologically confirmed invasive breast cancer.\n\nStep 4: Compare the patient's treatment plan to the treatment plan requirement.\nThe patient is planning for surgical resection of the breast tumor and axillary lymph node resection, which meets the requirement of planning for surgical resection of the breast tumor and sentinel node or axillary lymph node resection.\n\nStep 5: Compare the patient's cancer stage to the cancer stage requirement.\nThe patient has early breast cancer, which meets the requirement of having HER2-positive early breast cancer.\n\nStep 6: Compare the patient's measurable disease to the measurable disease requirement.\nThe patient has measurable disease in the breast after diagnostic biopsy, which meets the requirement of having measurable disease in the breast after diagnostic biopsy, defined as longest diameter \u2265 2.0 cm.\n\nStep 7: Compare the patient's hormone receptor status to the hormone receptor status requirement.\nThe patient's hormone receptor status is known (ER/PR negative), which meets the requirement of knowing the estrogen receptor (ER) and progesterone receptor (PR) hormone receptor status at study entry.\n\nStep 8: Compare the patient's bone marrow, liver, and kidney function to the organ function requirements.\nThe patient has normal bone marrow, liver, and kidney function, which meets the requirement of having normal bone marrow function, normal hepatic function, and normal renal function.\n\nStep 9: Compare the patient's left ventricular ejection fraction to the LVEF requirement.\nThe patient's LVEF is not mentioned, but since the requirement is \u2265 55%, we cannot determine eligibility based on",
        "label": 2
    },
    "220": {
        "output": "GPT4 Correct Assistant: Let's compare the patient note with the inclusion criteria of the clinical trial step by step.\n\n1. Histological confirmation of breast carcinoma: The patient note confirms that the patient has cytologically confirmed breast cancer.\n2. Metastatic disease with predominantly bone metastasis: The patient note mentions that the patient has metastatic lesions, but it does not specify the predominance of bone metastasis.\n3. ER expression in the primary tumor site by IHC: The patient note states that the tumor is ER/PR negative.\n4. Adequate hematologic function, cardiac function, renal function, and hepatic function: The patient note does not provide information about these factors.\n5. Serum calcium or albumin-adjusted serum calcium: The patient note does not provide information about this factor.\n6. Informed consent and age: The patient note states that the patient is 45 years old, which is within the age range of 18 years or older.\n7. Contraception for female patients of childbearing potential: The patient note states that the patient is postmenopausal, so this criterion does not apply.\n8. CTC >/=3: The patient note does not provide information about the number of circulating tumor cells.\n\nBased on the comparison, the patient does not have sufficient information to qualify for the trial (scale 1) due to the lack of information about metastatic disease predominance, hematologic, cardiac, renal, and hepatic function, serum calcium or albumin-adjusted serum calcium, and CTC count.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "221": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria\nThe patient is 45 years old, which is within the age range of \u226518 years.\n\nStep 2: Compare the patient's ECOG performance status with the inclusion criteria\nThe patient's ECOG performance status is not mentioned in the patient note.\n\nStep 3: Compare the patient's menopausal status with the inclusion criteria\nThe patient is postmenopausal, which matches the inclusion criteria.\n\nStep 4: Compare the patient's breast cancer diagnosis with the inclusion criteria\nThe patient has invasive ductal breast cancer, which matches the inclusion criteria.\n\nStep 5: Compare the patient's cancer stage with the inclusion criteria\nThe patient has Stage II-III breast cancer, which matches the inclusion criteria.\n\nStep 6: Compare the patient's tumor characteristics with the inclusion criteria\nThe patient's tumor is HER2-positive and ER/PR negative. The inclusion criteria state that the tumor must be estrogen receptor positive with an Allred score of 6, 7, or 8. Since the patient's tumor is ER/PR negative, she does not meet this criterion.\n\nStep 7: Compare the patient's other medical conditions and treatments with the inclusion criteria\nThe patient is using multivitamins and iron supplements, but there are no other medical conditions or treatments mentioned in the inclusion criteria that are relevant to her eligibility.\n\nStep 8: Assess the patient's eligibility based on the above comparisons\nThe patient meets most of the inclusion criteria, but she does not meet the criterion for having an estrogen receptor positive tumor with an Allred score of 6, 7, or 8. Therefore, her overall eligibility is:\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "222": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria\nThe patient is 45 years old, and the inclusion criteria state that patients must be age 18 or older. The patient meets this criterion.\n\nStep 2: Compare patient's gender with the inclusion criteria\nThe patient is a woman, and the inclusion criteria state that both female and male subjects are eligible. The patient meets this criterion.\n\nStep 3: Compare patient's breast cancer type with the inclusion criteria\nThe patient has cytologically confirmed breast cancer, and the inclusion criteria state that patients must have histologically confirmed breast cancer. The patient meets this criterion.\n\nStep 4: Compare patient's ER/PR status with the inclusion criteria\nThe patient's tumor is ER/PR negative, and the inclusion criteria state that patients must have ER/PR-positive breast cancer. The patient does not meet this criterion.\n\nStep 5: Compare patient's HER2 status with the inclusion criteria\nThe patient's tumor is HER2-positive, and the inclusion criteria state that patients must have HER2/neu negative breast cancer. The patient does not meet this criterion.\n\nStep 6: Compare patient's metastatic status with the inclusion criteria\nThe patient has metastatic lesions, and the inclusion criteria state that patients must have metastatic (stage IV) breast cancer. The patient meets this criterion.\n\nStep 7: Compare patient's disease progression with the inclusion criteria\nThe patient has progressive disease during at least one line of endocrine therapy for metastatic disease, and the inclusion criteria state that patients must have had progressive disease during at least one line of endocrine therapy for metastatic disease or have recurrent disease while or within 12 months of receiving adjuvant endocrine therapy. The patient meets this criterion.\n\nStep 8: Compare patient's organ and marrow function with the inclusion criteria\nThe patient's organ and marrow function is not mentioned in the patient note, so we cannot determine if they meet this criterion.\n\nStep 9: Compare patient's ability to swallow and tolerate oral medications with the inclusion criteria\nThe patient's ability to swallow and tolerate oral medications is not mentioned in the",
        "label": 0
    },
    "223": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria.\nPatient's age: 45 years old\nInclusion criteria: Age \u226518 years\nThe patient meets the age criteria.\n\nStep 2: Compare patient's cancer type to the inclusion criteria.\nPatient's cancer: Breast cancer\nInclusion criteria: AJCC Stage IIIB or IIIC cutaneous melanoma or unknown primary determined to be BRAF V600 mutation positive\nThe patient does not meet the cancer type criteria.\n\nStep 3: Compare patient's disease stage to the inclusion criteria.\nPatient's disease stage: Breast cancer with 5 positive lymph nodes and metastatic lesions\nInclusion criteria: Histologically confirmed AJCC Stage IIIB or IIIC\nThe patient does not meet the disease stage criteria.\n\nStep 4: Compare patient's ability to swallow and retain oral medication to the inclusion criteria.\nPatient's ability: Not mentioned in the patient note\nInclusion criteria: Able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption\nThe patient's information is not sufficient to determine eligibility.\n\nStep 5: Compare patient's ECOG Performance Status to the inclusion criteria.\nPatient's ECOG Performance Status: Not mentioned in the patient note\nInclusion criteria: Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1\nThe patient's information is not sufficient to determine eligibility.\n\nStep 6: Compare patient's organ function to the inclusion criteria.\nPatient's organ function: Not mentioned in the patient note\nInclusion criteria: Adequate baseline organ function\nThe patient's information is not sufficient to determine eligibility.\n\nStep 7: Compare patient's contraception requirements to the inclusion criteria.\nPatient's contraception: Not applicable for breast cancer patients\nInclusion criteria: Women of childbearing potential must have a negative serum pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception from 14 days prior to commencing study treatment, throughout the treatment period and for 4 months after the last dose of study treatment; Men",
        "label": 0
    },
    "224": {
        "output": "GPT4 Correct Assistant: Step 1: Check the patient's age\nThe patient is 45 years old, which falls within the range of II-III UICC stages.\n\nStep 2: Check the patient's gender\nThe patient is a female, which matches the inclusion criteria.\n\nStep 3: Check the type and stage of the disease\nThe patient has a unifocal breast tumor in stages II-III, which matches the inclusion criteria.\n\nStep 4: Check the tumor type\nThe patient has HER2-positive breast cancer, which matches the inclusion criteria.\n\nStep 5: Check the patient's performance status\nThe patient's ECOG performance status is not mentioned in the patient note.\n\nStep 6: Check the patient's response to neoadjuvant medical treatment\nThe patient's response to neoadjuvant medical treatment is not mentioned in the patient note.\n\nStep 7: Check the patient's eligibility for biopsy using radiofrequency\nThe patient's eligibility for biopsy using radiofrequency is not mentioned in the patient note.\n\nSince the patient's ECOG performance status, response to neoadjuvant medical treatment, and eligibility for biopsy using radiofrequency are not mentioned in the patient note, we cannot determine if the patient is eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "225": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nDisease Criteria:\nThe patient has breast cancer, not acute lymphoblastic leukemia (ALL).\n\nAge Criteria:\nThe patient is 45 years old, which is below the age range of 40-65 years.\n\nOrgan Function Criteria:\nThere is no information about the patient's cardiac, pulmonary, renal, and hepatic function in the patient note.\n\nConsent:\nThe patient note does not mention if the patient has been informed about the investigational nature of the study and has provided written informed consent.\n\nPresence of a willing adult HLA-matched sibling or HLA-matched unrelated donor:\nThe patient note does not mention the availability of a donor.\n\nStep 2: Determine eligibility based on the comparison\n\nSince the patient has breast cancer and not ALL, the disease criteria are not met. The patient's age is below the required range, and there is insufficient information about the patient's organ function and consent.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "226": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\n1. Patient age: 45 years old\n2. Gender: Female\n3. Disease: Breast cancer\n4. Tumor stage: cT2-3, cN0-3, HER2+\n5. No clinical evidence of metastasis\n6. Untreated\n7. Social security system patient\n8. French language mastery\n9. Free and informed consent\n\nStep 2: Check for exclusion criteria\n\n1. Age < 45 years at diagnosis\n2. CT2-3, cN0-3, HER2+(RH+or RH-) or RH-HER2-\n\nStep 3: Determine trial-level eligibility\n\nThe patient meets the inclusion criteria of being a female, having breast cancer, and being untreated. However, the patient does not meet the exclusion criteria of being < 45 years old at diagnosis and having a specific HER2 status. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "227": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient Note:\n- 45-year-old postmenopausal woman with cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- CXR was remarkable for metastatic lesions\n\nInclusion Criteria:\n- Newly diagnosed with a first occurrence of thyroid cancer <2-4 weeks of diagnosis\n- Histologically confirmed thyroid cancer (papillary, follicular, or medullary type; TNM classification system)\n- Willing to participate in the EG meetings\n- >18 years\n- Alert and capable of giving free and informed consent\n- Able to speak and read English or French\n\nStep 2: Determine eligibility based on the comparison\n\nThe patient note describes a patient with breast cancer, not thyroid cancer. Therefore, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "228": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age.\nThe patient is 45 years old.\n\nStep 2: Determine the patient's gender.\nThe patient is a woman.\n\nStep 3: Check for the presence of chronic pelvic pain.\nThe patient note does not mention chronic pelvic pain.\n\nStep 4: Check for the duration of the pain.\nThe patient note does not mention the duration of the pain.\n\nStep 5: Check for the type of pain.\nThe patient note does not mention the type of pain.\n\nStep 6: Compare the patient's information with the inclusion criteria.\nThe patient is a woman and is over 18 years old. However, the patient note does not provide sufficient information about the presence, duration, and type of chronic pelvic pain.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "229": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state that the patient must be at least 18 years old. The patient meets this criterion.\n\nStep 2: Compare the patient's medical condition to the inclusion criteria.\nThe patient has breast cancer, but the inclusion criteria are for a study involving PCI (percutaneous coronary intervention) for patients with angina, silent ischemia, NSTEMI, or recent STEMI. The patient does not meet this criterion.\n\nStep 3: Compare the patient's medical history to the inclusion criteria.\nThe patient has a history of breast cancer, but there is no information about the patient's cardiovascular history or risk factors, such as smoking or hypertension. The inclusion criteria do not provide sufficient information to determine the patient's eligibility based on medical history.\n\nStep 4: Compare the patient's willingness and ability to participate to the inclusion criteria.\nThe patient or legal guardian is willing and able to provide informed written consent and comply with follow-up visits and testing schedule. This criterion is met.\n\nStep 5: Determine the trial-level eligibility based on the above comparisons.\nSince the patient does not meet the inclusion criteria for the medical condition, the trial-level eligibility is 1) Not relevant.",
        "label": 0
    },
    "230": {
        "output": "GPT4 Correct Assistant: Let's analyze the patient note and inclusion criteria step by step:\n\n1. Life expectancy: The patient note does not provide information about the patient's life expectancy. (Not relevant)\n2. Reproductive potential and contraception: The patient note does not provide information about the patient's reproductive potential or contraception. (Not relevant)\n3. Tumor samples: The patient note does not provide information about the submission of tumor samples. (Not relevant)\n4. Informed consent: The patient note does not provide information about the patient's informed consent. (Not relevant)\n5. ECOG performance status: The patient note does not provide information about the patient's ECOG performance status. (Not relevant)\n6. Clinical staging: The patient note provides information about the tumor size and lymph node involvement, which match the clinical staging requirements.\n7. Diagnosis method: The patient note confirms that the diagnosis was made by core needle biopsy, which matches the inclusion criteria.\n8. Axillary lymph nodes: The patient note provides information about the axillary lymph nodes, which matches the inclusion criteria.\n9. Menopausal status: The patient is postmenopausal, which matches the inclusion criteria.\n10. HER2-positive status: The patient note confirms that the tumor is HER2-positive, which matches the inclusion criteria.\n11. ER/PR status: The patient note confirms that the tumor is ER/PR negative, which matches the inclusion criteria.\n12. Metastatic lesions: The patient note mentions metastatic lesions, which may exclude the patient based on the trial's exclusion criteria.\n13. Blood tests: The patient note provides information about the patient's blood tests, which matches the inclusion criteria.\n14. Liver and bone imaging: The patient note does not provide information about the patient's liver and bone imaging. (Not relevant)\n15. Serum creatinine: The patient note does not provide information about the patient's serum creatinine. (Not relevant)\n16. LVEF assessment: The patient note does not provide information about the patient's LVEF assessment. (Not relevant)\n\nBased on",
        "label": 0
    },
    "231": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria require a patient to be \u226560 years of age. The patient does not meet this criterion.\n\nStep 2: Compare the patient's diagnosis to the inclusion criteria.\nThe patient has breast cancer, while the inclusion criteria require a histological confirmation of DLBCL/follicular lymphoma grade IIIb. The patient does not meet this criterion.\n\nStep 3: Compare the patient's treatment history to the inclusion criteria.\nThe patient is not newly diagnosed and has already undergone a core biopsy and axillary sampling. The inclusion criteria require the patient to be newly diagnosed with no previous treatment. The patient does not meet this criterion.\n\nStep 4: Compare the patient's stage of disease to the inclusion criteria.\nThe patient has breast cancer, which is not a non-localised stage DLBCL/follicular lymphoma grade IIIb. The patient does not meet this criterion.\n\nStep 5: Compare the patient's performance status to the inclusion criteria.\nThe patient's ECOG performance status is not provided in the patient note. Without sufficient information, we cannot determine if the patient meets this criterion.\n\nStep 6: Compare the patient's laboratory values to the inclusion criteria.\nThe patient's laboratory values are not provided in the patient note. Without sufficient information, we cannot determine if the patient meets this criterion.\n\nStep 7: Compare the patient's cardiac function to the inclusion criteria.\nThe patient's LVEF and cardiac history are not provided in the patient note. Without sufficient information, we cannot determine if the patient meets this criterion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "232": {
        "output": "GPT4 Correct Assistant: Step 1: Check if the patient's clinical status of lymph nodes is available.\nThe patient note states that axillary sampling revealed 5 positive lymph nodes. This information is available.\n\nStep 2: Check if the sonographical status of lymph nodes is available.\nThe patient note does not provide information about the sonographical status of lymph nodes.\n\nStep 3: Check if the patient consents to documentation of cancer treatment.\nThe patient note does not provide information about the patient's consent to documentation of cancer treatment.\n\nStep 4: Check if the patient has a histologic diagnosis of invasive breast cancer, clinical stage T1-4, M0 (non-inflammatory T4c).\nThe patient note states that the patient has cytologically confirmed breast cancer and a 3 cm invasive ductal breast carcinoma. The stage of the cancer is not explicitly mentioned, but it is not specified as T1-4, M0.\n\nStep 5: Check if the patient is scheduled for neoadjuvant chemotherapy.\nThe patient note does not provide information about whether the patient is scheduled for neoadjuvant chemotherapy.\n\nStep 6: Check if the patient is treated with a 3-weekly FEC or AC regimen (3-4 cycles) followed by 3-4 cycles of q3 weekly docetaxel or paclitaxel.\nThe patient note does not provide information about the patient's chemotherapy regimen.\n\nStep 7: Check if the local HER2 status of the tumor biopsy is negative.\nThe patient note states that the tumor is HER2-positive, which is contradictory to the inclusion criteria.\n\nBased on the information provided in the patient note, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "233": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's relevant characteristics from the patient note.\n\n- Age: 45 years old\n- Gender: Female\n- Disease: Postmenopausal breast cancer (invasive ductal carcinoma)\n- HER2-positive, ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions in CXR\n- Multivitamins and iron supplements\n- No smoking or alcohol consumption\n- Not sexually active, no children\n- Candidate for tumor resection before chemotherapy\n\nStep 2: Compare the patient's characteristics with the inclusion criteria of the clinical trial.\n\nInclusion Criteria:\n- BRCA1/2 mutation carriers\n- Strong family history of breast and/or ovarian cancer suggestive for a germ line mutation in a relevant gene\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\nThe patient note does not provide any information about the patient's BRCA1/2 mutation status or family history of breast and/or ovarian cancer. Therefore, we cannot determine if the patient meets the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "234": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and cancer type.\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. The tumor is HER2-positive and ER/PR negative.\n\nStep 2: Compare the patient's age to the inclusion criteria.\nThe inclusion criteria state that patients must be 18-100 years old. The patient is 45 years old, which falls within the age range.\n\nStep 3: Compare the patient's cancer type to the inclusion criteria.\nThe patient has invasive ductal breast cancer, which matches the inclusion criteria of invasive ductal or invasive lobular carcinoma.\n\nStep 4: Determine if the patient is clinically node-negative.\nThe patient's axillary sampling revealed 5 positive lymph nodes. This means the patient is not clinically node-negative.\n\nStep 5: Determine if the patient is eligible for sentinel node dissection.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This suggests that the patient is eligible for sentinel node dissection.\n\nStep 6: Assess the patient's eligibility based on the inclusion and exclusion criteria.\nThe patient meets the inclusion criteria for age, cancer type, and eligibility for sentinel node dissection. The patient does not meet the exclusion criteria for being clinically node-negative.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "235": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to inclusion criteria\nThe patient is 45 years old, which meets the inclusion criteria of at least 18 years of age.\n\nStep 2: Compare patient's diagnosis to inclusion criteria\nThe patient has cytologically confirmed breast cancer, which meets the inclusion criteria of pathologically confirmed diagnosis of breast cancer.\n\nStep 3: Compare patient's metastatic status to inclusion criteria\nThe patient has metastatic lesions on CXR, which meets the inclusion criteria of metastatic or advanced breast cancer.\n\nStep 4: Compare patient's ECOG performance status to inclusion criteria\nThe patient's ECOG performance status is not mentioned, so we cannot determine if they meet the inclusion criteria of ECOG performance status 0-2.\n\nStep 5: Compare patient's life expectancy to inclusion criteria\nThe patient's life expectancy is not mentioned, so we cannot determine if they meet the inclusion criteria of life expectancy of at least 3 months.\n\nStep 6: Compare patient's hormone therapy history to inclusion criteria\nThe patient has ER/PR negative breast cancer, so they have not received prior hormone therapy for ER+ breast cancer, which meets the inclusion criteria for patients with ER+ breast cancer who have received prior hormone therapy.\n\nStep 7: Compare patient's laboratory values to inclusion criteria\nThe patient's laboratory values are not mentioned, so we cannot determine if they meet the inclusion criteria for absolute neutrophil count, platelets, hemoglobin, total bilirubin, AST, ALT, albumin, and renal function.\n\nStep 8: Compare patient's contraception status to inclusion criteria\nThe patient's contraception status is not mentioned, so we cannot determine if they meet the inclusion criteria for female subjects of childbearing potential and males to agree to use adequate contraception.\n\nStep 9: Compare patient's HIV status to inclusion criteria\nThe patient's HIV status is not mentioned, so we cannot determine if they meet the inclusion criteria for patients with HIV/AIDS who have an undetectable viral load, CD4 > 300, and are on a stable HAART regimen for 1 month prior to study enrollment.\n\nStep 1",
        "label": 2
    },
    "236": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria\nThe patient is 45 years old, and there is no specific age requirement in the inclusion criteria. So, this factor is not relevant.\n\nStep 2: Compare patient's gender with the inclusion criteria\nThe patient is a woman, and women are included in the study. So, this factor is not relevant.\n\nStep 3: Compare patient's disease type and stage with the inclusion criteria\nThe patient has HER2-positive breast cancer with metastatic lesions, and the inclusion criteria require histologically or cytologically confirmed adenocarcinoma of the breast with locally recurrent or metastatic disease. This factor is relevant and the patient meets the criteria.\n\nStep 4: Compare patient's HER2 status with the inclusion criteria\nThe patient's tumor is HER2-positive, and the inclusion criteria require primary tumors and/or metastatic lesions to demonstrate HER2-neu overexpression. This factor is relevant and the patient meets the criteria.\n\nStep 5: Compare patient's prior therapy with the inclusion criteria\nThe patient has progressed on at least two lines of HER2-directed therapy in the metastatic setting. The inclusion criteria require patients to have progressed on at least two lines of HER2-directed therapy in the metastatic setting. This factor is relevant and the patient meets the criteria.\n\nStep 6: Compare patient's organ function with the inclusion criteria\nThe patient's leukocytes, absolute neutrophil count, platelets, hemoglobin, total bilirubin, AST/ALT, and serum creatinine levels are all within the normal range, and the inclusion criteria require normal organ and marrow function. This factor is relevant and the patient meets the criteria.\n\nStep 7: Compare patient's ability to swallow, retain, and absorb oral medication with the inclusion criteria\nThe patient is able to swallow, retain, and absorb oral medication, and the inclusion criteria require patients to be able to swallow, retain, and absorb oral medication. This factor is relevant and the patient meets the criteria.\n\nStep 8: Compare patient's informed consent with the inclusion criteria\nThe patient has given informed consent, and the inclusion criteria require informed consent",
        "label": 2
    },
    "237": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which meets the inclusion criteria of age \u226518 years.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is female, which meets the inclusion criteria of female gender.\n\nStep 3: Compare the patient's performance status to the inclusion criteria.\nThe patient's ECOG performance status is not provided, so this criterion is not relevant.\n\nStep 4: Compare the patient's cancer type and size to the inclusion criteria.\nThe patient has invasive ductal breast cancer with a primary tumor greater than 1 cm diameter, which meets the inclusion criteria.\n\nStep 5: Compare the patient's lymph node status to the inclusion criteria.\nThe patient has 5 positive lymph nodes, which meets the inclusion criteria of any N.\n\nStep 6: Compare the patient's metastatic status to the inclusion criteria.\nThe patient has metastatic lesions, which is not allowed according to the inclusion criteria (no evidence of metastasis M0). Therefore, the patient is excluded.\n\nStep 7: Compare the patient's HER2 status to the inclusion criteria.\nThe patient's HER2 status is not provided, so this criterion is not relevant.\n\nStep 8: Compare the patient's hormone receptor status to the inclusion criteria.\nThe patient's hormone receptor status is not provided, so this criterion is not relevant.\n\nStep 9: Compare the patient's hematopoietic status to the inclusion criteria.\nThe patient's hematopoietic status is not provided, so this criterion is not relevant.\n\nStep 10: Compare the patient's hepatic status to the inclusion criteria.\nThe patient's hepatic status is not provided, so this criterion is not relevant.\n\nStep 11: Compare the patient's renal status to the inclusion criteria.\nThe patient's renal status is not provided, so this criterion is not relevant.\n\nStep 12: Compare the patient's cardiovascular status to the inclusion criteria.\nThe patient",
        "label": 1
    },
    "238": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria.\nPatient's age: 45 years\nInclusion criteria: Age \u2265 50 years at diagnosis\n\nStep 2: Compare patient's breast cancer stage with the inclusion criteria.\nPatient's stage: cytologically confirmed breast cancer with 5 positive lymph nodes and metastatic lesions\nInclusion criteria: AJCC 7th Edition stage 0 or I (TisN0 \u2264 2 cm or T1N0) histologically confirmed carcinoma of the breast\n\nStep 3: Compare patient's breast cancer type and receptor status with the inclusion criteria.\nPatient's breast cancer type: HER2-positive and ER/PR negative invasive ductal carcinoma\nInclusion criteria: Invasive ductal, lobular, medullary, papillary, colloid (mucinous), tubular histologies, or mixed histologies (lesions \u2264 2 cm) that are estrogen or progesterone receptor positive and do not exhibit HER2/neu gene amplification OR ductal carcinoma in situ (lesions \u2264 2 cm)\n\nStep 4: Compare patient's treatment history with the inclusion criteria.\nPatient's treatment: candidate for tumor resection and agrees to do so prior to chemotherapy\nInclusion criteria: Systemic therapy, if planned, must be adjuvant in nature and not be scheduled to begin for at least 4 weeks after completion of HG-PBI\n\nStep 5: Compare patient's postmenopausal status with the inclusion criteria.\nPatient's postmenopausal status: Yes\nInclusion criteria: Postmenopausal status\n\nStep 6: Compare patient's ability to understand and sign informed consent with the inclusion criteria.\nPatient's ability: Yes\nInclusion criteria: Able to understand and willing to sign IRB-approved written informed consent document\n\nStep 7: Determine the trial-level eligibility based on the comparison.\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "239": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age.\nThe patient is 45 years old.\n\nStep 2: Identify the patient's gender.\nThe patient is female.\n\nStep 3: Identify the stage of the patient's cancer.\nThe patient has stage I-III breast cancer.\n\nStep 4: Identify the type of cancer.\nThe patient has breast cancer.\n\nStep 5: Check if the patient meets the age criteria.\nThe patient is <65 years old.\n\nStep 6: Check if the patient meets the gender criteria.\nThe patient is female.\n\nStep 7: Check if the patient meets the stage criteria.\nThe patient has stage I-III breast cancer.\n\nStep 8: Check if the patient is scheduled to receive chemotherapy containing doxorubicin/cyclophosphamide once every 3 weeks for 4 cycles and weekly paclitaxel for 12 cycles starting in either the adjuvant or neoadjuvant setting.\nThe patient note does not provide information about the patient's chemotherapy plan.\n\nStep 9: Check if the patient may receive adjuvant endocrine therapy subsequently (endocrine therapy can be either tamoxifen or aromatase inhibitors).\nThe patient note does not provide information about the patient's endocrine therapy plan.\n\nStep 10: Check if the patient meets the inclusion criteria for healthy controls.\nThe patient is <65 years old and female, but she has breast cancer, so she does not meet the healthy control criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "240": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note with inclusion criteria\n\n1. Single enhancing lesion of the brain with MRI appearance consistent with GBM: Not mentioned in the patient note.\n2. Appropriate for Gliadel\u00ae wafer implant: Not mentioned in the patient note.\n3. Pathologic confirmation of GBM: The patient has cytologically confirmed breast cancer, not GBM.\n4. No gross residual tumor found on the immediate postoperative MRI scan: Not mentioned in the patient note.\n5. Volumetric measurements of the resection cavity margin being < 50 cc: Not mentioned in the patient note.\n6. Karnofsky performance status (KPS) 80% or better: Not mentioned in the patient note.\n7. Able to undergo MRI imaging with gadolinium: Not mentioned in the patient note.\n8. Willingness to have follow-up visits at Barrow Neurological Institute (BNI): Not mentioned in the patient note.\n\nStep 2: Determine the assessment of eligibility\n\nSince the patient has cytologically confirmed breast cancer and not GBM, she does not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "241": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nPatient's age: 45 years\nInclusion criteria: Age \u2265 18 years\nThe patient's age meets the inclusion criteria.\n\nStep 2: Compare the patient's diagnosis to the inclusion criteria.\nPatient's diagnosis: Cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\nInclusion criteria: Histologically proven metastatic or locally recurrent invasive breast cancer.\nThe patient's diagnosis meets the inclusion criteria.\n\nStep 3: Compare the patient's tumor tissue availability to the inclusion criteria.\nInclusion criteria: Tumor tissue (FFPE and frozen) from recurrent or metastatic lesions available for research purposes.\nThe patient note does not provide information about the availability of tumor tissue.\n\nStep 4: Determine the trial-level eligibility based on the comparison.\nSince there is not enough information about the availability of tumor tissue, we cannot determine the patient's eligibility for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "242": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria\nThe patient is 45 years old, which meets the criterion of \"Age \u2265 18 years at the time of consent.\"\n\nStep 2: Compare patient's ECOG Performance Status with the inclusion criteria\nThe patient's ECOG Performance Status is not mentioned in the patient note, so we cannot determine eligibility based on this criterion.\n\nStep 3: Compare patient's reproductive status with the inclusion criteria\nThe patient is postmenopausal, which meets the criterion of \"Women and men of childbearing potential must be willing to use an effective method of contraception.\"\n\nStep 4: Compare patient's pregnancy status with the inclusion criteria\nThe patient is not pregnant, which meets the criterion of \"Women must not be breastfeeding.\"\n\nStep 5: Compare patient's cancer status with the inclusion criteria\nThe patient has triple negative (ER-/PR-/HER2-) invasive breast cancer, which meets the criterion of \"must have histologically or cytologically confirmed triple negative (ER-/PR-/HER2-) invasive breast cancer.\"\n\nStep 6: Compare patient's cancer stage with the inclusion criteria\nThe patient's cancer stage is not mentioned in the patient note, so we cannot determine eligibility based on this criterion.\n\nStep 7: Compare patient's history of preoperative chemotherapy with the inclusion criteria\nThe patient has completed preoperative chemotherapy, which meets the criterion of \"Must have completed preoperative (neoadjuvant) chemotherapy.\"\n\nStep 8: Compare patient's surgery history with the inclusion criteria\nThe patient has completed definitive resection of the primary tumor, which meets the criterion of \"Must have completed definitive resection of primary tumor.\"\n\nStep 9: Compare patient's residual invasive disease with the inclusion criteria\nThe patient's residual invasive disease is not mentioned in the patient note, so we cannot determine eligibility based on this criterion.\n\nStep 10: Compare patient's tumor cellularity with the inclusion criteria\nThe patient's tumor cellularity is not mentioned in",
        "label": 0
    },
    "243": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note.\n- Age: 45 years old\n- Gender: Female\n- Diagnosis: Postmenopausal woman with cytologically confirmed breast cancer\n- Tumor type: Invasive ductal breast carcinoma (HER2-positive, ER/PR negative)\n- Stage: Metastatic (5 positive lymph nodes, metastatic lesions on CXR)\n- Treatment history: Not mentioned\n- Other medical conditions: None mentioned\n- Additional information: Multivitamins and iron supplements, no smoking or alcohol, not sexually active, no children, candidate for tumor resection\n\nStep 2: Compare the patient note to the inclusion criteria.\n\n1. Women or men with metastatic or locally relapsed breast cancer manageable with systemic therapy: Yes\n2. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1: Not mentioned\n3. Written informed consent prior to enrollment into the program: Not mentioned\n4. Patient aged \u2265 18 years: Yes\n5. Patient agrees to provide archived primary tumor tissue: Not mentioned\n6. Patient agrees to provide newly collected metastatic lesions tissue samples: Not mentioned\n7. Patient agrees to provide blood samples: Not mentioned\n\nStep 3: Determine the trial-level eligibility.\n\nSince there is not enough information about ECOG Performance Status, informed consent, archived primary tumor tissue, newly collected metastatic lesions tissue samples, and blood samples, the patient's eligibility cannot be determined.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "244": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nPatient age: 45 years old\nInclusion criteria: Patient aged over 18 and under 45\nThe patient is over 18 and under 45, so this criterion is met.\n\nStep 2: Compare the patient's menstrual status to the inclusion criteria.\nPatient status: Postmenopausal\nInclusion criteria: Patient without amenorrhea at diagnosis\nThe patient is postmenopausal, which means she has amenorrhea, so this criterion is not met.\n\nStep 3: Compare the patient's performance status to the inclusion criteria.\nPatient performance status: Not mentioned in the patient note\nInclusion criteria: Performance status less than 2 (according to WHO criteria )\nThe patient's performance status is not mentioned, so we cannot determine if this criterion is met.\n\nStep 4: Compare the patient's cancer stage to the inclusion criteria.\nPatient stage: Not mentioned in the patient note\nInclusion criteria: Clinical Stages I, IIA, IIB, and IIIA\nThe patient's stage is not mentioned, so we cannot determine if this criterion is met.\n\nStep 5: Compare the patient's hormone receptor status to the inclusion criteria.\nPatient hormone receptor status: ER/PR negative\nInclusion criteria: Positive Hormone Receptors (defined by a rate of 10% of labeled cells and immunohistochemistry (IHC) ) or negative\nThe patient is ER/PR negative, so this criterion is met.\n\nStep 6: Compare the patient's HER2 status to the inclusion criteria.\nPatient HER2 status: HER2-positive\nInclusion criteria: Positive or negative HER2 status (defined a score of 0 or 1 + by IHC , or a 2 + score by IHC and FISH / ISHS / CISH negative)\nThe patient is HER2-positive, so this criterion is met.\n\nStep 7: Compare the patient's treatment status to the inclusion criteria.\nPatient treatment status: Candidate for tumor resection and agrees to",
        "label": 0
    },
    "245": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the trial's age requirement.\nThe trial does not mention any specific age requirement, so the patient's age is not a factor in eligibility.\n\nStep 2: Compare patient's gender with the trial's gender requirement.\nThe trial does not mention any specific gender requirement, so the patient's gender is not a factor in eligibility.\n\nStep 3: Compare patient's disease type with the trial's disease type requirement.\nThe patient has breast cancer, while the trial is for advanced gastric cancer. Therefore, the patient does not meet the disease type requirement.\n\nStep 4: Compare patient's disease stage with the trial's disease stage requirement.\nThe patient has metastatic breast cancer, while the trial is for advanced gastric cancer. Therefore, the patient does not meet the disease stage requirement.\n\nStep 5: Compare patient's prior treatment history with the trial's prior treatment history requirement.\nThe patient has not had any prior treatment, while the trial requires no prior treatment. Therefore, the patient meets the prior treatment history requirement.\n\nStep 6: Compare patient's metastasis status with the trial's metastasis status requirement.\nThe patient has metastatic lesions, while the trial requires no metastases. Therefore, the patient does not meet the metastasis status requirement.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "246": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age\nPatient age: 45 years\nInclusion criteria: Age >=18 years\nThe patient meets the age criteria.\n\nStep 2: Compare patient gender\nPatient gender: Female\nInclusion criteria: Unilateral or bilateral primary carcinoma of the breast (female)\nThe patient meets the gender criteria.\n\nStep 3: Compare patient cancer type\nPatient cancer type: Invasive ductal breast carcinoma\nInclusion criteria: Unilateral or bilateral primary carcinoma of the breast\nThe patient meets the cancer type criteria.\n\nStep 4: Compare patient tumor stage\nPatient tumor stage: cT1c - cT4a-d disease\nInclusion criteria: Patients with HER2- positive or TNBC are eligible irrespective of nodal status (cN0-cN3)\nThe patient meets the tumor stage criteria.\n\nStep 5: Compare patient receptor status\nPatient receptor status: HER2-positive and ER/PR negative\nInclusion criteria: Centrally confirmed ER, PR and HER2 status. HER2-positive is defined as IHC 3+ or in-situ hybridization (ISH) and according to ASCO-CAP guidelines as of 2013). Formalin-fixed, paraffin-embedded (FFPE) breast tissue from core biopsy has therefore to be sent to the GBG central pathology laboratory prior to randomization.\nThe patient meets the receptor status criteria.\n\nStep 6: Compare patient number of positive lymph nodes\nPatient number of positive lymph nodes: 5 positive lymph nodes\nInclusion criteria: Patients with HER2- positive or TNBC are eligible irrespective of nodal status (cN0-cN3)\nThe patient meets the number of positive lymph nodes criteria.\n\nStep 7: Compare patient metastatic lesions\nPatient metastatic lesions: CXR was remarkable for metastatic lesions\nInclusion criteria: Patients with HER2- positive or TNBC are eligible irrespective of nodal status (cN0-cN3)\nThe patient meets the metastatic lesions",
        "label": 0
    },
    "247": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n- The patient has a clinical diagnosis of invasive ductal breast carcinoma.\n- The patient is a candidate for tumor resection.\n\nStep 2: Compare the patient's information to the inclusion criteria of the clinical trial.\n- The patient has a clinical diagnosis of invasive breast cancer (DCIS or invasive).\n- The patient is a candidate for breast conserving surgery or mastectomy (tumor resection).\n\nStep 3: Determine the trial-level eligibility based on the comparison.\n- The patient meets both inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "248": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\n1. Histologically confirmed invasive breast cancer with a primary tumor size of greater than (>) 2 cm: Patient note states \"A core biopsy revealed a 3 cm invasive ductal breast carcinoma.\"\n2. HER2-positive breast cancer: Patient note states \"The tumor is HER2-positive.\"\n3. Participants with multifocal tumors (more than one tumor confined to the same quadrant as the primary tumor) are eligible provided all discrete lesions are sampled and centrally confirmed as HER2 positive: Patient note does not provide information on multifocal tumors.\n4. Stage at presentation: cT2-cT4, cN0-cN3, cM0, according to American Joint Committee on Cancer (AJCC) staging system: Patient note states \"Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions.\" This suggests stage cN3, but the primary tumor size and stage are not clear from the information provided.\n5. Known hormone receptor status of the primary tumor: Patient note states \"The tumor is ER/PR negative.\"\n6. Participant agreement to undergo mastectomy or breast-conserving surgery after neoadjuvant therapy: Patient note states \"She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\"\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1: Patient note does not provide information on ECOG performance status.\n8. Baseline Left Ventricular Ejection Fraction (LVEF) >/= 55 percent (%) measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA): Patient note does not provide information on LVEF.\n9. Effective contraception as defined by protocol: Patient note does not provide information on contraception.\n\nStep 2: Determine eligibility based on the comparison\n\nBased on the information provided in the patient note, we can determine the following:\n\n- The patient meets the criteria for histologically confirmed invasive breast cancer with a primary tum",
        "label": 1
    },
    "249": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's condition in the patient note.\nThe patient has breast cancer, not a condition related to common bile duct stones.\n\nStep 2: Compare the patient's condition with the inclusion criteria of the clinical trial.\nThe patient does not meet the inclusion criteria, as they do not have common bile duct stones.\n\nStep 3: Determine the trial-level eligibility.\nSince the patient does not have common bile duct stones, they do not meet the inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "250": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient's age.\nThe patient is 45 years old, which meets the age requirement of 45 years or older.\n\nStep 2: Analyze the patient's cancer type and stage.\nThe patient has stage I-III, HER2-neu positive invasive ductal carcinoma, which meets the inclusion criteria.\n\nStep 3: Analyze the patient's treatment plan.\nThe patient is scheduled to receive adjuvant Trastuzumab, which is included in the trial's inclusion criteria. However, there is no mention of the patient receiving FEC-D chemotherapy or whole breast radiation therapy.\n\nStep 4: Analyze the patient's ECOG Performance status.\nThe patient's ECOG Performance status is not mentioned in the patient note.\n\nStep 5: Analyze the patient's cardiac ejection fraction and imaging.\nThe patient's cardiac ejection fraction and transthoracic echocardiography results are not mentioned in the patient note.\n\nStep 6: Determine the trial-level eligibility.\nSince the patient's ECOG Performance status, cardiac ejection fraction, and imaging results are not mentioned, we cannot determine if the patient meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "251": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria\nPatient's age: 45 years\nInclusion criterion: Patient must be \u2265 50 years\nResult: The patient does not meet the age criteria.\n\nStep 2: Compare patient's breast cancer type with the inclusion criteria\nPatient's breast cancer: Invasive ductal breast carcinoma, HER2-positive, ER/PR negative, stage I\nInclusion criterion: Core biopsy demonstrating breast cancer and receptors that are ER or PR positive\nResult: The patient does not meet the breast cancer type criteria.\n\nStep 3: Compare patient's node status with the inclusion criteria\nPatient's node status: 5 positive lymph nodes\nInclusion criterion: The patient must have clinical node negative, stage I breast cancer\nResult: The patient does not meet the node status criteria.\n\nStep 4: Compare patient's surgical treatment with the inclusion criteria\nPatient's surgical treatment: Candidate for tumor resection before chemotherapy\nInclusion criterion: The surgical treatment must be intended to be a lumpectomy\nResult: The patient does not meet the surgical treatment criteria.\n\nStep 5: Compare patient's other characteristics with the inclusion criteria\nPatient's other characteristics: Metastatic lesions, using multivitamins and iron supplements, no smoking or alcohol consumption, not sexually active, no children\nInclusion criteria: Patient must be able to tolerate lying in the prone position with arms extended forward, Must be able to tolerate MRI scan with contrast, At the time of enrollment, patients must have had bilateral mammograms within 6 months, Patients with a history of non-breast malignancies are eligible if they have been disease free for 5 or more years prior to enrollment, Patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin\nResult: The patient does not meet the other characteristics criteria.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "252": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nPatient age: 45 years old\nInclusion criteria: Patients must be 18 years of age or older.\nResult: The patient meets the age requirement.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nPatient gender: Female\nInclusion criteria: Patients must be female.\nResult: The patient meets the gender requirement.\n\nStep 3: Compare the patient's cancer stage to the inclusion criteria.\nPatient cancer stage: Cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma and 5 positive lymph nodes.\nInclusion criteria: Patients with stage I, II, or III breast cancer that is greater or equal to 2 cm on clinical examination.\nResult: The patient meets the cancer stage requirement.\n\nStep 4: Compare the patient's cancer type to the inclusion criteria.\nPatient cancer type: Invasive ductal breast carcinoma\nInclusion criteria: Patients that have biopsy proven invasive breast cancer diagnosed by core needle biopsy\nResult: The patient meets the cancer type requirement.\n\nStep 5: Compare the patient's treatment history to the inclusion criteria.\nPatient treatment history: Chemotherapy and radiotherapy na\u00efve for the treatment of the current breast cancer.\nInclusion criteria: Patients who are chemotherapy and radiotherapy na\u00efve for the treatment of the current breast cancer.\nResult: The patient meets the treatment history requirement.\n\nStep 6: Compare the patient's willingness to undergo neoadjuvant chemotherapy to the inclusion criteria.\nPatient willingness: The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\nInclusion criteria: Patients that accept to undergo neoadjuvant chemotherapy.\nResult: The patient meets the willingness requirement.\n\nStep 7: Compare the patient's consent to the inclusion criteria.\nPatient consent: The patient understands, accepts, and has signed the approved written consent form.\nInclusion criteria: Patients that understand, accept, and have signed the approved written consent form.\nResult: The patient meets the consent requirement.\n\nTrial-level eligibility: 2",
        "label": 2
    },
    "253": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria\nThe patient is 45 years old, which is within the range of \u226518 years and \u226470 years.\n\nStep 2: Compare the patient's disease with the inclusion criteria\nThe patient has histologically confirmed invasive breast cancer. The tumor size is not mentioned, but it is at least 2 cm. The tumor is T2-4 N0-2M0.\n\nStep 3: Compare the patient's hormone receptor and HER2 status with the inclusion criteria\nThe patient's ER/PR status is not mentioned, but the tumor is HER2-positive. ER/PR and HER-2 statuses are detected on core biopsy.\n\nStep 4: Compare the patient's treatment history with the inclusion criteria\nThe patient has not received any prior systemic or loco-regional treatment for breast cancer.\n\nStep 5: Compare the patient's ECOG performance status with the inclusion criteria\nThe patient's ECOG performance status is not mentioned, but it is assumed to be 0-2.\n\nStep 6: Compare the patient's bone marrow function and organ function with the inclusion criteria\nThe patient's bone marrow function and organ function are not mentioned, but it is assumed to be adequate.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "254": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age\nThe patient is 45 years old.\n\nStep 2: Identify the patient's gender\nThe patient is a female.\n\nStep 3: Identify the patient's cancer type\nThe patient has invasive ductal breast carcinoma.\n\nStep 4: Check if the patient meets the age criteria\nThe patient is older than 25 years old.\n\nStep 5: Check if the patient meets the gender criteria\nThe patient is a female.\n\nStep 6: Check if the patient has a positive indication of disease on mammogram or MRI scan\nThe patient has a core biopsy revealing a 3 cm invasive ductal breast carcinoma.\n\nStep 7: Check if the patient is a candidate for breast cancer surgery\nThe patient is a candidate for tumor resection.\n\nStep 8: Check if the patient can undergo up to 90 minutes of PEM imaging\nThere is no information about the patient's ability to undergo PEM imaging in the patient note.\n\nStep 9: Check if the patient is willing to sign informed consent\nThere is no information about the patient's willingness to sign informed consent in the patient note.\n\nStep 10: Repeat Trial-level eligibility\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "255": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state that participants must be fully postmenopausal. The trial does not specify an age range for participants, so the patient's age does not disqualify her from participation.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nThe patient is a woman, and the inclusion criteria state that participants must be female. The patient meets this criterion.\n\nStep 3: Compare the patient's hormone receptor status with the inclusion criteria.\nThe patient's tumor is ER/PR negative, but the inclusion criteria state that the tumor must be HR-positive. The patient does not meet this criterion, so she is excluded from the trial.\n\nStep 4: Compare the patient's cancer type and stage with the inclusion criteria.\nThe patient has invasive ductal breast carcinoma, not invasive lobular breast cancer, as required by the inclusion criteria. The patient does not meet this criterion, so she is excluded from the trial.\n\nStep 5: Compare the patient's ECOG performance status with the inclusion criteria.\nThe patient's ECOG performance status is not mentioned in the patient note, so we cannot determine if she meets this criterion.\n\nStep 6: Compare the patient's organ and marrow function with the inclusion criteria.\nThe patient's organ and marrow function is not mentioned in the patient note, so we cannot determine if she meets this criterion.\n\nStep 7: Compare the patient's prior use of hormone contraceptives and replacement therapy with the inclusion criteria.\nThe patient is using multivitamins and iron supplements, but there is no mention of hormone contraceptives or replacement therapy. We cannot determine if she meets this criterion.\n\nStep 8: Determine if the patient is aware of the nature of her malignancy and willing to sign a written informed consent document.\nThe patient's understanding of her malignancy and willingness to sign an informed consent document are not mentioned in the patient note, so we cannot determine if she meets this criterion.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "256": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nPatient's age: 45 years\nInclusion criteria: Women aged \u226518 years and \u226470 years\nThe patient's age is within the acceptable range, so this criterion is met.\n\nStep 2: Compare the patient's disease status with the inclusion criteria.\nPatient's disease: cytologically confirmed breast cancer, 3 cm invasive ductal breast carcinoma, HER2-positive, ER/PR negative, 5 positive lymph nodes, metastatic lesions\nInclusion criteria: Histologically confirmed invasive breast cancer, tumor size \u22652 cm, T2-4 N0-3M0; ER/PR/HER-2 and Ki-67 status detected on core biopsy\nThe patient's disease status meets the criteria for tumor size, stage, and receptor status, so this criterion is met.\n\nStep 3: Compare the patient's prior treatment history with the inclusion criteria.\nPatient's prior treatment: no prior systemic or loco-regional treatment of breast cancer\nInclusion criteria: No prior systemic or loco-regional treatment of breast cancer\nThe patient has not received prior treatment for breast cancer, so this criterion is met.\n\nStep 4: Compare the patient's bone marrow function with the inclusion criteria.\nPatient's bone marrow function: not provided\nInclusion criteria: Adequate bone marrow function: WBC\u22654.0\u00d7109/L, Absolute neutrophil count\uff08ANC\uff09\u22651.5\u00d7109/L, Platelets\uff08PLT\uff09\u2265100\u00d7109/L, Hemoglobin\uff08Hb\uff09\u226590g/L; aspartate aminotransferase(AST), Alanine aminotransferase (ALT)\u22641.5 upper normal limit (UNL), creatinine\u22641.5 UNL, bilirubin\u22641.5UNL; No obvious main organs dysfunction.\nThe patient's bone marrow function is not provided in the patient note, so this criterion is not relevant.\n\nStep 5: Comp",
        "label": 0
    },
    "257": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age.\nThe patient is 45 years old.\n\nStep 2: Identify the patient's gender.\nThe patient is a woman.\n\nStep 3: Identify the patient's disease.\nThe patient has cytologically confirmed breast cancer.\n\nStep 4: Identify the type and stage of the patient's disease.\nThe patient has a 3 cm invasive ductal breast carcinoma.\n\nStep 5: Identify the patient's medical history.\nThe patient is HER2-positive and ER/PR negative. She has 5 positive lymph nodes and metastatic lesions.\n\nStep 6: Identify the patient's treatment history.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nStep 7: Compare the patient's information to the inclusion criteria.\n- Invasive breast cancer (T1-T3): Yes\n- N0 on palpation: Unknown (not enough information)\n- Preoperative ultrasound performed: Unknown (not enough information)\n- Pathology report shows macrometastasis in 1-2 sentinel lymph nodes: Yes\n- Patients undergo breast-conserving therapy or mastectomy: Yes\n- The patient must have provided oral and written consent: Unknown (not enough information)\n- Age \u2265 18 years: Yes\n\nStep 8: Determine the patient's eligibility based on the inclusion criteria.\nThe patient meets most of the inclusion criteria, but there is not enough information to determine if they have undergone a preoperative ultrasound and if they have provided consent.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "258": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age, gender, and type of cancer.\n- Age: 45 years old\n- Gender: Female\n- Type of cancer: Breast cancer\n\nStep 2: Compare the patient's age, gender, and type of cancer to the inclusion criteria.\n- Known or suspected breast cancer: The patient has cytologically confirmed breast cancer, which meets the inclusion criteria.\n\nStep 3: Identify any exclusion criteria.\n- There are no exclusion criteria listed in the clinical trial summary.\n\nStep 4: Determine the patient's eligibility based on the inclusion and exclusion criteria.\n- The patient meets the inclusion criteria, and there are no exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "259": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nThe patient is a 45-year-old woman.\n\nStep 2: Compare the patient's age and gender to the inclusion criteria.\nThe inclusion criteria state that the patient must be female and age 30-49. The patient is female and within the age range of 30-49.\n\nStep 3: Determine if the patient can give informed consent.\nThe patient note does not provide information about the patient's ability to give informed consent.\n\nStep 4: Compare the patient's disease to the trial's focus.\nThe trial focuses on cervical neoplasia in HIV positive and negative women in Cambodia. The patient note mentions breast cancer, which is not the focus of this trial.\n\nStep 5: Assess the patient's eligibility based on the comparison.\nThe patient meets the inclusion criteria for gender and age, but the trial's focus is on cervical neoplasia, not breast cancer. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "260": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions\n- No children, not sexually active\n- Candidate for tumor resection\n\nStep 2: Compare the patient's characteristics to the inclusion criteria of the clinical trial.\n\n1. Female participants: Yes\n2. Postmenopausal status: Yes\n3. Histologically confirmed invasive breast carcinoma: Yes\n4. Stage I to operable Stage III breast cancer: Yes (5 positive lymph nodes)\n5. Estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-negative (HER2-): Yes\n6. Breast cancer eligible for primary surgery: Yes (candidate for tumor resection)\n7. Tumor tissue from formalin-fixed paraffin-embedded cores (FFPE) core biopsy of breast primary tumor: Not applicable (cytologically confirmed)\n8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1: Not specified\n9. Fasting glucose less than or equal to (</=) 125 milligrams per deciliter (mg/dL): Not specified\n10. Adequate hematological, renal, and hepatic function: Not specified\n11. Absence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule: Not specified\n12. Ability and willingness to comply with study visits, treatment, testing, and to comply with the protocol, in the investigator's judgment: Not specified\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\nSince several important criteria are not specified in the patient note, we cannot definitively determine the patient's eligibility. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "261": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer, not head and neck cancer. Therefore, she does not meet the first inclusion criterion.\n\nStep 2: Analyze the inclusion criteria\nInclusion Criteria 1: Histologically confirmed HNSCC, from any primary site. Nasopharyngeal carcinoma, WHO Type I (keratinizing), will be included. Squamous cell carcinoma of unknown primary, clearly related to the head and neck, will be included.\nThe patient has breast cancer, not head and neck cancer. She does not meet this inclusion criterion.\n\nStep 3: Continue analyzing the inclusion criteria\nInclusion Criteria 2: Recurrent/metastatic disease, fulfilling at least one of the criteria defined below:\nIncurable disease as assessed by surgical or radiation oncology\nMetastatic (M1) disease\nPersistent or progressive disease following curative-intent radiation, and not a candidate for surgical salvage due to incurability or morbidity. Patients who decline radical surgery are eligible.\nThe patient has breast cancer with metastatic lesions, so she meets this inclusion criterion.\n\nStep 4: Continue analyzing the inclusion criteria\nInclusion Criteria 3: Patients must have previously received, not tolerated, or been judged clinically unsuitable for platinum-containing therapy.\nInclusion Criteria 4: In the dose-expansion phase, patients must be cetuximab-resistant by fulfilling at least one of the criteria defined below:\nDisease recurrence within 6 months of completing definitive radiotherapy for locally advanced disease. Radiation must have included concurrent cetuximab. Induction chemotherapy, if given, may or may not have included cetuximab.\nDisease progression during, or within 6 months, of cetuximab treatment in the recurrent/metastatic setting. Prior cetuximab exposure may have occurred in first, second and/or third line.\nThe patient has breast cancer, not head and neck cancer, and does not meet these inclusion criteria.\n\nStep 5: Analyze the exclusion criteria\nExclusion Criteria 1: Prior",
        "label": 0
    },
    "262": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state \"Age \u2265 18 years.\" Since the patient is at least 18 years old, this criterion is met.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a female, and the inclusion criteria state \"Post-menopausal or pre/peri-menopausal women on tamoxifen.\" Since the patient is a female and meets the menopausal status requirement, this criterion is met.\n\nStep 3: Compare the patient's cancer type to the inclusion criteria.\nThe patient has breast cancer, and the inclusion criteria state \"Histologic diagnosis of unresectable, locally recurrent or MBC.\" Since the patient has metastatic breast cancer, this criterion is met.\n\nStep 4: Compare the patient's hormone receptor status to the inclusion criteria.\nThe patient's tumor is ER/PR negative, and the inclusion criteria state \"ER and/or PR-positive tumors.\" Since the patient's tumor is not ER/PR positive, this criterion is not met.\n\nStep 5: Compare the patient's HER2 status to the inclusion criteria.\nThe patient's tumor is HER2-positive, and the inclusion criteria state \"HER2-negative breast cancer.\" Since the patient's tumor is not HER2-negative, this criterion is not met.\n\nStep 6: Compare the patient's previous treatment history to the inclusion criteria.\nThe patient has not received chemotherapy for metastatic breast cancer, and the inclusion criteria state \"Only 1 previous chemotherapy regimen for MBC.\" Since the patient has not received more than one chemotherapy regimen for metastatic breast cancer, this criterion is met.\n\nStep 7: Compare the patient's previous anti-estrogen therapy to the inclusion criteria.\nThe patient has not received anti-estrogen therapy, and the inclusion criteria state \"Progressed on anti-estrogen therapy.\" Since the patient has not progressed on anti-estrogen therapy, this criterion is not met.\n\nStep 8: Compare the patient's",
        "label": 0
    },
    "263": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and menopausal status.\nThe patient is a 45-year-old postmenopausal woman.\n\nStep 2: Identify the patient's cancer type and stage.\nThe patient has cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions.\n\nStep 3: Compare the patient's cancer stage with the inclusion criteria.\nThe patient has clinical stage T1-2 (0-5 cm) and pathologic stage N0-1, M0 disease.\n\nStep 4: Check if the patient has undergone or will undergo the required surgery and treatment.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nStep 5: Check if the patient meets the other inclusion criteria.\nThe patient has undergone a lumpectomy with a 1-2 cm margin within 9 weeks of initiation of protocol radiotherapy.\n\nStep 6: Check if the patient meets the exclusion criteria.\nThe patient has metastatic lesions, which are an exclusion criterion for this trial.\n\nStep 7: Determine the patient's eligibility based on the assessment.\nThe patient meets the inclusion criteria but has metastatic lesions, which is an exclusion criterion. Therefore, the patient's eligibility is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "264": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note to inclusion criteria\n\nPatient note:\n- Patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer\n- Tumor is HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Patient is a candidate for tumor resection and agrees to do so prior to chemotherapy\n\nInclusion criteria for Part A of the study:\n- Women age greater than or equal to 18 years\n- AJCC 7 clinical stage II or III breast cancer\n- Biopsy-accessible breast tumor or participant candidates for primary surgery\n- Eastern Cooperative Oncology Group (ECOG) performance status 0 1\n\nThe patient meets the age, stage, and performance status criteria. However, the patient has metastatic lesions (CXR was remarkable for metastatic lesions), which is an exclusion criterion for Part A of the study.\n\nStep 2: Compare patient note to exclusion criteria\n\nExclusion criteria for Part A of the study:\n- Prior history of non-breast malignancy within 5 years prior to enrollment\n- Bilateral invasive or in-situ breast cancer\n- Inflammatory breast cancer\n- Clinical or radiological evidence of distant metastases\n- Prior hormone therapy, chemotherapy, biologic, targeted therapies, or radiation therapy for this malignancy\n- Pregnant and lactating women\n- Subjects with psychiatric illness and/or other specific situations that would limit compliance with study requirements and compromise participant follow-up\n- Lack of ability to understand and willingness to sign a written informed consent document\n\nThe patient has metastatic lesions, which is an exclusion criterion for Part A of the study. The patient does not have a history of non-breast malignancy, bilateral invasive or in-situ breast cancer, inflammatory breast cancer, or other exclusion criteria.\n\nStep 3: Determine trial-level eligibility\n\nBased on the comparison of the patient note to the inclusion and exclusion criteria for Part A of the study, the patient is not eligible for Part A of the study due to the presence of metastatic lesions.",
        "label": 2
    },
    "265": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age to the inclusion criteria\nThe patient is 45 years old, which falls within the age range of 18 years or older for both early and advanced/metastatic breast cancer settings.\n\nStep 2: Compare patient gender to the inclusion criteria\nThe patient is a woman, which matches the inclusion criteria for both early and advanced/metastatic breast cancer settings.\n\nStep 3: Compare patient diagnosis to the inclusion criteria\nThe patient has invasive ductal breast carcinoma, which matches the inclusion criteria for both early and advanced/metastatic breast cancer settings.\n\nStep 4: Compare patient tumor characteristics to the inclusion criteria\nThe patient's tumor is HER2-positive and ER/PR negative. This information is not directly mentioned in the inclusion criteria, but it is not an exclusion criterion either.\n\nStep 5: Compare patient medical history to the inclusion criteria\nThe patient has metastatic lesions, which are present in the advanced/metastatic breast cancer setting. However, the patient note does not provide information about the time since diagnosis or the patient's ability and willingness to sign the informed consent form.\n\nStep 6: Determine trial-level eligibility\nBased on the available information, the patient meets the inclusion criteria for the advanced/metastatic breast cancer setting. However, we cannot determine if the patient meets the criteria for the early breast cancer setting due to the lack of information about the time since diagnosis and the patient's ability and willingness to sign the informed consent form.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "266": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria.\nThe patient is 45 years old. The inclusion criteria do not mention age as a requirement. Therefore, we can proceed to the next step.\n\nStep 2: Compare patient's gender to the inclusion criteria.\nThe patient is a woman. The inclusion criteria do not mention gender as a requirement. Therefore, we can proceed to the next step.\n\nStep 3: Compare patient's disease type and stage to the inclusion criteria.\nThe patient has breast cancer. The inclusion criteria state that patients must have undergone surgical treatment for breast cancer with positive involvement of 1-3 axillary lymph nodes. The patient's biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant with 5 positive lymph nodes. Therefore, the patient meets this criterion.\n\nStep 4: Compare patient's performance status to the inclusion criteria.\nThe patient's ECOG performance status is not mentioned in the patient note. Therefore, we cannot determine if the patient meets this criterion.\n\nStep 5: Compare patient's treatment history to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The inclusion criteria state that patients must be candidates for treatment of their cancer with systemic chemotherapy in addition to hormonal therapy. Therefore, the patient meets this criterion.\n\nStep 6: Compare patient's tumor characteristics to the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative. The inclusion criteria state that breast tumors must be estrogen-receptor positive and HER2 positive. Therefore, the patient does not meet this criterion.\n\nStep 7: Compare patient's other medical conditions to the inclusion criteria.\nThe patient's other medical conditions are not mentioned in the patient note. Therefore, we cannot determine if the patient meets this criterion.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "267": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age, gender, and disease type.\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n\nStep 2: Compare the patient's age, gender, and disease type to the inclusion criteria.\n- The trial includes women with node positive breast cancer. The patient has node positive breast cancer.\n\nStep 3: Identify the patient's treatment history.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. She is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children.\n\nStep 4: Compare the patient's treatment history to the inclusion criteria.\n- The trial includes women treated with surgery, anthracycline-based or similar cardiotoxic chemotherapy, and regional nodal irradiation between 2000-2007. The patient's treatment history matches the inclusion criteria.\n\nStep 5: Determine the patient's eligibility based on the comparison.\n- The patient meets the inclusion criteria for the trial.\n\nStep 6: Repeat Trial-level eligibility.\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "268": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria\nThe patient is 45 years old, which falls within the age range of \u226518 and \u226470 years.\n\nStep 2: Compare the patient's ECOG performance status to the inclusion criteria\nThe patient's ECOG performance status is not mentioned in the patient note, so we cannot determine if they meet the criteria of 0 to 1.\n\nStep 3: Compare the patient's life expectancy to the inclusion criteria\nThe patient's life expectancy is not mentioned in the patient note, so we cannot determine if they meet the criteria of more than 12 weeks.\n\nStep 4: Compare the patient's measurable lesions to the inclusion criteria\nThe patient note does not mention the presence of measurable lesions, so we cannot determine if they meet the criteria.\n\nStep 5: Compare the patient's cancer type to the inclusion criteria\nThe patient has HER2-positive metastatic breast cancer, which matches the criteria of histologically or cytologically confirmed HER2 positive metastatic breast cancer.\n\nStep 6: Compare the patient's previous treatment to the inclusion criteria\nThe patient note does not mention the patient's previous treatment history, so we cannot determine if they meet the criteria of having failed prior therapies.\n\nStep 7: Compare the patient's laboratory values to the inclusion criteria\nThe patient note does not provide enough information on the patient's laboratory values to determine if they meet the criteria.\n\nStep 8: Compare the patient's informed consent to the inclusion criteria\nThe patient note does not mention if the patient has signed informed consent, so we cannot determine if they meet this criterion.\n\nSince we cannot determine if the patient meets several of the inclusion criteria, the patient's trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "269": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 45 years old, which meets the inclusion criteria of age 45 or greater.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nThe patient is female, which meets the inclusion criteria of being female.\n\nStep 3: Compare the patient's diagnosis with the inclusion criteria.\nThe patient has cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma, which meets the inclusion criteria of being diagnosed with operable invasive breast cancer, T1 and T2 (< 3.5 cm), N0, M0.\n\nStep 4: Compare the patient's suitability for breast conserving surgery with the inclusion criteria.\nThe patient is a candidate for tumor resection, which implies she is suitable for breast conserving surgery. This meets the inclusion criteria.\n\nStep 5: Compare the patient's ipsilateral diagnostic mammogram with the inclusion criteria.\nThe patient has had a diagnostic mammogram within 12 months of enrollment, which meets the inclusion criteria.\n\nSince the patient meets all the inclusion criteria, we can proceed to check for exclusion criteria.\n\nStep 6: Check for any exclusion criteria that may apply to the patient.\nThere are no specific exclusion criteria mentioned in the patient note that would disqualify her from participating in the trial.\n\nConclusion:\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "270": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria\nThe patient is 45 years old, and the inclusion criteria require the patient to be 50 years or greater. Therefore, the patient does not meet this criterion.\n\nStep 2: Compare patient's cancer stage to the inclusion criteria\nThe patient has cytologically confirmed breast cancer, but the inclusion criteria specify that the cancer must be newly diagnosed Stage 0 or I. Therefore, the patient does not meet this criterion.\n\nStep 3: Compare patient's tumor type to the inclusion criteria\nThe patient has a 3 cm invasive ductal breast carcinoma, while the inclusion criteria require the tumor to be DCIS or invasive non-lobular carcinoma of the breast. Therefore, the patient does not meet this criterion.\n\nStep 4: Compare patient's surgery to the inclusion criteria\nThe patient is a candidate for tumor resection, but the inclusion criteria require wide excision, lumpectomy, or partial mastectomy. Therefore, the patient does not meet this criterion.\n\nStep 5: Compare patient's hormone receptor status to the inclusion criteria\nThe patient's tumor is HER2-positive and ER/PR negative, while the inclusion criteria require ER positive and PR positive. Therefore, the patient does not meet this criterion.\n\nStep 6: Compare patient's axillary lymph nodes to the inclusion criteria\nThe patient has 5 positive lymph nodes, while the inclusion criteria allow no involved axillary lymph nodes or N0(i+) allowed. Therefore, the patient does not meet this criterion.\n\nStep 7: Compare patient's CyberKnife therapy initiation to the inclusion criteria\nThe patient's eligibility for CyberKnife therapy is not mentioned in the patient note, while the inclusion criteria require enrollment and the plan to initiate CyberKnife therapy within 12 weeks of the last breast cancer surgery. Therefore, the patient does not meet this criterion.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "271": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's condition and relevant information from the patient note.\n- The patient has breast cancer, which is not related to the clinical trial.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This is not related to the clinical trial.\n- The patient is not sexually active and has no children. This is not related to the clinical trial.\n- The patient is using multivitamins and iron supplements. This is not related to the clinical trial.\n- The patient does not smoke or consume alcohol. This is not related to the clinical trial.\n\nStep 2: Compare the patient's condition and relevant information to the inclusion criteria of the clinical trial.\n- Osteoarthrosis: The patient's condition is breast cancer, not osteoarthrosis.\n- TKR operation elective: The patient is a candidate for tumor resection, not a total knee replacement.\n- ASA I-III: The patient's medical condition is not provided to determine ASA classification.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n- The patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "272": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which meets the criteria of being \u2265 18 years of age.\n\nStep 2: Compare the patient's cancer type and stage to the inclusion criteria.\nThe patient has breast cancer, and the core biopsy revealed a 3 cm invasive ductal breast carcinoma. This meets the criteria of having histologically and radiographically confirmed non-metastatic breast cancer with minimal tumor size over 1 cm (\u2265T1c lesion).\n\nStep 3: Compare the patient's hormone receptor status to the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative. The inclusion criteria state that the study is for estrogen receptor (ER) strongly positive, human epithelial receptor (HER2) negative breast cancer. This patient does not meet this criterion.\n\nStep 4: Compare the patient's ECOG performance status to the inclusion criteria.\nThe patient's ECOG performance status is not mentioned in the patient note. Therefore, we cannot determine if they meet this criterion.\n\nStep 5: Compare the patient's blood counts and liver function to the inclusion criteria.\nThe patient's blood counts and liver function are not mentioned in the patient note. Therefore, we cannot determine if they meet these criteria.\n\nStep 6: Compare the patient's contraceptive status and pregnancy test to the inclusion criteria.\nThe patient is postmenopausal, so she is not of child-bearing potential. Therefore, this criterion does not apply to her.\n\nConclusion: The patient does not meet all the inclusion criteria for the clinical trial.\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "273": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the age range of 18 years or older required for the trial.\n\nStep 2: Compare the patient's diagnosis to the inclusion criteria.\nThe patient has a newly diagnosed infiltrating ductal carcinoma of the breast, which matches the inclusion criteria.\n\nStep 3: Compare the patient's primary tumor size to the inclusion criteria.\nThe patient's primary tumor is 3 cm in size, which is greater than or equal to 1.0 cm required for the trial.\n\nStep 4: Compare the patient's creatinine clearance to the inclusion criteria.\nThere is no information provided about the patient's creatinine clearance in the note.\n\nStep 5: Compare the patient's performance status to the inclusion criteria.\nThere is no information provided about the patient's ECOG performance status in the note.\n\nStep 6: Compare the patient's willingness and ability to provide informed consent to the inclusion criteria.\nThe patient is willing and able to provide informed consent, which matches the inclusion criteria.\n\nStep 7: Compare the patient's knowledge of the investigational nature of the trial to the inclusion criteria.\nThe patient is informed of the investigational nature of the trial, which matches the inclusion criteria.\n\nSince we do not have information about the patient's creatinine clearance and ECOG performance status, we cannot determine the trial-level eligibility with certainty. However, based on the available information, the patient meets most of the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "274": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Diagnosis: Invasive ductal breast carcinoma\n- Tumor size: 3 cm\n- HER2-positive and ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- Metastatic lesions on CXR\n- Multivitamins and iron supplements\n- No smoking or alcohol consumption\n- Not sexually active, no children\n- Candidate for tumor resection\n\nStep 2: Compare the patient's information to the inclusion criteria of the clinical trial.\n\n1. Tumor diameter \u22643 cm: The patient's tumor is 3 cm, which meets this criterion.\n2. Tumor from the papilla>2cm: This criterion is not applicable to the patient's note.\n3. Low grade ductal carcinoma in situ: The patient has invasive ductal breast carcinoma, not low grade ductal carcinoma in situ. This criterion is not met.\n4. Candidate for breast-conserving surgery: The patient is a candidate for tumor resection, which is a form of breast-conserving surgery. This criterion is met.\n5. Must have undergone lumpectomy with negative margins or minimal margin involvement: This criterion is not applicable to the patient's note.\n6. Currently undergoing re-excision of the biopsy cavity and/or sentinel lymph node biopsy or axillary lymph node dissection: This criterion is not applicable to the patient's note.\n7. No evidence of metastatic disease: The patient has metastatic lesions on CXR. This criterion is not met.\n8. Informed consent: This criterion is not applicable to the patient's note.\n\nStep 3: Determine the patient's trial-level eligibility based on the comparison.\n\nThe patient meets some inclusion criteria but does not meet others, specifically the criterion for low grade ductal carcinoma in situ and the criterion for no evidence of metastatic disease.\n\nTrial-level",
        "label": 0
    },
    "275": {
        "output": "GPT4 Correct Assistant: Let's compare the patient note and the inclusion criteria of the clinical trial step by step.\n\n1. Capable and willing to provide informed consent - Not mentioned in the patient note, but it's reasonable to assume the patient can provide consent.\n\n2. Women must not be pregnant or breast-feeding - The patient note states the patient is postmenopausal and not sexually active, so she is likely not pregnant or breast-feeding.\n\n3. Females of childbearing potential - The patient is postmenopausal, so she does not fit this criteria.\n\n4. Contraception for sexually active males - Not applicable, as the patient is not sexually active.\n\n5. Standard endocrine therapy planned after FES-PET/CT - The patient note states the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, so it's likely standard endocrine therapy will be planned after FES-PET/CT.\n\n6. Medically stable as judged by patient's physician - Not mentioned in the patient note, but it's reasonable to assume the patient is medically stable.\n\n7. Life expectancy > 6 months - Not mentioned in the patient note, but it's reasonable to assume the patient has a life expectancy of more than 6 months.\n\n8. ECOG performance status 0-3 - Not mentioned in the patient note, but it's reasonable to assume the patient has an ECOG performance status of 0-3.\n\n9. No history of allergic reaction to 18F-FES - Not mentioned in the patient note, but it's reasonable to assume the patient has no history of such an allergic reaction.\n\n10. No liver failure - Not mentioned in the patient note, but it's reasonable to assume the patient does not have liver failure.\n\n11. Histologically confirmed metastatic breast cancer - The patient note states the patient has cytologically confirmed breast cancer, which is a form of histological confirmation.\n\n12. Primary tumor and/or metastatic site ER+ - The patient note states the tumor is HER2-positive and ER/PR negative. This excludes the patient.\n\n13. Pathology report and either (1) tissue or (2) a",
        "label": 0
    },
    "276": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is a 45-year-old woman, and the inclusion criteria state that women aged 18 years and older can participate. The patient meets this criterion.\n\nStep 2: Compare the patient's ability to give informed consent to the inclusion criteria.\nThe patient note states that the patient is able to give informed consent. The inclusion criteria state that participants must be able to give informed consent themselves. The patient meets this criterion.\n\nStep 3: Compare the patient's WHO performance score to the inclusion criteria.\nThe patient note does not provide information about the patient's WHO performance score. Without this information, we cannot determine if the patient meets this criterion.\n\nStep 4: Compare the patient's breast cancer diagnosis to the inclusion criteria.\nThe patient has biopsy-proven cT1-2 N0-2 MX invasive breast cancer with a size of \u2264 3.0 cm. This matches the inclusion criteria, which state that participants must have biopsy-proven cT1-2 N0-2 MX invasive breast cancer with a size of \u2264 3.0 cm. The patient meets this criterion.\n\nStep 5: Compare the patient's tumor type to the inclusion criteria.\nThe patient has invasive ductal breast carcinoma, which matches the inclusion criteria, which state that participants must have a histological type of tumor: invasive ductal carcinoma (IDC), not otherwise specified (NOS) or no special type (NST). The patient meets this criterion.\n\nStep 6: Compare the patient's weight to the inclusion criteria.\nThe patient note does not provide information about the patient's weight. Without this information, we cannot determine if the patient meets this criterion.\n\nStep 7: Compare the patient's tumor location and distance to the inclusion criteria.\nThe patient note does not provide information about the distance of the tumor from the skin, nipple, and pectoral wall, or whether the tumor is located within the reach of the HIFU beam. Without this information, we cannot determine if the patient meets these criteria.\n\nTrial-level eligibility: 1",
        "label": 2
    },
    "277": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which falls within the age range of \u226518 and \u226470 years.\n\nStep 2: Compare the patient's ECOG performance status to the inclusion criteria.\nThe patient's ECOG performance status is not mentioned in the note. Therefore, this criterion is Not relevant (1).\n\nStep 3: Compare the patient's life expectancy to the inclusion criteria.\nThe patient's life expectancy is not mentioned in the note. Therefore, this criterion is Not relevant (1).\n\nStep 4: Compare the patient's cancer status to the inclusion criteria.\nThe patient has histologically confirmed HER2-positive advanced breast cancer, which failed prior therapies. This meets the criteria for histologically or cytologically confirmed HER2-positive advanced breast cancer which failed prior therapies.\n\nStep 5: Compare the patient's laboratory values to the inclusion criteria.\nThe patient's laboratory values are not mentioned in the note. Therefore, this criterion is Not relevant (1).\n\nStep 6: Compare the patient's informed consent to the inclusion criteria.\nThe patient has signed informed consent.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "278": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old. The inclusion criteria require women aged 50 and over. The patient does not meet this criterion.\n\nStep 2: Compare the patient's stage of breast cancer to the inclusion criteria.\nThe patient has stage IV (metastatic) breast cancer. The inclusion criteria require currently Stage IV breast cancer. The patient meets this criterion.\n\nStep 3: Compare the patient's ECOG Performance Score to the inclusion criteria.\nThe patient's ECOG Performance Score is not provided. The inclusion criteria require an ECOG Performance Score of 0 or 1. The patient does not have sufficient information to qualify for the trial.\n\nStep 4: Compare the patient's ability to participate in mildly strenuous physical effort to the inclusion criteria.\nThe patient's ability to participate in mildly strenuous physical effort is not provided. The inclusion criteria require the ability to participate occasionally in mildly strenuous physical effort. The patient does not have sufficient information to qualify for the trial.\n\nStep 5: Compare the patient's language abilities to the inclusion criteria.\nThe patient can read, speak, and write in English. The inclusion criteria require the ability to read, speak, and write in English. The patient meets this criterion.\n\nStep 6: Compare the patient's ability to be accompanied by their spouse or significant other to the inclusion criteria.\nThe patient's ability to be accompanied by their spouse or significant other is not provided. The inclusion criteria require the ability to be accompanied by their spouse or significant other. The patient does not have sufficient information to qualify for the trial.\n\nStep 7: Compare the patient's ability to travel to the retreat site to the inclusion criteria.\nThe patient's ability to travel to the retreat site is not provided. The inclusion criteria require the ability to travel to the retreat site. The patient does not have sufficient information to qualify for the trial.\n\nStep 8: Compare the patient's hand dominance to the inclusion criteria.\nThe patient's hand dominance is not provided. The inclusion criteria require being right-handed. The patient does not have sufficient information to qualify for the trial.\n\nStep 9: Compare the patient's ability to have",
        "label": 1
    },
    "279": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria\nThe patient is 45 years old. The inclusion criteria do not mention any specific age range or requirements.\n\nStep 2: Compare patient's gender with the inclusion criteria\nThe patient is a woman. The inclusion criteria mention that \"A woman of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [beta-hCG]) at screening and a negative urine pregnancy test at Week 0 before randomization.\" The patient's note does not provide information about her pregnancy status, so we cannot determine if she meets this criterion.\n\nStep 3: Compare patient's diagnosis with the inclusion criteria\nThe patient has breast cancer, not ankylosing spondylitis (AS) or axial spondyloarthritis (AxSpA). The inclusion criteria require a diagnosis of definite AS. The patient does not meet this criterion.\n\nStep 4: Compare patient's symptoms with the inclusion criteria\nThe patient's note does not provide information about her symptoms, so we cannot determine if she meets the criteria for active disease at screening and baseline.\n\nStep 5: Compare patient's laboratory values with the inclusion criteria\nThe patient's note does not provide information about her hsCRP level, so we cannot determine if she meets the criterion for an elevated hsCRP level.\n\nStep 6: Compare patient's medication use with the inclusion criteria\nThe patient is using multivitamins and iron supplements, but not NSAIDs or other analgesics for AS. The inclusion criteria mention that if using NSAIDs or other analgesics for AS, the participant must be on a stable dose for at least 2 weeks prior to the first administration of the study agent. The patient does not meet this criterion.\n\nStep 7: Compare patient's pregnancy status with the inclusion criteria\nThe patient's note does not provide information about her pregnancy status, so we cannot determine if she meets the criterion for being a woman of childbearing potential with a negative serum beta-hCG and a negative urine pregnancy test.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "280": {
        "output": "GPT4 Correct Assistant: Let's analyze the patient note and the inclusion criteria step by step:\n\n1. Age: The patient is 45 years old, which is within the range of 18-60 years for the trial.\n2. ECOG performance status: The patient's ECOG performance status is not mentioned in the note.\n3. Tumor type and characteristics: The patient has a HER2-positive, ER/PR-negative, invasive ductal breast carcinoma, which matches the trial's inclusion criteria.\n4. Stage: The patient has stage II/III operable breast cancer, which is eligible for the trial.\n5. Surgery: The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which aligns with the trial's requirements.\n6. Lymph node involvement: The patient has 5 positive lymph nodes, which is within the range of 1 or 2 positive nodes for the trial.\n7. Cardiac, renal, and bone marrow function: The patient's cardiac, renal, and bone marrow function is not mentioned in the note.\n8. Ability and willingness to comply with the study: The patient's ability and willingness to comply with the study is not mentioned in the note.\n\nSince we don't have information about the patient's ECOG performance status, cardiac, renal, and bone marrow function, and ability and willingness to comply with the study, we cannot determine the trial-level eligibility with certainty. However, based on the available information, the patient seems to meet most of the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "281": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's postmenopausal status.\nThe patient note states that the patient is a 45-year-old postmenopausal woman. This meets the first inclusion criterion.\n\nStep 2: Identify the patient's breast cancer type.\nThe patient note states that the patient has cytologically confirmed breast cancer. This meets the second inclusion criterion.\n\nStep 3: Determine the breast tumor size, HR+, and HER2- status.\nThe patient note states that the patient has a 3 cm invasive ductal breast carcinoma that is HER2-positive and ER/PR negative. This meets the third inclusion criterion.\n\nStep 4: Determine if neoadjuvant endocrine monotherapy is suitable.\nThe patient note states that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This implies that neoadjuvant endocrine monotherapy is suitable. This meets the fourth inclusion criterion.\n\nStep 5: Determine if the patient has a primary breast cancer suitable for baseline core biopsy.\nThe patient note states that a core biopsy was performed. This meets the fifth inclusion criterion.\n\nStep 6: Determine if the patient has adequate organ function.\nThe patient note does not provide information about the patient's organ function. Therefore, we cannot determine if this inclusion criterion is met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "282": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with inclusion criteria\nThe patient is 45 years old. The trial does not specify an age range, so this criterion is not relevant.\n\nStep 2: Compare patient's gender with inclusion criteria\nThe patient is female. The trial includes both male and female patients, so this criterion is not relevant.\n\nStep 3: Compare patient's cancer type with inclusion criteria\nThe patient has HER2-positive and ER/PR negative breast cancer. The trial includes patients with HER2-negative, ER/PR-negative, and triple-negative breast cancer. This criterion is met.\n\nStep 4: Compare patient's cancer stage with inclusion criteria\nThe patient has stage III breast cancer. The trial includes patients with clinical stage II-III breast cancer, so this criterion is met.\n\nStep 5: Compare patient's treatment history with inclusion criteria\nThe patient has not received cisplatin or carboplatin or capecitabine as part of their neoadjuvant therapy regimen. This criterion is met.\n\nStep 6: Compare patient's residual cancer status with inclusion criteria\nThe patient has residual invasive cancer in the breast. This criterion is met.\n\nStep 7: Compare patient's other medical conditions and treatments with inclusion criteria\nThe patient has no metastatic disease, which is an exclusion criterion for the trial. Therefore, the patient is excluded based on this criterion.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "283": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria do not specify an age range.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, and the inclusion criteria state \"Women with histologically confirmed breast cancer.\"\n\nStep 3: Compare the patient's disease type and stage to the inclusion criteria.\nThe patient has breast cancer, and the inclusion criteria state \"Women with histologically confirmed breast cancer.\" The patient has lymph node-positive disease, and the inclusion criteria state \"Lymph node-positive disease with less than 10 involved axillary lymph nodes.\"\n\nStep 4: Compare the patient's previous treatment history to the inclusion criteria.\nThe patient has not undergone surgery yet but is a candidate for tumor resection. The inclusion criteria state \"Women who had undergone radical mastectomy or breast-conserving surgery in addition to full ipsilateral axillary lymph node dissection.\" Since the patient has not had surgery yet, this criterion is not met.\n\nStep 5: Compare the patient's ECOG performance status to the inclusion criteria.\nThe patient's ECOG performance status is not mentioned in the patient note. The inclusion criteria state \"ECOG performance status 0.\"\n\nStep 6: Compare the patient's blood counts and liver function tests to the inclusion criteria.\nThe patient's blood counts and liver function tests are not mentioned in the patient note. The inclusion criteria state \"Absolute neutrophil count \u2265 2,000/mm\u00b3, WBC \u2265 3,000/mm\u00b3, Platelet count \u2265 100,000/mm\u00b3, Bilirubin \u2264 1.5 times upper limit of normal (ULN), AST and ALT \u2264 1.5 times ULN.\"\n\nStep 7: Compare the patient's consent status to the inclusion criteria.\nThe patient has not provided written informed consent. The inclusion criteria state \"Written informed consent.\"\n\nTrial-level eligibility: 0) Excluded",
        "label": 2
    },
    "284": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the trial's age requirement.\nThe patient is 45 years old, which is within the range for participation in the trial.\n\nStep 2: Compare the patient's gender to the trial's gender requirement.\nThe patient is a woman, which matches the trial's requirement for female participants.\n\nStep 3: Compare the patient's disease to the trial's disease requirements.\nThe patient has breast cancer, specifically HER2-positive and ER/PR negative. The trial is specifically for androgen receptor positive triple-negative metastatic breast cancer. The patient's disease type does not match the trial's requirements.\n\nStep 4: Compare the patient's tumor stage to the trial's tumor stage requirement.\nThe patient has clinical stage IV invasive mammary carcinoma, which matches the trial's requirement for stage IV cancer.\n\nStep 5: Compare the patient's receptor status to the trial's receptor requirements.\nThe patient is HER2-positive, which matches the trial's requirement for HER2-negative cancer. However, the patient is ER/PR negative, which does not match the trial's requirement for ER/PR negative cancer.\n\nStep 6: Compare the patient's androgen receptor status to the trial's androgen receptor requirement.\nThe patient's androgen receptor status is not mentioned in the patient note, so we cannot determine if they meet the trial's requirement for androgen receptor positivity.\n\nStep 7: Compare the patient's metastatic lesions to the trial's metastatic lesion requirement.\nThe patient has metastatic lesions, which matches the trial's requirement for measurable or bone-only evaluable disease.\n\nStep 8: Compare the patient's prior therapies to the trial's prior therapy requirement.\nThe patient has not received prior treatment with anti-androgens other than enzalutamide, which matches the trial's requirement for patients with any number of prior therapies.\n\nStep 9: Compare the patient's hematologic, hepatic, and renal function to the trial's laboratory requirements.\nThe patient's laboratory values are not",
        "label": 0
    },
    "285": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age.\nThe patient is 45 years old.\n\nStep 2: Identify the patient's gender.\nThe patient is a woman.\n\nStep 3: Identify the patient's disease.\nThe patient has breast cancer, not a pancreatic tumor.\n\nStep 4: Check if the patient's disease meets the inclusion criteria.\nThe patient does not have a solid pancreatic tumor mass.\n\nStep 5: Check if the patient's age meets the inclusion criteria.\nThe patient is within the age range of 18 to 90 years old.\n\nStep 6: Check if the patient's gender meets the inclusion criteria.\nThe patient is a woman, which meets the criteria for both men and women.\n\nStep 7: Check if the patient has signed informed consent.\nThe patient has not signed informed consent for EG-EUS, CE-EUS, and FNA biopsy.\n\nStep 8: Determine the trial-level eligibility.\nThe patient does not meet the inclusion criteria, and they have not signed informed consent.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "286": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age to inclusion criteria\nThe patient is 45 years old, which falls within the inclusion criteria of 18-65 years old.\n\nStep 2: Compare patient gender to inclusion criteria\nThe patient is female, which matches the inclusion criteria of being female.\n\nStep 3: Compare patient cancer stage to inclusion criteria\nThe patient has cT1-2N0-1M0 breast cancer, which matches the inclusion criteria of cT1-2N0-1M0.\n\nStep 4: Compare patient tumor type to inclusion criteria\nThe patient has invasive ductal breast carcinoma, which is a type of unilateral invasive carcinoma. This matches the inclusion criteria of unilateral invasive carcinoma.\n\nStep 5: Compare patient ER/PR/Her2 status to inclusion criteria\nThe patient's tumor is ER/PR negative and HER2 positive. According to the inclusion criteria, this means it is ER/PR negative and Her2 negative (as it is determined negative via FISH or CISH detected with no amplification). This matches the inclusion criteria.\n\nStep 6: Compare patient surgical eligibility to inclusion criteria\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which matches the inclusion criteria of newly diagnosed conditions allowing direct surgery without any absolute contraindication for surgery.\n\nStep 7: Compare patient ECOG performance score to inclusion criteria\nThe patient's ECOG performance score is not mentioned in the patient note, so we cannot determine if this criterion is met.\n\nStep 8: Compare patient follow-up willingness to inclusion criteria\nThe patient's willingness to return to the enrolling institution for follow-up during the Active Monitoring Phase is not mentioned in the patient note, so we cannot determine if this criterion is met.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "287": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age\nThe patient is a 45-year-old postmenopausal woman. The inclusion criteria state that the patient must be at least 18 years old. Since 45 is greater than 18, the patient meets the age criteria.\n\nStep 2: Identify the patient's gender\nThe patient is female. The inclusion criteria state that the patient must be male or female. Since the patient is female, she meets the gender criteria.\n\nStep 3: Identify the patient's cancer type and stage\nThe patient has invasive ductal breast carcinoma. The inclusion criteria state that the patient must have invasive mamma carcinoma as verified by core cut biopsy. Since the patient has invasive ductal breast carcinoma, she meets this criterion.\n\nStep 4: Identify the patient's tumor size and axillary lymph node status\nThe patient has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, and axillary sampling revealed 5 positive lymph nodes. The inclusion criteria state that the patient must have a clinical stage tumor T1-T3 and no signs of axillary lymph node metastasis on clinical examination including ultrasound examination. Since the patient has a clinical stage T3 tumor and 5 positive lymph nodes, she does not meet these criteria.\n\nStep 5: Identify the patient's distant metastatic disease status\nThe patient has metastatic lesions on CXR. The inclusion criteria state that the patient must have no signs of distant metastatic disease. Since the patient has metastatic lesions, she does not meet this criterion.\n\nStep 6: Identify the patient's performance status and informed consent\nThe patient's Karnofsky performance status is not provided, but the inclusion criteria state that the patient must have a Karnofsky performance status at least 70% or ECOG score not higher than 1. The patient's informed consent is not provided, but the inclusion criteria state that the patient must provide written informed consent. Since we do not have enough information to determine if the patient meets these criteria, the patient is Not relevant (1) for these criteria.\n\nTrial-level eligibility",
        "label": 1
    },
    "288": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria\nThe patient is 45 years old, which is within the range of 18-70 years stated in the inclusion criteria.\n\nStep 2: Compare patient's gender to the inclusion criteria\nThe patient is a woman, which matches the inclusion criteria for women with breast cancer.\n\nStep 3: Compare patient's disease stage to the inclusion criteria\nThe patient has a 3 cm invasive ductal breast carcinoma with 5 positive lymph nodes, which falls within the T1-3, N1-2a stage range mentioned in the inclusion criteria.\n\nStep 4: Compare patient's tumor characteristics to the inclusion criteria\nThe patient's tumor is HER2-positive and ER/PR negative, which matches the inclusion criteria for invasive adenocarcinoma of the breast.\n\nStep 5: Compare patient's treatment history to the inclusion criteria\nThe patient has not undergone neoadjuvant chemotherapy, which matches the inclusion criteria for patients who have not received neoadjuvant chemotherapy.\n\nStep 6: Compare patient's surgical status to the inclusion criteria\nThe patient is a candidate for tumor resection, which matches the inclusion criteria for patients who have undergone complete resection of known breast disease.\n\nStep 7: Compare patient's reproductive status to the inclusion criteria\nThe patient is postmenopausal, which matches the inclusion criteria for postmenopausal women.\n\nStep 8: Compare patient's eligibility for pregnancy prevention to the inclusion criteria\nThe patient is not sexually active and has no children, which matches the inclusion criteria for women of child-bearing potential who agree to use a medically accepted form of pregnancy prevention.\n\nConclusion: The patient meets all the inclusion criteria for the clinical trial, and there are no exclusion criteria mentioned in the provided information. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "289": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age.\nThe patient is a 45-year-old.\n\nStep 2: Identify the patient's condition.\nThe patient has cytologically confirmed breast cancer, not corneal endothelial dysfunction combined with cataract.\n\nStep 3: Check if the patient meets the age requirement.\nThe patient is older than 18 years, so they meet this criterion.\n\nStep 4: Check if the patient meets the condition requirement.\nThe patient does not have corneal endothelial dysfunction combined with cataract, so they do not meet this criterion.\n\nStep 5: Check if the patient meets the cataract severity requirement.\nThe patient's condition (breast cancer) is not related to the cataract severity, so this criterion is not applicable.\n\nStep 6: Check if the patient is able and willing to provide informed consent.\nThe patient's condition (breast cancer) is not related to the ability to provide informed consent, so this criterion is not applicable.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "290": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note with inclusion criteria\n- Patient has breast cancer (inclusion)\n- Patient has a lumpectomy (inclusion)\n- Patient has invasive ductal breast carcinoma (inclusion)\n- Patient is HER2-positive and ER/PR negative (not mentioned in inclusion criteria)\n- Patient has 5 positive lymph nodes (not mentioned in inclusion criteria)\n- Patient is 45 years old (not mentioned in inclusion criteria)\n- Patient is postmenopausal (not mentioned in inclusion criteria)\n\nStep 2: Determine if patient meets exclusion criteria\n- Patient is not eligible for trial if she has more than 3 positive lymph nodes, but she has 5 positive lymph nodes (exclusion)\n\nStep 3: Assess eligibility based on inclusion and exclusion criteria\n- Patient meets some inclusion criteria but also meets an exclusion criteria.\n\nStep 4: Determine trial-level eligibility\n- Since the patient meets an exclusion criteria, her trial-level eligibility is 0) Excluded.",
        "label": 1
    },
    "291": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\n1. Biopsy proven rectal adenocarcinoma: Not mentioned in the patient note, not enough information.\n2. Distance between tumour and anal verge\u2264 10cm: Not mentioned in the patient note, not enough information.\n3. Locally advanced tumour:(AJCC Cancer Staging:T3, T4 or N+): The patient has breast cancer, not rectal cancer. Excluded.\n4. Cancer Staging must be based on pelvic MRI: Not mentioned in the patient note, not enough information.\n5. Eastern Cooperative Oncology Group(ECOG) performance score \u2264 1: Not mentioned in the patient note, not enough information.\n6. Written informed consent: Not mentioned in the patient note, not enough information.\n7. Mentally and physically fit for chemotherapy: Not mentioned in the patient note, not enough information.\n8. Adequate blood counts: Not mentioned in the patient note, not enough information.\n9. No excision of tumor, chemotherapy or other anti-tumor treatment after the diagnosis: The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. Excluded.\n\nBased on the comparison, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "292": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nThe patient is a 45-year-old postmenopausal woman.\n\nStep 2: Identify the patient's diagnosis.\nThe patient has cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n\nStep 3: Check if the patient's diagnosis matches the inclusion criteria.\nThe inclusion criteria state that the study is for participants with a histopathological diagnosis of invasive breast cancer. The patient's diagnosis matches the inclusion criteria.\n\nStep 4: Check if the patient's sample type matches the inclusion criteria.\nThe inclusion criteria state that anatomopathological samples (surgical specimens or core needle biopsy) are required. The patient's diagnosis was confirmed by a core biopsy, which matches the inclusion criteria.\n\nStep 5: Check if the patient's HER2 status matches the inclusion criteria.\nThe inclusion criteria do not mention any specific HER2 status requirements.\n\nStep 6: Determine the patient's eligibility based on the assessment.\nThe patient meets all the inclusion criteria. There are no exclusion criteria mentioned in the trial description.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "293": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the age criteria in the inclusion and exclusion criteria.\n\nThe patient is 45 years old, which is within the age range of \u226518 years and < 70 years specified in the inclusion criteria.\n\nStep 2: Compare the patient's medical history to the medical history criteria in the inclusion and exclusion criteria.\n\nThe patient has cytologically confirmed breast cancer, which is a requirement for participation in the trial. The patient is HER2-positive and ER/PR negative, which does not match the inclusion criteria of ER positive, Her2 negative breast cancer. However, the exclusion criteria are not provided, so we cannot determine if this disqualifies the patient.\n\nStep 3: Compare the patient's tumor stage to the tumor stage criteria in the inclusion and exclusion criteria.\n\nThe patient has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, which is not specified in the inclusion or exclusion criteria. It is unclear if this would disqualify the patient.\n\nStep 4: Compare the patient's treatment history to the treatment history criteria in the inclusion and exclusion criteria.\n\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This is not specified in the inclusion or exclusion criteria, so it is unclear if this would disqualify the patient.\n\nStep 5: Compare the patient's liver and renal function to the liver and renal function criteria in the inclusion and exclusion criteria.\n\nThere is no information provided about the patient's liver and renal function, so we cannot determine if they meet the criteria.\n\nStep 6: Compare the patient's ECOG Performance Score to the ECOG Performance Score criteria in the inclusion and exclusion criteria.\n\nThere is no information provided about the patient's ECOG Performance Score, so we cannot determine if they meet the criteria.\n\nStep 7: Compare the patient's pregnancy status to the pregnancy status criteria in the inclusion and exclusion criteria.\n\nThe patient is not sexually active and has no children, but there is no information provided about her pregnancy status within 7 days of drug administration.\n\nStep 8: Compare the patient's informed consent to",
        "label": 0
    },
    "294": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative\n- 3 cm invasive ductal breast carcinoma\n- Metastatic lesions\n\nInclusion criteria:\n- DM type 1 or 2 diagnosis\n- DFU persisting for a minimum of 4 weeks\n- DFU 's rating according to the PEDIS system (Perfusion, Extension, Depth, Infection, Sensitivity)\n\nStep 2: Determine if patient meets inclusion criteria\n\nThe patient note does not provide any information about the patient having diabetes or a diabetic foot ulcer. Therefore, we cannot determine if the patient meets the inclusion criteria.\n\nStep 3: Repeat Trial-level eligibility\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "295": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nThe patient is a 45-year-old postmenopausal woman.\n\nStep 2: Check if the patient has a histologically proven infiltrating carcinoma of the breast on diagnostic biopsy.\nThe patient has a core biopsy revealing a 3 cm invasive ductal breast carcinoma.\n\nStep 3: Check if the patient meets the ER, PR, and HER2 status requirements.\nThe patient has HER2-positive and ER/PR negative breast cancer.\n\nStep 4: Check if the patient has unresected, untreated breast cancer planning surgical management with mastectomy.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nStep 5: Check if the patient is willing and able to sign an informed consent form.\nThe patient's note does not provide information on whether she is willing and able to sign an informed consent form.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "296": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is greater than 18 and less than 75. This meets the age criteria.\n\nStep 2: Compare the patient's tumor type to the inclusion criteria.\nThe patient has invasive ductal breast carcinoma, which is a primary lesion. This meets the tumor type criteria.\n\nStep 3: Compare the patient's IHC score to the inclusion criteria.\nThe patient's tumor is HER2-positive, but the IHC score is not provided. Without the IHC score, we cannot determine if this meets the criteria.\n\nStep 4: Compare the patient's tumor sample to the inclusion criteria.\nThe patient's tumor is a sample, but it's not clear if it's primary or from a lymph node. Without this information, we cannot determine if this meets the criteria.\n\nStep 5: Compare the patient's sample to the inclusion criteria.\nThe patient's sample is not specified as being 10% neutral buffered formalin-fixed and paraffin embedded tissue samples. Without this information, we cannot determine if this meets the criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "297": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nPatient's age: 45 years\nInclusion criteria: Subject aged 18 years and above\nThe patient meets the age criteria.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nPatient's gender: Female\nInclusion criteria: Subject being male or female\nThe patient meets the gender criteria.\n\nStep 3: Compare the patient's diagnosis with the inclusion criteria.\nPatient's diagnosis: Breast cancer\nInclusion criteria: Subject being operated for a papillary thyroid cancer, re-operated for persistent/relapsed lymphadenopathy, or for benign thyroid pathology (Graves disease, multinodular goitre, toxic nodule)\nThe patient does not meet the diagnosis criteria.\n\nStep 4: Compare the patient's social security coverage with the inclusion criteria.\nPatient's social security coverage: Not mentioned\nInclusion criteria: Subject with a valid social security coverage\nThe patient's social security coverage is not mentioned, so we cannot determine if they meet this criterion.\n\nStep 5: Compare the patient's willingness to participate with the inclusion criteria.\nPatient's willingness to participate: Not mentioned\nInclusion criteria: Subject willing to participate in the study with a signed informed consent\nThe patient's willingness to participate is not mentioned, so we cannot determine if they meet this criterion.\n\nStep 6: Compare the patient's blood test history with the inclusion criteria.\nPatient's blood test history: Not mentioned\nInclusion criteria: Subject having had a blood test for plasma Tg levels and circulating anti-Tg antibodies in the week preceding the surgical intervention\nThe patient's blood test history is not mentioned, so we cannot determine if they meet this criterion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "298": {
        "output": "GPT4 Correct Assistant: Step 1: Determine the patient's age and gender.\nPatient is a 45-year-old woman.\n\nStep 2: Determine the patient's cancer type and stage.\nPatient has cytologically confirmed breast cancer, and a core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions.\n\nStep 3: Compare the patient's cancer type and stage to the inclusion criteria.\nThe patient has Clinical T1 or T2 invasive breast cancer, which matches the inclusion criteria.\n\nStep 4: Determine if the patient has suspicious palpable adenopathy.\nThe patient has 5 positive lymph nodes, which is a form of adenopathy. This does not match the inclusion criteria.\n\nStep 5: Determine if the patient is eligible for the trial.\nThe patient does not meet the inclusion criteria due to having adenopathy.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "299": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender\nThe patient is a 45-year-old postmenopausal woman. The trial requires female patients at least 21 years old. Since the patient is 45 and female, she meets this criterion.\n\nStep 2: Identify the patient's cancer type and stage\nThe patient has cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma. The trial includes patients with invasive ductal carcinoma staged T1 or T2. Since the patient has invasive ductal carcinoma and it is staged T1 or T2, she meets this criterion.\n\nStep 3: Identify the patient's hormone receptor status\nThe patient's tumor is HER2-positive and ER/PR negative. The trial includes patients with estrogen receptor and progesterone receptor positive (ER+/PR+) tumors. Since the patient's tumor is ER/PR negative, she does not meet this criterion.\n\nStep 4: Identify if the patient is scheduled for sentinel lymph node biopsy\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This implies that she will undergo sentinel lymph node biopsy. She meets this criterion.\n\nStep 5: Identify if the patient has signed consent to participate\nThe patient's note does not provide information about whether she has signed consent to participate in the trial. Therefore, we cannot determine if she meets this criterion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "300": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age to inclusion criteria\nThe patient is 45 years old, which is within the age range of 18 years or older for the trial.\n\nStep 2: Compare patient gender to inclusion criteria\nThe patient is a woman, and there is no specific gender requirement in the inclusion criteria.\n\nStep 3: Compare patient medical condition to inclusion criteria\nThe patient has breast cancer, but the trial is focused on biliary tract disease (choledocholithiasis, benign biliary strictures, malignant biliary strictures). The patient's condition does not match the inclusion criteria.\n\nStep 4: Compare patient imaging results to inclusion criteria\nThe patient has a confirmed breast cancer diagnosis, but there is no mention of imaging results related to biliary tract disease in the patient note.\n\nStep 5: Determine trial-level eligibility\nSince the patient's medical condition does not match the inclusion criteria, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "301": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria.\nThe patient is a 45-year-old postmenopausal woman, and the inclusion criteria state that female patients aged 18 years or older can participate. The patient meets this criterion.\n\nStep 2: Compare patient's gender with the inclusion criteria.\nThe patient is a woman, and the inclusion criteria state that only female patients can participate. The patient meets this criterion.\n\nStep 3: Compare patient's cancer type and stage with the inclusion criteria.\nThe patient has cytologically confirmed breast cancer, and the inclusion criteria state that patients with early high-risk and locally advanced or inflammatory breast cancers can participate. The patient meets this criterion.\n\nStep 4: Compare patient's tumor histology with the inclusion criteria.\nThe patient has invasive ductal breast carcinoma, and the inclusion criteria state that patients with invasive ductal histology not otherwise specified (NOS) can participate. The patient meets this criterion.\n\nStep 5: Compare patient's HER2 status with the inclusion criteria.\nThe patient's tumor is HER2-positive, but the inclusion criteria state that patients with HER2-negative disease can participate. The patient does not meet this criterion.\n\nStep 6: Compare patient's ER/PR status with the inclusion criteria.\nThe patient's tumor is ER/PR negative, and the inclusion criteria state that patients with negative estrogen receptor (ER) and progesterone receptor (PgR), both < 1% locally assessed, can participate. The patient meets this criterion.\n\nStep 7: Compare patient's ECOG performance status with the inclusion criteria.\nThe patient's ECOG performance status is not mentioned, but the inclusion criteria state that patients with an ECOG performance status of 0 or 1 can participate. The patient's eligibility is not affected by this criterion.\n\nStep 8: Compare patient's consent to participate with the inclusion criteria.\nThe patient has given written informed consent to participate in the trial, and the inclusion criteria state that patients who have obtained written informed consent can participate. The patient meets this criterion.",
        "label": 0
    },
    "302": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria\nThe patient is 45 years old, and the inclusion criteria require participants to be at least 18 years old. The patient meets this criterion.\n\nStep 2: Compare patient's gender to the inclusion criteria\nThe patient is a woman, and the inclusion criteria require participants to be female. The patient meets this criterion.\n\nStep 3: Compare patient's diagnosis to the inclusion criteria\nThe patient has breast cancer, not endometrial cancer. The patient does not meet this criterion.\n\nStep 4: Compare patient's stage of disease to the inclusion criteria\nThe patient has metastatic lesions, which is not specified in the inclusion criteria. The patient does not meet this criterion.\n\nStep 5: Compare patient's treatment plan to the inclusion criteria\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This is not specified in the inclusion criteria, but it is not an exclusion criterion either. The patient meets this criterion.\n\nStep 6: Compare patient's performance status to the inclusion criteria\nThe patient's GOG performance status is not provided. The patient does not meet this criterion.\n\nStep 7: Compare patient's laboratory values to the inclusion criteria\nThe patient's laboratory values are not provided. The patient does not meet this criterion.\n\nStep 8: Compare patient's contraceptive status to the inclusion criteria\nThe patient is not sexually active and has no children. The patient meets this criterion.\n\nStep 9: Compare patient's informed consent to the inclusion criteria\nThe patient agrees to sign an informed consent document. The patient meets this criterion.\n\nTrial-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).",
        "label": 0
    },
    "303": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age\nThe patient is a 45-year-old woman.\n\nStep 2: Identify the patient's gender\nThe patient is a woman.\n\nStep 3: Identify the patient's condition\nThe patient has cytologically confirmed breast cancer.\n\nStep 4: Compare the patient's condition to the inclusion criteria\nThe inclusion criteria state that women having breast cancer are eligible for the trial.\n\nStep 5: Determine if there are any exclusion criteria\nThere are no exclusion criteria mentioned in the patient note.\n\nStep 6: Assess the patient's eligibility\nThe patient meets the inclusion criteria and exclusion criteria do not apply.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "304": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria\nThe patient is 45 years old, and the inclusion criteria state that the patient must be \u2265 18 years of age at the time of consent. The patient meets this criterion.\n\nStep 2: Compare patient's disease stage with the inclusion criteria\nThe patient has stage II breast cancer, which is included in the inclusion criteria as stage I and II breast cancer. The patient meets this criterion.\n\nStep 3: Compare patient's hormone receptor status with the inclusion criteria\nThe patient has HER2-positive and ER/PR negative breast cancer. The inclusion criteria state that the patient must have Hormone Receptor positive (ER+ PR-, ER- PR+ or ER+ PR+) or Hormone Receptor negative (ER- and PR-) breast cancer. The patient does not meet this criterion.\n\nStep 4: Compare patient's axillary lymph node status with the inclusion criteria\nThe patient has 5 positive lymph nodes, which exceeds the inclusion criteria of 0-3 involved lymph nodes. The patient does not meet this criterion.\n\nConclusion: Based on the comparison of the patient's information with the inclusion criteria, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "305": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note and clinical trial inclusion criteria\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- CXR shows metastatic lesions\n- No children, not sexually active\n- Candidate for tumor resection prior to chemotherapy\n\nClinical Trial Inclusion Criteria:\n- Biopsy-verified breast cancer\n- Primary tumor more than 2 cm (ultrasound or clinically)\n- Capable of understanding and giving full informed written consent\n\nStep 2: Compare the patient note to the inclusion criteria\n\n1. Biopsy-verified breast cancer: The patient has cytologically confirmed breast cancer, which is equivalent to a biopsy-verified diagnosis.\n2. Primary tumor more than 2 cm (ultrasound or clinically): The patient's tumor is 3 cm, which is greater than 2 cm.\n3. Capable of understanding and giving full informed written consent: The patient's note does not provide information about her ability to give consent.\n\nStep 3: Determine the patient's eligibility based on the comparison\n\nSince the patient meets the first two inclusion criteria, we can assess her eligibility as follows:\n\nTrial-level eligibility: 1) Not relevant (patient does not have sufficient information to qualify for the trial).",
        "label": 2
    },
    "306": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient note to the inclusion criteria\n\n1. Unilateral or bilateral primary carcinoma of the breast, confirmed histologically by core biopsy.\n   - Patient has a confirmed breast cancer by core biopsy.\n\n2. Tumor lesion in the breast with a palpable size of 2 cm or a sonographical size of 1 cm in maximum diameter.\n   - Patient's tumor is 3 cm, which is larger than the maximum diameter of 1 cm.\n\n3. Patients must have stage cT1c - cT4a-d disease.\n   - Patient has axillary sampling revealing 5 positive lymph nodes, indicating stage cT1c.\n\n4. Centrally confirmed ER-negative and PR-negative status. Central pathology includes also assessment of HER2, Ki-67, TIL and RANK status on core biopsy.\n   - Patient's tumor is HER2-positive and ER/PR negative.\n\n5. Exclusion criteria:\n   - Patient does not meet any exclusion criteria.\n\nStep 2: Determine the eligibility based on the comparison\n\nSince the patient does not meet all inclusion criteria, the eligibility is 0) Excluded.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "307": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is a 45-year-old postmenopausal woman. The inclusion criteria do not specify an age range.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman. The inclusion criteria do not specify a gender requirement.\n\nStep 3: Compare the patient's cancer type and stage to the inclusion criteria.\nThe patient has cytologically confirmed breast cancer. The inclusion criteria are for patients with histologically confirmed muscle-invasive urothelial cancer.\n\nStep 4: Compare the patient's CT, PET, or MRI results to the inclusion criteria.\nThe patient has metastatic lesions, which means they have distant metastases. The inclusion criteria require no pelvic nodal metastases or distant metastases.\n\nStep 5: Compare the patient's Karnofsky performance status (KPS) to the inclusion criteria.\nThe patient's KPS is not provided. The inclusion criteria require a KPS >= 70.\n\nStep 6: Compare the patient's ability to understand and willingness to sign informed consent to the inclusion criteria.\nThe patient's ability to understand and willingness to sign informed consent is not provided. The inclusion criteria require ability to understand and willingness to sign informed consent.\n\nStep 7: Compare the patient's treatment option to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The inclusion criteria require patients to have either opted for bladder-sparing treatment as compared to radical cystectomy, or deemed medically inoperable.\n\nStep 8: Compare the patient's additional conditions to the inclusion criteria.\nThe patient's additional conditions are not provided. The inclusion criteria do not specify any additional conditions.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "308": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria. The patient is 45 years old, and there is no specific age requirement in the inclusion criteria.\n\nStep 2: Compare the patient's gender with the inclusion criteria. The patient is a woman, and there is no specific gender requirement in the inclusion criteria.\n\nStep 3: Compare the patient's cancer type with the inclusion criteria. The patient has invasive ductal breast carcinoma, which matches the inclusion criteria for invasive duct or lobular adenocarcinoma of the breast.\n\nStep 4: Compare the patient's tumor stage with the inclusion criteria. The patient has a 3 cm tumor, which matches the inclusion criteria for pathologic T1-3, N1-2 disease.\n\nStep 5: Compare the patient's HER2 status with the inclusion criteria. The patient's tumor is HER2-positive, which matches the inclusion criteria for HER2(human epidermal growth factor receptor 2) testing.\n\nStep 6: Compare the patient's ER and PR status with the inclusion criteria. The patient's tumor is ER/PR negative, which does not match the inclusion criteria for 5- ER(estrogen-receptor), PR (progesterone-receptor), and HER2(human epidermal growth factor receptor 2) testing.\n\nStep 7: Compare the patient's lymph node status with the inclusion criteria. The patient has 5 positive lymph nodes, which matches the inclusion criteria for axillary nodal involvement.\n\nStep 8: Compare the patient's surgery type with the inclusion criteria. The patient is a candidate for tumor resection, which matches the inclusion criteria for complete resection of known breast disease by one of the following surgeries.\n\nStep 9: Compare the patient's consent to participate with the inclusion criteria. The patient agrees to do tumor resection prior to chemotherapy, which matches the inclusion criteria for ability to understand and willingness to sign the consent form.\n\nStep 10: Compare the patient's use of multivitamins and iron supplements with the inclusion criteria. There is no specific requirement or exclusion related to supplements in the inclusion criteria.",
        "label": 2
    },
    "309": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR was remarkable for metastatic lesions.\n\nStep 2: Compare the patient note with the inclusion criteria\n\n1. Aged 18 or older: The patient is 45 years old, which meets the age requirement.\n2. Radiographic or histologic proof of metastatic bone disease: The patient has metastatic lesions in the chest X-ray (CXR).\n3. Histologic diagnosis of the primary tumour or - if the diagnosis is unknown - at least adequate diagnostic investigations into the origin of the metastasis: The patient has cytologically confirmed breast cancer.\n4. Bone metastasis deriving from the bones of the extremities: The patient's metastatic lesions are not specified to be in the bones of the extremities.\n\nStep 3: Determine the trial-level eligibility based on the comparison\nSince the patient meets most of the inclusion criteria, but there is no information about the location of the bone metastases, we cannot determine if the patient is eligible or not.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "310": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which meets the inclusion criteria of being aged 18 or older.\n\nStep 2: Compare the patient's diagnosis to the inclusion criteria.\nThe patient has breast cancer, which is not one of the specified bones (humerus, ulna, radius, femur, tibia, fibula) for the trial. Therefore, the patient does not meet the inclusion criteria.\n\nStep 3: Compare the patient's treatment to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This is a surgical treatment, but it is not specified whether it is for a pathologic fracture or impending pathologic fracture. Therefore, we cannot determine if the patient meets the inclusion criteria for this aspect.\n\nConclusion: Based on the information provided, the patient does not meet the inclusion criteria for the clinical trial. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "311": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age, gender, and cancer type.\n- Age: 45 years old\n- Gender: Female\n- Cancer type: Invasive ductal breast carcinoma\n\nStep 2: Check if the patient's cancer type matches the trial's inclusion criteria.\n- Inclusion Criteria: Histologically/cytologically confirmed diagnosis of breast cancer.\n- The patient's diagnosis matches the inclusion criteria.\n\nStep 3: Check if the patient's cancer stage matches the trial's inclusion criteria.\n- Inclusion Criteria: Radiological evidence of inoperable locally advanced or metastatic breast cancer.\n- The patient has metastatic lesions, indicating metastatic breast cancer.\n\nStep 4: Check if the patient's HER2 status matches the trial's inclusion criteria.\n- Inclusion Criteria: HER2 negative breast cancer (based on the most recent analyzed biopsy) defined as a negative in situ hybridization test or an immunohistochemistry status of 0, 1+ or 2+.\n- The patient's cancer is HER2-positive, which is not eligible for this trial.\n\nStep 5: Check if the patient's ER/PR status matches the trial's inclusion criteria for the expansion part.\n- For Expansion part: Triple-negative breast cancer defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0,1+ or 2+ER abnd PR status <10% by local laboratory testing.\n- The patient's ER/PR status is not provided, so we cannot determine eligibility for the expansion part.\n\nStep 6: Determine the patient's trial-level eligibility.\n- The patient's HER2-positive status excludes her from the trial, regardless of the other criteria.\n- Trial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "312": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note\n- Patient is a 45-year-old postmenopausal woman\n- Diagnosed with cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions in CXR\n\nStep 2: Compare the patient note with the inclusion criteria\n- Age: 45-year-old postmenopausal woman, which is within the age range (<70 years old)\n- Breast cancer: Yes, invasive ductal breast carcinoma\n- HER2-positive and ER/PR negative: Yes, but this is not a requirement for the trial\n- Metastatic lesions: No, patient has metastatic lesions, which is an exclusion criterion\n\nStep 3: Determine the patient's eligibility\nSince the patient has metastatic lesions, she is excluded from the trial based on the exclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "313": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria.\nThe patient is a 45-year-old woman. The inclusion criteria state that participants must be women aged \u2265 18 years. The patient meets this criterion.\n\nStep 2: Compare patient's disease with the inclusion criteria.\nThe patient has cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The patient has 5 positive lymph nodes and metastatic lesions. The inclusion criteria state that subjects must have histologically confirmed invasive breast cancer and registration must occur within 14 months after the first histologic diagnosis of invasive breast cancer. The patient meets this criterion.\n\nStep 3: Compare patient's HER2 status with the inclusion criteria.\nThe patient's tumor is HER2-positive. The inclusion criteria state that subjects must be Her-2 negative. The patient does not meet this criterion.\n\nStep 4: Compare patient's ER/PR status with the inclusion criteria.\nThe patient's tumor is ER/PR negative. The inclusion criteria state that eligible tumor-node-metastasis (TNM) Stages include: Estrogen receptor (ER) and Progesterone receptor (PR) negative (defined as <1% staining for ER and PR by IHC): T2 or T3 N0, T0-3N1-3. The patient meets this criterion.\n\nStep 5: Compare patient's history of invasive breast cancer with the inclusion criteria.\nThe patient has a history of breast cancer. The inclusion criteria state that there should be no history of invasive breast cancer in 5 years prior to study registration other than the current diagnosis. The patient does not meet this criterion.\n\nStep 6: Compare patient's mammogram with the inclusion criteria.\nThe patient had a mammogram within 12 months prior to registration. The inclusion criteria state that patients must have had a bilateral mammogram within 12 months prior to registration, unless the initial surgery was a total mastectomy. The patient meets this criterion.\n\nStep 7: Compare patient's prior treatment with the inclusion criteria.\nThe patient has undergone chemotherapy",
        "label": 0
    },
    "314": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n- The patient has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nStep 2: Compare the patient's information with the inclusion criteria of the clinical trial.\n- The patient has biopsy-proven breast cancer.\n- The patient has biopsy-proven axillary lymph node metastases (5 positive lymph nodes).\n\nStep 3: Determine the trial-level eligibility based on the comparison.\n- The patient meets both inclusion criteria.\n- There are no exclusion criteria mentioned in the patient note.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "315": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n\n- Patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- Tumor is 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- Metastatic lesions in the CXR.\n- Taking multivitamins and iron supplements.\n- No smoking or alcohol consumption.\n- Not sexually active and has no children.\n- Candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nStep 2: Compare the patient's characteristics with the inclusion and exclusion criteria of the clinical trial.\n\nInclusion Criteria:\n- Pathologically confirmed metastatic triple negative invasive breast cancer.\n- Hormone receptor status (ER and PR) both \u2264 5% by immunohistochemistry, and HER2 status confirmed by means of immunohistochemistry (with 0 or 1+ indicating negative status) or fluorescence in situ hybridization (with amplification ratio < 2.0 indicating negative status).\n- Have either Evaluable disease, or have measurable clinical disease.\n- Age > 18 years.\n- Disease stage: Unresectable metastatic disease.\n- Patients received up to 2 prior regimens for their disease in the metastatic setting.\n- Patients are candidates for chemotherapy with carboplatin and gemcitabine.\n- ECOG performance status 0 - 2.\n- Adequate organ function tests and hematologic indices within 10 days of registration.\n- Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to registration.\n- Female subjects of childbearing potential must be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication.\n- Signed written Informed Consent in accordance with regulatory and institutional guidelines.\n\nExclusion Criteria:",
        "label": 0
    },
    "316": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria\nThe patient is 45 years old, and the inclusion criteria state that patients must be 18 years of age or older.\n\nStep 2: Compare patient's gender with the inclusion criteria\nThe patient is a woman, and the inclusion criteria state that women are eligible.\n\nStep 3: Compare patient's disease stage with the inclusion criteria\nThe patient has cytologically confirmed breast cancer, but the inclusion criteria specify that patients must have Stage I to III histologically confirmed invasive carcinoma of the breast.\n\nStep 4: Compare patient's tumor size with the inclusion criteria\nThe patient's tumor is 3 cm, and the inclusion criteria require a minimum tumor size of at least 1.5 cm.\n\nStep 5: Compare patient's hormone receptor status with the inclusion criteria\nThe patient's tumor is HER2-positive and ER/PR negative, while the inclusion criteria require patients to have histologically confirmed hormone receptor positive (ER and/or PR), HER2 negative, invasive breast cancer.\n\nStep 6: Compare patient's histological subtype with the inclusion criteria\nThe patient has invasive ductal breast carcinoma, and the inclusion criteria allow patients with invasive lobular carcinoma or invasive ductal carcinoma.\n\nStep 7: Compare patient's ECOG performance status with the inclusion criteria\nThe patient's ECOG performance status is not mentioned, but the inclusion criteria state that patients must have an ECOG performance status of 0 or 1.\n\nStep 8: Compare patient's laboratory values with the inclusion criteria\nThe patient's laboratory values are not mentioned, but the inclusion criteria list required laboratory values.\n\nStep 9: Compare patient's menopausal status with the inclusion criteria\nThe patient is postmenopausal, and the inclusion criteria state that postmenopausal patients are eligible.\n\nStep 10: Compare patient's willingness to participate in research biopsies with the inclusion criteria\nThe patient's willingness to participate in research biopsies is not mentioned, but the inclusion criteria state that patients must agree to the required research biopsies.\n\nStep 11:",
        "label": 0
    },
    "317": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n\n- Age: 45 years old\n- Gender: Female\n- Diagnosis: Cytologically confirmed breast cancer\n- Tumor type: Invasive ductal breast carcinoma\n- Tumor location: Left upper outer quadrant\n- Tumor size: 3 cm\n- HER2 status: Positive\n- ER/PR status: Negative\n- Axillary sampling: 5 positive lymph nodes\n- CXR: Metastatic lesions\n- Medications: Multivitamins and iron supplements\n- Smoking: No\n- Alcohol consumption: No\n- Sexual activity: Not sexually active\n- Children: No\n- Treatment plan: Candidate for tumor resection before chemotherapy\n\nStep 2: Compare the patient's characteristics with the inclusion criteria of the clinical trial.\n\nInclusion Criteria:\n- Histologically confirmed primary invasive breast cancer by core needle biopsy\n\nThe patient has a histologically confirmed primary invasive breast cancer by core needle biopsy.\n\nStep 3: Determine the trial-level eligibility.\n\nThe patient meets the inclusion criteria for the clinical trial. There are no exclusion criteria mentioned in the clinical trial summary.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "318": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is a 45-year-old woman, which falls within the age range of 18 to 80 years specified in the inclusion criteria.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nThe patient is a female, which matches the inclusion criteria.\n\nStep 3: Compare the patient's diagnosis with the inclusion criteria.\nThe patient has histologically confirmed metastatic breast cancer (stage IV), which matches the inclusion criteria.\n\nStep 4: Compare the patient's treatment history with the inclusion criteria.\nThe patient has undergone at least three lines of chemotherapy, which matches the inclusion criteria.\n\nStep 5: Compare the patient's expected survival time with the inclusion criteria.\nThe patient has an expected survival time of at least 3 months, which matches the inclusion criteria.\n\nStep 6: Compare the patient's eligibility based on the exclusion criteria.\nThe patient does not meet any of the exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "319": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria.\nPatient age: 45 years old\nInclusion criteria: Female patients aged 18 years or older.\nThe patient meets the age requirement.\n\nStep 2: Compare patient's gender with the inclusion criteria.\nPatient gender: Female\nInclusion criteria: Female patients aged 18 years or older.\nThe patient meets the gender requirement.\n\nStep 3: Compare patient's cancer type and stage with the inclusion criteria.\nPatient cancer type: Invasive ductal breast carcinoma\nPatient cancer stage: Unknown (metastatic lesions present)\nInclusion criteria: Histologically or cytologically confirmed untreated invasive carcinoma of the breast\nThe patient meets the cancer type and stage requirement.\n\nStep 4: Compare patient's hormone receptor status with the inclusion criteria.\nPatient HR status: ER/PR negative, HER2-positive\nInclusion criteria: HR-positive (defined as either ER and/or PR expression >10% by immunohistochemistry or by PCR)\nThe patient does not meet the HR status requirement.\n\nStep 5: Compare patient's metastatic status with the inclusion criteria.\nPatient metastatic status: Yes (metastatic lesions present)\nInclusion criteria: No evidence of metastatic disease.\nThe patient does not meet the metastatic status requirement.\n\nStep 6: Compare patient's ECOG performance status with the inclusion criteria.\nPatient ECOG performance status: Not provided\nInclusion criteria: Eastern Cooperative Oncology Group (ECOG) performance status 0/1.\nThe patient's ECOG performance status is not provided, so the eligibility is not determined.\n\nStep 7: Compare patient's pregnancy status with the inclusion criteria.\nPatient pregnancy status: Not provided (postmenopausal)\nInclusion criteria: Negative pregnancy test in women of childbearing potential within 14 days prior to treatment initiation (premenopausal or less than 12 months of amenorrhea post-menopause, and who have not undergone surgical sterilization).\nThe patient's pregnancy",
        "label": 0
    },
    "320": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which meets the criteria of being at least 18 years old.\n\nStep 2: Compare the patient's diagnosis to the inclusion criteria.\nThe patient has cytologically confirmed breast cancer, which meets the criteria of a confirmed histologic diagnosis of invasive adenocarcinoma of the breast.\n\nStep 3: Compare the patient's tumor characteristics to the inclusion criteria.\nThe patient's tumor is HER2-positive, which meets the criteria of permitted HER2-positive pathology.\n\nStep 4: Compare the patient's nodal status to the inclusion criteria.\nThe patient has 5 positive lymph nodes, which is not specified in the inclusion criteria. However, the criteria do not exclude patients with any nodal status.\n\nStep 5: Compare the patient's tumor size to the inclusion criteria.\nThe patient's tumor is 3 cm, which is greater than the minimal diameter of 1.5 cm required.\n\nStep 6: Compare the patient's tumor location to the inclusion criteria.\nThe patient's tumor is in the left upper outer quadrant, which does not conflict with the criteria.\n\nStep 7: Compare the patient's tumor resection plans to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which meets the criteria of breast surgery planned.\n\nStep 8: Compare the patient's performance status to the inclusion criteria.\nThe patient's ECOG performance status score is not provided, but the criteria do not exclude patients with a score of 0 or 1.\n\nStep 9: Compare the patient's laboratory values to the inclusion criteria.\nThe patient's laboratory values are not provided, but the criteria do not exclude patients based on these values.\n\nStep 10: Compare the patient's contraception status to the inclusion criteria.\nThe patient's contraception status is not provided, but the criteria do not exclude patients based on contraception status.\n\nStep 11: Compare the patient's pregnancy and breastfeeding status to the inclusion criteria.\nThe patient is not",
        "label": 2
    },
    "321": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 45 years old. According to the inclusion criteria, postmenopausal women are defined as:\n- Age >60 years\n- Age >45 with intact uterus and amenorrhea for \u2265 12 consecutive months or Follicle stimulating hormone (FSH) levels within postmenopausal range according to the ranges established by the testing facility\n- Premenopausal women who have been on a GnRH agonist for at least 6 weeks prior to study entry. Women in this group MUST remain on the GnRH agonist for the duration of protocol treatment\n- Status post bilateral oophorectomy, after adequate healing post surgery\nMen are eligible, as long as on a GnRH agonist for at least 6 weeks prior to study entry. Men MUST remain on the GnRH agonist for the duration of protocol treatment.\n\nSince the patient is 45 years old and has amenorrhea for \u2265 12 consecutive months, she meets the criteria for being postmenopausal.\n\nStep 2: Compare the patient's cancer type with the inclusion criteria.\nThe patient has cytologically confirmed breast cancer. The inclusion criteria require participants to have histologically or cytologically confirmed hormone receptor (HR)-positive, Her2-negative metastatic breast cancer. The patient meets this criterion.\n\nStep 3: Compare the patient's previous treatment history with the inclusion criteria.\nThe patient has a 3 cm invasive ductal breast carcinoma that is HER2-positive and ER/PR negative. The inclusion criteria require participants to have radiological or objective evidence of progression to a CDK4/6 inhibitor regimen in the metastatic setting AND relapse/progression on an NSAI (defined as either relapsed \u2264 12 months after completing adjuvant NSAI or progressed through an NSAI for metastatic or locally advanced breast cancer). The patient meets this criterion.\n\nStep 4: Compare the patient's other medical conditions and eligibility criteria.\nThe patient meets all other eligibility criteria, including having measurable disease as per RECIST",
        "label": 0
    },
    "322": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nThe patient is a 45-year-old postmenopausal woman.\n\nStep 2: Determine if the patient has breast cancer.\nThe patient has cytologically confirmed breast cancer.\n\nStep 3: Check if there is an available primary breast tumor sample with adjacent normal epithelial structures.\nThe patient has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. This indicates that there is a primary breast tumor sample available.\n\nStep 4: Verify if informed consent has been obtained and signed.\nIn the patient note, it is mentioned that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This implies that informed consent has been obtained and signed.\n\nStep 5: Compare the patient's characteristics with the inclusion criteria.\nThe patient is a female with breast cancer, is over 18 years old, has an available primary breast tumor sample with adjacent normal epithelial structures, and has obtained informed consent.\n\nStep 6: Determine the trial-level eligibility.\nAll inclusion criteria are met, and there are no exclusion criteria mentioned in the patient note.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "323": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age with the inclusion criteria\nThe patient is 45 years old, and the trial includes patients aged 18 and above. The patient meets the age requirement.\n\nStep 2: Compare patient gender with the inclusion criteria\nThe patient is a woman, and the trial includes women. The patient meets the gender requirement.\n\nStep 3: Compare patient breast cancer type with the inclusion criteria\nThe patient has breast cancer, and the trial includes patients with breast cancer. The patient meets the cancer type requirement.\n\nStep 4: Compare patient cancer stage with the inclusion criteria\nThe patient has stage II-III breast cancer, and the trial includes patients with stage II-III breast cancer. The patient meets the cancer stage requirement.\n\nStep 5: Compare patient tumor size with the inclusion criteria\nThe patient's tumor is 3 cm, which is larger than the 2 cm minimum required by the trial. The patient meets the tumor size requirement.\n\nStep 6: Compare patient performance status with the inclusion criteria\nThe patient's ECOG performance status is not provided, so we cannot determine if she meets this requirement.\n\nStep 7: Compare patient organ function with the inclusion criteria\nThe patient's organ function is not provided, so we cannot determine if she meets this requirement.\n\nStep 8: Compare patient's ability to understand and willingness to sign informed consent with the inclusion criteria\nThe patient's ability to understand and willingness to sign informed consent is not provided, so we cannot determine if she meets this requirement.\n\nStep 9: Compare patient's ability to use adequate contraception with the inclusion criteria\nThe patient's contraceptive status is not provided, so we cannot determine if she meets this requirement.\n\nSince we do not have enough information to determine if the patient meets all the inclusion criteria, her trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "324": {
        "output": "GPT4 Correct Assistant: Patient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions in CXR\n- Taking multivitamins and iron supplements\n- No smoking or alcohol consumption\n- Not sexually active and no children\n- Candidate for tumor resection and agrees to do so prior to chemotherapy\n\nClinical Trial:\nTitle: Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab\n\nInclusion Criteria:\n- Female or male subjects aged > 18 years\n- Signed informed consent\n- ECOG performance status 0 or 1\n- Completed treatment with curative intent, including surgery and adjuvant chemotherapy\n- No more than 10 weeks between last adjuvant treatment and randomization\n- Normal organ and marrow function\n- WBC \u2265 2.5 x 109/L\n- ANC \u2265 1.5 x 109/L\n- Lymphocyte count \u2265 0.5 x 109/L\n- Platelet count \u2265 100 x 109/L\n- Hemoglobin \u2265 9 g/dL\n- Serum creatinine \u2264 1.5 x ULN\n- Adequate hepatic function\n- Highly effective contraception for both male and female subjects if the risk of conception exists\n- Ability to understand and willingness to sign a written informed consent\n\nInclusion Criteria for Stratum A (Adjuvant patients):\n- Non-metastatic, histologically confirmed primary invasive breast carcinoma\n- Triple negative breast cancer: hormone receptor negative (ER < 10% and PgR < 10%) and HER2 negative (IHC 0/1+ or ISH non-amplified)\n- Adequately excised: either breast-conserving surgery or mastectomy/n",
        "label": 0
    },
    "325": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age - The patient is 45 years old.\n\nStep 2: Identify the patient's gender - The patient is female.\n\nStep 3: Identify the patient's disease - The patient has cytologically confirmed breast cancer.\n\nStep 4: Check if the patient's disease matches the trial's inclusion criteria - The trial is for breast cancer patients undergoing lumpectomy. The patient is scheduled for tumor resection before chemotherapy.\n\nStep 5: Identify the patient's tumor characteristics - The patient has a 3 cm invasive ductal breast carcinoma, which is a type of breast cancer. The tumor is HER2-positive and ER/PR negative.\n\nStep 6: Check if the patient's tumor characteristics match the trial's inclusion criteria - The trial includes patients with invasive breast cancer or DCIS, and HER2 IHC and/or FISH ordered on core biopsy if biopsy indicates invasive cancer.\n\nStep 7: Identify the patient's eligibility for breast conserving surgery - The patient is a candidate for tumor resection, which is a form of breast conserving surgery.\n\nStep 8: Check if the patient's eligibility for breast conserving surgery matches the trial's inclusion criteria - The trial includes patients eligible for breast conserving surgery, lumpectomy, and radiation.\n\nStep 9: Determine if the patient is willing to sign a written informed consent document - The patient is willing to sign a written informed consent document.\n\nStep 10: Repeat Trial-level eligibility - Trial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "326": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is a 45-year-old postmenopausal woman, and the inclusion criteria state \"Adult women greater than 18 years old.\" Since the patient is older than 18, she meets this criterion.\n\nStep 2: Compare the patient's performance status to the inclusion criteria.\nThe patient's performance status is not mentioned in the patient note, so we cannot determine if she meets the ECOG performance status criteria of 0-2. Therefore, the patient does not have sufficient information to qualify for the trial based on this criterion.\n\nStep 3: Compare the patient's cancer type and stage to the inclusion criteria.\nThe patient has cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma, and she is a candidate for tumor resection. The inclusion criteria state \"New diagnosis of invasive cyclin D1 +, ER+, PR +/-, Her2- breast cancer.\" Since the patient's cancer type and stage match the criteria, she meets this criterion.\n\nStep 4: Compare the patient's hormone receptor status to the inclusion criteria.\nThe patient's hormone receptor status is ER/PR negative, which does not match the criteria of \"Hormone receptor positive as defined as \u2265 10% positive stained cells.\" Therefore, the patient does not meet this criterion.\n\nStep 5: Compare the patient's HER2 status to the inclusion criteria.\nThe patient's HER2 status is positive, which does not match the criteria of \"HER2-normal (IHC score 0-1 or FISH negative [in-situ hybridization (ISH) ratio <= 2.0 status]).\" Therefore, the patient does not meet this criterion.\n\nStep 6: Compare the patient's pregnancy status to the inclusion criteria.\nThe patient's pregnancy status is not mentioned in the patient note, so we cannot determine if she meets the criterion of \"A negative urine dipstick pregnancy test.\" Therefore, the patient does not have sufficient information to qualify for the trial based on this criterion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "327": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note.\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. She has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. She has 5 positive lymph nodes and metastatic lesions.\n\nStep 2: Compare the patient's information with the inclusion criteria.\n\nCohort A:\n- Age 40 years or older: The patient is 45 years old, which meets the age requirement.\n- Female sex: The patient is female, which meets the sex requirement.\n- HER2 positive or triple receptor negative: The patient's tumor is HER2-positive, which meets the requirement.\n- Patient desires breast conserving therapy: The patient agrees to tumor resection before chemotherapy, which implies she desires breast conserving therapy.\n\nCohort A does not have specific requirements for tumor size, nodal involvement, or ER/PR status, so the patient meets the requirements for Cohort A.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "328": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the age range of at least 18 years old.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is female, which matches the inclusion criteria.\n\nStep 3: Compare the patient's cancer type and status to the inclusion criteria.\nThe patient has HER2-negative breast cancer, which matches the inclusion criteria of ER+ Her2- breast cancer.\n\nStep 4: Compare the patient's metastatic status to the inclusion criteria.\nThe patient has metastatic lesions, which matches the inclusion criteria of metastatic breast cancer.\n\nStep 5: Compare the patient's eligibility for fulvestrant therapy to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which means she is eligible for fulvestrant therapy.\n\nStep 6: Compare the patient's ability to swallow the study drug and comply with study requirements to the inclusion criteria.\nThe patient is able to swallow the study drug and comply with study requirements.\n\nStep 7: Compare the patient's blood counts and liver function to the inclusion criteria.\nThe patient's ANC is >1000/uL, platelets are >75,000/uL, total bilirubin is <1.5 times ULN, AST and ALT are <3 times ULN, creatinine is <1.5 times ULN, and INR is <1.5 times ULN.\n\nStep 8: Compare the patient's willingness to donate blood for research and obtain informed consent to the inclusion criteria.\nThe patient is willing to donate blood for research and has obtained informed consent.\n\nStep 9: Compare the patient's willingness to use contraception to the inclusion criteria.\nThe patient is willing to use contraception as required.\n\nBased on the comparison of the patient's information to the inclusion criteria, the patient meets all the requirements for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "329": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age, gender, and type of cancer.\n- Age: 45 years old\n- Gender: Female\n- Type of cancer: Breast cancer\n\nStep 2: Identify the patient's HER2 status.\n- HER2-positive\n\nStep 3: Check if the patient has a proven result of HER2 testing.\n- The patient has a cytologically confirmed breast cancer, which implies she has undergone HER2 testing.\n\nStep 4: Determine if the patient is alive or not alive.\n- The patient is alive, as indicated in the patient note.\n\nStep 5: Compare the patient's information with the inclusion criteria.\n- Initially diagnosed with breast cancer: Yes\n- Has a proven result of HER2 testing: Yes\n- Alive or not alive: Yes\n\nStep 6: Determine the trial-level eligibility.\n- Since the patient meets all the inclusion criteria, the trial-level eligibility is 2) Eligible.",
        "label": 2
    },
    "330": {
        "output": "GPT4 Correct Assistant: First, let's compare the patient note with the inclusion criteria of the clinical trial:\n\n1. The patient is 45 years old, which is within the age range of the trial (>= 18 years).\n2. The patient has cytologically confirmed breast cancer, which is a type of cancer included in the trial.\n3. The tumor is HER2-positive and ER/PR negative, which is consistent with the trial's inclusion criteria for triple-receptor-negative breast cancer.\n4. The patient has 5 positive lymph nodes, which is included in the trial's criteria for ypN1mi, ypN1, ypN2, or ypN3.\n5. The patient has not received and is not planning to receive adjuvant anti-HER2 or endocrine therapies after completion of neoadjuvant chemotherapy, which is consistent with the trial's criteria.\n6. The patient has residual disease greater than or equal to 1 cm in greatest dimension, which is included in the trial's criteria.\n7. The patient has not metastatic disease, which is consistent with the trial's criteria (i.e., must be clinically M0 or Mx).\n8. The patient has undergone axillary lymph node sampling after completion of neoadjuvant chemotherapy, which is a recommended practice in the trial's guidelines.\n9. The patient has adequate tumor tissue available for PD-L1 testing, which is a requirement in the trial.\n10. The patient has not received immunotherapy with anti-PD-L1, anti-PD-1, anti-CTLA4, or similar drugs, which is consistent with the trial's criteria.\n11. The patient has not received concurrent radiation therapy, which is allowed in the trial.\n12. The patient is not planning to receive any of the prohibited therapies during the screening or treatment phases of the study, which is consistent with the trial's criteria.\n13. The patient is not planning to receive chemotherapy, hormonal therapy, or other anti-cancer therapy concurrently with MK-3475 (pembrolizumab), which is consistent with the trial's criteria.\n14. The patient has a Zubrod performance status <= 2",
        "label": 0
    },
    "331": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age.\nThe patient is a 45-year-old postmenopausal woman.\n\nStep 2: Identify the patient's gender.\nThe patient is a woman.\n\nStep 3: Identify the patient's breast cancer type.\nThe patient has invasive ductal breast carcinoma, which is HER2-positive and ER/PR negative.\n\nStep 4: Identify the patient's lymph node status.\nThe patient has 5 positive lymph nodes.\n\nStep 5: Identify the patient's metastatic status.\nThe patient has metastatic lesions.\n\nStep 6: Identify the patient's eligibility for Cohort A or Cohort B.\nThe patient's breast cancer is HER2-positive and ER/PR negative, which makes her eligible for Cohort A.\n\nStep 7: Compare the patient's eligibility to the inclusion criteria.\nThe patient meets the following inclusion criteria:\n- Invasive adenocarcinoma of the breast diagnosed by core needle biopsy\n- Breast cancer determined to be HER2-negative per current American Society of Clinical Oncologists/College of American Pathologists (ASCO/CAP) HER2 Guidelines\n- Breast cancer determined to be hormone receptor-negative defined as < 10% staining by IHC for both ER and PgR\n- Locally advanced breast cancer defined as any of the following per American Joint Committee on Cancer (AJCC) Staging Criteria\n- Age \u2265 18 years\n- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n- Adequate bone marrow function\n- Adequate renal function\n- Adequate hepatic function\n- LVEF assessment indicates an LVEF \u2265 50%\n- Ability to understand and willingness to sign the consent form\n\nThe patient does not meet the following inclusion criteria:\n- Breast cancer determined to be hormone receptor-positive or hormone receptor-negative defined as follows:\n  - Hormone receptor-positive: \u2265 10% staining by IHC for either",
        "label": 0
    },
    "332": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria\nThe patient is 45 years old, which is within the range of 18 to 75 years specified in the inclusion criteria.\n\nStep 2: Compare patient's performance status with the inclusion criteria\nThe patient's ECOG performance status is not provided in the patient note, so we cannot determine if they meet the inclusion criteria for ECOG performance status of 0 to 1.\n\nStep 3: Compare patient's life expectancy with the inclusion criteria\nThe patient's life expectancy is not provided in the patient note, so we cannot determine if they meet the inclusion criteria for life expectancy of more than 12 weeks.\n\nStep 4: Compare patient's measurable lesion with the inclusion criteria\nThe patient has metastatic lesions, which are measurable, so they meet the inclusion criteria for at least one measurable lesion.\n\nStep 5: Compare patient's cancer type and prior treatment with the inclusion criteria\nThe patient has HER2-positive advanced breast cancer, which is the same as the required cancer type in the inclusion criteria. The patient has also received prior treatment with trastuzumab, anthracyclin, and taxane, which are the required prior treatments in the inclusion criteria.\n\nStep 6: Compare patient's laboratory values with the inclusion criteria\nThe patient's laboratory values are not provided in the patient note, so we cannot determine if they meet the inclusion criteria for the required laboratory values.\n\nStep 7: Compare patient's informed consent with the inclusion criteria\nThe patient has signed informed consent, which is a requirement in the inclusion criteria.\n\nSince we cannot determine if the patient meets the inclusion criteria for ECOG performance status, life expectancy, and required laboratory values, we cannot definitively determine their trial-level eligibility.",
        "label": 1
    },
    "333": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n- Age: 45 years\n- Gender: Female\n- Cancer type: Breast cancer (invasive ductal carcinoma)\n- Hormone receptor status: ER/PR negative, HER2-positive\n- Stage: Histological stage not specified, but metastatic lesions present\n- Previous treatment: Core biopsy, axillary sampling, no previous chemotherapy or endocrine therapy\n- ECOG score: Not specified\n- Tumor location: Left upper outer quadrant\n- Other medical conditions: Normal or acceptable kidney, liver, cardiovascular, and bone marrow functions (implied by no mention of issues)\n\nStep 2: Compare the patient's characteristics with the inclusion criteria of the clinical trial.\n\nInclusion Criteria:\n1. Estrogen receptor-positive and HER2-negative breast cancer patients\n2. Histological stage of IIa-IIIc\n3. Without previous chemotherapy or endocrine therapy\n4. ECOG scores of 0-2 points\n5. Measurable and evaluable breast tumor pathologically confirmed as invasive ductal carcinoma\n6. Age: 18-70 years\n7. Lateral breast cancer\n8. Normal or acceptable kidney, liver, cardiovascular, and bone marrow functions\n\nComparison:\n- Cancer type: The patient has invasive ductal carcinoma, which matches the inclusion criteria.\n- Hormone receptor status: The patient is HER2-positive and ER/PR negative, which does not match the inclusion criteria of ER-positive and HER2-negative breast cancer.\n- Stage: The patient's stage is not specified, but metastatic lesions are present, which may not match the inclusion criteria of stage IIa-IIIc.\n- Previous treatment: The patient has not received previous chemotherapy or endocrine therapy, which matches the inclusion criteria.\n- ECOG score: The patient's ECOG score is not specified, which is not relevant to the inclusion criteria.\n- Tumor location: The tumor location is left upper outer quadrant, which is not relevant to the inclusion criteria.\n- Other medical conditions: The patient has normal",
        "label": 0
    },
    "334": {
        "output": "GPT4 Correct Assistant: Step 1: Age\nThe patient is a 45-year-old postmenopausal woman. The clinical trial does not specify an age range, so the patient's age is not a factor in determining eligibility.\n\nStep 2: Gender\nThe patient is a woman. The clinical trial is for breast cancer patients, so the patient's gender is not a factor in determining eligibility.\n\nStep 3: Type and stage of disease\nThe patient has cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The trial is for early-stage invasive breast cancer patients, so the patient's stage of disease is not a factor in determining eligibility.\n\nStep 4: Previous treatment history\nThe patient has not undergone neoadjuvant chemotherapy, endocrinotherapy, or targeted therapy previously. The clinical trial specifies that patients who have not undergone these treatments are eligible, so the patient's previous treatment history is not a factor in determining eligibility.\n\nStep 5: Medical conditions\nThe patient has no history of breast and axillary surgery. The clinical trial specifies that patients without breast and axillary surgery history are eligible, so the patient's medical conditions are not a factor in determining eligibility.\n\nStep 6: Other factors\nThe patient has an Ejection fraction score in the normal range according to cardiac doppler and an Eastern Cooperative Oncology Group score of 0, both of which are within the trial's requirements. The patient also has axillary lymph node clinical negativity, which is a requirement of the trial.\n\nConclusion:\nThe patient meets the inclusion criteria of the clinical trial and does not meet any exclusion criteria. Therefore, the trial-level eligibility is 2) Eligible.",
        "label": 0
    },
    "335": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the age range of \u2265 18 years for inclusion in the trial.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, which is not specified in the inclusion criteria, but women are generally allowed in clinical trials unless specifically excluded.\n\nStep 3: Compare the patient's disease to the inclusion criteria.\nThe patient has breast cancer, not pancreatic ductal adenocarcinoma (PDAC), so she does not meet the inclusion criteria for this trial.\n\nStep 4: Compare the patient's treatment history to the inclusion criteria.\nThe patient has not received chemotherapy or any investigational agent for the treatment of PDAC, which meets the inclusion criteria.\n\nStep 5: Compare the patient's other medical conditions to the inclusion criteria.\n\nThe patient has no children, is not sexually active, does not smoke or consume alcohol, and is a candidate for tumor resection and agrees to do so prior to chemotherapy. These factors do not conflict with the inclusion criteria.\n\nStep 6: Compare the patient's laboratory values to the inclusion criteria.\nThe patient's laboratory values are not provided in the patient note, so we cannot determine if she meets the inclusion criteria based on this information.\n\nStep 7: Compare the patient's performance status and life expectancy to the inclusion criteria.\nThe patient's performance status and life expectancy are not provided in the patient note, so we cannot determine if she meets the inclusion criteria based on this information.\n\nStep 8: Compare the patient's contraception and pregnancy status to the inclusion criteria.\nThe patient's contraception and pregnancy status are not provided in the patient note, so we cannot determine if she meets the inclusion criteria based on this information.\n\nStep 9: Compare the patient's ability to access treatment and follow-up to the inclusion criteria.\nThe patient's ability to access treatment and follow-up is not provided in the patient note, so we cannot determine if she meets the inclusion criteria based on this information.\n\nBased on the information provided in the patient note, the patient does not meet the inclusion criteria for the clinical trial. Therefore,",
        "label": 0
    },
    "336": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age. The patient is 45 years old, which is within the age range of 18 years or more.\n\nStep 2: Identify the patient's condition. The patient has a breast lesion requiring image-guided localization prior to excision. This meets the first inclusion criterion.\n\nStep 3: Check for any exclusion criteria. There are no exclusion criteria mentioned in the trial information.\n\nConclusion: Based on the provided information, the patient meets the inclusion criteria and there are no exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "337": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note and compare it to the inclusion criteria of the clinical trial.\n\nPatient note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions in CXR\n- No children, not sexually active\n- Candidate for tumor resection before chemotherapy\n\nInclusion criteria:\n- Histologically or cytologically confirmed invasive breast cancer, stage IV\n- HER2+ breast cancer per ASCO CAP guidelines 2013\n- Prior chemotherapy with trastuzumab and a taxane\n- One line of prior therapy for metastatic breast cancer or disease recurrence within 6 months after completing adjuvant therapy\n- No prior treatment with T-DM1\n- Last dose of chemotherapy at least 21 days prior to registration\n- Age \u226518 years\n- ECOG performance status \u22642\n- Normal organ and marrow function\n- Tissue amenable to biopsy and willing to undergo a fresh tissue biopsy at baseline\n- Women of child-bearing potential and men of child-bearing potential must agree to use adequate contraception\n\nStep 2: Determine if the patient meets all inclusion criteria.\n\nThe patient meets the following criteria:\n- Histologically confirmed breast cancer\n- HER2-positive breast cancer\n- Prior chemotherapy with trastuzumab and a taxane\n- Last dose of chemotherapy at least 21 days prior to registration\n- Age \u226518 years\n- ECOG performance status \u22642\n- Normal organ and marrow function\n- Tissue amenable to biopsy and willing to undergo a fresh tissue biopsy at baseline\n- Women of child-bearing potential and men of child-bearing potential must agree to use adequate contraception\n\nThe patient does not meet the following criteria:\n- Stage IV disease (the patient's stage is not specified in the note)\n- One line of prior therapy for metastatic breast cancer or disease recurrence within 6 months after completing adjuvant therapy (the",
        "label": 1
    },
    "338": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state that the target population is up to 30 adult patients at least 18 years of age. Since the patient is older than 18, this criterion is met.\n\nStep 2: Compare the patient's diagnosis to the inclusion criteria.\nThe patient has cytologically confirmed breast cancer, and the inclusion criteria state that the target population is metastatic breast cancer patients. This criterion is met.\n\nStep 3: Compare the patient's imaging findings to the inclusion criteria.\nThe patient has metastatic lesions on CXR, and the inclusion criteria state that at least one lesion outside the liver must be present by standard imaging. This criterion is met.\n\nStep 4: Compare the patient's planned treatment to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This indicates that the patient plans to start new systemic therapy for metastatic disease, which meets the inclusion criteria.\n\nStep 5: Check if the patient has provided informed consent.\nThe patient has not provided any information about informed consent in the patient note. However, the inclusion criteria do not explicitly state that informed consent is required at the time of the patient note. Therefore, this criterion is not relevant.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "339": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note for the inclusion criteria.\n\n- Age: The patient is 45 years old, which meets the age requirement of 18 years or older.\n- Histological confirmation of invasive breast cancer: The patient has cytologically confirmed breast cancer, which meets this criterion.\n- Receptor status: The patient's tumor is HER2-positive and ER/PR negative, which meets the ER/PR-negative criterion. However, the note does not provide information on HER2 status, so this criterion cannot be fully assessed.\n- Tumor stage: The patient's tumor is described as 3 cm invasive ductal breast carcinoma, which is within the T1c-4 tumor stage range.\n- Nodal status: The patient has 5 positive lymph nodes, which makes her a candidate for conservative surgery upfront. However, the note does not specify whether this makes her ineligible due to non-candidate status.\n- Informed consent: The patient agrees to undergo tumor resection prior to chemotherapy, which suggests she has provided informed consent.\n- Social insurance coverage: The patient's social insurance coverage is not mentioned in the note.\n\nStep 2: Determine the trial-level eligibility based on the information provided.\n\nSince the patient's HER2 status and nodal status are not fully assessed, we cannot definitively determine her eligibility. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "340": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with inclusion criteria\nThe patient is 45 years old, and the trial includes adult females. According to local regulations, this is likely eligible.\n\nStep 2: Compare patient's gender with inclusion criteria\nThe patient is a female, which matches the inclusion criteria.\n\nStep 3: Compare patient's cancer type and stage with inclusion criteria\nThe patient has cytologically confirmed breast cancer, and the trial includes patients with HER2-ve breast cancer with evidence of metastatic disease. This is a match.\n\nStep 4: Compare patient's treatment history with inclusion criteria\nThe patient has started treatment with 1st line systemic cytotoxic chemotherapy for metastatic breast cancer in the last 90 days. This matches the inclusion criteria.\n\nStep 5: Compare patient's hormone receptor status with inclusion criteria\nThe patient's tumor is HER2-positive and ER/PR negative. The trial includes patients who have exhausted hormone therapy options (if HR+ve). Since the patient's tumor is HER2-positive and not ER/PR positive, this is a match.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "341": {
        "output": "GPT4 Correct Assistant: Step 1: Check if the patient has histological confirmation of breast cancer.\nPatient note: \"The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\"\nInclusion criteria: Histological confirmation of breast cancer\nAssessment: 1) Not relevant (patient does not have sufficient information to qualify for the trial)\n\nStep 2: Check if the patient is able to provide written informed consent for the trial.\nPatient note: No information provided.\nInclusion criteria: Able to provide written informed consent for the trial\nAssessment: 1) Not relevant (patient does not have sufficient information to qualify for the trial)\n\nStep 3: Check if the patient's performance status is =< 1 on the ECOG performance scale.\nPatient note: No information provided.\nInclusion criteria: Performance status of =< 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale\nAssessment: 1) Not relevant (patient does not have sufficient information to qualify for the trial)\n\nStep 4: Check if the patient is able to swallow oral medication.\nPatient note: No information provided.\nInclusion criteria: Able to swallow oral medication\nAssessment: 1) Not relevant (patient does not have sufficient information to qualify for the trial)\n\nStep 5: Check if the patient's left ventricular ejection fraction (LVEF) assessment is >= 50%.\nPatient note: No information provided.\nInclusion criteria: Left ventricular ejection fraction (LVEF) assessment by 2-dimensional (D) echocardiogram or multi-gated acquisition (MUGA) scan performed within 90 days prior to registration must be >= 50%\nAssessment: 1) Not relevant (patient does not have sufficient information to qualify for the trial)\n\nStep 6: Check if the patient meets the absolute neutrophil count, platelets, hemoglobin, and creatinine clearance criteria.\nPatient note: No information provided.\nInclusion criteria: Absolute neutrophil count >= 1,500 /uL, Platelets >= 100,000 /uL, Hemoglobin >= 9 g/dL, Creatin",
        "label": 2
    },
    "342": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the note\n- Age: 45 years old\n- Gender: Female\n- Disease: Invasive ductal breast carcinoma\n- HER2-positive, ER/PR negative\n- Axillary lymph nodes: 5 positive\n- Metastatic lesions\n- No exclusionary factors mentioned\n\nStep 2: Compare the patient's characteristics to the inclusion criteria\n- CCI / CLI to be operated: The patient is a candidate for tumor resection.\n- Grade SBR 1, 2, or 3: The patient's tumor size is 3 cm.\n- Undifferentiated RE / PR status: The patient is ER/PR negative.\n- HER2 status undifferentiated: The patient is HER2-positive.\n- Ki 67 indifferent: Not mentioned in the note.\n- Metastatic or not: The patient has metastatic lesions.\n- ADP axillary invaded or not: The patient has 5 positive lymph nodes.\n- Major Patients: The patient is a postmenopausal woman.\n\nStep 3: Determine the patient's eligibility based on the inclusion criteria\n- The patient meets the majority of the inclusion criteria.\n\nStep 4: Consider any exclusion criteria (if provided)\n- No exclusion criteria are mentioned in the note.\n\nStep 5: Assign the trial-level eligibility\n- Trial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "343": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's diagnosis and treatment plan.\n\nThe patient has a 3 cm invasive ductal breast carcinoma, which is HER2-positive and ER/PR negative. She has 5 positive lymph nodes and has metastatic lesions. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nStep 2: Compare the patient's diagnosis and treatment plan to the inclusion criteria of the clinical trial.\n\nThe patient has invasive breast cancer, which meets the first inclusion criterion. She is scheduled for breast conserving surgery or mastectomy and axillary lymph node dissection, which meets the second inclusion criterion. She is not receiving neo-adjuvant therapy, but she is having axillary lymph node dissection as part of her surgical treatment, which meets the third inclusion criterion.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\nThe patient meets all the inclusion criteria for the clinical trial.\n\nStep 4: Repeat Trial-level eligibility.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "344": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n- Age: 45 years old\n- Gender: Female, postmenopausal\n- Disease: Cytologically confirmed breast cancer\n- Tumor type: 3 cm invasive ductal breast carcinoma, HER2-positive, ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- Treatment: Candidate for tumor resection and chemotherapy\n\nStep 2: Compare the patient's characteristics with the inclusion criteria of the clinical trial.\n- Inclusion Criteria 1: Histologically confirmed invasive breast cancer - Patient meets this criterion.\n- Inclusion Criteria 2: With axillary lymph node with thickened cortex - Patient does not have sufficient information to qualify for this criterion.\n- Inclusion Criteria 3: Planned for sentinel lymph node biopsy or axillary clearance - Patient does not have sufficient information to qualify for this criterion.\n\nStep 3: Determine the trial-level eligibility based on the comparison.\n- Trial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "345": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age\nThe patient is 45 years old.\n\nStep 2: Identify the patient's condition\nThe patient has cytologically confirmed breast cancer, which is not related to the clinical trial's focus on myocardial infarction and coronary revascularization.\n\nStep 3: Compare the patient's age to the inclusion criteria\nThe patient's age (45 years) meets the inclusion criteria of age \u2265 18 years.\n\nStep 4: Identify the patient's medical history and other conditions\nThe patient does not have a history of myocardial infarction or coronary artery disease, which are the focus of the trial.\n\nStep 5: Compare the patient's medical history and other conditions to the inclusion criteria\nThe patient's medical history and conditions (breast cancer) are not relevant to the trial's focus on myocardial infarction and coronary revascularization.\n\nStep 6: Identify the patient's suitability for the trial procedures\nThe patient's condition does not meet the inclusion criteria for suitability for PCI from femoral or radial access, coronary anatomy suitable for complete coronary revascularization with Synergy\u00ae stent implantation, identifiable culprit lesion/artery, at least one non-culprit coronary stenosis \u2265 70% in at least two projections, in a vessel with a lumen diameter \u22652.25 - \u22645.75 mm, other than the culprit artery, TIMI Flow 3 or TIMI flow 2 after revascularization of the culprit artery, and stable hemodynamics at the end of the culprit vessel revascularization.\n\nStep 7: Determine the patient's eligibility based on the comparison\nSince the patient does not meet the inclusion criteria for suitability for the trial procedures, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "346": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state that the patient must be postmenopausal.\n\nStep 2: Compare the patient's cancer type and stage to the inclusion criteria.\nThe patient has cytologically confirmed breast cancer, which is invasive ductal carcinoma. The inclusion criteria state that the patient must have histologically confirmed hormonal positive (ER and/or PR) invasive breast cancer stages I-III with no evidence of metastatic disease (M0). The patient's cancer is hormone receptor negative (ER/PR negative), so she does not meet this criterion.\n\nStep 3: Compare the patient's treatment history to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The inclusion criteria state that the patient must have completed local treatment (surgery/radiation) and recovered from all side effects of chemotherapy and surgery. The patient has not yet undergone surgery or chemotherapy, so she does not meet this criterion.\n\nStep 4: Compare the patient's ability to complete questionnaires to the inclusion criteria.\nThe patient must be able to complete a demographic and the MMAS-8 questionnaires in English or Spanish. The patient's language abilities are not mentioned in the patient note, so we cannot determine if she meets this criterion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "347": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age and gender with the inclusion criteria\nThe patient is a 45-year-old woman, which meets the inclusion criteria of being female and at least 18 years of age.\n\nStep 2: Compare patient's medical condition with the inclusion criteria\nThe patient has cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma. This meets the inclusion criteria of having a diagnosis of ductal carcinoma in situ (DCIS) or ductal carcinoma in situ with microinvasion.\n\nStep 3: Check if the patient has adequate samples of breast tissue available for use in the study\nThe patient's core biopsy revealed a 3 cm invasive ductal breast carcinoma, which means there are adequate samples of breast tissue available.\n\nStep 4: Check if the patient has signed an informed consent form\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which implies that she has signed an informed consent form.\n\nStep 5: Determine trial-level eligibility based on the comparison\nThe patient meets the inclusion criteria and does not have any exclusion criteria mentioned in the trial description.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "348": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender\nThe patient is a 45-year-old postmenopausal woman.\n\nStep 2: Identify the patient's disease and type of cancer\nThe patient has cytologically confirmed breast cancer, specifically an invasive ductal breast carcinoma.\n\nStep 3: Identify the patient's hormonal status and risk factors\nThe patient is ER/PR negative and HER2-positive.\n\nStep 4: Compare the patient's information with the inclusion criteria\nThe inclusion criteria for this clinical trial are: all patients undergoing breast MRI.\n\nStep 5: Determine the patient's eligibility\nThe patient is undergoing a breast MRI, which meets the inclusion criteria. There are no exclusion criteria mentioned in the trial information.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "349": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note and the clinical trial inclusion criteria.\n\nPatient note:\n- Age: 45 years old\n- Gender: Female\n- Diagnosis: Breast cancer, 3 cm invasive ductal breast carcinoma\n- Stage: Stage IV\n- ER/PR negative, HER2-positive\n- Axillary sampling: 5 positive lymph nodes\n- Metastatic lesions\n- No other malignancies in the past 5 years\n- Plans to undergo tumor resection and chemotherapy\n\nInclusion criteria:\n- Age \u2265 18 years\n- Female gender\n- Biopsy proven diagnosis of breast cancer\n- Stage IV disease\n- ER+ by immunohistochemistry (patient is ER/PR negative)\n- HER2 non-amplified (patient is HER2-positive)\n- Progressed on at least one prior line of endocrine therapy for metastatic disease\n- Three or fewer prior endocrine-containing therapies for recurrent/metastatic disease\n- Two or fewer prior lines of cytotoxic chemotherapy for recurrent/metastatic disease\n- Plans to initiate 2nd, 3rd, or 4th line endocrine therapy for metastatic disease\n- Recent re-staging scans within 4 weeks of study enrollment\n- No concurrent or prior diagnosis of malignancy other than breast cancer for the past 5 years\n- Intends to pursue treatment as well as clinical and radiographic follow-up at UNC Health Care\n- Signed an institutional review board (IRB)-approved informed consent document for this protocol and HIPAA consent form\n\nStep 2: Compare the patient note to the inclusion criteria and determine eligibility.\n\n- Age: The patient is 45 years old, which meets the age requirement (\u2265 18 years).\n- Gender: The patient is female, which meets the gender requirement.\n- Diagnosis: The patient has a biopsy proven diagnosis of breast cancer, which meets the diagnosis requirement.\n- Stage: The patient has Stage IV disease, which meets the stage requirement.\n- ER/PR negative, HER2-positive: The patient does not meet the ER+ requirement,",
        "label": 0
    },
    "350": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age to inclusion criteria\nThe patient is 45 years old, which falls within the age range of 18 to 75 years for the trial.\n\nStep 2: Compare patient gender to inclusion criteria\nThe patient is a woman, which is included in the trial for both male and female patients.\n\nStep 3: Compare patient cancer type to inclusion criteria\nThe patient has breast cancer, not one of the specified digestive system cancers (colorectal cancer, esophagus squamous cell carcinoma, biliary tract cancer).\n\nStep 4: Compare patient HER2 status to inclusion criteria\nThe patient has HER2-positive breast cancer, but the trial is for HER2-positive metastatic carcinoma of the digestive system.\n\nStep 5: Compare other trial inclusion criteria to patient information\nThe other inclusion criteria (performance status, previous therapy, organ function, etc.) are not relevant to the patient's note as the cancer type is not a match.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "351": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the range of stage II-IIIA breast cancer.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, which matches the inclusion criteria for breast cancer.\n\nStep 3: Compare the patient's disease type and stage to the inclusion criteria.\nThe patient has breast cancer, which matches the inclusion criteria for stage II-IIIA breast cancer.\n\nStep 4: Compare the patient's tumor characteristics to the inclusion criteria.\nThe patient has a 3 cm invasive ductal breast carcinoma that is HER2-positive and ER/PR negative. This matches the inclusion criteria for HER2-positive, HER2-equivocal, or HER2-negative tumors.\n\nStep 5: Compare the patient's medical history to the inclusion criteria.\nThe patient has not smoked or consumed alcohol and is not sexually active. This information is not relevant to the inclusion criteria.\n\nStep 6: Compare the patient's treatment history to the inclusion criteria.\nThe patient has had a core biopsy and axillary sampling, but the note does not mention if she has had a biopsy marker placed within the tumor bed with imaging confirmation. This information is not sufficient to determine eligibility based on the inclusion criteria.\n\nStep 7: Compare the patient's treatment intent to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This information is not relevant to the inclusion criteria.\n\nStep 8: Compare the patient's eligibility for the clinical trial based on the inclusion criteria.\nThe patient meets the inclusion criteria for age, gender, disease type and stage, tumor characteristics, and treatment intent. However, there is not enough information to determine if she has had a biopsy marker placed within the tumor bed with imaging confirmation.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "352": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria\nPatient's age: 45 years old\nInclusion criteria: Age 18 years or older\nThe patient meets the age requirement.\n\nStep 2: Compare patient's medical condition to the inclusion criteria\nPatient's condition: Breast cancer\nInclusion criteria: Have documented or reported microscopic hematuria within 3 month of study enrollment\nThe patient does not meet the condition requirement.\n\nStep 3: Compare patient's ability to consent to the inclusion criteria\nPatient's consent: Willing and able to give written informed consent\nInclusion criteria: Willing and able to give written informed consent\nThe patient meets the consent requirement.\n\nStep 4: Compare patient's history to the exclusion criteria\nPatient's history: \n- Breast cancer\n- No history of previous cancer (excluding basal and squamous cell skin cancer)\n- No history of active urinary tract infection or urinary retention\n- No history of active stone disease (renal or bladder) or renal insufficiency (creatinine >2.0 mg/dL)\n- No history of ureteral stents, nephrostomy tubes or bowel interposition\n- No history of recent genitourinary instrumentation (within 10 days prior to signing consent)\n- No history of being unable or unwilling to complete the hematuria evaluation (i.e., cystoscopy and upper tract imaging)\nExclusion criteria: Have history of BCa\nThe patient meets the exclusion requirement for having breast cancer.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "353": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nThe patient is a 45-year-old postmenopausal woman.\n\nStep 2: Identify the type and stage of the patient's disease.\nThe patient has cytologically confirmed breast cancer, with a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. It is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes, and CXR was remarkable for metastatic lesions.\n\nStep 3: Compare the patient's disease type and stage with the clinical trial's inclusion criteria.\nThe patient has histologically confirmed breast cancer, with a radiographic size \u2265 1.5 cm. The histology is ductal, which matches the clinical trial's inclusion criteria.\n\nStep 4: Identify the patient's hormone receptor status.\nThe patient's tumor is HER2-positive and ER/PR negative, which does not match the clinical trial's inclusion criteria of ER+, Her2 negative invasive carcinoma.\n\nStep 5: Determine the patient's eligibility based on the comparison.\nSince the patient's hormone receptor status does not match the clinical trial's inclusion criteria, the patient is excluded from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "354": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics and compare them to the inclusion criteria.\n\n- Female: The patient is a woman.\n- Age \u226518 years: The patient is 45 years old, which meets the age requirement.\n- Pathologically proven diagnosis of invasive breast cancer, clinically stage I-II: The patient has a confirmed diagnosis of breast cancer.\n- Clinically lymph node negative, confirmed by clinical exam and/or ultrasound imaging: The patient has 5 positive lymph nodes, which excludes her from this criterion.\n- Estrogen- and/or progesterone-receptor-positive tumor, defined \u22651% positively staining cells by immunohistochemistry: The patient's tumor is HER2-positive and ER/PR negative, which does not meet this criterion.\n- HER2/neu must be negative by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH): The patient's tumor is HER2-positive, which excludes her from this criterion.\n- Eastern Cooperative Oncology Group (ECOG) performance status 0-2: The patient's ECOG performance status is not mentioned in the note.\n- Pretreatment evaluations (minimum diagnostic workup) within 28 days prior to study: The patient's pretreatment evaluations are not mentioned in the note.\n- Qualify for anti-endocrine treatment (per medical oncologist): The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which does not qualify her for anti-endocrine treatment.\n- Informed consent provided: The patient's informed consent is not mentioned in the note.\n- If history of contralateral breast cancer, patient completed all treatment two years prior: The patient's history of contralateral breast cancer is not mentioned in the note.\n- No treatment for this breast cancer or any malignancy within two years (except non-melanomatous skin cancer, carcinoma in situ of the cervix, and contralateral breast cancer): The patient's treatment history is not mentioned in the note.\n- Using adequate methods of contraception; negative pregnancy",
        "label": 0
    },
    "355": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\n1. Signed and dated informed consent form (ICF) - Not mentioned in the patient note\n2. Women >=18 years - Patient is 45 years old, so included\n3. Patients with newly diagnosed resectable primary breast cancer scheduled to undergo treatment with curative intent by surgery - Patient has breast cancer and scheduled for surgery\n4. Histologically confirmed invasive breast cancer involving a palpable tumor of any size, or a tumor with an ultrasound assessed diameter of \u2265 1.0 cm - Patient has a 3 cm invasive ductal breast carcinoma\n5. Any clinical nodal status - Patient has 5 positive lymph nodes\n6. ER+ breast cancer - Patient's cancer is ER/PR negative\n7. HER2- breast cancer - Patient's cancer is HER2-positive\n8. Eastern Co-operative Oncology group (ECOG) performance status 0-1 - Not mentioned in the patient note\n9. Post-menopausal status - Patient is postmenopausal\n10. Pre-treatment biopsy sample not likely to provide adequate tissue sections for the biomarker assays - Not mentioned in the patient note\n11. Previous systemic or local treatment for the new primary breast cancer currently under investigation - Patient has not received previous treatment\n12. Inflammatory breast cancer - Not mentioned in the patient note\n13. Evidence of metastases - Patient has metastatic lesions\n14. Patients currently receiving medications or herbal supplements known to be strong inhibitors/inducers of CYP3A4/5 or strong inhibitors of CYP2C8 or that are sensitive substrates of CYP2C8 inhibition - Patient is taking multivitamins and iron supplements\n15. Concurrent treatment with other experimental drugs within 4 weeks prior to receiving study treatment - Not mentioned in the patient note\n16. Use of hormone-replacement therapy from <4 weeks of the diagnostic/baseline core biopsy to the start of trial treatment - Patient is not using hormone-replacement therapy\n17. Patients with second primary cancer - Not mentioned in the patient note",
        "label": 0
    },
    "356": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state that the participant must be of any age. Therefore, the patient meets this criterion.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nThe patient is a woman, and the inclusion criteria do not specify a gender requirement. Therefore, the patient meets this criterion.\n\nStep 3: Compare the patient's cancer type and stage with the inclusion criteria.\nThe patient has HER2-positive breast cancer, and the inclusion criteria state that the participant must have HER2-positive breast cancer. Therefore, the patient meets this criterion.\n\nStep 4: Compare the patient's tumor size with the inclusion criteria.\nThe patient's tumor is 3 cm in diameter, and the inclusion criteria state that the breast tumor must be >1.5 cm in maximum diameter by clinical or any radiologic measurement. Therefore, the patient meets this criterion.\n\nStep 5: Compare the patient's cancer status with the inclusion criteria.\nThe patient has metastatic lesions, and the inclusion criteria state that study participants must be cT1c - cT4a-d, any node (N), no metastases (M0). Therefore, the patient does not meet this criterion.\n\nStep 6: Compare the patient's previous treatment history with the inclusion criteria.\nThe patient has not received cancer chemotherapy, and the inclusion criteria state that no prior cancer chemotherapy is allowed. Therefore, the patient meets this criterion.\n\nStep 7: Compare the patient's organ and marrow function with the inclusion criteria.\nThe patient's ejection fraction is not mentioned, but the inclusion criteria state that ejection fraction (EF) greater than 50% by MUGA or ECHO within 4 weeks prior to first dose of study treatment. Therefore, we cannot determine if the patient meets this criterion.\n\nStep 8: Compare the patient's pregnancy status with the inclusion criteria.\nThe patient is not sexually active and does not have children, and the inclusion criteria state that women of child-bearing potential must agree to use adequate contraception for the duration of study participation and for 9",
        "label": 2
    },
    "357": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nPatient's age: 45 years\nInclusion criteria: Age 18-65\nThe patient's age is within the specified range.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nPatient's gender: Female\nInclusion criteria: No specific gender requirement\nThe patient's gender is not specified in the inclusion criteria, but there is no exclusion based on gender.\n\nStep 3: Compare the patient's diagnosis with the inclusion criteria.\nPatient's diagnosis: Cytologically confirmed breast cancer\nInclusion criteria: Diagnosed breast cancer\nThe patient has breast cancer, meeting the inclusion criteria.\n\nStep 4: Compare the patient's treatment history with the inclusion criteria.\nPatient's treatment history: Received chemotherapy\nInclusion criteria: Received chemotherapy\nThe patient has received chemotherapy, meeting the inclusion criteria.\n\nStep 5: Compare the patient's ECOG performance status with the inclusion criteria.\nPatient's ECOG performance status: Not mentioned\nInclusion criteria: ECOG performance status 0 or 1\nThe patient's ECOG performance status is not mentioned, so we cannot determine if they meet this criterion.\n\nStep 6: Compare the patient's blood cell counts with the inclusion criteria.\nPatient's ANC: Not mentioned\nInclusion criteria: ANC\u22651.5\u00d710 9/L\nThe patient's ANC is not mentioned, so we cannot determine if they meet this criterion.\n\nPatient's PLT: Not mentioned\nInclusion criteria: PLT\u2265100\u00d710 9/L\nThe patient's PLT is not mentioned, so we cannot determine if they meet this criterion.\n\nStep 7: Compare the patient's blood chemistry with the inclusion criteria.\nPatient's Cr: Not mentioned\nInclusion criteria: Cr\u22641.5\u00d7ULN\nThe patient's Cr is not mentioned, so we cannot determine if they meet this criterion.\n\nPatient's TBIL: Not mentioned\nInclusion criteria: TBIL\u22641.5\u00d7ULN\nThe patient's T",
        "label": 1
    },
    "358": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information in the patient note.\n\n- The patient has cytologically confirmed breast cancer.\n- A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- Axillary sampling revealed 5 positive lymph nodes.\n\nStep 2: Compare the patient's information to the inclusion criteria of the clinical trial.\n\n- Invasive breast cancer with axillary lymph node metastasis: The patient has invasive breast cancer and axillary lymph node metastasis.\n- Underwent computed tomography (CT) reconstruction for assessment of axillary lymph node status before and after neoadjuvant chemotherapy (NAC): The patient has not undergone CT reconstruction yet, but is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n- Attend the study voluntarily, sign the informed consent: The patient's eligibility for this is not mentioned in the patient note.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\nSince the patient has invasive breast cancer with axillary lymph node metastasis and is a candidate for tumor resection and chemotherapy, she is eligible for the clinical trial. However, we do not have information about her attending the study voluntarily and signing the informed consent. Therefore, her eligibility is not definitive.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "359": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria\nThe patient is 45 years old, and the inclusion criteria state that the patient must be \u226518 years old. The patient meets this criterion.\n\nStep 2: Compare the patient's gender to the inclusion criteria\nThe inclusion criteria do not specify a gender requirement. The patient is a woman, but this does not exclude her from the trial.\n\nStep 3: Compare the patient's medical condition to the inclusion criteria\nThe patient has breast cancer, but the inclusion criteria are focused on patients with suspected bladder cancer. The patient does not meet this criterion.\n\nStep 4: Compare the patient's eligibility for informed consent\nThe patient is capable of giving written informed consent, which is an inclusion criterion.\n\nStep 5: Compare the patient's referral to a haematuria clinic\nThe patient's medical record does not mention a referral to a haematuria clinic, so we cannot determine if the patient meets this criterion.\n\nStep 6: Determine the trial-level eligibility\nSince the patient does not meet the inclusion criteria for having suspected bladder cancer, we cannot determine if the patient is eligible for the trial. However, because the patient meets some criteria and there is not enough information to determine eligibility, we can conclude that:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "360": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 45 years old, and the clinical trial does not specify an age range for participants. Therefore, this factor is not relevant for eligibility.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nThe patient is a woman, and the clinical trial does not specify a gender requirement for participants. Therefore, this factor is not relevant for eligibility.\n\nStep 3: Compare the patient's breast cancer type with the inclusion criteria.\nThe patient has invasive ductal breast carcinoma, and the clinical trial includes patients with histologically proven invasive carcinoma of the breast. Therefore, this factor is relevant for eligibility.\n\nStep 4: Compare the patient's axillary lymph node status with the inclusion criteria.\nThe patient has 5 positive axillary lymph nodes, and the clinical trial includes patients with one to three positive axillary lymph nodes (pN1). Therefore, this factor is relevant for eligibility.\n\nStep 5: Compare the patient's surgery and chemotherapy history with the inclusion criteria.\nThe patient has undergone breast-conserving surgery and post-operative adjuvant chemotherapy, including taxane. The clinical trial includes patients who have prior breast-conserving surgery and post-operative adjuvant chemotherapy, including taxane. Therefore, this factor is relevant for eligibility.\n\nStep 6: Compare the patient's hormone receptor status with the inclusion criteria.\nThe patient's tumor is ER/PR negative, and the clinical trial does not mention hormone receptor status as an inclusion or exclusion criterion. Therefore, this factor is not relevant for eligibility.\n\nStep 7: Compare the patient's HER2 status with the inclusion criteria.\nThe patient's tumor is HER2-positive, and the clinical trial includes patients with HER2-positive tumors. Therefore, this factor is relevant for eligibility.\n\nStep 8: Compare the patient's additional medical conditions and treatments with the exclusion criteria.\nThe patient is using multivitamins and iron supplements, and the clinical trial does not mention any specific medications or supplements",
        "label": 0
    },
    "361": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\n\nThe patient is a 45-year-old postmenopausal woman. The clinical trial requires participants to be female.\n\nStep 2: Check for histologically confirmed breast cancer.\n\nThe patient has cytologically confirmed breast cancer. This meets the criteria for histologically confirmed breast cancer.\n\nStep 3: Check for evidence of measurable metastatic disease.\n\nThe patient has metastatic lesions on CXR. This meets the criteria for evidence of measurable metastatic disease.\n\nStep 4: Check for HER2 status.\n\nThe patient's tumor is HER2-positive. This meets the criteria for HER2 status determination.\n\nStep 5: Check for other inclusion criteria.\n\nThe patient is \u2265 18 years old, has a performance status (PS) ECOG 0-1, and has a life expectancy \u2265 3 months. She is eligible for apheresis and has adequate organ function. She is also willing and able to provide written informed consent.\n\nStep 6: Check for exclusion criteria.\n\nThe patient does not have any mention of prior therapy lines, which is not an exclusion criterion in this case. The rest of the exclusion criteria (e.g., pregnancy, certain medical conditions) do not apply to this patient.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "362": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender\nThe patient is a 45-year-old postmenopausal woman.\n\nStep 2: Identify the patient's disease type and stage\nThe patient has cytologically confirmed breast cancer, with a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions.\n\nStep 3: Compare the patient's disease type and stage with the inclusion criteria\nThe clinical trial includes women with early-stage breast cancer treated at general surgery department, Assuit University Hospitals. Selection criteria include women with a pre-operative diagnosis (clinical examination, imaging and needle biopsy) of Tis, T1 and T2 tumours without extensive skin involvement.\n\nThe patient's disease stage (metastatic lesions) does not match the inclusion criteria of early-stage breast cancer.\n\nStep 4: Determine the patient's eligibility\nSince the patient's disease stage does not match the inclusion criteria, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "363": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the age range for clinical trials.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, which matches the inclusion criteria for the trial.\n\nStep 3: Compare the patient's disease status to the inclusion criteria.\nThe patient has cytologically confirmed breast cancer, which is a requirement for the trial.\n\nStep 4: Compare the patient's HER2 and ER/PR status to the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative, which matches the inclusion criteria for the trial.\n\nStep 5: Compare the patient's prior therapy to the inclusion criteria.\nThe patient has not received endocrine therapy in the metastatic setting and has no more than one prior line of chemotherapy in the advanced/metastatic setting, which matches the inclusion criteria for the trial.\n\nStep 6: Compare the patient's measurable disease to the inclusion criteria.\nThe patient has measurable disease, which is a requirement for the trial.\n\nStep 7: Compare the patient's ECOG performance status to the inclusion criteria.\nThe patient's ECOG performance status is not provided, so we cannot determine if they meet the criteria.\n\nStep 8: Compare the patient's ability to swallow oral formulations to the inclusion criteria.\nThe patient's ability to swallow oral formulations is not provided, so we cannot determine if they meet the criteria.\n\nStep 9: Compare the patient's laboratory values to the inclusion criteria.\nThe patient's laboratory values are not provided, so we cannot determine if they meet the criteria.\n\nStep 10: Compare the patient's willingness to participate in the trial to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which is a requirement for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "364": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age to inclusion criteria\nThe patient is 45 years old, and the inclusion criteria state that participants must have histologically or cytologically confirmed inoperable locally advanced or metastatic ER+ breast cancer. There is no specific age requirement mentioned in the inclusion criteria.\n\nStep 2: Compare patient gender to inclusion criteria\nThe patient is a woman, and the inclusion criteria state that women \u2265 18 years of age are eligible, and men are not eligible.\n\nStep 3: Compare patient cancer type to inclusion criteria\nThe patient has cytologically confirmed breast cancer, and the inclusion criteria state that participants must have histologically or cytologically confirmed inoperable locally advanced or metastatic ER+ breast cancer.\n\nStep 4: Compare patient cancer stage to inclusion criteria\nThe patient has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, and the inclusion criteria state that participants must have histologically or cytologically confirmed inoperable locally advanced or metastatic ER+ breast cancer.\n\nStep 5: Compare patient hormone receptor status to inclusion criteria\nThe patient's tumor is HER2-positive and ER/PR negative, and the inclusion criteria state that participants must have documented HER2+ disease by overexpression and/or gene amplification on the most recent biopsy.\n\nStep 6: Compare patient prior treatment history to inclusion criteria\nThe patient has not received prior therapy with the agents listed in the inclusion criteria, and the inclusion criteria state that participants must have received prior therapy with the following agents in any combination.\n\nStep 7: Compare patient organ function to inclusion criteria\nThe patient's organ function is not mentioned in the patient note, and the inclusion criteria state that participants must have normal organ and marrow function as described.\n\nStep 8: Compare patient performance status to inclusion criteria\nThe patient's ECOG performance status is not mentioned in the patient note, and the inclusion criteria state that participants must have an ECOG performance status of 0-2.\n\nStep 9: Compare patient contraception requirements to inclusion criteria\nThe patient is not sexually active and has no children, and the inclusion criteria state that women of childbearing potential must agree to be abstinent or use a highly effective double barrier method of contraception",
        "label": 0
    },
    "365": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age to the inclusion criteria.\nThe patient is 45 years old, which meets the age requirement of 18 years or older.\n\nStep 2: Compare patient gender to the inclusion criteria.\nThe patient is a woman, which meets the gender requirement.\n\nStep 3: Compare patient cancer type and receptor status to the inclusion criteria.\nThe patient has HER2-positive and ER/PR negative breast cancer, which matches the inclusion criteria for HER2 overexpressing, triple negative, or ER positive invasive ductal or invasive lobular breast cancer.\n\nStep 4: Compare patient treatment history to the inclusion criteria.\nThe patient has undergone neoadjuvant chemotherapy, which matches the inclusion criteria for operable breast cancer treated with NAC.\n\nStep 5: Compare patient MRI results to the inclusion criteria.\nThe patient has metastatic lesions on CXR, which indicates the presence of distant metastases (M+), which excludes the patient based on the inclusion criteria of no indication of distant metastases (M0).\n\nStep 6: Compare patient's eligibility for MRI-guided biopsy to the inclusion criteria.\nThe patient's tumor site is not mentioned in the note, so we cannot determine if it is amenable to MRI-guided biopsy.\n\nStep 7: Compare patient's surgical plans and performance status to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which matches the inclusion criteria for definitive surgery being performed at MSKCC within 0-60 days of completing NAC. The patient's ECOG performance status score is not mentioned in the note, so we cannot determine if it is between 0 and \u2264 2 and/or KPS performance status score is between 80% and 100%.\n\nStep 8: Compare patient's reproductive status to the inclusion criteria.\nThe patient is not sexually active and has no children, which meets the requirement for women of childbearing potential (WOCBP) not being pregnant. It is not mentioned if the patient is breastfeeding, so we cannot determine if she meets the requirement for not breastfeeding.\n\nStep",
        "label": 0
    },
    "366": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient Note:\n- 45-year-old postmenopausal woman\n- Cytologically confirmed breast cancer\n- HER2-positive and ER/PR negative\n- 3 cm invasive ductal breast carcinoma\n- 5 positive lymph nodes\n- Metastatic lesions in CXR\n- Candidate for tumor resection and chemotherapy\n\nInclusion Criteria:\n- ER and PR-negative (patient is ER/PR negative)\n- HER2-negative (patient is HER2-positive, so excluded)\n- Clinical tumor size of at least 2.1 cm (patient has a 3 cm tumor, so eligible)\n- Ipsilateral regional lymph nodes involved (patient has 5 positive lymph nodes, so eligible)\n- Candidate for neoadjuvant chemotherapy (patient is a candidate, so eligible)\n- Age > 18 years and < 75 years (patient is 45 years old, so eligible)\n- ECOG Performance Status < 1 (patient's status is not mentioned, so not relevant)\n- LVEF \u2265 LLN (patient's LVEF is not mentioned, so not relevant)\n- Adequate organ and marrow function (patient's status is not mentioned, so not relevant)\n- Non-pregnant (patient's status is not mentioned, so not relevant)\n- Female subjects must meet one of the following (patient is female, so not relevant)\n- Male subjects must agree to one of the following (patient is female, so not relevant)\n- Ability to understand a written informed consent document (patient's status is not mentioned, so not relevant)\n\nStep 2: Determine trial-level eligibility\n\nBased on the comparison, the patient meets some inclusion criteria and has not met any exclusion criteria. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "367": {
        "output": "GPT4 Correct Assistant: Trial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "368": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria do not mention any specific age requirement. So, this factor is not relevant.\n\nStep 2: Compare patient's gender with the inclusion criteria.\nThe patient is a woman, and the inclusion criteria do not mention any specific gender requirement. So, this factor is not relevant.\n\nStep 3: Compare patient's disease type and stage with the inclusion criteria.\nThe patient has breast cancer, and the inclusion criteria require patients to have operable breast cancers. The patient's cancer is HER2-positive and ER/PR negative, but the inclusion criteria do not mention these specific molecular markers. The patient has no distant metastasis, which is a requirement in the inclusion criteria. So, this factor is relevant.\n\nStep 4: Compare patient's previous treatment history with the inclusion criteria.\nThe patient has not received any anti-cancer therapies, including chemotherapy, radiation therapy, hormone therapy, and surgical therapy. This matches the inclusion criteria, which require patients to have no history of anti-cancer therapies. So, this factor is relevant.\n\nStep 5: Compare patient's cardiac function with the inclusion criteria.\nThe patient's cardiac function is not mentioned in the patient note. The inclusion criteria require patients to have normal cardiac functions by echocardiography. So, this factor is not relevant.\n\nStep 6: Compare patient's ECOG score with the inclusion criteria.\nThe patient's ECOG score is not mentioned in the patient note. The inclusion criteria require patients to have ECOG scores \u2264 0-1. So, this factor is not relevant.\n\nStep 7: Compare patient's contraceptive disposition with the inclusion criteria.\nThe patient's disposition to practice contraception during the whole trial is not mentioned in the patient note. The inclusion criteria require patients to be disposed to practice contraception during the whole trial. So, this factor is not relevant.\n\nStep 8: Compare patient's blood test results with the inclusion criteria.\nThe patient's blood test results are not mentioned in the patient note. The inclusion criteria require patients to have blood test results within the specified normal ranges. So",
        "label": 2
    },
    "369": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note with inclusion criteria\n- Invasive ductal carcinoma diagnosed by biopsy: Yes (patient note states \"a 3 cm invasive ductal breast carcinoma\")\n- Clinically positive node diagnosed by contrast enhance computer tomography (CECT), the number of strengthened nodes at Level I \u2265 1 with the longest diameter of the strengthened node \u2265 2cm: Unknown (patient note states \"Axillary sampling revealed 5 positive lymph nodes\" but does not mention CECT or the size of the strengthened node)\n- NAC regimen followed the NCCN guideline: Unknown (patient note does not mention any specific NAC regimen)\n- No prior history of breast cancer or other malignancies: Yes (patient note states \"cytologically confirmed breast cancer\" which means it is her first occurrence)\n\nStep 2: Determine trial-level eligibility based on the comparison\n- Since we do not have enough information about the CECT and the NAC regimen, we cannot determine if the patient meets all the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "370": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\n1. Histologically confirmed diagnosis of non-metastatic operable TNBC subjected to diagnostic core biopsy\n- Patient note: \"cytologically confirmed breast cancer\" and \"core biopsy revealed a 3 cm invasive ductal breast carcinoma\"\n- The patient has a confirmed diagnosis of breast cancer, but it is not clear if it is TNBC.\n\n1. TNBC defined as HER2/ER/PgR negative receptors\n- Patient note: \"The tumor is HER2-positive and ER/PR negative\"\n- The patient's tumor is HER2-positive and ER/PR negative, which meets the criteria for TNBC.\n\n1. Female, aged \u2265 18 years\n- Patient note: \"45-year-old postmenopausal woman\"\n- The patient is a female and is 45 years old, which meets the age criteria.\n\n1. ECOG (Eastern Cooperative Oncology Group) performance status \u2264 1\n- Patient note: No information on ECOG performance status\n- Not enough information to determine eligibility.\n\n1. Clinical indication for a neoadjuvant approach according to the investigator's judgment.\n- Patient note: \"She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\"\n- The patient is a candidate for tumor resection, which indicates a neoadjuvant approach.\n\n1. Availability of paraffin-embedded tumor block (FFPE) taken at diagnostic biopsy for IHC and RNA-Seq molecular determinations\n- Patient note: No information on FFPE tumor block\n- Not enough information to determine eligibility.\n\n1. Patients with reproductive potential must have a negative serum pregnancy test within 7 days prior to study entry.\n- Patient note: \"She is not sexually active and has no children.\"\n- The patient is not sexually active and has no children, so she is likely not of reproductive potential.\n\n1. Written informed consent signed prior to enrolment according to ICH/GCP.\n- Patient note: No information",
        "label": 0
    },
    "371": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nPatient age: 45 years\nInclusion criteria: Women age \u2265 18 years\nThe patient meets the age requirement.\n\nStep 2: Compare the patient's performance status to the inclusion criteria.\nPatient performance status: Not mentioned in the patient note\nInclusion criteria: Eastern Cooperative Oncology Group performance status 0-2 (Karnofsky >60%)\nThe patient's performance status is not mentioned in the patient note, so we cannot determine if she meets this criterion.\n\nStep 3: Compare the patient's cancer type to the inclusion criteria.\nPatient cancer type: Metastatic breast cancer\nInclusion criteria: Patients with metastatic breast cancer\nThe patient meets the cancer type requirement.\n\nStep 4: Compare the patient's HER2 status to the inclusion criteria.\nPatient HER2 status: HER2-positive\nInclusion criteria: HER2 (human epidermal growth factor receptor 2)-positive breast cancer\nThe patient meets the HER2 status requirement.\n\nStep 5: Compare the patient's hormone receptor status to the inclusion criteria.\nPatient hormone receptor status: ER/PR negative\nInclusion criteria: Estrogen/progesterone receptor positive OR negative disease allowed\nThe patient meets the hormone receptor status requirement.\n\nStep 6: Compare the patient's measurable disease to the inclusion criteria.\nPatient measurable disease: Not mentioned in the patient note\nInclusion criteria: Patients must have measurable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1\nThe patient's measurable disease status is not mentioned in the patient note, so we cannot determine if she meets this criterion.\n\nStep 7: Compare the patient's treatment history to the inclusion criteria.\nPatient treatment history: Has failed at least one anti-HER2 therapy in the metastatic setting\nInclusion criteria: Patients that have failed at least one anti-HER2 therapy in the metastatic setting\nThe patient meets the treatment history requirement.\n\nStep 8: Compare the patient's organ and marrow function to the inclusion criteria.\nPat",
        "label": 1
    },
    "372": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics\n- Age: 45 years old\n- Gender: Female\n- Diagnosis: Invasive ductal breast carcinoma, HER2-positive, ER/PR negative\n- Stage: Operable breast cancer with metastatic lesions\n- Treatment history: None\n- Cardiac function: Not mentioned\n- ECOG score: Not mentioned\n- Contraception: Not applicable (postmenopausal)\n\nStep 2: Compare patient characteristics with inclusion criteria\n1. Informed consent: Not mentioned, but assumed (required)\n2. Operable breast cancer, no distant metastasis: Yes\n3. No history of anti-cancer therapies: Yes\n4. Normal cardiac functions: Not mentioned\n5. ECOG score \u2264 1: Not mentioned\n6. Disposed to practice contraception: Not applicable (postmenopausal)\n7. Blood test results: Not mentioned\n8. ER+ Her2- early-stage breast cancer: Yes\n\nStep 3: Determine trial-level eligibility\n- Most of the inclusion criteria are met, but some information is missing (cardiac function, ECOG score, blood test results).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "373": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note to the inclusion criteria.\n\n1. Invasive breast cancer diagnosed with core needle biopsy - Patient note: \"core biopsy revealed a 3 cm invasive ductal breast carcinoma\"\n2. Staging cT1b-2N0M0 - Patient note: No information on staging\n3. ER/PR positive cells ratio <10%, or HER2 positive - Patient note: \"The tumor is HER2-positive and ER/PR negative\"\n4. Without chemotherapy contraindications, and planned or has started neoadjuvant chemotherapy - Patient note: \"She is a candidate for tumor resection and agrees to do so prior to chemotherapy\"\n5. With axillary sentinel lymph node biopsy indications confirmed prior to neoadjuvant therapy - Patient note: \"Axillary sampling revealed 5 positive lymph nodes\"\n6. Voluntarily join the study and sign an informed consent form - Patient note: No information on informed consent\n\nStep 2: Determine if the patient meets the inclusion criteria and if there are any exclusion criteria.\n\nThe patient meets the following inclusion criteria:\n1, 3, 4, 5\n\nThe patient does not meet the following inclusion criteria:\n2, 6\n\nThere are no exclusion criteria mentioned in the patient note.\n\nStep 3: Assess the patient's eligibility based on the trial-level eligibility scale.\n\nSince the patient meets the inclusion criteria and there are no exclusion criteria mentioned, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "374": {
        "output": "GPT4 Correct Assistant: Based on the patient notes and the inclusion criteria for the clinical trial, the patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer with a 3 cm invasive ductal carcinoma in the left upper outer quadrant. The cancer is HER2 negative, ER positive, PR positive, and has metastasized to the axillary lymph nodes. The patient also has metastatic lesions in the chest X-ray. The patient is not on any medications and has no history of smoking or alcohol consumption. The patient is a candidate for tumor resection before chemotherapy.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "375": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's BMI and ASA class from the patient note.\n\nThe patient note does not provide information about the patient's BMI or ASA class. Therefore, we cannot determine if the patient meets the inclusion criteria for BMI and ASA class.\n\nStep 2: Identify if the patient is undergoing elective primary unilateral knee arthroplasty.\n\nThe patient note states that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This indicates that the patient is not undergoing elective primary unilateral knee arthroplasty.\n\nStep 3: Identify if the patient is undergoing spinal anaesthesia.\n\nThe patient note does not provide information about the type of anaesthesia the patient will undergo. Therefore, we cannot determine if the patient meets the inclusion criteria for spinal anaesthesia.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "376": {
        "output": "GPT4 Correct Assistant: First, let's compare the patient's information to the inclusion criteria:\n\n1. ECOG performance status of 0 or 1: Not mentioned in the patient note.\n2. Diagnosis of invasive adenocarcinoma of the breast by core needle biopsy: Yes.\n3. Primary breast tumor palpable and measures greater than or equal 2.0 cm: Not mentioned in the patient note.\n4. Regional lymph nodes cN0, cN1, or cN2a: Not mentioned in the patient note.\n5. Histological grade II or III tumor: Not mentioned in the patient note.\n6. Ipsilateral axillary lymph nodes evaluated by imaging within 6 weeks prior to initiating chemotherapy: Not mentioned in the patient note.\n7. Nodal status (negative or positive): Not mentioned in the patient note.\n8. ER and PgR analysis assessed by current ASCO/CAP Guidelines: Not mentioned in the patient note.\n9. HER2-negative as follows: Not mentioned in the patient note.\n10. Blood counts performed within 6 weeks prior to initiating chemotherapy: Not mentioned in the patient note.\n11. Evidence of adequate hepatic function performed within 6 weeks prior to initiating chemotherapy: Not mentioned in the patient note.\n12. Alkaline phosphatase and AST: Not mentioned in the patient note.\n13. Serum creatinine performed within 6 weeks prior to initiating chemotherapy: Not mentioned in the patient note.\n14. LVEF assessment by echocardiogram or MUGA scan performed within 90 days prior to initiating chemotherapy: Not mentioned in the patient note.\n15. Patients with reproductive potential must agree to use an effective non-hormonal method of contraception during therapy and for at least 7 months after the last dose of study: Not mentioned in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "377": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nPatient's age: 45 years old\nInclusion criteria: Female, \u226518 and \u226465 years of age\nThe patient is within the age range, so she meets this criterion.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nPatient's gender: Female\nInclusion criteria: Female\nThe patient's gender matches the inclusion criteria, so she meets this criterion.\n\nStep 3: Compare the patient's cancer type and stage to the inclusion criteria.\nPatient's cancer type: Invasive ductal breast carcinoma (Stage II, IIIa)\nInclusion criteria: Histologically-confirmed invasive carcinoma of the breast (American Joint Committee on Cancer [AJCC, vs. 8.0] Stage II, IIIa)\nThe patient's cancer type and stage match the inclusion criteria, so she meets this criterion.\n\nStep 4: Compare the patient's tumor characteristics to the inclusion criteria.\nPatient's tumor: HER2-positive and ER/PR negative, 3 cm in diameter, 5 positive lymph nodes\nInclusion criteria: HER2 positive tumor, unilateral, measurable tumor of the breast >2 cm in diameter, operable breast cancer, planned surgical resection of breast tumor (mastectomy or lumpectomy) and sentinel or axillary lymph nodes\nThe patient's tumor characteristics match the inclusion criteria, so she meets this criterion.\n\nStep 5: Compare the patient's laboratory values to the inclusion criteria.\nThe patient's laboratory values are not provided in the patient note.\n\nStep 6: Compare the patient's ECOG score to the inclusion criteria.\nPatient's ECOG score: Not provided in the patient note.\nInclusion criteria: ECOG score of 0 or 1\nThe patient's ECOG score is not provided, so we cannot determine if she meets this criterion.\n\nStep 7: Compare the patient's LVEF to the inclusion criteria.\nPatient's LVEF: Not provided in",
        "label": 1
    },
    "378": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n- Patient is a 45-year-old postmenopausal woman\n- Diagnosed with cytologically confirmed breast cancer\n- Tumor is HER2-positive and ER/PR negative\n\nStep 2: Compare the patient's information with the inclusion criteria of the clinical trial.\n- Inclusion Criteria: Adult female patients with breast cancer\n\nStep 3: Determine the patient's eligibility based on the comparison.\n- The patient is an adult female with breast cancer, so she meets the inclusion criteria.\n\nStep 4: Consider any exclusion criteria, if applicable.\n- There are no exclusion criteria mentioned in the patient note or clinical trial summary.\n\nStep 5: Assign the appropriate eligibility score.\n- Since the patient meets the inclusion criteria and there are no exclusion criteria, the patient is eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "379": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the age range in the inclusion criteria.\nThe patient is 45 years old, which falls within the age range of 22 to 75 years.\n\nStep 2: Compare the patient's gender to the gender specified in the inclusion criteria.\nThe patient is a woman, which matches the gender specified for both men and women in the inclusion criteria.\n\nStep 3: Compare the patient's condition to the condition specified in the inclusion criteria.\nThe patient has breast cancer, not essential tremor. Therefore, the patient does not meet the condition specified in the inclusion criteria.\n\nStep 4: Compare the patient's medical history and treatment history to the exclusion criteria.\nThe patient has a history of cancer, which may be an exclusion criterion for this study. However, the inclusion criteria do not mention any exclusion criteria related to cancer.\n\nStep 5: Assess the patient's eligibility based on the comparison of the patient note and inclusion criteria.\nSince the patient does not have essential tremor, she does not meet the condition specified in the inclusion criteria. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "380": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and breast cancer status.\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n\nStep 2: Compare the patient's age to the inclusion criteria.\nThe inclusion criteria state that every adult (above 18) years old patient with breast cancer can participate in the trial. The patient is 45 years old, which meets the age requirement.\n\nStep 3: Identify the patient's breast cancer status.\nThe patient has cytologically confirmed breast cancer.\n\nStep 4: Compare the patient's breast cancer status to the inclusion criteria.\nThe inclusion criteria state that patients with histologic diagnosis of Breast Cancer that refuse or are not suitable for surgical treatment, or with metastatic disease, remaining this way in active surveillance can participate in the trial. The patient has metastatic disease and is in active surveillance, so she meets the breast cancer status requirement.\n\nStep 5: Check for any exclusion criteria.\nThere are no exclusion criteria mentioned in the given information.\n\nStep 6: Determine the trial-level eligibility.\nSince the patient meets both the inclusion criteria and does not have any exclusion criteria, the trial-level eligibility is 2) Eligible.",
        "label": 0
    },
    "381": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information in the patient note.\n- The patient is 45 years old.\n- The patient is postmenopausal.\n- The patient has cytologically confirmed breast cancer.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- The patient is using multivitamins and iron supplements.\n- The patient does not smoke or consume alcohol.\n- The patient is not sexually active and has no children.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nStep 2: Compare the patient's information with the inclusion criteria of the clinical trial.\n\n1. Germline BRCA 1/2 Mutation Positive: The patient note does not provide information about the patient's BRCA 1/2 mutation status.\n2. Women and men at least 18 years of age or older: The patient is 45 years old, which meets this criterion.\n3. Histologically confirmed invasive adenocarcinoma of the breast: The patient note confirms the patient has breast cancer.\n4. HER2 negative breast cancer as defined by ASCO-CAP criteria: The patient note states the tumor is HER2-positive, which excludes the patient from this trial.\n5. Tumor greater than or equal to T1, N0-3: The patient note states the tumor is 3 cm, which is T1, and axillary sampling revealed 5 positive lymph nodes, which is N1, which meets this criterion.\n6. No evidence of distant metastasis: The patient note states the patient has metastatic lesions, which excludes the patient from this trial.\n7. Adequate bone marrow, hepatic, and renal function: The patient note does not provide information about the patient's bone marrow, hepatic, and renal function.\n8. ECOG performance status 0 or 1: The patient note does not provide information about the patient's ECOG performance status.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\nThe patient meets some inclusion criteria (age,",
        "label": 0
    },
    "382": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's condition\nThe patient in the note has breast cancer, not pancreatic cancer.\n\nStep 2: Compare the patient's condition to the inclusion criteria\nThe inclusion criteria for the clinical trial require non-metastatic pancreatic cancer. Since the patient has breast cancer, they do not meet this criterion.\n\nStep 3: Determine the patient's eligibility\nBased on the comparison, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "383": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age, gender, and disease type.\n\nPatient's age: 45 years old\nPatient's gender: Female\nPatient's disease type: Postmenopausal woman with cytologically confirmed breast cancer\n\nStep 2: Compare the patient's age, gender, and disease type with the inclusion criteria.\n\nInclusion criteria: unpremedicated patient scheduled for elective or emergency trauma surgery of hand and forearm under ultrasound-guided BPB\n\nThe patient's age, gender, and disease type do not match the inclusion criteria, as the patient has breast cancer and is not scheduled for trauma surgery of the hand and forearm.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\nSince the patient's age, gender, and disease type do not match the inclusion criteria, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "384": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient age: 45 years old (meets criteria)\nPatient gender: Female (meets criteria)\nPatient diagnosis: Breast cancer (meets criteria)\nPathology report: Invasive ductal carcinoma, HER2-positive, ER/PR negative (meets criteria)\nTumor size: 3 cm (meets criteria)\nNodal status: 5 positive lymph nodes (meets criteria)\nMetastatic lesions: Present (excluded)\nTumor resection: Planned (meets criteria)\nECOG performance status: Not mentioned (not relevant)\nLaboratory values: Not mentioned (not relevant)\nContraception: Not mentioned (not relevant)\nPregnancy test: Not mentioned (not relevant)\nBreastfeeding: Not mentioned (not relevant)\n\nStep 2: Determine eligibility based on comparison\n\nThe patient meets most of the inclusion criteria, but she has metastatic lesions, which is an exclusion criterion. Therefore, the patient is Excluded.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "385": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age.\nThe patient is 45 years old.\n\nStep 2: Identify the patient's gender.\nThe patient is a woman.\n\nStep 3: Identify the patient's medical condition.\nThe patient has breast cancer.\n\nStep 4: Compare the patient's medical condition to the inclusion criteria of the clinical trial.\nThe clinical trial is for patients with muscle-invasive urothelial carcinoma (bladder cancer). The patient has breast cancer, which is not the same as bladder cancer.\n\nStep 5: Determine the patient's eligibility based on the comparison.\nSince the patient has a different type of cancer than the clinical trial is designed for, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "386": {
        "output": "GPT4 Correct Assistant: Step 1: Check if the patient is female and of non-childbearing potential or has negative urinary pregnancy test.\nThe patient is a postmenopausal woman, which means she is of non-childbearing potential. She also does not smoke or consume alcohol and is not sexually active, which further supports this conclusion.\n\nStep 2: Check if the patient's age is \u2265 18 years old.\nThe patient is 45 years old, which is greater than 18 years old.\n\nStep 3: Check if the patient has a histologically confirmed HER2-/HR+ locally advanced or metastatic invasive breast carcinoma.\nThe patient has a histologically confirmed 3 cm invasive ductal breast carcinoma that is HER2-positive and ER/PR negative.\n\nStep 4: Check if the patient has a history of previous therapy with maximum one line of anti-hormonal treatment.\nThe patient's history does not mention any previous treatment for breast cancer, which implies she has not received any anti-hormonal treatment.\n\nStep 5: Check if the patient has a history of previous neoadjuvant/adjuvant therapy and if treatment was completed more than 5 years before study entry.\nThe patient's history does not mention any previous neoadjuvant/adjuvant therapy.\n\nStep 6: Check if the patient has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.\nThe patient's ECOG performance status is not mentioned in the patient note.\n\nStep 7: Check if the patient has resolution of all acute toxic effects of prior anti-cancer therapy or surgical procedures to NCI CTCAE version 4.03 Grade \u2264 1 (except alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion).\nThe patient's history does not mention any toxic effects of prior therapy.\n\nStep 8: Check if the patient is accessible for scheduled visits, treatment, and follow-up and has a life-expectancy > 6 months.\nThe patient's life-expectancy and accessibility for treatment are not mentioned in the patient note.\n\nBased on the information provided, the patient meets most of the",
        "label": 0
    },
    "387": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state that the patient must have a World Health Organization (WHO) performance status \u2264 2. There is no specific age requirement mentioned in the inclusion criteria.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, and the inclusion criteria do not mention any specific gender requirement.\n\nStep 3: Compare the patient's type and stage of disease to the inclusion criteria.\nThe patient has cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The inclusion criteria state that the patient must have biopsy-proven invasive breast cancer with a size of \u22643.0 cm (TNM classification: cT1-2 N0-2 MX). The patient's cancer type and stage match the inclusion criteria.\n\nStep 4: Compare the patient's tumor characteristics to the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative, and the inclusion criteria state that the patient must have a histological type of tumor: invasive ductal carcinoma (IDC). The patient's tumor characteristics match the inclusion criteria.\n\nStep 5: Compare the patient's treatment history to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The inclusion criteria state that the patient must be scheduled for surgical resection of the tumor at the study site. The patient's treatment history matches the inclusion criteria.\n\nStep 6: Compare the patient's other medical conditions and treatments to the inclusion criteria.\nThe patient is using multivitamins and iron supplements, does not smoke or consume alcohol, is not sexually active, and has no children. The inclusion criteria do not mention any specific medical conditions or treatments that would exclude the patient.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "388": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's condition and characteristics from the patient note.\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. She has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. She has 5 positive lymph nodes and metastatic lesions on CXR. She is taking multivitamins and iron supplements and is a candidate for tumor resection.\n\nStep 2: Compare the patient's condition and characteristics to the inclusion criteria of the clinical trial.\n\nClinical trial: Staged Versus Simultaneous Bilateral Knee Arthroplasty\nInclusion criteria:\n- Patients considering bilateral knee arthroplasty\n- Patients must sign the consent form\n- Patients must be willing to complete the study questionnaires for the duration of the study\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\nThe patient is not eligible for this clinical trial because she has breast cancer and is not considering bilateral knee arthroplasty.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "389": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the age range in the inclusion criteria.\nPatient age: 45 years\nInclusion criteria age range: 18-80 years\nThe patient's age is within the age range, so this criterion is met.\n\nStep 2: Compare the patient's gender to the gender specified in the inclusion criteria.\nPatient gender: Female\nInclusion criteria gender: Female\nThe patient's gender matches the criteria, so this criterion is met.\n\nStep 3: Compare the patient's disease type and stage to the disease type and stage in the inclusion criteria.\nPatient disease: Metastatic breast cancer (stage IV)\nInclusion criteria disease: Metastatic breast cancer (stage IV)\nThe patient's disease type and stage match the criteria, so this criterion is met.\n\nStep 4: Compare the patient's previous treatment history to the treatment history in the inclusion criteria.\nPatient treatment history: The patient has not undergone at least three lines of chemotherapy.\nInclusion criteria treatment history: Patients must have undergone at least three lines of chemotherapy.\nThe patient's treatment history does not match the criteria, so this criterion is not met.\n\nStep 5: Compare the patient's expected survival time to the expected survival time in the inclusion criteria.\nPatient expected survival time: Not mentioned\nInclusion criteria expected survival time: At least 3 months\nThe patient's expected survival time is not mentioned, so this criterion is not relevant.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "390": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's condition\nThe patient has cytologically confirmed breast cancer.\n\nStep 2: Compare the patient's condition to the inclusion criteria\nInclusion Criteria: History of known or suspected solid tumor.\n\nThe patient has a solid tumor (breast cancer), which meets the inclusion criteria.\n\nStep 3: Identify any exclusion criteria\nThere are no exclusion criteria mentioned in the provided information.\n\nStep 4: Determine the patient's eligibility\nSince the patient meets the inclusion criteria and there are no exclusion criteria, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "391": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria\nThe patient is 45 years old, and the inclusion criteria state that patients must be \u2265 50 years at diagnosis. This criterion is not met.\n\nStep 2: Compare patient's postmenopausal status to the inclusion criteria\nThe patient is postmenopausal, and the inclusion criteria state that patients must be postmenopausal. This criterion is met.\n\nStep 3: Compare patient's cancer stage to the inclusion criteria\nThe patient has cytologically confirmed breast cancer, but the inclusion criteria specify AJCC 7th Edition stage 0 or I (TisN0 \u2264 2 cm or T1N0) histologically confirmed carcinoma of the breast. The patient's cancer stage is not specified in the note, so we cannot determine if this criterion is met.\n\nStep 4: Compare patient's tumor size to the inclusion criteria\nThe patient's tumor is 3 cm, and the inclusion criteria state that tumor size is determined by the pathologist, but it must be \u2264 2 cm. This criterion is not met.\n\nStep 5: Compare patient's tumor histology to the inclusion criteria\nThe patient's tumor is HER2-positive and ER/PR negative, and the inclusion criteria state that patients must have invasive ductal, lobular, medullary, papillary, colloid (mucinous), tubular histologies, or mixed histologies (lesions \u2264 2 cm) that are estrogen or progesterone receptor positive and do not exhibit HER2/neu gene amplification OR ductal carcinoma in situ (lesions \u2264 2 cm). The patient's tumor histology is not specified in the note, so we cannot determine if this criterion is met.\n\nStep 6: Compare patient's treatment history to the inclusion criteria\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, and the inclusion criteria state that neoadjuvant hormone therapy, chemotherapy, or biologic therapy is not allowed prior to TRI-APBI, but adjuvant hormone therapy may have been started after surgery. The",
        "label": 0
    },
    "392": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and medical history.\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n\nStep 2: Compare the patient's age to the clinical trial's inclusion criteria.\nThe clinical trial includes patients who are 18 years old or older. Since the patient is 45 years old, she meets this criterion.\n\nStep 3: Identify the patient's surgical history and medical conditions.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. However, the clinical trial is focused on orthopedic foot or ankle surgery, which is not relevant to the patient's condition.\n\nStep 4: Compare the patient's medical conditions to the clinical trial's inclusion criteria.\nThe clinical trial's inclusion criteria are focused on orthopedic foot or ankle surgery, which is not relevant to the patient's condition. Therefore, the patient does not have sufficient information to qualify for the trial.\n\nStep 5: Identify any exclusion criteria that may apply to the patient.\nThe clinical trial's exclusion criteria include patients with peripheral neuropathy, motor weakness, infection at the injection site, and any contraindications for medications in the study. There is no information in the patient note that suggests she meets any of these criteria.\n\nStep 6: Determine the patient's trial-level eligibility.\nBased on the information provided, the patient does not have sufficient information to qualify for the clinical trial. Therefore, her trial-level eligibility is 1) Not relevant.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "393": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state that the patient must be at least 20 years old. Since the patient is 45, which is greater than 20, this criterion is met.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nThe patient is a woman, and the inclusion criteria do not specify any gender requirements. Therefore, this criterion is met.\n\nStep 3: Compare the patient's cancer type with the inclusion criteria.\nThe patient has breast cancer, not salivary duct carcinoma or any of the other specified salivary gland carcinomas. Therefore, this criterion is not met.\n\nStep 4: Compare the patient's cancer stage with the inclusion criteria.\nThe patient has stage IV or recurrent cancer, which matches the inclusion criteria. Therefore, this criterion is met.\n\nStep 5: Compare the patient's performance status with the inclusion criteria.\nThe patient's ECOG performance status is not provided. Therefore, this criterion is not relevant.\n\nStep 6: Compare the patient's measurable tumor lesion with the inclusion criteria.\nThe patient's measurable tumor lesion is not provided. Therefore, this criterion is not relevant.\n\nStep 7: Compare the patient's expected survival with the inclusion criteria.\nThe patient's expected survival is not provided. Therefore, this criterion is not relevant.\n\nStep 8: Compare the patient's prior systemic chemotherapy with the inclusion criteria.\nThe patient has not received prior systemic chemotherapy, which matches the inclusion criteria. Therefore, this criterion is met.\n\nStep 9: Compare the patient's time since surgery or radiotherapy with the inclusion criteria.\nThe patient's time since surgery or radiotherapy is not provided. Therefore, this criterion is not relevant.\n\nStep 10: Compare the patient's written informed consent with the inclusion criteria.\nThe patient has provided written informed consent, which matches the inclusion criteria. Therefore, this criterion is met.\n\nTrial-level eligibility: 0) Excluded (patient meets inclusion criteria, but",
        "label": 0
    },
    "394": {
        "output": "GPT4 Correct Assistant: Let's compare the patient note and the inclusion criteria of the clinical trial step by step.\n\n1. Age: The patient is 45 years old, which falls within the age range of 18 and older for all cohorts.\n2. Informed consent and HIPAA Authorization: The patient has provided informed consent and HIPAA Authorization.\n3. Cohort A: The patient has a recent abnormal mammogram followed by a breast biopsy and is diagnosed with Stage IV invasive breast cancer. This meets the criteria for Cohort A.\n4. Cohort B: The patient does not have a benign breast tumor with high-risk pathology, so she does not meet the criteria for Cohort B.\n5. Cohort C: The patient does not have a diagnosed benign breast tumor, so she does not meet the criteria for Cohort C.\n6. Cohort D: The patient does not have a normal screening mammogram within the last 6 months, so she does not meet the criteria for Cohort D.\n\nBased on the comparison, the patient meets the criteria for Cohort A. The trial-level eligibility for this patient is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "395": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nPatient's age: 45 years old\nInclusion criteria: Patients must be premenopausal.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nPatient's gender: Female\nInclusion criteria: No specific gender requirement mentioned.\n\nStep 3: Compare the patient's breast cancer type to the inclusion criteria.\nPatient's breast cancer: HER2-positive and ER/PR negative invasive ductal breast carcinoma\nInclusion criteria: Operable hormonal receptor (HR) positive (ER/PR greater than or equal to 10%), HER2-negative, invasive early breast cancer\n\nStep 4: Compare the patient's menopausal status to the inclusion criteria.\nPatient's menopausal status: Postmenopausal\nInclusion criteria: Patients must be premenopausal.\n\nStep 5: Compare the patient's breast cancer stage to the inclusion criteria.\nPatient's breast cancer stage: Invasive ductal breast carcinoma with metastatic lesions\nInclusion criteria: Operable hormonal receptor (HR) positive (ER/PR greater than or equal to 10%), HER2-negative, invasive early breast cancer\n\nStep 6: Compare the patient's breast tumor size to the inclusion criteria.\nPatient's breast tumor size: 3 cm\nInclusion criteria: A breast tumor with an ultrasound size of at least 2.0 cm\n\nStep 7: Compare the patient's ability to swallow oral medication to the inclusion criteria.\nPatient's ability to swallow oral medication: Unknown\nInclusion criteria: Patients must have the ability to swallow oral medication.\n\nStep 8: Compare the patient's ECOG performance status to the inclusion criteria.\nPatient's ECOG performance status: Unknown\nInclusion criteria: ECOG performance status of 0 or 1.\n\nStep 9: Compare the patient's blood counts to the inclusion criteria.\nPatient's blood counts: Unknown\nInclusion criteria: ANC must be greater than or equal to 1",
        "label": 0
    },
    "396": {
        "output": "GPT4 Correct Assistant: Step 1: Determine the patient's age.\nThe patient is 45 years old.\n\nStep 2: Determine the type and stage of the patient's cancer.\nThe patient has invasive ductal breast carcinoma.\n\nStep 3: Determine if the patient has a history of conservative surgery.\nThe patient has undergone core biopsy and is a candidate for tumor resection.\n\nStep 4: Determine if the patient has a history of sentinel lymph node biopsy (SLND).\nThe patient has already received SLND for her initial cancer, regardless of the SLND result.\n\nStep 5: Determine if the patient has a history of pregnancy.\nThe patient is postmenopausal, so she is not premenopausal.\n\nStep 6: Determine if the patient has a history of radiation therapy.\nThe patient has not received radiation therapy.\n\nStep 7: Determine if the patient has a history of alcohol or drug use.\nThe patient does not smoke or consume alcohol.\n\nStep 8: Determine if the patient has a history of sexual activity or childbearing.\nThe patient is not sexually active and has no children.\n\nStep 9: Determine if the patient has a history of metastatic lesions.\nThe patient has metastatic lesions.\n\nStep 10: Determine if the patient has a history of multivitamin or iron supplement use.\nThe patient is using multivitamins and iron supplements.\n\nStep 11: Determine if the patient meets the minimum delay requirement between initial breast cancer treatment and ipsilateral recurrence treatment.\nThe patient has not yet received treatment for her recurrence.\n\nStep 12: Determine if the patient has given informed consent.\nThe patient has agreed to tumor resection prior to chemotherapy.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "397": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria\nThe patient is 45 years old, which meets the age requirement of \u2265 18 years.\n\nStep 2: Compare the patient's gender to the inclusion criteria\nThe patient is a female, which meets the gender requirement of male or female.\n\nStep 3: Compare the patient's medical history to the inclusion criteria\nThe patient has invasive breast cancer, which meets the requirement for invasive breast cancer.\n\nStep 4: Check if the patient has given written informed consent for the study\nThe patient has agreed to tumor resection prior to chemotherapy, which implies that she has given informed consent for the study.\n\nStep 5: Check if the patient is scheduled to undergo routine fine needle aspiration (FNA) or core biopsy of abnormal axillary lymph node\nThe patient has a core biopsy of a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, which meets the requirement for being scheduled to undergo FNA or core biopsy of abnormal axillary lymph node.\n\nBased on the comparison of the patient note and the inclusion criteria of the clinical trial, the patient meets all the requirements. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "398": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Disease: Postmenopausal breast cancer\n- Tumor size: 3 cm invasive ductal breast carcinoma\n- Hormone receptor status: ER/PR negative, HER2-positive\n- Lymph nodes: 5 positive lymph nodes\n- Metastasis: Metastatic lesions in CXR\n- Other characteristics: Multivitamins and iron supplements, no smoking or alcohol, not sexually active, no children, candidate for tumor resection\n\nStep 2: Compare the patient's characteristics with the inclusion criteria of the clinical trial.\n\n1. Histologically confirmed invasive breast cancer: Yes (patient has breast cancer)\n2. Early breast cancer with tumor size >1 cm: Yes (tumor size is 3 cm)\n3. No clinical evidence of regional lymph node metastasis (cN0) OR clinical evidence of cN1 status: Yes (patient has 5 positive lymph nodes, which is cN1 status)\n4. No evidence of metastasis (M0): No (patient has metastatic lesions)\n5. Postmenopausal: Yes (patient is postmenopausal)\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1: Not mentioned (insufficient information)\n7. Primary tumor must have positive estrogen receptor (ER) \u226510%: Yes (HER2-positive, ER/PR negative)\n8. Primary tumor must be HER2-positive (by IHC and/or ISH): Yes (patient is HER2-positive)\n9. Baseline LVEF \u226555%: Not mentioned (insufficient information)\n10. Normal hematologic status: Not mentioned (insufficient information)\n11. Normal renal function: Not mentioned (insufficient information)\n12. Normal liver function: Not mentioned (insufficient information)\n13. Written Informed Consent: Not mentioned (insufficient information)\n14. Patient agrees to data transfer and handling, and tumor submission for central pathology review and",
        "label": 0
    },
    "399": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the trial's age requirement.\nThe patient is 45 years old, but the trial does not specify an age requirement.\n\nStep 2: Compare patient's gender to the trial's gender requirement.\nThe patient is a woman, and the trial does not specify a gender requirement.\n\nStep 3: Compare patient's diagnosis to the trial's diagnosis requirement.\nThe patient has breast cancer, while the trial is for eccrine porocarcinoma. These are two different types of cancer, so the patient does not meet the diagnosis requirement.\n\nStep 4: Compare patient's treatment history to the trial's treatment history requirement.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The trial does not specify any treatment history requirements.\n\nStep 5: Compare patient's medical conditions to the trial's medical conditions requirement.\nThe patient has metastatic lesions, while the trial does not specify any medical conditions requirements.\n\nStep 6: Compare patient's use of supplements to the trial's supplement use requirement.\nThe patient is using multivitamins and iron supplements, while the trial does not specify any supplement use requirements.\n\nStep 7: Compare patient's lifestyle to the trial's lifestyle requirement.\nThe patient does not smoke or consume alcohol, while the trial does not specify any lifestyle requirements.\n\nStep 8: Compare patient's reproductive status to the trial's reproductive status requirement.\nThe patient is not sexually active and has no children, while the trial does not specify any reproductive status requirements.\n\nSince the patient does not meet the diagnosis requirement, she is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "400": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's condition and characteristics.\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nStep 2: Compare the patient's condition and characteristics with the inclusion criteria of the clinical trial.\n\nInclusion Criteria:\n1. Patients with invasive ductal carcinoma of the breast\n2. Patients who received surgery for primary invasive breast cancer between 2010 and 2015\n\nThe patient has invasive ductal carcinoma of the breast, which matches the first inclusion criterion. However, there is no information about whether the patient received surgery for primary invasive breast cancer between 2010 and 2015.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\nSince there is not enough information to determine if the patient received surgery between 2010 and 2015, the patient's eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "401": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n\n- Age: 45 years old\n- Gender: Female\n- Disease: Postmenopausal with cytologically confirmed breast cancer\n- Tumor type: Invasive ductal breast carcinoma (3 cm) in the left upper outer quadrant\n- Tumor markers: HER2-positive, ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- CXR: Metastatic lesions\n- Medications: Multivitamins and iron supplements\n- Other factors: Non-smoker, non-alcohol consumer, not sexually active, no children, candidate for tumor resection before chemotherapy\n\nStep 2: Compare the patient's characteristics with the inclusion criteria of the clinical trial.\n\nInclusion Criteria: Metastatic breast cancer\n\nThe patient has metastatic breast cancer, which matches the inclusion criteria.\n\nStep 3: Determine the trial-level eligibility based on the comparison.\n\nSince the patient meets the inclusion criteria, the trial-level eligibility is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "402": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age.\nThe patient is a 45-year-old postmenopausal woman.\n\nStep 2: Identify the patient's gender.\nThe patient is a woman.\n\nStep 3: Identify the patient's disease.\nThe patient has cytologically confirmed breast cancer.\n\nStep 4: Check if the patient is newly diagnosed.\nThe patient is not specified as newly diagnosed or not in the note.\n\nStep 5: Check if the patient has operable breast cancer.\nThe patient has a 3 cm invasive ductal breast carcinoma, but it is not specified if it is operable or not.\n\nStep 6: Check if the patient is eligible based on the inclusion criteria.\nThe patient meets some of the inclusion criteria, but not all. The patient is not specified as being newly diagnosed or having operable breast cancer.\n\nStep 7: Determine the trial-level eligibility.\nSince the patient does not meet all the inclusion criteria, the trial-level eligibility is 1) Not relevant.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "403": {
        "output": "GPT4 Correct Assistant: Step 1: Check if the patient has given appropriate written informed consent.\nThe patient note does not provide information about informed consent.\n\nStep 2: Check if the patient's age is 18 or older.\nThe patient is 45 years old, which is older than 18.\n\nStep 3: Check if the patient is receiving neoadjuvant chemotherapy for breast cancer.\nThe patient note states that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This indicates that the patient is receiving neoadjuvant chemotherapy.\n\nStep 4: Check if the patient has a biopsy-confirmed diagnosis of invasive breast cancer.\nThe patient note states that the patient has cytologically confirmed breast cancer and a core biopsy revealed a 3 cm invasive ductal breast carcinoma. This confirms the patient has invasive breast cancer.\n\nStep 5: Check if the patient's disease is Stage I-III according to the AJCC v7 criteria.\nThe patient note states that axillary sampling revealed 5 positive lymph nodes and CXR was remarkable for metastatic lesions. This indicates that the patient's disease is Stage III.\n\nStep 6: Check if the patient's cancer is HER2-positive and ER/PR negative.\nThe patient note states that the tumor is HER2-positive and ER/PR negative.\n\nStep 7: Check if the patient meets any exclusion criteria.\nThe clinical trial does not list any exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "404": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age.\nThe patient is 45 years old.\n\nStep 2: Identify the patient's condition.\nThe patient has cytologically confirmed breast cancer with a HER2-positive and ER/PR negative tumor.\n\nStep 3: Compare the patient's condition with the inclusion criteria.\nThe patient does not have a confirmed benign postsurgical biliary stricture, as she has breast cancer.\n\nStep 4: Determine the patient's eligibility.\nSince the patient does not have a confirmed benign postsurgical biliary stricture, she does not meet the inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "405": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nPatient age: 45 years old\nInclusion criteria: Age \u2264 75 years old, female\n\nThe patient's age is within the range specified in the inclusion criteria.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nPatient gender: Female\nInclusion criteria: Female\n\nThe patient's gender matches the inclusion criteria.\n\nStep 3: Compare the patient's cancer type with the inclusion criteria.\nPatient cancer type: Breast cancer\nInclusion criteria: Histologically confirmed breast cancer\n\nThe patient's cancer type matches the inclusion criteria.\n\nStep 4: Compare the patient's ipsilateral supraclavicular lymph node metastasis with the inclusion criteria.\nPatient ipsilateral supraclavicular lymph node metastasis: Yes (metastatic lesions in CXR)\nInclusion criteria: Histologically or cytologically confirmed ipsilateral supraclavicular lymph node metastasis\n\nThe patient's ipsilateral supraclavicular lymph node metastasis matches the inclusion criteria.\n\nStep 5: Compare the patient's cancer stage with the inclusion criteria.\nPatient cancer stage: cT0-T3 (from the information about the tumor size)\nInclusion criteria: cT0-T3\n\nThe patient's cancer stage matches the inclusion criteria.\n\nStep 6: Compare the patient's anesthesia risk with the inclusion criteria.\nPatient anesthesia risk: Not specified in the patient note\nInclusion criteria: Low and moderate risk for anesthesia\n\nThe patient's anesthesia risk is not specified in the patient note.\n\nStep 7: Determine the trial-level eligibility based on the comparison.\nSince the patient's anesthesia risk is not specified in the patient note, we cannot determine if they meet all the inclusion criteria. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "406": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is a 45-year-old postmenopausal woman. The inclusion criteria do not specify an age range.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman. The inclusion criteria do not specify a gender requirement.\n\nStep 3: Compare the patient's cancer type and stage to the inclusion criteria.\nThe patient has cytologically confirmed breast cancer. The inclusion criteria state that the patient must have localized invasive breast ductal adenocarcinoma, confirmed by the local pathologist, that includes either T1c-T2 (tumor size \u22652 cm), clinical node stage (cN)1-cN2, or T3-T4, cN0-cN2. The patient's tumor is 3 cm, which meets the size requirement. The patient's axillary sampling revealed 5 positive lymph nodes, which meets the node stage requirement.\n\nStep 4: Compare the patient's hormone receptor status to the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative. The inclusion criteria state that the patient must have centrally confirmed ER+/HER2-, Grade 3 breast cancer of ductal histology. The patient's tumor is HER2-negative, which does not meet the criteria.\n\nStep 5: Compare the patient's performance status to the inclusion criteria.\nThe patient's ECOG performance status is not mentioned in the patient note. The inclusion criteria state that the patient must have an ECOG performance status of 0 or 1.\n\nStep 6: Compare the patient's organ function to the inclusion criteria.\nThe patient's organ function is not mentioned in the patient note. The inclusion criteria state that the patient must have adequate organ function.\n\nTrial-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).",
        "label": 0
    },
    "407": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state that patients must be 18 years of age on the day of signing informed consent. Therefore, the patient meets this criterion.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, and the inclusion criteria do not specify a gender requirement. Therefore, the patient meets this criterion.\n\nStep 3: Compare the patient's disease to the inclusion criteria.\nThe patient has breast cancer, and the inclusion criteria state that patients must have metastatic confirmed breast cancer. Therefore, the patient meets this criterion.\n\nStep 4: Compare the patient's disease progression to the inclusion criteria.\nThe patient's disease progression is within 12 months prior to signing informed consent, and the inclusion criteria state that patients must have disease progression by radiological techniques within 12 months prior to signing informed consent. Therefore, the patient meets this criterion.\n\nStep 5: Compare the patient's BRCA1/2 mutation status to the inclusion criteria.\nThe patient's BRCA1/2 mutation status is not mentioned in the patient note, and the inclusion criteria state that patients must have a documented mutation in BRCA1 or BRCA2 genes that is predicted to be deleterious or suspected deleterious. Therefore, the patient does not meet this criterion.\n\nStep 6: Compare the patient's measurable disease to the inclusion criteria.\nThe patient's measurable disease is not mentioned in the patient note, and the inclusion criteria state that patients must have measurable disease based on RECIST 1.1. Therefore, the patient does not meet this criterion.\n\nStep 7: Compare the patient's prior chemotherapy to the inclusion criteria.\nThe patient's prior chemotherapy with anthracyclines and taxanes is not mentioned in the patient note, and the inclusion criteria state that patients must have prior chemotherapy with anthracyclines and taxanes. Therefore, the patient does not meet this criterion.\n\nStep 8: Compare the patient's performance status to the inclusion criteria.\nThe patient's performance status is not mentioned in the patient note,",
        "label": 0
    },
    "408": {
        "output": "GPT4 Correct Assistant: First, let's break down the patient note and the clinical trial inclusion and exclusion criteria to determine the patient's eligibility for the trial.\n\nPatient note:\n1. 45-year-old postmenopausal woman\n2. Cytologically confirmed breast cancer\n3. 3 cm invasive ductal breast carcinoma\n4. HER2-positive and ER/PR negative\n5. Axillary sampling revealed 5 positive lymph nodes\n6. Metastatic lesions in CXR\n7. Using multivitamins and iron supplements\n8. No smoking or alcohol consumption\n9. No children, not sexually active\n10. Candidate for tumor resection and agrees to do so prior to chemotherapy\n\nClinical trial:\nInclusion criteria:\n1. Aged \u226518 years old\n2. Histologically confirmed invasive triple negative breast cancer (TNBC)\n3. Planned definitive surgical treatment after at least 6 cycles of neoadjuvant chemotherapy (NACT)\n4. Eastern Oncology Cooperative Group (ECOG) performance status 0-1\n5. Considered fit enough to have breast cancer surgery with curative intent\n6. Considered fit to complete at least 2 weeks of pre-operative trial treatment in the WOP\n7. Patients must be suitable for a mandatory pre-treatment baseline biopsy performed Day -1 or 1 of the window of opportunity (WOP) and a post-treatment biopsy performed on Day 14 of the WOP.\n8. Patients with clinical stage II disease or clinical suspicion of metastatic disease must have staging studies as per standard of care to exclude metastatic disease (axillary lymph nodes or internal mammary node involvement will not be regarded as evidence of metastatic disease);\n9. Patients with stage III disease must have staging studies as per standard of care at any point after diagnosis but before Trial Registration, to exclude metastatic disease (axillary lymph nodes or internal mammary node involvement will not be regarded as evidence of metastatic disease), even if asymptomatic.\n10. Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the trial",
        "label": 0
    },
    "409": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with inclusion criteria\nThe patient is 45 years old, which falls within the postmenopausal age range specified in the inclusion criteria (\u226518 years of age).\n\nStep 2: Compare patient's hormone receptor status with inclusion criteria\nThe patient has HER2-positive and ER/PR negative breast cancer, which matches the criteria of ER-positive and HER2-negative breast cancer.\n\nStep 3: Compare patient's surgical resection status with inclusion criteria\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which matches the criteria of patients who will undergo surgical treatment with either segmental resection or total mastectomy.\n\nStep 4: Compare patient's measurable tumor status with inclusion criteria\nThe patient has metastatic lesions, which indicates a measurable tumor.\n\nStep 5: Compare patient's other characteristics with inclusion criteria\nThe patient is postmenopausal, does not have a history of chemotherapy for this primary breast cancer, and meets the criteria for adequate hepatic and renal function.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "410": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note and the clinical trial inclusion criteria.\n\nPatient Note:\n- The patient has cytologically confirmed breast cancer.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- CXR was remarkable for metastatic lesions.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nClinical Trial Inclusion Criteria:\n- ER-positive/HER2-negative in primary tumor\n- Oligometastases: \u2264 2 lesions in single organ or site (lung, bone, liver, adrenal glands, distant LNs)\n- Recurrent cancer after completion of primary treatment (RFI\u22651year)\n- Metastatic lesions are feasible for resection or radiotherapy (Size\u22643cm)\n\nStep 2: Compare the patient note with the inclusion criteria.\n\n- The patient's tumor is HER2-positive, which is not included in the inclusion criteria.\n- The patient has metastatic lesions, but the number of lesions is not specified.\n- The patient has not had primary treatment, so the recurrent cancer criterion does not apply.\n- The size of the metastatic lesions is not specified in the patient note.\n\nStep 3: Determine the trial-level eligibility.\n\nSince the patient's tumor is HER2-positive and the number of metastatic lesions is not specified, the patient does not meet the inclusion criteria. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "411": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. She has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. She is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nStep 2: Analyze the clinical trial\nTitle: Methotrexate in the Treatment of Distal Interphalangeal Joint Extensor Tendon Enthesopathy in Nail Psoriasis\n\nSummary: The primary aim of the study is to assess the effect of methotrexate on the development of distal interphalangeal joint extensor tendon enthesopathy.\n\nInclusion criteria: Patients with psoriatic changes in nails treated at the Rheumatological Clinic in Olsztyn and the Clinic of Dermatology, Sexually Transmitted Diseases and Clinical Immunology of the University of Warmia and Mazury in Olsztyn, in whom a US examination revealed DIP joint extensor tendon enthesopathy\n\nStep 3: Compare patient note and clinical trial\nThe patient note describes a patient with breast cancer, while the clinical trial is focused on patients with psoriatic changes in nails and distal interphalangeal joint extensor tendon enthesopathy. There is no overlap between the patient's condition and the clinical trial's inclusion criteria.\n\nStep 4: Determine trial-level eligibility\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "412": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Disease: Postmenopausal breast cancer\n- Tumor type: Invasive ductal carcinoma, 3 cm, HER2-positive, ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- CXR: Metastatic lesions\n- Other medical conditions: None mentioned\n\nStep 2: Compare the patient's characteristics to the inclusion criteria of the clinical trial.\n- Inclusion Criteria: Patients with hormone receptor positive metastatic breast cancer for whom there is a reasonable expectation that abemaciclib may provide clinical benefit and who are suitable to receive abemaciclib.\n\nStep 3: Determine if the patient meets the inclusion criteria.\n- The patient has hormone receptor positive metastatic breast cancer.\n- The patient is suitable to receive abemaciclib.\n\nStep 4: Check if the patient meets any exclusion criteria (if provided).\n- No exclusion criteria are provided in the given information.\n\nStep 5: Assess the patient's eligibility based on the inclusion and exclusion criteria.\n- The patient meets the inclusion criteria and no exclusion criteria apply.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "413": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's diagnosis\nThe patient's diagnosis is breast cancer, not colorectal cancer. Therefore, the patient does not meet the first inclusion criterion (colorectal cancer diagnosis).\n\nStep 2: Identify the patient's cancer type\nThe patient's cancer type is invasive ductal breast carcinoma, not medullary carcinoma. Therefore, the patient does not meet the second inclusion criterion (medullary carcinoma).\n\nSince the patient does not meet both inclusion criteria, they are not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "414": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Disease: Breast cancer\n- Tumor type: Invasive ductal carcinoma\n- Tumor location: Left upper outer quadrant\n- Tumor size: 3 cm\n- HER2 status: Positive\n- ER/PR status: Negative\n- Axillary sampling: 5 positive lymph nodes\n- Metastatic lesions: Present (CXR)\n- Medications: Multivitamins and iron supplements\n- Smoking status: Non-smoker\n- Alcohol consumption: Non-consumer\n- Sexual activity: Not sexually active\n- Children: None\n- Treatment plan: Tumor resection before chemotherapy\n\nStep 2: Compare the patient's characteristics with the inclusion criteria of the clinical trial.\n\nInclusion Criteria 1: First treated or recurrent metastatic breast cancer, confirmed by CT or MRI, have at least one measurable lesion.\n- Patient has metastatic breast cancer (CXR) and has at least one measurable lesion (tumor size).\n\nInclusion Criteria 2: HER2 positive or triple negative patients.\n- Patient is HER2 positive.\n\nInclusion Criteria 3: Patients with anti-HER2 treatment as first-line or not, and patients with HER2 positive can be treated with adjuvant therapy containing trastuzumab.\n- Patient is HER2 positive and can be treated with adjuvant therapy containing trastuzumab.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\nThe patient meets all the inclusion criteria. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "415": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's cancer type and characteristics.\nThe patient has breast cancer, which is HER2-positive and ER/PR negative.\n\nStep 2: Compare the patient's cancer characteristics with the inclusion criteria.\nThe trial is for ER-positive and/or PR-positive breast cancer. The patient's cancer is HER2-positive and ER/PR negative, which does not match the inclusion criteria.\n\nStep 3: Determine the trial-level eligibility based on the comparison.\nSince the patient's cancer characteristics do not match the inclusion criteria, the patient is excluded from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "416": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the range of \u2265 18 years old.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is female, which matches the requirement of being female.\n\nStep 3: Compare the patient's ECOG performance status to the inclusion criteria.\nThe patient's ECOG performance status is not mentioned in the patient note, so we cannot determine if she meets this criterion.\n\nStep 4: Compare the patient's tumor diagnosis to the inclusion criteria.\nThe patient has a diagnosis of invasive ductal breast carcinoma, which matches the requirement of having a diagnosis of invasive adenocarcinoma of the breast.\n\nStep 5: Compare the patient's tumor size and nodal status to the inclusion criteria.\nThe patient's tumor size is 3 cm, which is larger than the required size of \u2265 1.0 cm. The patient has 5 positive lymph nodes, which is more than the allowed number of \u2264 1 positive lymph node.\n\nStep 6: Compare the patient's tumor receptor status to the inclusion criteria.\nThe patient's tumor is HER2-positive, which does not match the requirement of being HER2-negative.\n\nStep 7: Compare the patient's blood counts and liver function to the inclusion criteria.\nThe patient's blood counts, liver function, and alkaline phosphatase and AST levels are not mentioned in the patient note, so we cannot determine if she meets these criteria.\n\nStep 8: Compare the patient's eligibility for chemotherapy to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which matches the requirement of being a candidate for weekly paclitaxel and carboplatin chemotherapy.\n\nStep 9: Compare the patient's reproductive status to the inclusion criteria.\nThe patient is not sexually active and has no children, but her use of multivitamins and iron supplements is not mentioned, so we cannot determine if she meets this criterion.\n\nStep 1",
        "label": 0
    },
    "417": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note for relevant information.\n\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nStep 2: Compare the patient's information to the inclusion criteria.\n\n1. Histologically confirmed invasive breast cancer: Yes (patient has breast cancer)\n2. First proven ipsilateral local and/or regional recurrence of a primary invasive breast cancer: Yes (patient has recurrent breast cancer)\n3. Completion of locoregional therapy: Not relevant (patient's therapy status is not mentioned)\n4. Negative or microscopically involved margins: Not relevant (patient's margin status is not mentioned)\n5. Female or male aged 18 years or older: Yes (patient is 45 years old)\n6. ECOG performance status 0 or 1: Not relevant (patient's performance status is not mentioned)\n7. Recurrent tumor must be hormone receptor positive: No (patient's tumor is ER/PR negative)\n8. Normal hematological, renal, and liver function: Not relevant (patient's function status is not mentioned)\n9. Patient agrees to make tumor available for central pathology review: Not relevant (patient's consent is not mentioned)\n10. Patients must either be planned to initiate, or have already started, endocrine therapy for ipsilateral isolated locoregional recurrence: Not relevant (patient's therapy status is not mentioned)\n11. Written Informed Consent prior to randomization: Not relevant (patient's consent is not mentioned)\n\nStep 3: Determine the patient's eligibility based on the inclusion criteria.\n\nThe patient meets some of the inclusion criteria, but not all. The most relevant criteria that the patient does not meet are:\n- Recurrent tumor must be hormone receptor positive: ER/PR negative\n- Patients must either be planned to initiate, or have already started, endocr",
        "label": 0
    },
    "418": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which meets the requirement of being a female patient aged \u2265 18 years.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is female, which meets the requirement of being a female patient.\n\nStep 3: Compare the patient's diagnosis to the inclusion criteria.\nThe patient has a histological diagnosis of breast cancer, which meets the requirement of having a histological diagnosis of breast cancer.\n\nStep 4: Compare the patient's HER2 status to the inclusion criteria.\nThe patient has a HER2-positive breast cancer, which meets the requirement of having a known HER2 status.\n\nStep 5: Compare the patient's target lesion diameter to the inclusion criteria.\nThe patient's tumor is 3 cm, which is greater than the required \u2265 15 mm.\n\nStep 6: Compare the patient's performance status to the inclusion criteria.\nThere is no information on the patient's ECOG performance status, so it is not possible to determine if they meet this requirement.\n\nStep 7: Compare the patient's urine pregnancy test to the inclusion criteria.\nThere is no information on the patient's urine pregnancy test, so it is not possible to determine if they meet this requirement.\n\nStep 8: Compare the patient's life expectancy to the inclusion criteria.\nThere is no information on the patient's life expectancy, so it is not possible to determine if they meet this requirement.\n\nStep 9: Compare the patient's organ function to the inclusion criteria.\nThere is no information on the patient's organ function, so it is not possible to determine if they meet this requirement.\n\nStep 10: Compare the patient's staging to the inclusion criteria.\nThere is no information on the patient's staging, so it is not possible to determine if they meet this requirement.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "419": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria.\nPatient's age: 45 years old\nInclusion criteria: Must be at least 18\nThe patient meets the age requirement.\n\nStep 2: Compare patient's gender to the inclusion criteria.\nInclusion criteria: No specific gender requirement\nThe patient meets the gender requirement.\n\nStep 3: Compare patient's diagnosis to the inclusion criteria.\nPatient's diagnosis: Invasive ductal breast carcinoma\nInclusion criteria: Clinical diagnosis of IPNBs\nThe patient does not meet the diagnosis requirement.\n\nStep 4: Compare patient's ECOG Performance status to the inclusion criteria.\nInclusion criteria: ECOG Performance status of 0, 1, or 2\nThe patient's ECOG Performance status is not provided.\n\nStep 5: Compare patient's liver function to the inclusion criteria.\nInclusion criteria: Adequate liver function, bilirubin < 1.5 times ULN, ALT or AST < 2.5 times ULN\nThe patient's liver function is not provided.\n\nStep 6: Compare patient's renal function to the inclusion criteria.\nInclusion criteria: Adequate renal function: creatinine < 1.8\nThe patient's renal function is not provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "420": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\n1. Breast cancer stage: The patient has stage III breast cancer, which does not meet the inclusion criteria of stage I-III.\n2. Tumor size: The patient has a 3 cm tumor, which is greater than the 0.5 cm inclusion criteria.\n3. Lymph nodes: The patient has 5 positive lymph nodes, which does not meet the inclusion criteria of lymph nodes negative.\n4. Hormone receptors: The patient is ER/PR negative, which does not meet the inclusion criteria of hormone receptor positive.\n5. HER2 status: The patient is HER2-positive, which does not meet the inclusion criteria of HER2 negative.\n6. Treatment: The patient is a candidate for tumor resection and chemotherapy, which does not meet the inclusion criteria of receiving endocrine therapy only.\n7. FFPE samples: The patient has not provided enough information about FFPE samples to determine eligibility.\n8. Integrated medical records: The patient has integrated medical records, which meets the inclusion criteria.\n\nStep 2: Determine trial-level eligibility\n\nBased on the comparison, the patient does not meet the majority of the inclusion criteria. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "421": {
        "output": "GPT4 Correct Assistant: Patient Note: \n1. Age: 30 years old, which is >= 18 years\n2. Gender: Female\n3. Histology: Breast cancer\n4. Stage: 4\n5. Hormone Receptor Status: HER2+, ER-, PR-\n6. Metastases: Axillary lymph nodes positive\n7. No history of other malignancies\n8. ECOG Performance Status: 0\n9. No prior treatment with MET or VEGFR inhibitors\n10. No prior treatment with any therapy on the PD-1/PD-L1 axis or anti-CTLA-4/CTLA-4 inhibitors\n11. No HIV-positive patients\n12. No rheumatologic arthropathies, Sjogren's syndrome, psoriasis, vitiligo, endocrine deficiencies, or active diverticulitis, intra-abdominal abscess, or gastrointestinal (GI) obstruction\n13. No pregnancy or breastfeeding\n14. No cytotoxic chemotherapy, biologic agents, radiation therapy, small molecule kinase inhibitors, hormonal therapy, investigational agent, or warfarin within specified timeframes\n15. No active brain metastases or epidural disease\n16. No concomitant treatment with warfarin\n17. No history of organ or allogeneic stem cell transplant\n18. No history of severe hypersensitivity reaction to any monoclonal antibody\n19. No evidence of active autoimmune disease or history of autoimmune disease that might recur\n20. No positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "422": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria\nThe patient is 45 years old, which is over the age of 18. This meets the age requirement.\n\nStep 2: Compare patient's diagnosis to the inclusion criteria\nThe patient has a core biopsy proven invasive ductal breast carcinoma, which is a malignant condition, not a borderline or high-risk non-malignant breast lesion. This does not meet the diagnosis requirement.\n\nStep 3: Compare patient's consent to the inclusion criteria\nThe patient has given informed consent, which meets the consent requirement.\n\nStep 4: Determine if the patient meets all inclusion criteria\nThe patient meets the age and consent requirements, but not the diagnosis requirement. Therefore, the patient does not meet all inclusion criteria.\n\nStep 5: Determine the patient's eligibility\nSince the patient does not meet all inclusion criteria, they are not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "423": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nPatient's age: 45 years old\nInclusion criteria: Age >= 18 years old\nThe patient meets the age requirement.\n\nStep 2: Compare the patient's cancer type and treatment to the inclusion criteria.\nPatient's cancer: Breast cancer requiring a treatment by paclitaxel\nInclusion criteria: Breast cancer requiring a treatment by paclitaxel or colorectal cancer requiring a treatment by oxaliplatine\nThe patient meets the cancer type and treatment requirement.\n\nStep 3: Compare the number of planned chemotherapy cycles to the inclusion criteria.\nPatient's planned chemotherapy cycles: Not mentioned\nInclusion criteria: At least 8 chemotherapy cycles planned\nThe patient does not have sufficient information to qualify for the trial.\n\nStep 4: Compare the patient's language proficiency to the inclusion criteria.\nPatient's language proficiency: Not mentioned\nInclusion criteria: Able to understand, read and write French language\nThe patient does not have sufficient information to qualify for the trial.\n\nStep 5: Compare the patient's insurance coverage to the inclusion criteria.\nPatient's insurance coverage: Not mentioned\nInclusion criteria: Covered by a social insurance\nThe patient does not have sufficient information to qualify for the trial.\n\nStep 6: Compare the patient's informed consent to the inclusion criteria.\nPatient's informed consent: Not mentioned\nInclusion criteria: Dated and signed informed consent\nThe patient does not have sufficient information to qualify for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "424": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note and compare it to the inclusion criteria of the clinical trial.\n\nPatient age: 45 years old\nPatient gender: Female\nTumor type: HER2-positive and ER/PR negative breast cancer\nTumor stage: T2-T3 N0 invasive breast cancer\nPrevious treatment: Core biopsy, axillary sampling, and chemotherapy planned\nClinical complete response: Not mentioned\nRadiological complete response: Not mentioned\nNode-negative prediction: Not mentioned\n\nStep 2: Compare the patient's information to the inclusion criteria.\n\n1. Patient aged 18 years or older: Yes, the patient is 45 years old.\n2. Written informed consent provided: Not mentioned, but we can assume it is provided.\n3. Triple negative or HER2-positive / ER-negative or HER2-positive / ER-positive breast tumours: Yes, the patient has HER2-positive breast cancer.\n4. Patients eligible for breast conservation after NAC: Not mentioned, but we can assume the patient is eligible based on the information provided.\n5. Patients with T2-T3 N0 invasive breast cancer initially treated by NAC to allow breast conservation: Yes, the patient has T2-T3 N0 invasive breast cancer.\n6. Clinical complete response after NAC: Not mentioned.\n7. Radiological (mammography, breast US, breast MRI) complete response after NAC: Not mentioned.\n8. Patients predicted to be node-negative at treatment initiation: Not mentioned.\n\nStep 3: Determine the trial-level eligibility based on the comparison.\n\nThe patient meets most of the inclusion criteria, but there is not enough information to determine if the patient has clinical complete response, radiological complete response, and is predicted to be node-negative at treatment initiation.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "425": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria.\nThe patient is 45 years old, which falls within the age range of 18 to 70 years old.\n\nStep 2: Compare patient's tumor size with the inclusion criteria.\nThe patient has a 3 cm invasive ductal breast carcinoma, which is larger than the required minimum of 2 cm.\n\nStep 3: Compare patient's HER2 status with the inclusion criteria.\nThe patient's tumor is 3+ positive HER2 status by IHC, which matches the inclusion criteria of having 3+ positive HER2 status.\n\nStep 4: Compare patient's clinical stage with the inclusion criteria.\nThe patient has clinical stages IIA - IIIC, which matches the inclusion criteria of clinical stages IIA - IIIC.\n\nStep 5: Compare patient's chemotherapy status with the inclusion criteria.\nThe patient is chemotherapy/hormonal treatment naive, which matches the inclusion criteria of chemotherapy-naive patients.\n\nStep 6: Compare patient's performance status with the inclusion criteria.\nThe patient's ECOG performance status is not provided, so we cannot determine if she meets the inclusion criteria of ECOG performance status 0-1.\n\nStep 7: Compare patient's pregnancy status with the inclusion criteria.\nThe patient is not pregnant and not nursing, which matches the inclusion criteria of being non-pregnant and not nursing.\n\nStep 8: Compare patient's laboratory data with the inclusion criteria.\nThe patient's laboratory data is not provided, so we cannot determine if she meets the inclusion criteria for adequate hematologic, renal, and hepatic function.\n\nStep 9: Compare patient's left ventricular ejection fraction with the inclusion criteria.\nThe patient's left ventricular ejection fraction is not provided, so we cannot determine if she meets the inclusion criteria of having a baseline left ventricular ejection fraction of \u2265 55%.\n\nBased on the provided information, the patient meets most of the inclusion criteria, but we cannot determine if she meets the criteria for ECOG performance status, laboratory data, and left ventricular ejection fraction. Therefore, the trial-level eligibility is:",
        "label": 2
    },
    "426": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria for Psoriatic Arthritis (PsA)\n\nThe patient note mentions that the patient has breast cancer, not Psoriatic Arthritis. Therefore, the patient does not meet the first inclusion criterion.\n\nStep 2: Compare patient note and inclusion criteria for tumor necrosis factor (TNFi) exposure\n\nThe patient note states that the patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This indicates that the patient has not yet been exposed to biologics or TNF inhibitors. Therefore, the patient meets this inclusion criterion.\n\nStep 3: Compare patient note and inclusion criteria for plaque psoriasis lesion\n\nThe patient note does not provide any information about plaque psoriasis lesions. Therefore, we cannot determine if the patient meets this inclusion criterion.\n\nStep 4: Compare patient note and inclusion criteria for active arthritis\n\nThe patient note does not provide any information about the patient's joints or arthritis. Therefore, we cannot determine if the patient meets this inclusion criterion.\n\nStep 5: Compare patient note and inclusion criteria for high sensitivity C-reactive protein (hsCRP)\n\nThe patient note does not provide any information about the patient's hsCRP levels. Therefore, we cannot determine if the patient meets this inclusion criterion.\n\nStep 6: Compare patient note and inclusion criteria for Women of Childbearing Potential (WOCBP)\n\nThe patient note does not provide any information about the patient's reproductive status. Therefore, we cannot determine if the patient meets this inclusion criterion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "427": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria.\nThe patient is a 45-year-old postmenopausal woman, and the inclusion criteria require subjects who have scheduled elective spine surgery. Age is not mentioned in the inclusion criteria, so we cannot compare the patient's age with the inclusion criteria.\n\nStep 2: Compare patient's gender with the inclusion criteria.\nThe patient is a woman, and the inclusion criteria require subjects who have scheduled elective spine surgery. Gender is not mentioned in the inclusion criteria, so we cannot compare the patient's gender with the inclusion criteria.\n\nStep 3: Compare patient's medical condition with the inclusion criteria.\nThe patient has breast cancer, while the inclusion criteria require subjects who have scheduled elective spine surgery. These medical conditions are different, so the patient does not meet the inclusion criteria.\n\nStep 4: Determine if the patient meets any exclusion criteria.\nThe patient does not have any information that matches the exclusion criteria.\n\nStep 5: Assess the patient's eligibility.\nSince the patient does not meet the inclusion criteria, we cannot determine if the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "428": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria. The patient is 45 years old, and the inclusion criteria do not specify an age range.\n\nStep 2: Compare the patient's gender to the inclusion criteria. The patient is a woman, and the inclusion criteria do not specify a gender requirement.\n\nStep 3: Compare the patient's cancer type and stage to the inclusion criteria. The patient has invasive ductal breast carcinoma, while the inclusion criteria specify ductal carcinoma in situ (DCIS).\n\nStep 4: Compare the patient's hormone receptor status to the inclusion criteria. The patient's tumor is ER/PR negative, while the inclusion criteria allow for both positive and negative ER/PR status.\n\nStep 5: Compare the patient's HER2 status to the inclusion criteria. The patient's tumor is HER2-positive, while the inclusion criteria allow for HER2-positive, negative, or unknown status.\n\nStep 6: Compare the patient's previous treatment history to the inclusion criteria. The patient has not had prior treatment, and the inclusion criteria do not specify a requirement for prior treatment.\n\nStep 7: Compare the patient's other medical conditions to the inclusion criteria. The patient has metastatic lesions, which are not allowed in the inclusion criteria.\n\nBased on the comparison, the patient does not meet the inclusion criteria due to having invasive ductal breast carcinoma instead of ductal carcinoma in situ and having metastatic lesions. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "429": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which falls within the range of Stage I-III operable breast cancer for postmenopausal women.\n\nStep 2: Compare the patient's breast cancer type to the inclusion criteria.\nThe patient has cytologically confirmed breast cancer, which is consistent with the inclusion criteria.\n\nStep 3: Compare the patient's tumor characteristics to the inclusion criteria.\nThe patient has a 3 cm invasive ductal breast carcinoma, which is greater than or equal to 1.5 cm in largest diameter. The tumor is HER2-positive and ER/PR negative, which does not meet the inclusion criteria of ER-positive tumor and HER2-negative breast cancer.\n\nStep 4: Compare the patient's postmenopausal status to the inclusion criteria.\nThe patient is postmenopausal, which meets the inclusion criteria.\n\nStep 5: Compare the patient's breast cancer eligibility for primary surgery to the inclusion criteria.\nThe patient is a candidate for tumor resection, which meets the inclusion criteria of breast cancer eligible for primary surgery.\n\nStep 6: Compare the patient's ECOG Performance Status to the inclusion criteria.\nThe patient's ECOG Performance Status is not provided, so we cannot determine if she meets this criterion.\n\nStep 7: Compare the patient's organ function to the inclusion criteria.\nThe patient's organ function is not provided, so we cannot determine if she meets this criterion.\n\nSince the patient does not meet all the inclusion criteria (specifically, the ER-positive tumor and HER2-negative breast cancer requirement), the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "430": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with inclusion criteria\nThe patient is 45 years old, and the inclusion criteria require subjects to be age > 50 years at breast cancer diagnosis. Therefore, the patient does not meet this criterion.\n\nStep 2: Compare patient's hormone receptor status with inclusion criteria\nThe patient's tumor is ER/PR negative, while the inclusion criteria require subjects to be hormone receptor positive. Therefore, the patient does not meet this criterion.\n\nStep 3: Compare patient's HER2 status with inclusion criteria\nThe patient's tumor is HER2-positive, while the inclusion criteria require subjects to be HER2 negative. Therefore, the patient does not meet this criterion.\n\nStep 4: Compare patient's stage with inclusion criteria\nThe patient has 5 positive lymph nodes and metastatic lesions, which indicates a more advanced stage than pT1N0 or pT2N0. Therefore, the patient does not meet this criterion.\n\nStep 5: Compare patient's Prosigna\u00ae score with inclusion criteria\nSince the patient has not undergone Prosigna\u00ae screening, we cannot determine if she meets this criterion.\n\nStep 6: Compare patient's treatment history with inclusion criteria\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This does not conflict with the inclusion criteria, which state that no chemotherapy has been given or planned for this breast cancer.\n\nStep 7: Compare patient's life expectancy with inclusion criteria\nThere is no information in the patient note about the patient's life expectancy, so we cannot determine if she meets this criterion.\n\nBased on the above comparisons, the patient does not meet the inclusion criteria for this clinical trial. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "431": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions.\n\nStep 2: Analyze the inclusion criteria\nInclusion Criteria:\n- Patients with pathologically confirmed invasive ductal carcinoma (Grade 2 or 3)\n- Undergoing wide local excision surgery or mastectomy\n\nStep 3: Compare the patient note to the inclusion criteria\n1. The patient has pathologically confirmed invasive ductal carcinoma, which matches the first inclusion criterion.\n2. The patient is undergoing surgery, which matches the second inclusion criterion.\n\nStep 4: Determine the trial-level eligibility\nSince the patient meets both inclusion criteria, the trial-level eligibility is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "432": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's stage and type of cancer.\nThe patient note states that the patient has cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions.\n\nStep 2: Compare the patient's stage and type of cancer with the inclusion criteria.\nThe inclusion criteria state that patients must have stage 0, I, or II (Tis, Ti, or T2 <=3cm & NO) histologically confirmed invasive non-lobular carcinoma or ductal carcinoma in situ of the breast with a lesion <= 3 cm.\n\nStep 3: Determine if the patient meets the inclusion criteria.\nThe patient's cancer is stage II and is a ductal carcinoma, which meets the first part of the inclusion criteria. The tumor size is also <= 3 cm, which meets the second part of the inclusion criteria.\n\nStep 4: Identify any other inclusion criteria that must be met.\nThe inclusion criteria also state that patients must have negative inked histologic margins of excision or reexcision and clear of invasive tumor and DClS by at least 2mm, negative post-excision or post-reexcision mammography if cancer presented with malignancy-associated microcalcifications, no remaining suspicious microcalcifications in the breast before radiotherapy, no involved axillary lymph nodes by routine histologic examination (H&E) of sentinel node(s) or of nodes identified from axillary dissection, and enrollment and initiation of CyberKnife therapy within 42 days of last breast cancer surgery or last chemotherapy treatment.\n\nStep 5: Determine if the patient meets the remaining inclusion criteria.\nThere is not enough information in the patient note to determine if the patient meets the remaining inclusion criteria, such as negative inked histologic margins, negative post-excision mammography, and no involved axillary lymph nodes.\n\nStep 6: Assess the patient's eligibility based on the information available.\nBased on the information available, the patient meets some of the inclusion criteria",
        "label": 0
    },
    "433": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the age range in the inclusion criteria.\nPatient's age: 45 years\nInclusion criteria: 18 to 75 years old\nThe patient's age falls within the age range specified in the inclusion criteria.\n\nStep 2: Compare the patient's gender with the gender specified in the inclusion criteria.\nPatient's gender: Female\nInclusion criteria: No specific gender requirement mentioned\nThe patient's gender is not specified in the inclusion criteria, but there is no exclusion based on gender.\n\nStep 3: Compare the patient's cancer type with the cancer type specified in the inclusion criteria.\nPatient's cancer type: Breast cancer\nInclusion criteria: Confirmed by pathology and/or histology/cytology as breast cancer\nThe patient's cancer type matches the cancer type specified in the inclusion criteria.\n\nStep 4: Compare the patient's cancer stage with the cancer stage specified in the inclusion criteria.\nPatient's cancer stage: Recurrent or metastatic breast cancer\nInclusion criteria: Patients with recurrent or metastatic breast cancer\nThe patient's cancer stage matches the cancer stage specified in the inclusion criteria.\n\nStep 5: Compare the patient's ECOG score with the ECOG score specified in the inclusion criteria.\nPatient's ECOG score: Not mentioned\nInclusion criteria: Physical strength: ECOG score 0-1\nThe patient's ECOG score is not provided in the patient note, so we cannot determine if they meet this criterion.\n\nStep 6: Compare the patient's expected survival period with the expected survival period specified in the inclusion criteria.\nPatient's expected survival period: Not mentioned\nInclusion criteria: The expected survival period is more than 3 months\nThe patient's expected survival period is not provided in the patient note, so we cannot determine if they meet this criterion.\n\nStep 7: Compare the patient's willingness to provide tissue specimens with the requirement to provide tissue specimens in the inclusion criteria.\nPatient's willingness to provide tissue specimens: Agrees to do so prior to chemotherapy\nInclusion criteria: Agree to be collected tissue specimen\nThe",
        "label": 2
    },
    "434": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's information from the patient note.\n\n- Age: 45 years old\n- Gender: Female\n- Diagnosis: Breast cancer\n- Tumor type: Invasive ductal breast carcinoma\n- HER2 status: Positive\n- ER/PR status: Negative\n- Axillary sampling: 5 positive lymph nodes\n- CXR: Metastatic lesions\n- Medications: Multivitamins and iron supplements\n- Alcohol consumption: None\n- Smoking: None\n- Sexual activity: Not sexually active\n- Children: None\n- Treatment plan: Tumor resection before chemotherapy\n\nStep 2: Compare the patient's information to the inclusion criteria of the clinical trial.\n\n- The clinical trial is focused on pancreatico-biliary Volumetric Laser Endomicroscopy (VLE) and indeterminate biliary or pancreatic duct strictures.\n- The patient has breast cancer, not a condition related to pancreatico-biliary strictures.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\n- The patient does not meet the inclusion criteria for the clinical trial.\n\nStep 4: Output the scale for the assessment of eligibility.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "435": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nThe patient is a 45-year-old postmenopausal woman.\n\nStep 2: Identify the patient's breast cancer characteristics.\nThe patient has cytologically confirmed breast cancer, a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, and is HER2-positive and ER/PR negative.\n\nStep 3: Identify the patient's axillary lymph node status.\nAxillary sampling revealed 5 positive lymph nodes.\n\nStep 4: Compare the patient's characteristics to the inclusion criteria.\nThe patient is a female aged \u2265 18 years, and has cN+ based on the following criteria: lymph node is palpable, cortical asymmetry (focal or diffuse cortical thickening of >3mm) under US, cortex:hilum ratio >2:1 under US, and loss of hilum/cortex structure under US. The patient also has written informed consent.\n\nStep 5: Determine the patient's trial-level eligibility.\nThe patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "436": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age to inclusion criteria\nThe patient is a 45-year-old woman. The inclusion criteria state that women must be age >=18 years. Since the patient is 45 years old, she meets the age requirement.\n\nStep 2: Compare patient tumor type and stage to inclusion criteria\nThe patient has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The inclusion criteria state that the patient must have clinical T1-4, N0-3, M0 breast cancer at diagnosis (prior to the start of neoadjuvant chemotherapy). The patient's tumor is stage T3, which is within the clinical T1-4 range. Therefore, the patient meets the tumor type and stage requirement.\n\nStep 3: Compare patient hormone receptor status to inclusion criteria\nThe patient's tumor is HER2-positive and ER/PR negative. The inclusion criteria state that the patient must have histological confirmation of triple negative invasive breast cancer (defined as estrogen receptor [ER] <= 10%, progesterone receptor [PR] <= 10% and HER2 not amplified by in situ hybridization [ISH] or immunohistochemistry [IHC] 0/1). Since the patient's tumor is triple negative, she meets the hormone receptor requirement.\n\nStep 4: Compare patient previous treatment history to inclusion criteria\nThe patient has not received neoadjuvant chemotherapy. The inclusion criteria state that the patient must not have received neoadjuvant chemotherapy. Since the patient has not received neoadjuvant chemotherapy, she meets this requirement.\n\nStep 5: Compare patient eligibility for tumor resection to inclusion criteria\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The inclusion criteria do not mention tumor resection, so this is not a requirement for eligibility.\n\nStep 6: Compare patient other characteristics to inclusion criteria\nThe patient does not have any other characteristics mentioned in the inclusion criteria that would disqualify her from participating in the trial.\n\nConclusion: Based on the comparison of the patient note and the inclusion criteria, the patient meets all the requirements for participation in the clinical trial.",
        "label": 0
    },
    "437": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's cancer type and receptors status.\n\nPatient note: \"A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative.\"\n\nStep 2: Compare the patient's cancer type and receptors status to the inclusion criteria.\n\nInclusion criteria: \"Biopsy proven triple negative (TN) (ER-/PR-/HER2-) or HER2 positive (ERany/PRany/HER2+) breast cancer for which neoadjuvant chemotherapy is planned\"\n\nThe patient's cancer is HER2-positive and ER/PR negative, which matches the inclusion criteria.\n\nStep 3: Identify the patient's age.\n\nPatient note: \"The patient is a 45-year-old postmenopausal woman\"\n\nStep 4: Compare the patient's age to the inclusion criteria.\n\nInclusion criteria: \"18 years of age or older\"\n\nThe patient is 45 years old, which meets the age requirement.\n\nStep 5: Determine the patient's ability to read and write in English and provide written consent.\n\nPatient note: There is no information about the patient's ability to read and write in English or provide written consent.\n\nStep 6: Determine if the patient meets all inclusion criteria.\n\nThe patient meets the inclusion criteria for cancer type and receptors status, and age. However, there is insufficient information to determine if the patient can read and write in English and provide written consent.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "438": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria\nThe patient is 45 years old, which meets the age requirement of \u2265 18 years.\n\nStep 2: Compare patient's gender to the inclusion criteria\nThe patient is a woman, which meets the gender requirement.\n\nStep 3: Compare patient's cancer type and stage to the inclusion criteria\nThe patient has HER2-positive and ER/PR negative infiltrating ductal carcinoma of the breast. This does not meet the inclusion criteria of HER2-negative, ER/PR positive or negative.\n\nStep 4: Compare patient's reproductive status to the inclusion criteria\nThe patient is not sexually active and has no children, which meets the reproductive status requirement.\n\nStep 5: Compare patient's performance status to the inclusion criteria\nThe patient's ECOG Performance status is not mentioned in the patient note, so we cannot determine if they meet the requirement of ECOG Performance status 0 or 1.\n\nStep 6: Compare patient's chemotherapy eligibility to the inclusion criteria\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. However, we do not have enough information to determine if the patient meets the requirement of being able to receive neoadjuvant anthracycline/taxane based chemotherapy in the opinion of the treating physician.\n\nStep 7: Compare patient's contraception use to the inclusion criteria\nThe patient's contraception use is not mentioned in the patient note, so we cannot determine if they meet the requirement of agreeing to use adequate contraception.\n\nStep 8: Compare patient's MRI requirements to the inclusion criteria\nThe patient's MRI requirements are not mentioned in the patient note, so we cannot determine if they meet the requirement of having had (or being scheduled to have) a pre neoadjuvant chemotherapy MRI of the breast with gadolinium contrast.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "439": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the key information in the patient note:\n- The patient has breast cancer.\n- The patient has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n- The tumor is HER2-positive and ER/PR negative.\n- The patient has 5 positive lymph nodes.\n- The patient is a candidate for tumor resection.\n\nStep 2: Compare the patient note information with the inclusion criteria:\n- Histological diagnosis of breast cancer: The patient has breast cancer, so this criterion is met.\n- Availability of primary tumor tissue: The patient's note mentions a core biopsy, so primary tumor tissue is available.\n- Availability of plasma DNA with a high ctDNA content: The patient's note does not provide information about the availability of plasma DNA or ctDNA content, so this criterion is not relevant.\n\nStep 3: Determine the trial-level eligibility based on the comparison:\nSince the patient meets the first two inclusion criteria and the third criterion is not relevant due to insufficient information, the trial-level eligibility is 1) Not relevant.",
        "label": 2
    },
    "440": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is a 45-year-old woman, and the inclusion criteria do not specify an age range. However, the patient is postmenopausal, which is typically associated with being older than 40 years old. This factor is not explicitly mentioned in the inclusion criteria, but it is not an exclusion criterion either.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, and the inclusion criteria do not specify a gender requirement.\n\nStep 3: Compare the patient's disease type and stage to the inclusion criteria.\nThe patient has invasive ductal breast cancer, which is a type of breast cancer. The inclusion criteria specify that the cancer must be Stage II-IIIC, locally advanced, inflammatory, or early-stage, unilateral, and histologically confirmed invasive breast cancer. The patient's cancer is Stage II-IIIC, meeting this criterion.\n\nStep 4: Compare the patient's tumor size to the inclusion criteria.\nThe patient's tumor is 3 cm in diameter, which is greater than 2 cm, meeting the criterion for primary tumor size.\n\nStep 5: Compare the patient's HER2 status to the inclusion criteria.\nThe patient's tumor is HER2-positive, meeting the criterion for HER2 status.\n\nStep 6: Compare the patient's hormone receptor status to the inclusion criteria.\nThe patient's hormone receptor status is not specified in the patient note, but it is not an exclusion criterion in the inclusion criteria. Therefore, this factor is not relevant to the patient's eligibility.\n\nStep 7: Compare the patient's surgical agreement to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, meeting the criterion for patient agreement to undergo mastectomy or breast conserving surgery after neoadjuvant therapy.\n\nStep 8: Compare the patient's contraception requirements to the inclusion criteria.\nThe patient is postmenopausal and not sexually active, so she does not need to meet the contraception",
        "label": 1
    },
    "441": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age, gender, and disease type.\nThe patient is a 45-year-old postmenopausal woman with breast cancer.\n\nStep 2: Compare the patient's age to the inclusion criteria.\nThe inclusion criteria state that the patient must be between 18 and 70 years old. The patient is 45 years old, which meets the age requirement.\n\nStep 3: Compare the patient's gender to the inclusion criteria.\nThe inclusion criteria state that the patient must be female. The patient is female, which meets the gender requirement.\n\nStep 4: Compare the patient's disease type to the inclusion criteria.\nThe patient has breast cancer, which matches the inclusion criteria for patients with \"pathologically confirmed invasive breast cancer.\"\n\nStep 5: Compare the patient's tumor stage to the inclusion criteria.\nThe patient's tumor is T1-3N0-3M0, which matches the inclusion criteria for \"pathologically stage is T1-3N0-3M0.\"\n\nStep 6: Compare the patient's immunohistochemical examination results to the inclusion criteria.\nThe patient's immunohistochemical examination results are not provided in the patient note. This information is not sufficient to determine eligibility.\n\nStep 7: Compare the patient's treatment history to the inclusion criteria.\nThe patient has not received neoadjuvant chemotherapy, which meets the inclusion criteria for \"No neoadjuvant chemotherapy.\"\n\nStep 8: Compare the patient's fitness for postoperative radiotherapy to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which implies that she is fit for postoperative radiotherapy. This meets the inclusion criteria for \"Fit for postoperative radiotherapy. No contraindications to radiotherapy.\"\n\nStep 9: Compare the patient's Karnofsky Performance Status (KPS) to the inclusion criteria.\nThe patient's KPS is not provided in the patient note. This information is not sufficient to determine eligibility.\n\nStep 10: Compare the patient's signed informed consent to the inclusion criteria.\nThe patient's signed informed consent",
        "label": 1
    },
    "442": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nPatient's age: 45 years old\nInclusion criteria: Women aged 18-75 years old\nThe patient is within the age range, so this criterion is met.\n\nStep 2: Compare the patient's hormone receptor status with the inclusion criteria.\nPatient's status: HR/HER2 positive (immunohistochemistry or FISH test confirmed)\nInclusion criteria: HR positive and HER2 positive (immunohistochemistry or FISH test confirmed)\nThe patient's status matches the inclusion criteria, so this criterion is met.\n\nStep 3: Compare the patient's ECOG score with the inclusion criteria.\nPatient's ECOG score: Not mentioned in the patient note\nInclusion criteria: ECOG score \u2264 2\nThere is not enough information to determine if this criterion is met.\n\nStep 4: Compare the patient's survival expectations with the inclusion criteria.\nPatient's survival expectations: Not mentioned in the patient note\nInclusion criteria: Expected survival \u2265 3 months\nThere is not enough information to determine if this criterion is met.\n\nStep 5: Compare the patient's cancer history with the inclusion criteria.\nPatient's cancer history: Cytologically confirmed breast cancer\nInclusion criteria: Histology or cytology confirmed as breast cancer\nThe patient's history matches the inclusion criteria, so this criterion is met.\n\nStep 6: Compare the patient's prior treatment history with the inclusion criteria.\nPatient's prior treatment history: Prior to trastuzumab and endocrine therapy and progression/recurrence\nInclusion criteria: Prior to trastuzumab and endocrine therapy and progression/recurrence\nThe patient's history matches the inclusion criteria, so this criterion is met.\n\nStep 7: Compare the patient's measurable lesions with the inclusion criteria.\nPatient's measurable lesions: At least one RECIST 1.1 defined measurable lesions\nInclusion criteria: At least one RECIST 1.1 defined measurable lesions\nThe patient's status matches",
        "label": 0
    },
    "443": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information in the patient note.\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n- Axillary sampling revealed 5 positive lymph nodes.\n\nStep 2: Compare the patient's information with the inclusion criteria of the clinical trial.\n- Inclusion Criteria: Node-positive breast cancer patients confirmed by biopsy or cytology.\n- The patient has node-positive breast cancer confirmed by cytology.\n\nStep 3: Determine if the patient meets the inclusion criteria.\n- The patient meets the inclusion criteria.\n\nStep 4: Check if there are any exclusion criteria.\n- There are no exclusion criteria mentioned in the patient note.\n\nStep 5: Determine the patient's eligibility based on the inclusion and exclusion criteria.\n- The patient meets the inclusion criteria and does not meet any exclusion criteria.\n\nStep 6: Repeat Trial-level eligibility.\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "444": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age with inclusion criteria\nThe patient is 45 years old and is postmenopausal. The inclusion criteria state that the patient should be postmenopausal, which is satisfied.\n\nStep 2: Compare patient gender with inclusion criteria\nThe patient is a woman. The inclusion criteria do not specify a gender requirement, so this criterion is satisfied.\n\nStep 3: Compare patient cancer type with inclusion criteria\nThe patient has breast cancer. The inclusion criteria state that patients should have hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. The patient's breast cancer is HER2-positive and ER/PR negative, which means it is hormone receptor-positive/human epidermal growth factor receptor 2-negative. This criterion is satisfied.\n\nStep 4: Compare patient treatment history with inclusion criteria\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The inclusion criteria state that eligible patients should be receiving one or more treatment strategies who are followed up in the center where they receive treatment. This criterion is satisfied.\n\nStep 5: Compare patient informed consent with inclusion criteria\nThe patient has provided written informed consent. This criterion is satisfied.\n\nSince all the inclusion criteria are satisfied, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "445": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n\n- Age: 45 years old\n- Gender: Female\n- Cancer type: Invasive ductal breast carcinoma\n- HER2-positive and ER/PR negative\n- Number of positive lymph nodes: 5\n- Metastatic lesions on CXR\n- Treatment: Multivitamins and iron supplements, tumor resection before chemotherapy\n\nStep 2: Compare the patient's characteristics to the inclusion criteria of the clinical trial.\n\n- Estrogen receptor (\u2265 10%): Not mentioned in the patient note\n- Progesterone receptor (\u2265 10%): Not mentioned in the patient note\n- Epidermal growth factor receptor 2 negative: Yes (HER2-positive)\n- Proliferation index Ki-67 < 20%: Not mentioned in the patient note\n- No lymph node metastasis: No (5 positive lymph nodes)\n- Systemic therapy in accordance with National Comprehensive Cancer Network guidelines: Not mentioned in the patient note\n- Informed consent: Not mentioned in the patient note\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\n- The patient is HER2-positive and ER/PR negative, which matches the inclusion criteria.\n- The patient has 5 positive lymph nodes, which excludes her from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "446": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n\n- Age: 45 years old\n- Gender: Female\n- Cancer type: Invasive ductal breast carcinoma\n- Tumor size: 3 cm\n- HER2-positive and ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- CXR: Metastatic lesions\n- Other information: Multivitamins and iron supplements, no smoking or alcohol, not sexually active, no children, candidate for tumor resection\n\nStep 2: Compare the patient's information with the inclusion criteria.\n\nStage 1:\n- Female: Yes\n- \u226518 years old: Yes (45 years old)\n- Invasive ductal carcinoma or DCIS: Yes (Invasive ductal carcinoma)\n- Tumor size \u2264 5 cm: Yes (3 cm)\n- Negative preoperative axillary assessment: No (5 positive lymph nodes)\n\nStage 2:\n- Female: Yes\n- \u226518 years old: Yes (45 years old)\n- Invasive carcinoma: Yes (Invasive ductal carcinoma)\n- Plan for breast conserving surgery and adjuvant radiation: Not mentioned\n- Negative preoperative axillary assessment: No (5 positive lymph nodes)\n\nStep 3: Determine the trial-level eligibility based on the comparison.\n\nSince the patient does not meet the negative preoperative axillary assessment criteria for both stages, she is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "447": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to inclusion criteria\nThe patient is 45 years old, which is within the range of ASA physical status of I, II, or III.\n\nStep 2: Compare patient's medical condition to inclusion criteria\nThe patient has breast cancer, but the clinical trial is for patients scheduled for elective craniotomy for tumor resection. The patient's medical condition does not match the inclusion criteria.\n\nStep 3: Compare patient's anticipated recovery time to inclusion criteria\nThe patient participates with an anticipated fully recovery within 2 hours postoperatively, which matches the inclusion criteria.\n\nTrial-level eligibility: 0) Excluded (patient does not meet the inclusion criteria for the clinical trial due to having breast cancer instead of being scheduled for elective craniotomy for tumor resection).",
        "label": 0
    },
    "448": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's condition\nThe patient has cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative, and there are 5 positive lymph nodes. The patient is a candidate for tumor resection.\n\nStep 2: Compare the patient's condition with the inclusion criteria\nThe inclusion criteria state that patients with a primary or relapsed solid tumor or lymphoma who require excision of the tumor or metastatic lesions are eligible. The patient has breast cancer, which is a solid tumor, and requires excision of the tumor.\n\nStep 3: Determine the patient's eligibility\nBased on the comparison in Step 2, the patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "449": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note with inclusion criteria\n\n1. Female: The patient is a woman.\n2. Age >= 45 years: The patient is 45 years old.\n3. Unicentric pathological stage I (pT1 or T2 pN0_M0) invasive ductal breast cancer or DCIS measuring <3 cm in longest diameter on pathology and/or mammogram that is histologically confirmed: The patient has a 3 cm invasive ductal breast carcinoma.\n4. Histologically negative tumor margin or no tumor in a re-excision specimen on final shaved specimen: Not mentioned in the patient note.\n5. ECOG Performance Status of 0 or 1: Not mentioned in the patient note.\n6. Clips must be placed in the lumpectomy cavity at the time of final excision in order to aid in the delineation of the tumor cavity at the time of simulation and radiation delivery: Not mentioned in the patient note.\n7. Negative serum pregnancy test within 14 days prior to study treatment if a woman has child-bearing potential: Not applicable as the patient is postmenopausal.\n8. Written informed consent obtained from subject and ability for subject or comply with the requirements of the study: Not mentioned in the patient note.\n9. Female subjects of childbearing potential should be willing to use 2 methods or birth control or be surgically sterile or abstain from heterosexual activity for the duration of study participation: Not applicable as the patient is postmenopausal.\n10. Inclusion Criteria for intermediate risk substudy: Multiple criteria, some of which are not applicable or not mentioned in the patient note.\n\nStep 2: Determine eligibility based on the comparison\n\nThe patient meets most of the inclusion criteria, but there are some criteria that are not mentioned or not applicable in the patient note.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "450": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria\nThe patient is 45 years old, and the clinical trial does not specify an age range. Therefore, this factor is not relevant for eligibility.\n\nStep 2: Compare the patient's gender with the inclusion criteria\nThe patient is a woman, and the clinical trial does not specify a gender requirement. Therefore, this factor is not relevant for eligibility.\n\nStep 3: Compare the patient's disease type with the inclusion criteria\nThe patient has breast cancer, not cervical cancer. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nStep 4: Compare the patient's disease stage with the inclusion criteria\nThe patient has advanced breast cancer with metastatic lesions, not early-stage cervical cancer. Therefore, the patient does not meet the inclusion criteria for this clinical trial.\n\nStep 5: Compare the patient's treatment history with the inclusion criteria\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The clinical trial requires treatment with radical hysterectomy with bilateral pelvic lymphadenectomy. Therefore, the patient meets the treatment history inclusion criteria for this clinical trial.\n\nConclusion:\nSince the patient has breast cancer and not cervical cancer, the patient does not meet the inclusion criteria for this clinical trial. Therefore, the trial-level eligibility is 0) Excluded.",
        "label": 0
    },
    "451": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\n1. Written informed consent prior to breast-conserving surgery\n- Patient note: Patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\n1. Histologically confirmed unilateral primary invasive carcinoma of the breast (core biopsy)\n- Patient note: Core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant.\n\n1. Age at diagnosis at least 18 years\n- Patient note: Patient is a 45-year-old postmenopausal woman.\n\n1. Imaging techniques with estimated tumor stage between cT1-T3 prior to NAST\n- Patient note: The tumor is 3 cm invasive ductal breast carcinoma.\n\n1. Triple-negative or HER2-positive invasive breast cancer\n- Patient note: The tumor is HER2-positive and ER/PR negative.\n\n1. Clinically and sonographically tumor-free axilla prior to core biopsy (cN0/iN0)\n- Patient note: Axillary sampling revealed 5 positive lymph nodes.\n\n1. No evidence for distant metastasis (M0)\n- Patient note: CXR was remarkable for metastatic lesions.\n\n1. Standard NAST with radiologic complete response (rCR)\n- Patient note: Not mentioned in the patient note.\n\n1. Planned breast-conserving surgery with postoperative external whole-breast irradiation (conventional fractionation or hypofractionation)\n- Patient note: Not mentioned in the patient note.\n\nStep 2: Determine eligibility based on the comparison\n\n1. Informed consent: Yes\n2. Histologically confirmed unilateral primary invasive carcinoma of the breast: Yes\n3. Age at diagnosis: Yes\n4. Imaging techniques with estimated tumor stage between cT1-T3 prior to NAST: Yes\n5. Triple-negative or HER2-positive invasive breast cancer: Yes\n6. Clinically and sonographically tumor-free axilla prior to core biopsy",
        "label": 0
    },
    "452": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note:\n- Age: 45 years old\n- Gender: Female\n- Disease: Breast cancer\n- Tumor type: Invasive ductal breast carcinoma\n- Tumor size: 3 cm\n- Location: Left upper outer quadrant\n- HER2 status: Positive\n- ER/PR status: Negative\n- Axillary lymph nodes: 5 positive lymph nodes\n- Metastatic lesions: CXR revealed metastatic lesions\n- Treatment: Candidate for tumor resection and chemotherapy\n\nStep 2: Compare the patient's information with the inclusion criteria:\n\n1. cT1-3N1M0 breast cancer at diagnosis (prior to NACT) by AJCC staging 8th edition\n2. Fine-needle aspiration (FNA) or core biopsy confirmed axillary nodal metastases at presentation\n3. Oestrogen receptor and HER2 status evaluated on primary tumour\n4. Received standard NACT as per local guidelines (Patients undergoing neoadjuvant endocrine therapy as part of another clinical trial are eligible)\n5. Imaging of the axilla to assess response to NACT (as per local guidelines)\n6. Undergo dual tracer sentinel node biopsy (SNB) after NACT and at least 3 nodes removed in total (sentinel nodes and marked node).\n7. If single tracer is used, the patient will be eligible if the involved node is marked before or during NACT, and the marked node and at least 3 nodes (including the marked node) are removed during sentinel node biopsy.\n8. If axillary node sampling is performed following failed localisation of sentinel nodes, patient will be eligible if at least 3 nodes removed (including the marked node).\n9. If node is not marked, or marked node is not removed, the patient will be eligible if the histology report shows evidence of down-staging with complete pathological response e.g. fibrosis or scarring in at least one node and at least 3 nodes removed.\n10. If fewer than 3 nodes are found on histology, the patient is eligible if: a) involved",
        "label": 0
    },
    "453": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics\n- Age: 45 years old\n- Gender: Female\n- Disease: Breast cancer\n- Tumor type: Invasive ductal breast carcinoma\n- HER2 status: Positive\n- ER/PR status: Negative\n- Axillary lymph nodes: 5 positive\n- Metastatic lesions: Present\n- Other treatments: Multivitamins and iron supplements\n- Lifestyle: Non-smoker, non-alcohol consumer, not sexually active, no children\n- Treatment plan: Candidate for tumor resection before chemotherapy\n\nStep 2: Compare patient characteristics to inclusion criteria\n- Histologically confirmed primary breast cancer: Yes\n- No prior chemotherapy: Yes\n- ER positive, PR positive or negative, HER2 negative, lymph node status negative or micro-invasive disease: No (HER2 positive, ER/PR negative, 5 positive lymph nodes)\n- Tumor >1 cm in size (or if equal or <1 cm, must be grade 2/3 or have lymph node micrometastasis): Yes (3 cm tumor)\n\nStep 3: Determine eligibility based on comparison\n- The patient meets some inclusion criteria, but not all. Specifically, she does not meet the criteria for ER/PR status and lymph node status.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "454": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with inclusion criteria\nThe patient is 45 years old, which falls within the age range of 18-70 years old as stated in the inclusion criteria.\n\nStep 2: Compare patient's gender with inclusion criteria\nThe patient is a female, which matches the inclusion criteria for female patients.\n\nStep 3: Compare patient's breast cancer type with inclusion criteria\nThe patient has invasive ductal breast carcinoma, which is a type of unilateral invasive breast cancer. This matches the inclusion criteria for histologically confirmed unilateral invasive breast cancer.\n\nStep 4: Compare patient's surgery status with inclusion criteria\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This implies that she has operable breast cancer at first diagnosis, without any absolute surgical contraindication, which matches the inclusion criteria.\n\nStep 5: Compare patient's tumor status with inclusion criteria\nThe patient has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. This information is not sufficient to determine if the patient meets the inclusion criteria for either PANSY-1 or PANSY-2.\n\nStep 6: Compare patient's other medical conditions with inclusion criteria\nThe patient is using multivitamins and iron supplements, does not smoke or consume alcohol, and is not sexually active with no children. These conditions do not conflict with the inclusion criteria.\n\nStep 7: Compare patient's laboratory values with inclusion criteria\nThe patient's laboratory values are not provided in the patient note, so we cannot determine if she meets the inclusion criteria for adequate bone marrow function, liver function, kidney function, and cardiac function.\n\nStep 8: Determine trial-level eligibility\nSince we do not have enough information about the patient's tumor status and laboratory values, we cannot determine if the patient meets all the inclusion criteria for either PANSY-1 or PANSY-2. Therefore, the patient's trial-level eligibility is:\n\nTrial-level el",
        "label": 1
    },
    "455": {
        "output": "GPT4 Correct Assistant: Let's analyze the patient note and the inclusion criteria step by step:\n\n1. Age: The patient is 45 years old, which is within the age range of 18-60 years.\n2. ECOG score: Not mentioned in the patient note.\n3. TNBC diagnosis: The patient has TNBC, as confirmed by the core biopsy.\n4. Tumor size: The tumor is 3 cm, which is larger than the 2 cm minimum mentioned in the inclusion criteria.\n5. Organ function: The patient's blood routine, biochemical, and coagulation test results are not mentioned in the patient note.\n6. Distant metastases: The patient has metastatic lesions, which exclude her from the trial.\n7. Core biopsy: The patient has provided a core biopsy for TNBC status and biomarker analysis.\n8. Contraception: The patient is postmenopausal and not sexually active, so this criterion is not applicable.\n9. Informed consent: The patient has agreed to tumor resection and chemotherapy.\n\nTrial-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).",
        "label": 0
    },
    "456": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria.\nThe patient is a 45-year-old postmenopausal woman. The inclusion criteria state that patients must be female and \u2265 18 years of age. The patient meets this criterion.\n\nStep 2: Compare patient's menopausal status with the inclusion criteria.\nThe patient is postmenopausal. The inclusion criteria define post-menopausal status in several ways, and the patient meets at least one of them.\n\nStep 3: Compare patient's disease status with the inclusion criteria.\nThe patient has cytologically confirmed breast cancer. The inclusion criteria state that patients must have a biopsy-proven diagnosis of HR+HER2- metastatic breast cancer. The patient meets this criterion.\n\nStep 4: Compare patient's performance status with the inclusion criteria.\nThe patient's Eastern Cooperative Oncology Group (ECOG) performance status is not mentioned in the patient note. Therefore, we cannot determine if the patient meets this criterion.\n\nStep 5: Compare patient's laboratory values with the inclusion criteria.\nThe patient's laboratory values are not mentioned in the patient note. Therefore, we cannot determine if the patient meets this criterion.\n\nStep 6: Compare patient's eligibility for the trial.\nBased on the information provided, the patient meets the inclusion criteria for the trial, except for the performance status and laboratory values. However, since we do not have enough information to determine if the patient meets the exclusion criteria, we cannot definitively determine the patient's eligibility for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "457": {
        "output": "GPT4 Correct Assistant: Step 1: Age\nThe patient is 45 years old, which meets the inclusion criteria of being a woman aged \u2265 18 years.\n\nStep 2: Gender\nThe patient is a woman, which meets the inclusion criteria.\n\nStep 3: Type and stage of disease\nThe patient has invasive ductal breast cancer, which is a type of breast cancer. The clinical stage is not mentioned in the patient note, but the tumor is described as 3 cm, which could be considered T1-3.\n\nStep 4: Neoadjuvant systemic therapy\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which implies that she will receive neoadjuvant systemic therapy. This meets the inclusion criteria.\n\nStep 5: Tumor stage assessment\nThe patient's tumor stage was assessed with a core biopsy, but it is not clear if this was done with breast MRI before the start of neoadjuvant systemic therapy. This information is not sufficient to determine eligibility.\n\nStep 6: Clinical node status\nThe patient has 5 positive lymph nodes, which means she is not clinically node-negative before starting neoadjuvant systemic therapy. This excludes her from the trial.\n\nStep 7: Radiologic complete response\nThere is no information about the patient's response to neoadjuvant systemic therapy in the patient note. This information is not sufficient to determine eligibility.\n\nStep 8: Informed consent\nThe patient has not signed an informed consent form, which is a requirement for participation in the trial. This excludes her from the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "458": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria\nThe patient is 45 years old, which is within the range of 18 years or older required for the trial.\n\nStep 2: Compare patient's gender to the inclusion criteria\nThe patient is a female, which is one of the accepted genders for the trial.\n\nStep 3: Compare patient's cancer type and status to the inclusion criteria\nThe patient has a histologically confirmed diagnosis of invasive breast cancer, which is one of the accepted cancer types for the trial. The cancer is HER2-positive and ER/PR negative, which matches the criteria of being ER-, PR-, and HER2-negative.\n\nStep 4: Compare patient's tumor size and stage to the inclusion criteria\nThe patient has a 3 cm invasive ductal breast carcinoma, which is larger than the required 1 cm primary tumor size. The patient has axillary sampling revealing 5 positive lymph nodes, which is within the acceptable AJCC TNM stages N0-N2. The patient also has metastatic lesions, which is not within the acceptable absence of distant metastatic disease (AJCC TNM stage M0).\n\nStep 5: Compare patient's ECOG performance status to the inclusion criteria\nThe patient's ECOG performance status is not provided, so we cannot determine if they meet the inclusion criteria.\n\nStep 6: Compare patient's ability to understand and sign informed consent to the inclusion criteria\nThe patient's ability to understand and sign informed consent is not provided, so we cannot determine if they meet the inclusion criteria.\n\nStep 7: Compare patient's bone marrow and organ function to the inclusion criteria\nThe patient's bone marrow and organ function values are not provided, so we cannot determine if they meet the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "459": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which meets the criteria of being 18 years or older.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is female, which meets the criteria of being female.\n\nStep 3: Compare the patient's cancer type to the inclusion criteria.\nThe patient has invasive ductal breast carcinoma, which meets the criteria of having invasive ductal breast carcinoma and ductal carcinoma in situ.\n\nStep 4: Compare the patient's treatment history to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which may include neo-adjuvant treated subjects (chemotherapeutic, endocrine therapy, or radiation).\n\nStep 5: Compare the patient's ability to understand and willingness to sign a written informed consent document to the inclusion criteria.\nThe patient's note does not provide information about her ability to understand and willingness to sign a written informed consent document, so this criterion is not relevant.\n\nStep 6: Repeat Trial-level eligibility.\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "460": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note with inclusion criteria\n\n1. Pathologically proven diagnosis of invasive breast cancer: Yes, the patient has cytologically confirmed breast cancer.\n2. cT1-T3, cN0-N3, cM0: The patient has a 3 cm tumor, which is within the range of cT1-T3. The patient has 5 positive lymph nodes, which is within the range of cN0-N3. There is no information about metastasis, so we cannot determine if the patient meets cM0 criteria.\n3. HR+ (ER+ and/or PR+) HER2 negative or HR- (ER- and PR-) HER2 negative/triple negative breast cancer: The patient's tumor is HER2-positive and ER/PR negative, so she does not meet this criterion.\n4. Tumors with positive PD-L1 and/or PD-L1 protein expression: The patient's tumor PD-L1 status is not mentioned in the note.\n5. Estrogen and/or progesterone receptor positive tumor: The patient's tumor is ER/PR negative, so she does not meet this criterion.\n6. HER2/neu must be negative: The patient's tumor is HER2-positive, so she does not meet this criterion.\n7. Candidate for neoadjuvant chemotherapy: The patient is a candidate for tumor resection before chemotherapy.\n8. Breast imaging with mammogram and/or ultrasound and/or MRI: The patient's imaging is not mentioned in the note.\n9. Systemic imaging with CT scan, bone scan, positron emission tomography (PET) scan or MRI if clinically indicated: The patient's imaging is not mentioned in the note.\n10. Left ventricular ejection fraction (LVEF) \u2265 lower limit of normal: The patient's LVEF is not mentioned in the note.\n11. Age \u226518 years: The patient is 45 years old, which is within the age range.\n12. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2: The patient's performance status",
        "label": 0
    },
    "461": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the trial's age requirement.\nThe patient is 45 years old, but the inclusion criteria do not specify an age requirement. Therefore, we cannot determine eligibility based on age.\n\nStep 2: Compare the patient's gender to the trial's gender requirement.\nThe patient is a woman, and the inclusion criteria do not specify a gender requirement. Therefore, we cannot determine eligibility based on gender.\n\nStep 3: Compare the patient's diagnosis to the trial's diagnosis requirement.\nThe patient has invasive ductal breast cancer, which matches the trial's requirement of breast cancer patients with DCIS or invasive breast cancer.\n\nStep 4: Compare the patient's treatment plan to the trial's treatment requirement.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The trial requires subjects to be undergoing breast conserving surgery and adjuvant radiation. Since the patient is undergoing surgery, they meet this criterion.\n\nStep 5: Compare the patient's ability to provide breast skin samples to the trial's sample requirement.\nThe patient is willing and able to provide breast skin samples, which meets the trial's requirement.\n\nBased on the comparison of the patient's information to the trial's inclusion criteria, the patient meets all the necessary requirements for participation in the clinical trial. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "462": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nPatient's age: 45 years old\nInclusion criteria: Age >18 years old\n\nThe patient's age is greater than 18 years old, so she meets this criterion.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nPatient's gender: Female\nInclusion criteria: Women\n\nThe patient is a female, so she meets this criterion.\n\nStep 3: Compare the patient's cancer type and receptor status with the inclusion criteria.\nPatient's cancer: ER/PR negative, HER2-positive breast cancer\nInclusion criteria: ER/PR positive, HER2-negative MBC\n\nThe patient's cancer is ER/PR negative and HER2-positive, which is different from the inclusion criteria. Therefore, she does not meet this criterion.\n\nStep 4: Compare the patient's therapy status with the inclusion criteria.\nPatient's therapy status: Candidate for tumor resection and agrees to do so prior to chemotherapy\nInclusion criteria: Patients initiating first or second line therapy for ER/PR positive, HER2-negative MBC\n\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This means she has not yet started first or second line therapy for ER/PR positive, HER2-negative MBC. Therefore, she does not meet this criterion.\n\nStep 5: Compare the patient's hematologic, renal, and hepatic function with the inclusion criteria.\nPatient's hematologic, renal, and hepatic function: Not mentioned in the patient note\nInclusion criteria: Adequate hematologic, renal and hepatic function\n\nThere is not enough information in the patient note to determine if the patient has adequate hematologic, renal, and hepatic function. Therefore, we cannot determine if she meets this criterion.\n\nStep 6: Compare the patient's signed informed consent with the inclusion criteria.\nPatient's signed informed consent: Not mentioned in the patient note\nInclusion criteria: Signed informed consent (ICF)\n\nThere is not",
        "label": 0
    },
    "463": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the age range of 18 years or greater for the clinical trial.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, which is not specified in the inclusion criteria, but it is not an exclusion criterion either.\n\nStep 3: Compare the patient's cancer type to the inclusion criteria.\nThe patient has invasive ductal breast carcinoma, not invasive lobular carcinoma. This means the patient does not meet the inclusion criteria for the clinical trial.\n\nStep 4: Compare the patient's cancer stage to the inclusion criteria.\nThe patient's cancer is within the past 12 weeks, which meets the inclusion criteria for the clinical trial.\n\nStep 5: Compare the patient's willingness to participate to the inclusion criteria.\nThe patient is willing to have their clinical records reviewed for at least 24 months after enrollment, which meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).",
        "label": 0
    },
    "464": {
        "output": "GPT4 Correct Assistant: Step 1: Age\nPatient note: \"The patient is a 45-year-old postmenopausal woman\"\nInclusion criteria: \"Adult female patients with advanced breast cancer diagnosed by pathology (aged 18-75, including 18 and 75 years old)\"\nThe patient's age is within the range of 18-75 years, so the age criterion is met.\n\nStep 2: Gender\nPatient note: \"The patient is a 45-year-old postmenopausal woman\"\nInclusion criteria: \"Adult female patients with advanced breast cancer diagnosed by pathology\"\nThe patient is a female, so the gender criterion is met.\n\nStep 3: Disease status\nPatient note: \"A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions.\"\nInclusion criteria: \"Pathological examination confirmed ER and / or PR positive, HER-2 negative (Positive ER expression: immunohistochemistry >1% tumor cell staining; Positive PR expression: immunohistochemistry >1% tumor cell staining; HER-2 negative: immunohistochemistry is 0,1+, or FISH/CISH negative when immunohistochemistry is 2+); Patients with advanced breast cancer who have no disease progression after a 4-8-course first-line chemotherapy regimen (the effect is evaluated as complete response/ partial response/ stable disease).\"\nThe patient has advanced breast cancer, is HER2-negative, and ER/PR-negative, so the disease status criteria are met.\n\nStep 4: Previous treatment\nPatient note: \"The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\"\nInclusion criteria: \"Patients with advanced breast cancer who have no disease progression after a 4-8-course first-line chemotherapy regimen (the effect is evaluated as complete response/ partial response/ stable disease).\"\nThe patient has not yet",
        "label": 0
    },
    "465": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age with inclusion criteria\nThe patient is 45 years old, which is within the age range of \u226518 years for the trial.\n\nStep 2: Compare patient gender with inclusion criteria\nThe patient is a female, which matches the inclusion criteria for both male and female participants.\n\nStep 3: Compare patient diagnosis with inclusion criteria\nPhase 2a Cohort A: HR+/HER2- locally advanced, recurrent, or metastatic breast cancer with disease progression after first-line endocrine therapy (not fulvestrant) or intolerant of it, histologically confirmed by the primary and/or metastatic lesions, not amenable to chemotherapy or curative treatment of surgical resection or radiation therapy; if the pathology of the primary and metastatic lesions are inconsistent, diagnosis should be based on metastatic lesions' pathology.\nPhase 2a Cohort B: HR+/HER2- locally advanced, recurrent, or metastatic breast cancer with no prior systemic therapy in this disease setting or relapse more than 1 years from completion of adjuvant endocrine therapy, histologically confirmed by the primary and/or metastatic lesions, not amenable to chemotherapy or curative treatment of surgical resection or radiation therapy; if the pathology of the primary and metastatic lesions are inconsistent, diagnosis should be based on metastatic lesions' pathology.\nThe patient has HER2-positive and ER/PR negative breast cancer, which matches the HR+/HER2- criteria for both cohorts.\n\nStep 4: Compare patient eligibility for Phase 2a cohorts\nThe patient meets the criteria for both Phase 2a Cohort A and B, as she has disease progression after first-line endocrine therapy and is not amenable to chemotherapy or curative treatment of surgical resection or radiation therapy.\n\nStep 5: Compare patient other characteristics with inclusion criteria\nThe patient has at least one measurable lesion based on the RECIST v1.1 criteria, has a life expectancy of \u226512 weeks, and has an ECOG Performance Status (PS)\u22641.\nThe patient has adequate bone marrow and organ function, as evidenced by her blood",
        "label": 0
    },
    "466": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient note: The patient has breast cancer, not ovarian germ cell tumors.\n\nInclusion criteria: Ovarian germ cell tumors\n\nStep 2: Determine eligibility\n\nSince the patient has breast cancer and not ovarian germ cell tumors, the patient does not meet the inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "467": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is outside the age range of 18-65 years for the trial.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a female, which matches the criteria for female breast cancer patients.\n\nStep 3: Compare the patient's disease type and stage to the inclusion criteria.\nThe patient has HER2-positive invasive ductal breast cancer, which matches the criteria for HER2-positive invasive breast cancer.\n\nStep 4: Compare the patient's hormone receptor status to the inclusion criteria.\nThe patient's tumor is ER/PR negative, which matches the criteria for any hormone receptor status.\n\nStep 5: Compare the patient's tumor size to the inclusion criteria.\nThe patient's tumor is 3 cm, which is larger than 2 cm as required by the trial.\n\nStep 6: Compare the patient's ECOG performance status to the inclusion criteria.\nThe patient's ECOG performance status is not provided in the patient note.\n\nStep 7: Compare the patient's blood test results to the inclusion criteria.\nThe patient's blood test results are not provided in the patient note.\n\nStep 8: Compare the patient's pregnancy status to the inclusion criteria.\nThe patient is postmenopausal and does not have children, which matches the criteria for women of childbearing age who are tested negative for serum pregnancy test.\n\nStep 9: Compare the patient's willingness to participate to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which matches the criteria for being a volunteer to participate in the study.\n\nStep 10: Determine the patient's trial-level eligibility based on the above comparisons.\nThe patient meets some inclusion criteria but does not meet the age requirement. Therefore, the patient's trial-level eligibility is 0) Excluded.",
        "label": 2
    },
    "468": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria state that patients must be less than 22 years of age at the time of study enrollment. The patient is excluded based on this criterion.\n\nStep 2: Compare the patient's diagnosis with the inclusion criteria.\nThe patient has breast cancer, not acute myeloid leukemia (AML). The patient is excluded based on this criterion.\n\nStep 3: Compare the patient's other characteristics with the inclusion criteria.\nThe patient does not meet any other inclusion criteria, such as the presence of bone marrow blasts, FLT3/ITD allelic ratio, or congenital heart conditions.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "469": {
        "output": "GPT4 Correct Assistant: Patient-level eligibility: 2) Eligible.",
        "label": 2
    },
    "470": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze patient note\n- Patient is a 45-year-old postmenopausal woman\n- Diagnosed with cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions in CXR\n\nStep 2: Compare patient note with inclusion criteria\n\n1. HR+ breast cancer: Patient is ER/PR negative, not HR+\n2. Loco regional breast cancer (Stage I, II, or III): Patient has metastatic lesions, not loco regional\n3. Localized recurrence while on adjuvant endocrine therapy: Patient has not had adjuvant endocrine therapy\n4. Molecular evidence of endocrine resistance: Patient does not have molecular evidence of endocrine resistance\n5. Age \u2265 18 years: Patient is 45 years old, meets age requirement\n6. ECOG performance status 0-1: Not mentioned in patient note\n7. Post-menopausal status: Patient is postmenopausal\n8. At least one measurable disease: Not mentioned in patient note\n9. Adequate organ and marrow function: Not mentioned in patient note\n10. Able to swallow oral medications: Not mentioned in patient note\n11. Recovered from radiotherapy/chemotherapy: Not mentioned in patient note\n12. Known markers of response or resistance to CDK 4/6 inhibitors: Not mentioned in patient note\n13. Able to sign informed consent: Not mentioned in patient note\n\nStep 3: Determine trial-level eligibility\nBased on the comparison, the patient does not meet the majority of inclusion criteria. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "471": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is a 45-year-old woman, which meets the criteria for both stage 1 and stage 2, as they both include \"female \u226518 years old.\"\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a female, which meets the criteria for both stage 1 and stage 2.\n\nStep 3: Compare the patient's breast cancer type to the inclusion criteria.\nThe patient has invasive ductal breast carcinoma, which meets the criteria for both stage 1 and stage 2.\n\nStep 4: Compare the patient's tumor size to the inclusion criteria.\nThe patient has a 3 cm tumor, which is larger than the 2 cm maximum diameter for stage 1 and 1.5 cm maximum diameter for stage 2. Therefore, the patient does not meet these criteria.\n\nStep 5: Compare the patient's tumor location to the inclusion criteria.\nThe patient has a tumor in the left upper outer quadrant, which does not conflict with the inclusion criteria.\n\nStep 6: Compare the patient's tumor receptors to the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative, which does not conflict with the inclusion criteria.\n\nStep 7: Compare the patient's lymph node status to the inclusion criteria.\nThe patient has 5 positive lymph nodes, which does not conflict with the inclusion criteria.\n\nStep 8: Compare the patient's ECOG level to the inclusion criteria.\nThe patient's ECOG level is not provided, but it is not mentioned as a requirement in the inclusion criteria.\n\nStep 9: Compare the patient's serum creatinine level to the inclusion criteria.\nThe patient's serum creatinine level is not provided, but it is not mentioned as a requirement in the inclusion criteria.\n\nStep 10: Compare the patient's pregnancy status to the inclusion criteria.\nThe patient is not pregnant and has no plans for pregnancy in 2 years, which meets the criteria for both stage 1 and stage 2.\n\nStep 11: Compare the patient'",
        "label": 0
    },
    "472": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 45 years old, which falls within the age range of 18-75 years for postmenopausal women or 60 years and older for all women.\n\nStep 2: Compare the patient's menopausal status with the inclusion criteria.\nThe patient is postmenopausal.\n\nStep 3: Compare the patient's breast cancer type with the inclusion criteria.\nThe patient has HER2-positive and ER/PR-negative breast cancer.\n\nStep 4: Compare the patient's metastatic status with the inclusion criteria.\nThe patient has metastatic lesions, but they are not in visceral organs.\n\nStep 5: Compare the patient's previous treatment history with the inclusion criteria.\nThe patient has not received previous treatment with HER2 inhibitors or chemotherapy, biological, or target therapy for recurrent or metastatic disease.\n\nStep 6: Compare the patient's ECOG performance score and life expectancy with the inclusion criteria.\nThe patient's ECOG performance score is not provided, but life expectancy is greater than 24 weeks.\n\nStep 7: Compare the patient's LVEF with the inclusion criteria.\nLVEF is not mentioned in the patient note.\n\nStep 8: Compare the patient's previous adjuvant treatment with the inclusion criteria.\nThe patient has not received previous adjuvant trastuzumab treatment, but previous adjuvant chemotherapy is allowed.\n\nStep 9: Compare the patient's hormone therapy discontinuation with the inclusion criteria.\nHormone therapy has been discontinued at least 1 month prior to recruitment.\n\nStep 10: Compare the patient's compliance and recovery from previous treatments with the inclusion criteria.\nPatient has good compliance and has recovered from any side effects of previous treatments.\n\nStep 11: Compare the patient's HIV status with the inclusion criteria.\nThe patient's HIV status is not provided.\n\nStep 12: Compare the patient's liver function tests with the inclusion criteria.\nALT, AST, TBIL, ALK, GGT, Scr,",
        "label": 0
    },
    "473": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria\nThe patient is 45 years old, which is within the age range of \u226518 years at A/MBC diagnosis.\n\nStep 2: Compare patient's sex with the inclusion criteria\nThe patient is a female, which matches the inclusion criteria of either female or male sex.\n\nStep 3: Compare patient's diagnosis with the inclusion criteria\nThe patient has a confirmed diagnosis of breast cancer with distant metastasis, which matches the inclusion criteria of A/MBC.\n\nStep 4: Compare patient's treatment history with the inclusion criteria\nThe patient has initiated CDK4/6i in combination with an AI as initial endocrine-based therapy, which matches the inclusion criteria.\n\nStep 5: Compare patient's hormone receptor status with the inclusion criteria\nThe patient's tumor is ER/PR negative, which does not match the inclusion criteria of evidence of ER or PR positive disease, or absence of any indication of ER and PR negative disease.\n\nStep 6: Compare patient's HER2 status with the inclusion criteria\nThe patient's tumor is HER2-positive, which does not match the inclusion criteria of evidence of HER2 negative disease, or absence of any indication of HER2 positive disease.\n\nBased on the comparison, the patient does not meet the inclusion criteria for the clinical trial. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "474": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nThe patient is a 45-year-old postmenopausal woman.\n\nStep 2: Identify the patient's cancer type and stage.\nThe patient has cytologically confirmed breast cancer, and a core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The patient has stage II or III breast cancer according to the AJCC cancer staging manual anatomic staging table, 8th edition.\n\nStep 3: Check the patient's tumor characteristics.\nThe tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions.\n\nStep 4: Compare the patient's characteristics with the inclusion criteria.\nThe patient meets the criteria for stage II or III breast cancer, HER2-positive status, and ER/PR negative status.\n\nStep 5: Check for any exclusion criteria.\nThere are no exclusion criteria mentioned in the patient note that would disqualify the patient from participating in the trial.\n\nStep 6: Determine the patient's eligibility.\nThe patient meets the inclusion criteria and does not have any exclusion criteria, so the patient is eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "475": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Disease: Breast cancer\n- Tumor type: Invasive ductal breast carcinoma\n- Tumor size: 3 cm\n- Tumor location: Left upper outer quadrant\n- Tumor characteristics: HER2-positive, ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- Metastatic lesions: Present in CXR\n- Treatment: Candidate for tumor resection and chemotherapy\n\nStep 2: Compare the patient's characteristics with the inclusion criteria of the clinical trial.\n- cT2 cN0/1 breast cancer: The patient has a T2 breast cancer, but the axillary sampling reveals 5 positive lymph nodes, which means the patient does not meet this criterion.\n- Scheduled for neoadjuvant chemotherapy: The patient is a candidate for tumor resection and chemotherapy, which means the patient meets this criterion.\n- Informed consent: The patient's consent is not mentioned in the patient note, but we can assume it is present since it is a standard requirement for clinical trials.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n- The patient does not meet the inclusion criteria of cT2 cN0/1 breast cancer, so the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "476": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age.\nThe patient is a 45-year-old postmenopausal woman. The clinical trial does not specify an age range, so we can proceed to the next step.\n\nStep 2: Identify the patient's gender.\nThe patient is a woman. The clinical trial does not specify a gender requirement, so we can proceed to the next step.\n\nStep 3: Identify the patient's cancer type and characteristics.\nThe patient has cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. The clinical trial includes patients with triple negative breast cancer (hormone receptor negative and HER2 negative). The patient's tumor characteristics match the inclusion criteria.\n\nStep 4: Identify the patient's clinical stage.\nThe patient has axillary sampling revealing 5 positive lymph nodes. The clinical trial includes patients with clinical stage T1-4, N0-3, M0, with indications for neoadjuvant chemotherapy. The patient's clinical stage matches the inclusion criteria.\n\nStep 5: Identify the patient's treatment history.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. The clinical trial includes patients who have received platinum and taxanes neoadjuvant chemotherapy for at least 4 cycles and no tumor progression occurred. The patient's treatment history matches the inclusion criteria.\n\nStep 6: Identify the patient's residual disease.\nThe patient has residual invasive disease. The clinical trial includes patients with residual invasive disease \u22651 cm in the breast, and/or have positive axillary lymph nodes observed on pathologic exam after neoadjuvant chemotherapy. The patient's residual disease matches the inclusion criteria.\n\nStep 7: Identify the patient's performance status and organ function.\nThe patient's ECOG Performance Status is not specified. The clinical trial includes patients with ECOG Performance Status 0-1. The patient's performance status is not relevant for eligibility determination.\n\nStep 8: Identify the patient's",
        "label": 0
    },
    "477": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria\nThe patient is 45 years old, and the inclusion criteria require the patient to be \u2265 18 years old. The patient meets this criterion.\n\nStep 2: Compare patient's gender with the inclusion criteria\nThe patient is a female, and the inclusion criteria allow both male and female subjects. The patient meets this criterion.\n\nStep 3: Compare patient's breast cancer type with the inclusion criteria\nThe patient has HER2-positive and ER/PR negative breast cancer, which does not match the inclusion criteria of Her2 negative on immunohistochemistry or nonamplified breast cancer. The patient does not meet this criterion.\n\nStep 4: Compare patient's metastatic status with the inclusion criteria\nThe patient has metastatic breast cancer, which matches the inclusion criteria of metastatic or recurrent unresectable breast cancer. The patient meets this criterion.\n\nStep 5: Compare patient's treatment history with the inclusion criteria\nThe patient has had axillary sampling revealing 5 positive lymph nodes and metastatic lesions on CXR, which indicates that she has exhausted or refused all endocrine monotherapy or endocrine therapeutic combinatorial options and has not yet been treated with chemotherapy in the metastatic settings, but for whom chemotherapy is indicated. The patient meets this criterion.\n\nStep 6: Compare patient's tumor accessibility with the inclusion criteria\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This indicates that the tumor is reasonably accessible to tumor collection. The patient meets this criterion.\n\nStep 7: Compare patient's life expectancy with the inclusion criteria\nThe patient has a life expectancy of \u2265 6 months as assessed by the treating investigator. The patient meets this criterion.\n\nStep 8: Compare patient's ECOG Performance Status with the inclusion criteria\nThe patient's ECOG Performance Status \u2264 2. The patient meets this criterion.\n\nStep 9: Compare patient's post-menopausal status with the inclusion criteria\nThe patient is postmenopausal, as she is 45",
        "label": 0
    },
    "478": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note for relevant information.\n\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nStep 2: Compare the patient's characteristics with the inclusion criteria of the clinical trial.\n\nInclusion criteria:\n\n1. HER2-positive status\n2. Known hormone receptor (HR) status\n3. Clinical stage T1-4, N0-3 disease at presentation and residual invasive disease postoperatively\n4. Residual HR-negative, HER2 positive (+) disease in the breast and/or lymph nodes\n5. Weakly ER-positive (1-10%) breast cancer (based on the pretreatment core biopsy) with node-negative disease\n6. Synchronous bilateral invasive disease (both lesions confirmed to be HER2-positive)\n7. Received neoadjuvant chemotherapy with one of the specified regimens\n8. Prior receipt of T-DM1 in the neoadjuvant setting is not allowed\n9. Prior treatment must have consisted of >= 6 cycles of chemotherapy and HER2-directed therapy, with a total duration of >= 12 weeks, including at least 9 weeks of preoperative taxane and trastuzumab with or without pertuzumab\n10. Patients who received neoadjuvant systemic therapy which included experimental HER2-targeted therapy/therapies are potentially eligible, as long as the investigational agent was not a HER2-targeted antibody-drug conjugate (e.g. T-DM1, DS-8201a [trastuzumab derux",
        "label": 1
    },
    "479": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's diagnosis and characteristics.\n- The patient has cytologically confirmed breast cancer.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n\nStep 2: Compare the patient's characteristics with the inclusion criteria.\n- Inclusion Criteria 1: Triple-negative or HER2-positive invasive breast cancer with axillary lymph node metastasis by confirmed by fine needle aspiration or core needle biopsy.\n  - The patient has HER2-positive invasive breast cancer with axillary lymph node metastasis, so this criterion is met.\n- Inclusion Criteria 2: Underwent computed tomography for assessment of axillary lymph node status before and after neoadjuvant chemotherapy.\n  - The patient note does not mention if the patient underwent computed tomography for assessment of axillary lymph node status before and after neoadjuvant chemotherapy, so this criterion is not met.\n- Inclusion Criteria 3: Attend the study voluntarily, sign the informed consent.\n  - The patient note does not mention if the patient attended the study voluntarily and signed the informed consent, so this criterion is not met.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n- The patient meets Inclusion Criteria 1 but does not meet Inclusion Criteria 2 and 3. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "480": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age, gender, and disease type.\n- The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer.\n\nStep 2: Determine if the patient is eligible for neoadjuvant chemotherapy and planning surgical treatment.\n- The patient has 5 positive lymph nodes and is a candidate for tumor resection, indicating that she is eligible for neoadjuvant chemotherapy and planning surgical treatment.\n\nStep 3: Assess if the patient can give informed consent.\n- The patient note does not provide information on whether the patient can give informed consent.\n\nStep 4: Evaluate the patient's eligibility based on the available information.\n- The patient meets the inclusion criteria for neoadjuvant chemotherapy and planning surgical treatment. However, we do not have enough information about her ability to give informed consent.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "481": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n- Patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer\n- Patient has HER2-positive and ER/PR negative breast cancer\n- Patient has 5 positive lymph nodes\n- Patient is a candidate for tumor resection and agrees to do so prior to chemotherapy\n\nInclusion criteria:\n- Patient is an adult male or female (\u2265 18 years of age) with advanced (locoregionally recurrent not amenable to curative therapy or metastatic) hormone receptor-positive, HER2-negative breast cancer\n- Patient has documented evidence of a mutation in the PIK3CA gene\n- If female, then the patient is postmenopausal\n- Patient has evidence of recurrence or progression during or after AI therapy\n- Patient has a histologically and/or cytologically confirmed diagnosis of ER+ and/or PgR+ breast cancer\n- Patient has adequate bone marrow and organ function\n\nStep 2: Compare patient note and exclusion criteria\n- Patient is not receiving any treatment with a PI3K, mTOR, or AKT inhibitor\n- Patient has no known hypersensitivity to alpelisib or any of its excipients\n- Patient has not had major surgery within 14 days prior to treatment and has recovered from major side effects\n- Patient does not have diabetes mellitus type I or uncontrolled type II\n- Patient does not have impairment of gastrointestinal function or GI disease that may significantly alter the absorption of the drugs\n- Patient does not have pneumonitis/interstitial lung disease\n- Patient does not have Child Pugh score B or C\n- Patient does not have uncontrolled hypertension\n- Patient does not have clinically significant, uncontrolled heart disease and/or recent cardiac events\n- Patient does not have any other concurrent severe and/or uncontrolled medical condition that would contraindicate participation in the trial\n- Patient is not currently receiving any of the following medications and cannot be discontinued 7 days prior to the start of the treatment: Strong CYP3A4 inducers",
        "label": 0
    },
    "482": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, and the inclusion criteria require patients to be between 18 and 70 years old. The patient does not meet this criterion.\n\nStep 2: Compare the patient's breast cancer characteristics to the inclusion criteria.\nThe patient has cytologically confirmed breast cancer, but the inclusion criteria require the cancer to be pathologically confirmed. This criterion is not met.\n\nStep 3: Compare the patient's hormone receptor status to the inclusion criteria.\nThe patient's breast cancer is HER2-positive and ER/PR negative, which does not match the inclusion criteria that require the cancer to be positive for estrogen receptor and/or progesterone receptor.\n\nStep 4: Compare the patient's treatment history to the inclusion criteria.\nThe patient has not completed standard endocrine therapy for 5 years without recurrence and metastasis, which means they do not meet this criterion.\n\nStep 5: Compare the patient's other characteristics to the inclusion criteria.\nThe patient does not have sufficient information to qualify for the trial based on the given criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "483": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note\nThe patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. She has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions.\n\nStep 2: Compare patient note with inclusion criteria\nInclusion Criteria: Newly diagnosed women with biopsy-verified invasive breast cancer planned for breast conserving surgery. Age > 18 year\n\nThe patient is a woman with biopsy-verified invasive breast cancer and is planned for breast conserving surgery. She is 45 years old, which is above the age of 18.\n\nStep 3: Determine trial-level eligibility\nThe patient meets the inclusion criteria for the clinical trial. There are no exclusion criteria mentioned in the patient note that would disqualify her from participating in the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "484": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old. The inclusion criteria state that the first occurrence breast cancer must be diagnosed from Jan 1, 2020. The patient's age is not relevant to the inclusion criteria.\n\nStep 2: Compare the patient's cancer stage to the inclusion criteria.\nThe patient has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The inclusion criteria state that the cancer stage must be 0-III. Since the patient has invasive ductal breast carcinoma, they meet the stage criteria.\n\nStep 3: Compare the patient's tumor type to the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative. The inclusion criteria state that invasive tumors must be HER2 positive (regardless of ER, PR) or ER negative. Since the patient's tumor meets one of the criteria, they meet the tumor type criteria.\n\nStep 4: Compare the patient's cancer to the inclusion criteria.\nThe patient has breast cancer. The inclusion criteria state that the cancer must be a first occurrence breast cancer. Since this is the patient's first occurrence of breast cancer, they meet the cancer type criteria.\n\nStep 5: Compare the patient's metastatic status to the inclusion criteria.\nThe patient has metastatic lesions. The inclusion criteria state that the cancer must be non-metastatic. Since the patient has metastatic lesions, they do not meet the metastatic status criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "485": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n\n- Age: 45 years old\n- Gender: Female\n- Disease: Breast cancer\n- Tumor type: Invasive ductal breast carcinoma (HER2-positive and ER/PR negative)\n- Stage: Clinical T1-T3, N+, M0\n- Treatment history: None (candidate for tumor resection)\n- Other medical conditions: None (does not smoke, does not consume alcohol, no children)\n\nStep 2: Compare the patient's characteristics to the inclusion and exclusion criteria of the clinical trial.\n\nInclusion Criteria:\n- Ability to understand and willingness to sign a written informed consent document.\n- Females (regardless of menopausal status)\n- Biopsy proven ER and/or PR positive\n- HER2 non-amplified\n- Clinical T1-T3, any N, M0 invasive breast cancer\n- Unilateral, multi-focal breast cancer (if applicable)\n- Planned for neoadjuvant chemotherapy\n- No prior anti-cancer therapy for the treatment of their breast cancer (except allowable endocrine therapy)\n- Able to swallow oral medications\n- Blood counts and liver function within normal limits\n- No evidence of recurrence > 5 years (if a cancer survivor)\n- Female participants of childbearing potential follow appropriate contraception guidelines\n- Male participants follow appropriate contraception guidelines\n- No blood donation during the study or for 90 days after the last dose of study treatment\n- Stable corticosteroid use allowed (if applicable)\n- Normal blood pressure or adequately controlled hypertension\n\nExclusion Criteria:\n- Inability to understand or unwillingness to sign a written informed consent document\n- Males (unless specified as eligible in the trial)\n- Biopsy proven ER and/or PR negative\n- HER2 amplified\n- Clinical stage T4 or higher, any N, M1 invasive breast cancer\n- Prior anti-cancer therapy for the treatment of their breast cancer (except allowable endocrine therapy)\n- Ineligible for biopsy or unwilling to provide required research biopsies\n- ECO",
        "label": 0
    },
    "486": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's disease and stage.\nThe patient has cytologically confirmed breast cancer, and a core biopsy revealed a 3 cm invasive ductal breast carcinoma. The tumor is HER2-positive and ER/PR negative, and axillary sampling revealed 5 positive lymph nodes. The patient also has metastatic lesions in the CXR.\n\nStep 2: Compare the patient's disease and stage to the inclusion criteria.\nThe inclusion criteria state \"Early stage Breast Cancer\" and \"DCIS gr III\". The patient's cancer is invasive ductal breast carcinoma, which is not DCIS (ductal carcinoma in situ). Therefore, the patient does not meet the inclusion criteria.\n\nStep 3: Determine the trial-level eligibility.\nSince the patient does not meet the inclusion criteria, the trial-level eligibility is 0) Excluded.",
        "label": 2
    },
    "487": {
        "output": "GPT4 Correct Assistant: Step 1: Check if the patient is an adult over 19 years old.\nThe patient is 45 years old, which means she is an adult over 19 years old.\n\nStep 2: Check if the patient has been diagnosed with breast ductal carcinoma in situ through preoperative tissue biopsy.\nThe patient has been diagnosed with breast cancer through a core biopsy, but the note does not specify if it is ductal carcinoma in situ (DCIS).\n\nStep 3: Check if the patient understands the study and agrees to participate.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This implies that she understands the study and agrees to participate.\n\nSince the patient's diagnosis is not confirmed to be ductal carcinoma in situ, we cannot determine her eligibility based on the available information. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "488": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is a 45-year-old woman, and the inclusion criteria state that women aged 18 years or older can participate in the trial. The patient meets this criterion.\n\nStep 2: Compare the patient's breast mass score to the inclusion criteria.\nThe patient has cytologically confirmed breast cancer, but there is no information about her breast mass score (M3, M4, or M5; MRI5; U3, U4, or U5). We cannot determine if the patient meets this criterion based on the given information.\n\nStep 3: Compare the patient's histological confirmation of breast cancer to the inclusion criteria.\nThe patient has histologically confirmed breast cancer, which meets the inclusion criterion.\n\nStep 4: Compare the patient's axillary lymph nodes to the inclusion criteria.\nThe patient has 5 positive lymph nodes, and the inclusion criteria state that participants must have ipsilateral axillary lymph nodes described as indeterminate or suspicious for metastatic disease and indicated for biopsy. The patient meets this criterion.\n\nStep 5: Compare the patient's ability to give informed consent to the inclusion criteria.\nThe patient's note does not provide information about her ability to give informed consent for the trial. We cannot determine if the patient meets this criterion based on the given information.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "489": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze patient note\n- Patient is 45 years old and postmenopausal\n- Diagnosed with cytologically confirmed breast cancer\n- 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- HER2-positive and ER/PR negative\n- Axillary sampling revealed 5 positive lymph nodes\n- Metastatic lesions on CXR\n- Taking multivitamins and iron supplements\n- No smoking or alcohol consumption\n- Not sexually active and no children\n- Candidate for tumor resection before chemotherapy\n\nStep 2: Compare patient note with inclusion criteria\n\n1. Informed consent: Not mentioned in the patient note, but assumed as given\n2. Age: 45 years old, meets criteria\n3. Gender: Female, meets criteria\n4. Triple-negative breast cancer: HER2-positive and ER/PR negative, meets criteria\n5. No evidence of metastasis: Patient has metastatic lesions, excluded\n6. Surgery: Not mentioned in the patient note, but assumed as given\n7. Pathological complete remission: Not applicable, as patient has metastatic lesions\n8. Axillary lymph node involvement: 5 positive lymph nodes, meets criteria\n9. Primary tumor size: 3 cm, meets criteria\n10. Ki-67 index: Not mentioned in the patient note, but assumed as given\n11. Comprehensive score: Not mentioned in the patient note, but assumed as given\n12. ECOG PS: Not mentioned in the patient note, but assumed as given\n13. Adjuvant chemotherapy: Not mentioned in the patient note, but assumed as given\n14. Time window between chemotherapy and study randomization: Not mentioned in the patient note, but assumed as given\n15. Laboratory tests: Not mentioned in the patient note, but assumed as given\n\nStep 3: Determine trial-level eligibility\nThe patient meets most of the inclusion criteria, but has metastatic lesions, which is an exclusion criterion. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "490": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender\nThe patient is a 45-year-old postmenopausal woman. The age of majority in Nebraska is 19 years.\n\nStep 2: Compare the patient's age to the inclusion criteria\nThe patient is 45 years old, which is greater than 19 years old.\n\nStep 3: Identify the patient's medical condition\nThe patient has cytologically confirmed breast cancer, which is a primary tumor, not a brain tumor.\n\nStep 4: Compare the patient's medical condition to the inclusion criteria\nThe patient does not meet the inclusion criteria for brain tumor subjects or healthy subjects.\n\nStep 5: Determine the patient's eligibility\nSince the patient does not meet the inclusion criteria, they are not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "491": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which falls within the age range of 18 to 65 years.\n\nStep 2: Compare the patient's performance status to the inclusion criteria.\nThe patient's performance status is not mentioned in the note, so we cannot determine if she meets this criterion.\n\nStep 3: Compare the patient's tumor stage to the inclusion criteria.\nThe patient has clinical T2-T4d, or T1c with axillary LN+, which meets the inclusion criterion of Clinical T2-T4d, or T1c with axillary LN+.\n\nStep 4: Compare the patient's breast cancer type to the inclusion criteria.\nThe patient has HER2-positive invasive breast cancer, which meets the inclusion criterion of HER2 + invasive breast cancer.\n\nStep 5: Compare the patient's measurable lesions to the inclusion criteria.\nThe patient has measurable lesions revealed by ultrasound, which meets the inclusion criterion of clinically measurable lesions.\n\nStep 6: Compare the patient's organ and bone marrow function test results to the inclusion criteria.\nThe patient's organ and bone marrow function test results are not mentioned in the note, so we cannot determine if she meets this criterion.\n\nStep 7: Compare the patient's blood counts to the inclusion criteria.\nThe patient's absolute neutrophil count, hemoglobin, and platelet count are not mentioned in the note, so we cannot determine if she meets these criteria.\n\nStep 8: Compare the patient's liver and kidney function to the inclusion criteria.\nThe patient's total bilirubin, creatinine, AST/ALT, and echocardiography results are not mentioned in the note, so we cannot determine if she meets these criteria.\n\nStep 9: Compare the patient's pregnancy status to the inclusion criteria.\nThe patient is postmenopausal and not of childbearing age, so she meets the criterion of serum pregnancy test negative 14 days before randomization.\n\nStep 10: Compare the patient",
        "label": 2
    },
    "492": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is over 20 years old.\n\nStep 2: Compare the patient's diagnosis to the inclusion criteria.\nThe patient has cytologically confirmed breast cancer, but the trial is specifically for metaplastic carcinoma of triple negative breast cancer. The patient's cancer type is not specified in the patient note.\n\nStep 3: Compare the patient's treatment decision to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy. This indicates that they have decided to perform neoadjuvant chemotherapy under clinical judgement.\n\nStep 4: Determine the trial-level eligibility.\nThe patient meets the age and treatment decision inclusion criteria, but the cancer type is not specified, making it unclear if the patient meets the cancer type inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "493": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient note:\n- Age: 45 years old\n- Gender: Female\n- Cancer type: Invasive ductal breast carcinoma\n- HER2-positive and ER/PR negative\n- 5 positive lymph nodes\n- Metastatic lesions\n- Multivitamins and iron supplements\n- No smoking or alcohol\n- Not sexually active, no children\n- Candidate for tumor resection\n\nInclusion criteria:\n- Female\n- Age \u2265 18 years\n- Histological diagnosis of invasive lobular breast adenocarcinoma that is ER+, and HER2-\n- Multifocal unilateral or bilateral breast adenocarcinoma tumours are allowed if all tested foci are lobular, ER+ and HER2-\n- ER positive (ER+ is defined as having an IHC of 1% or more and/or an Allred of 3 or more and HER2-)\n- HER2 negative as defined by 2018 ASCO / CAP Guidelines\n- A primary non metastatic or locally advanced tumour of 15 mm or more, cN0 or cN1 without prior treatment candidate for preoperative treatment\n- ECOG Performance Status (PS) 0 or 1\n- Adequate Bone Marrow Function\n- Adequate Renal Function\n- Adequate Liver Function\n- Signed Informed Consent form (ICF) obtained prior to any study related procedure\n- Completion of all necessary screening procedures within 28 days prior to enrolment\n- Subject is willing and able to comply with the protocol for the duration of the study including treatment and scheduled visits and examinations\n- Women who are not postmenopausal or have not undergone hysterectomy must have documented negative pregnancy test (serum) within 28 days prior to enrolment\n- Women of childbearing potential and their partners, who are sexually active, must agree to use one highly effective form of contraception (see protocol section 6.6.1) from the signing of the ICF until at least 5 weeks after last administration of entrectinib, or they must totally/truly abstain from any form",
        "label": 0
    },
    "494": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which meets the criteria of being a female \u2265 18 years of age.\n\nStep 2: Compare the patient's menopausal status to the inclusion criteria.\nThe patient is postmenopausal, which meets the criteria for postmenopausal status.\n\nStep 3: Compare the patient's disease to the inclusion criteria.\nThe patient has metastatic breast cancer, which meets the criteria for metastatic disease.\n\nStep 4: Compare the patient's hormone receptor status to the inclusion criteria.\nThe patient's cancer is HER2-positive and ER/PR negative, which does not meet the criteria for HR+HER2- metastatic breast cancer.\n\nStep 5: Compare the patient's performance status to the inclusion criteria.\nThe patient's ECOG performance status is not mentioned in the patient note, so we cannot determine if she meets the criteria.\n\nStep 6: Compare the patient's laboratory values to the inclusion criteria.\nThe patient's laboratory values are not mentioned in the patient note, so we cannot determine if she meets the criteria.\n\nStep 7: Compare the patient's willingness to participate to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which indicates a willingness to participate.\n\nConclusion:\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "495": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the age requirement in the inclusion criteria.\nThe patient is 45 years old, which is within the range of \u226518 years of age required for the trial.\n\nStep 2: Compare the patient's gender to the gender requirement in the inclusion criteria.\nThe patient is a woman, which matches the requirement of male or female patients in the trial.\n\nStep 3: Compare the patient's breast cancer stage to the stage requirement in the inclusion criteria.\nThe patient has stage IV breast cancer, which matches the requirement of patients with stage IV breast cancer in the trial.\n\nStep 4: Compare the patient's HER2 status to the HER2 status requirement in the inclusion criteria.\nThe patient has HER2+ status, which matches the requirement of patients with HER2+ status in the metastatic setting in the trial.\n\nStep 5: Compare the patient's number of lines of therapy to the number of lines of therapy required in the inclusion criteria.\nThe patient has received at least two lines of active anti-cancer drugs due to disease progression, which matches the requirement of patients that received at least two lines of active anti-cancer drugs in the trial.\n\nStep 6: Compare the patient's start of third-line therapy to the start date requirement in the inclusion criteria.\nThe patient began third-line therapy prior to October 31, 2018, which matches the requirement of patients that began third-line therapy prior to October 31, 2018 in the trial.\n\nSince the patient meets all the inclusion criteria and does not have any exclusion criteria mentioned in the trial, the trial-level eligibility is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "496": {
        "output": "GPT4 Correct Assistant: Step 1: Assess patient's age\nThe patient is 45 years old, which is within the age range for the trial (stage II or III, HER2 negative, ER positive invasive breast cancer in male or female patients).\n\nStep 2: Assess patient's breast cancer type and stage\nThe patient has a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant, which is stage II or III. The tumor is HER2-positive and ER/PR negative, which matches the trial criteria for HER2 negative, ER positive breast cancer.\n\nStep 3: Assess patient's axillary lymph nodes\nThe patient has 5 positive lymph nodes, which is within the trial criteria for high risk for recurrence (1-3 involved axillary lymph nodes).\n\nStep 4: Assess patient's metastatic lesions\nThe patient has metastatic lesions, which would exclude her from the trial (Exclusion Criteria 4.1.7).\n\nStep 5: Assess patient's eligibility for randomization\nThe patient has metastatic lesions, which would exclude her from randomization (Exclusion Criteria 4.2.5).\n\nTrial-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).",
        "label": 0
    },
    "497": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the age range specified for the clinical trial (women over 18 years of age).\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a woman, which matches the criteria for the clinical trial (women only).\n\nStep 3: Compare the patient's cancer type and stage to the inclusion criteria.\nThe patient has invasive ductal breast cancer and is in clinical Stage III, which matches the criteria for the clinical trial (Clinical Stage I-III invasive breast cancer).\n\nStep 4: Compare the patient's hormone receptor status to the inclusion criteria.\nThe patient's cancer is ER/PR negative, which does not match the criteria for the clinical trial (ER staining present in greater than 50% of invasive cancer cells by IHC).\n\nStep 5: Compare the patient's HER2 status to the inclusion criteria.\nThe patient's cancer is HER2-positive, which does not match the criteria for the clinical trial (HER2-negative).\n\nStep 6: Compare the patient's baseline tumor size to the inclusion criteria.\nThe patient's tumor is 3 cm, which is greater than the minimum size specified for the clinical trial (baseline tumor must be \u22651 cm).\n\nStep 7: Compare the patient's history of multicentric or bilateral disease to the inclusion criteria.\nThe patient does not have multicentric or bilateral disease, but the clinical trial states that patients with such disease are eligible if they are candidates for clinically indicated neoadjuvant endocrine therapy.\n\nStep 8: Compare the patient's laboratory values to the inclusion criteria.\nThe patient's laboratory values are not provided in the patient note, so we cannot compare them to the criteria.\n\nStep 9: Compare the patient's eligibility for neoadjuvant treatment with an aromatase inhibitor to the inclusion criteria.\nThe patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which matches the criteria for the clinical trial (women for whom neoadjuvant treatment with an aromatase inhib",
        "label": 0
    },
    "498": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n- Age: 45 years old\n- Gender: Female\n- Disease: Breast cancer\n- Tumor type: Invasive ductal breast carcinoma\n- Tumor size: 3 cm\n- HER2 status: Positive\n- ER/PR status: Negative\n- Axillary sampling: 5 positive lymph nodes\n- Treatment: Candidate for tumor resection\n\nStep 2: Compare the patient's characteristics to the inclusion criteria of the clinical trial.\n- Inclusion Criteria: Clinically lymph node negative breast cancer patients T1-T3\n\nStep 3: Determine the patient's eligibility based on the comparison.\n- The patient has breast cancer, but the axillary sampling revealed 5 positive lymph nodes, which means she does not have clinically lymph node negative breast cancer.\n\nStep 4: Output the scale for the assessment of eligibility.\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "499": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n- The patient has cytologically confirmed breast cancer.\n- The tumor is HER2-positive and ER/PR negative.\n- Axillary sampling revealed 5 positive lymph nodes.\n- The patient is a candidate for tumor resection.\n\nStep 2: Compare the patient's information with the inclusion criteria of the clinical trial.\n- Inclusion Criteria: Patients diagnosed with metastatic HER2-negative breast cancer and AR expression of \u2265 10%.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n- The patient has metastatic breast cancer, but the note does not mention the AR expression.\n\nStep 4: Assign the eligibility scale based on the information available.\n- Trial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "500": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\n- Age: The patient is 45 years old, which meets the age requirement of at least 40 years old.\n- Gender: The patient is female, which meets the gender requirement.\n- Diagnosis: The patient has histologically confirmed breast cancer, which meets the diagnosis requirement.\n- HER2 status: The patient's tumor is HER2-positive, which meets the HER2 status requirement.\n- PAM50 HER2-enriched subtype and ERBB2-high: The patient's tumor is HER2-enriched and ERBB2-high, which meets the subtype requirement.\n- Tumor size: The patient's tumor is 3 cm in diameter, which is within the allowed 4 cm or less.\n- Nodal involvement: The patient has 5 positive lymph nodes, which is not within the allowed no nodal involvement (cN0).\n- Distant metastasis: The patient has metastatic lesions, which is not within the allowed no evidence of distant metastasis (M0).\n- ER and PR status: The patient's tumor is ER/PR negative, which meets the ER and PR status requirement.\n- Taxane eligibility: The patient's tumor is eligible for taxane therapy, which meets the taxane eligibility requirement.\n- Willingness to omit surgery: The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy, which meets the willingness to omit surgery requirement.\n- Estimated life expectancy: The patient's estimated life expectancy is not mentioned, but it is assumed to be at least 5 years.\n- Archival tumor tissue sample: The patient has a core biopsy, which provides a sample for archival tumor tissue.\n- ECOG performance status: The patient's performance status is not mentioned, but it is assumed to be 0 to 1.\n- Ability and willingness to comply: The patient's ability and willingness to comply with study visits, treatment, testing, and protocol are not mentioned, but it is assumed to be present.\n- Organ function: The patient's organ function is not mentioned, but it is assumed to be adequate.",
        "label": 1
    },
    "501": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nThe patient is a 45-year-old postmenopausal woman. The clinical trial is for women at term (over 37 weeks), so the patient's age is not relevant to the inclusion criteria.\n\nStep 2: Check for the patient's medical condition.\nThe patient has cytologically confirmed breast cancer, but the clinical trial is for women interested in having external cephalic version at a gestational age of 37+0/7 or more. The patient's medical condition is not relevant to the inclusion criteria.\n\nStep 3: Check for any exclusion criteria.\nThe clinical trial does not provide any exclusion criteria.\n\nStep 4: Determine the patient's eligibility.\nSince the patient's age and medical condition are not relevant to the inclusion criteria and there are no exclusion criteria, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "502": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note and identify relevant information.\n\n- Age: 45 years old\n- Gender: Female\n- Diagnosis: Cytologically confirmed breast cancer\n- Tumor type: Invasive ductal breast carcinoma, HER2-positive, ER/PR negative\n- Stage: Metastatic (5 positive lymph nodes, metastatic lesions on CXR)\n- Treatment: Candidate for tumor resection and chemotherapy\n\nStep 2: Compare the patient note with the inclusion criteria of the clinical trial.\n\n1. Age 18+: The patient is 45 years old, which meets the age requirement.\n2. Metastatic breast cancer irrespective of subtype: The patient has metastatic breast cancer (HER2-positive).\n3. Measurable disease as per RECIST 1.1 criteria: The patient has measurable disease (5 positive lymph nodes, metastatic lesions).\n4. Metastatic disease involving the lymph nodes and/or visceral organs is required: The patient has metastatic disease involving lymph nodes.\n5. Willingness to undergo a biopsy prior to the start of planned systemic therapy: The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nStep 3: Determine the trial-level eligibility based on the comparison.\n\nAll inclusion criteria are met, and there are no exclusion criteria mentioned in the patient note. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "503": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the trial's age requirement.\nThe patient is 45 years old, and there is no specific age requirement mentioned in the trial's inclusion criteria.\n\nStep 2: Compare the patient's gender to the trial's gender requirement.\nThe patient is a woman, and the trial is for women.\n\nStep 3: Compare the patient's cancer type and stage to the trial's inclusion criteria.\nThe patient has invasive ductal breast carcinoma, and the trial includes invasive ductal carcinoma of the breast. The patient's tumor measures 3 cm, and the trial includes tumors measuring 50 mm or smaller. The patient has axillary lymph node metastasis, which is not allowed in the trial.\n\nStep 4: Compare the patient's location of the tumor to the trial's inclusion criteria.\nThe patient's tumor is in the left upper outer quadrant, and the trial does not specify a location requirement.\n\nStep 5: Compare the patient's tumor status to the trial's inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative, and the trial does not specify a HER2 or ER/PR status requirement.\n\nStep 6: Compare the patient's use of supplements and lifestyle factors to the trial's inclusion criteria.\nThe patient is taking multivitamins and iron supplements, and there is no specific requirement or exclusion related to supplement use in the trial. The patient does not smoke or consume alcohol, and there is no specific requirement or exclusion related to smoking or alcohol consumption in the trial. The patient is not sexually active and has no children, and there is no specific requirement or exclusion related to sexual activity or childbearing in the trial.\n\nStep 7: Determine the patient's eligibility based on the comparison.\nThe patient meets some inclusion criteria (gender, cancer type, and supplement use) but does not meet others (tumor stage and location). The patient also has axillary lymph node metastasis, which is an exclusion criterion.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "504": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's condition\nThe patient has breast cancer, not rectal cancer.\n\nStep 2: Compare the patient's condition to the inclusion criteria\nThe inclusion criteria are for middle to low-lying rectal adenocarcinoma patients with enlarged lateral lymph node \u22655mm for short diameter in CT and/or MRI.\n\nStep 3: Determine the patient's eligibility\nSince the patient has breast cancer and not rectal cancer, they do not meet the inclusion criteria for this clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "505": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria\nThe patient is 45 years old, which is within the age range of \u226518 years specified in the inclusion criteria.\n\nStep 2: Compare patient's gender to the inclusion criteria\nThe patient is a woman, which matches the gender specified in the inclusion criteria (women).\n\nStep 3: Compare patient's disease type to the inclusion criteria\nThe patient has breast cancer, which matches the disease type specified in the inclusion criteria (invasive breast carcinoma).\n\nStep 4: Compare patient's disease stage to the inclusion criteria\nThe patient has stage III breast cancer, which matches the stage specified in the inclusion criteria (Stage III IBC).\n\nStep 5: Compare patient's performance status to the inclusion criteria\nThe patient's ECOG performance status is not provided in the patient note, so we cannot determine if she meets this criterion.\n\nStep 6: Compare patient's ability to understand and comply with study procedures to the inclusion criteria\nThe patient's ability to understand and comply with study procedures is not provided in the patient note, so we cannot determine if she meets this criterion.\n\nStep 7: Compare patient's disease characteristics to the inclusion criteria\nThe patient's breast cancer is HER2-positive and ER/PR negative, but the inclusion criteria do not specify any requirements for these characteristics.\n\nStep 8: Compare patient's exclusion criteria to the trial's exclusion criteria\nThe patient's exclusion criteria are not provided in the patient note, so we cannot determine if she meets any exclusion criteria.\n\nTrial-level eligibility: 1) Not relevant",
        "label": 0
    },
    "506": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria.\nThe patient is 45 years old, which is within the range of \u2265 18 years old.\n\nStep 2: Compare patient's breast cancer type to the inclusion criteria.\nThe patient has invasive ductal breast carcinoma, which is included in the criteria for invasive ductal or lobular breast carcinoma.\n\nStep 3: Compare patient's clinical T stage to the inclusion criteria.\nThe patient's tumor is T1-T2, which is included in the criteria for clinical T1 or T2 invasive ductal or lobular breast carcinoma.\n\nStep 4: Compare patient's receptor status to the inclusion criteria.\nThe patient's tumor is HER2-positive and ER/PR negative, which is included in the criteria for any estrogen/progesterone/human epidermal growth factor receptor 2 (HER2) receptor status.\n\nStep 5: Compare patient's axillary lymph node status to the inclusion criteria.\nThe patient has 5 positive lymph nodes, which is within the range of up to two suspicious lymph nodes on axillary ultrasound.\n\nStep 6: Compare patient's ECOG Performance Status to the inclusion criteria.\nThe patient's ECOG Performance Status is not mentioned, but it is not a requirement for inclusion in the trial.\n\nStep 7: Compare patient's consent to the inclusion criteria.\nThe patient must understand, accept, and have signed the approved consent form, which is not mentioned but is not a requirement for inclusion in the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "507": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the note:\n\n- Age: 45 years old\n- Gender: Female\n- Disease: Cytologically confirmed breast cancer\n- Tumor type: Invasive ductal breast carcinoma\n- Tumor size: 3 cm\n- Tumor location: Left upper outer quadrant\n- Hormone receptor status: ER/PR negative\n- HER2 status: Positive\n- Number of lymph nodes involved: 5\n- Metastatic lesions: Present (CXR)\n- Treatment history: Multivitamins and iron supplements\n- Lifestyle: Non-smoker, non-alcohol user, not sexually active, no children\n- Treatment plan: Candidate for tumor resection before chemotherapy\n\nStep 2: Compare the patient's characteristics to the inclusion and exclusion criteria:\n\nInclusion Criteria:\n\n- Primary confirmed distant metastatic breast cancer (M1): Yes\n- Histologically proven diagnosis of the breast tumor: Yes\n- Known hormonal and HER2Neu status: Yes\n- TNM classification: T1-T3, resectable T4 status, and N0-N3: Not enough information\n- Performance status and comorbidity should allow surgery and/or systemic therapy: Not enough information\n- Accepting the surgery by written informed consent: Not enough information\n\nExclusion Criteria:\n\n- No confirmed primary invasive breast cancer in the medical history: Not enough information\n- Having another malignancy within the last 10 years, besides basal cell carcinoma of the skin or early-stage cervical cancer: Not enough information\n- Having the history of surgical treatment and/or radiotherapy of the breast tumor before randomization: Not enough information\n- Having irresectable T4 breast tumor: Not enough information\n- Having synchronous bilateral breast cancer: Not enough information\n\nStep 3: Determine the patient's eligibility based on the available information:\n\nSince we do not have enough information about the patient's TNM classification, performance status, comorbidity, treatment history, and acceptance of surgery, we cannot determine if the patient meets all the inclusion criteria or if they have any exclusion criteria.\n\nT",
        "label": 2
    },
    "508": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's condition and whether they are eligible for implantation of a pancreatic or biliary stent.\n\nPatient note: The patient has cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma. The patient is a candidate for tumor resection and agrees to do so prior to chemotherapy.\n\nInclusion Criteria: Patient eligible for implantation of a pancreatic or biliary stent prior to participate in the study and according to current guidelines.\n\nStep 2: Determine if the patient has provided a signed and dated informed consent.\n\nPatient note: There is no information about the patient providing signed and dated informed consent.\n\nInclusion Criteria: Patient has provided a signed and dated informed consent (according to the laws and regulations of the country in which the observational study is conducted).\n\nStep 3: Assess the patient's eligibility based on the inclusion criteria.\n\nSince the patient has breast cancer and is eligible for implantation of a pancreatic or biliary stent, but there is no information about the patient providing signed and dated informed consent, the patient's eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "509": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria\nThe patient is 45 years old, which is over 19 years old. This meets the age inclusion criterion.\n\nStep 2: Compare patient's diagnosis to the inclusion criteria\nThe patient has a diagnosis of ipsilateral breast tumor recurrence with a 3 cm invasive ductal breast carcinoma. This meets the diagnosis inclusion criterion.\n\nStep 3: Compare patient's previous surgery to the inclusion criteria\nThe patient had a core biopsy and is a candidate for tumor resection, which is consistent with the inclusion criteria of having partial mastectomy and sentinel lymph node biopsy for the initially diagnosed breast cancer.\n\nStep 4: Compare patient's axillary lymph node status to the inclusion criteria\nThe patient has 5 positive lymph nodes, which means she does not meet the inclusion criterion of being considered axillary lymph node negative from clinical findings.\n\nStep 5: Determine if the patient understands and willingly participates in the study\nThe patient's note does not provide information about her understanding and willingness to participate in the study. Therefore, this criterion is not relevant.\n\nConclusion:\nThe patient meets the age and diagnosis inclusion criteria, but does not meet the axillary lymph node status criterion. Due to the unknown status of the patient's understanding and willingness to participate in the study, the trial-level eligibility is 1) Not relevant.",
        "label": 0
    },
    "510": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics from the patient note.\n\n- Age: 45 years old\n- Gender: Female\n- Disease: Cytologically confirmed breast cancer\n- Tumor type: 3 cm invasive ductal breast carcinoma in the left upper outer quadrant\n- Hormone receptor status: HER2-positive, ER/PR negative\n- Axillary sampling: 5 positive lymph nodes\n- Metastatic lesions: CXR was remarkable for metastatic lesions\n- Treatment: Candidate for tumor resection and agrees to do so prior to chemotherapy\n\nStep 2: Compare the patient's characteristics to the inclusion criteria of the clinical trial.\n\nInclusion Criteria:\n- Pathologically confirmed HER2 positive breast cancer\n- Treated with Pyrotinib in the metastatic settings\n- Underwent whole-body FDG PET/CT within 4 weeks before the initiation of pyrotinib and capecitabine\n\nComparison:\n- The patient has pathologically confirmed HER2-positive breast cancer.\n- The patient has metastatic breast cancer (5 positive lymph nodes and metastatic lesions).\n- The patient has not undergone whole-body FDG PET/CT within 4 weeks before the initiation of pyrotinib and capecitabine.\n\nStep 3: Determine the trial-level eligibility based on the comparison.\n\nSince the patient meets the first two inclusion criteria but has not undergone whole-body FDG PET/CT within 4 weeks before the initiation of pyrotinib and capecitabine, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "511": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nPatient's age: 45 years\nInclusion criteria: Age 20-65 years\nThe patient's age is outside the age range for the trial.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nPatient's gender: Female\nInclusion criteria: Female\nThe patient's gender matches the inclusion criteria.\n\nStep 3: Compare the patient's cancer type to the inclusion criteria.\nPatient's cancer type: Invasive ductal breast carcinoma\nInclusion criteria: Invasive carcinoma confirmed by core biopsy\nThe patient's cancer type matches the inclusion criteria.\n\nStep 4: Compare the patient's cancer stage to the inclusion criteria.\nPatient's cancer stage: HER2-positive and ER/PR negative, with 5 positive lymph nodes and metastatic lesions\nInclusion criteria: Newly diagnosed breast cancer patients, without adjuvant therapy, single breast tumor with a maximum diameter of 3 cm, no distant metastasis, and no invasion of the skin and chest wall\nThe patient's cancer stage does not match the inclusion criteria.\n\nStep 5: Compare the patient's medical history to the inclusion criteria.\nPatient's medical history: Multivitamins and iron supplements, no smoking or alcohol consumption, not sexually active, no children, candidate for tumor resection\nInclusion criteria: Surgical treatment was planned\nThe patient's medical history matches the inclusion criteria.\n\nStep 6: Compare the patient's organ function to the inclusion criteria.\nThe patient's organ function is not mentioned in the patient note.\n\nStep 7: Compare the patient's thyroid function to the inclusion criteria.\nThe patient's thyroid function is not mentioned in the patient note.\n\nStep 8: Compare the patient's urinalysis to the inclusion criteria.\nThe patient's urinalysis is not mentioned in the patient note.\n\nStep 9: Evaluate the patient's voluntary participation and willingness to cooperate with follow-up.\nThe patient's voluntary participation and willingness to cooperate with follow-up are not mentioned",
        "label": 1
    },
    "512": {
        "output": "GPT4 Correct Assistant: Step 1: Check if the patient has histology-confirmed epithelial cancer of the mammary gland.\n- Patient note: \"cytologically confirmed breast cancer\"\n- Inclusion Criteria: Histology-confirmed epithelial cancer of the mammary gland\n- Trial-level eligibility: 2) Eligible.\n\nStep 2: Check if the patient is pre or post-menopausal with early breast cancer and involved axillary lymph nodes (T1-3 N1 M0) or high-risk N0 patients.\n- Patient note: \"45-year-old postmenopausal woman\"\n- Inclusion Criteria: Pre and post-menopausal patients with early breast cancer and involved axillary lymph nodes (T1-3 N1 M0) or high-risk N0 patients\n- Trial-level eligibility: 2) Eligible.\n\nStep 3: Check if the patient meets at least one high-risk criterion.\n- Patient note: \"3 cm invasive ductal breast carcinoma in the left upper outer quadrant\"\n- Inclusion Criteria: High-risk N0 patients (T>= 2cm, ER/PgR negative, HER-2 3+, infiltration of blood or lymphatic vessels or nerves, grade 3)\n- Trial-level eligibility: 2) Eligible.\n\nStep 4: Check if the patient has a white blood cell count (WBC) > 4 x 109 / l, platelets > 100 x 109 / l.\n- Patient note: No information on WBC and platelets\n- Inclusion Criteria: White Blood Cell count (WBC) > 4 x 109 / l, platelets > 100 x 109 / l\n- Trial-level eligibility: 1) Not relevant.\n\nStep 5: Check if the patient has serum creatinine, AST/SGOT, ALT/SGPT, gamma-glutamyltransferase, serum bilirubin 1.3 mg/ml inside the normal range of the participating hospital.\n- Patient note",
        "label": 1
    },
    "513": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nPatient's age: 45 years\nInclusion criteria: Age \u2265 50 years at diagnosis\n\nStep 2: Compare the patient's stage of cancer with the inclusion criteria.\nPatient's stage: cytologically confirmed breast cancer with a 3 cm invasive ductal breast carcinoma, HER2-positive and ER/PR negative, 5 positive lymph nodes, and metastatic lesions\nInclusion criteria: AJCC 7th Edition stage 0 or I (TisN0 \u2264 2 cm or T1N0) histologically confirmed carcinoma of the breast\n\nStep 3: Compare the patient's treatment history with the inclusion criteria.\nPatient's treatment history: Multivitamins and iron supplements, candidate for tumor resection and chemotherapy\nInclusion criteria: Neoadjuvant hormone therapy, chemotherapy, or biologic therapy is not allowed prior to APBI, but adjuvant hormone therapy may have been started after surgery. Planned chemotherapy or biologic therapy must not start for at least 4 weeks after the completion of APBI.\n\nStep 4: Compare the patient's other characteristics with the inclusion criteria.\nPatient's characteristics: Postmenopausal woman, no smoking or alcohol consumption, not sexually active, no children\nInclusion criteria: Good candidate for treatment per protocol in the judgment of the PI and/or treating physician following simulation. Postmenopausal status. Able to understand and willing to sign IRB-approved written informed consent document.\n\nBased on the comparison of the patient's characteristics with the inclusion criteria, the patient does not meet the criteria for this clinical trial. The patient has stage III breast cancer, which is not within the inclusion criteria of stage 0 or I breast cancer. Additionally, the patient has received multivitamins and iron supplements, which are not allowed before APBI treatment.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "514": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age, gender, and medical conditions.\n- Age: 46 years old\n- Gender: Male\n- Medical conditions: Family history of CAD, severe stenosis in the left internal carotid artery (LICA), moderate stenosis in the right internal carotid artery (RICA), and carotid plaque\n\nStep 2: Compare the patient's medical conditions to the inclusion criteria.\n- Inclusion criteria 1: Men and women, normocholesterolemic, with 30 percent or greater narrowing of a coronary artery lumen as revealed by angiography. (Cholesterol-Lowering Agent Trial)\n- Inclusion criteria 2: Men and women with angiographically-documented coronary heart disease (Fish Oil Trial)\n\nStep 3: Assess the patient's eligibility based on the inclusion criteria.\n- The patient is a male, which matches the gender requirement.\n- The patient has a family history of CAD, severe stenosis in the LICA, and moderate stenosis in the RICA, which matches the requirement of having a narrowing of a coronary artery lumen as revealed by angiography.\n- The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively, indicating hypercholesterolemia. However, this does not exclude the patient from the trial, as the inclusion criteria specifically mention normocholesterolemic patients.\n\nStep 4: Determine the trial-level eligibility.\n- Based on the comparison of the patient's medical conditions to the inclusion criteria, the patient meets the requirements for both the Cholesterol-Lowering Agent Trial and the Fish Oil Trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "515": {
        "output": "GPT4 Correct Assistant: Step 1: Determine if the patient has type 2 diabetes mellitus.\nThe patient note states that the patient has a family history of CAD but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. The patient's fasting glucose and triglyceride levels are within normal limits. Therefore, the patient does not meet the inclusion criteria for type 2 diabetes mellitus.\n\nStep 2: Determine if the patient has a history of CVD or is at high risk for CVD.\nThe patient note states that the patient has a family history of CAD but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. The patient is physically active and has no history of heart attack, stroke, or revascularization procedures. Therefore, the patient does not meet the inclusion criteria for CVD history or high risk for CVD.\n\nStep 3: Determine if the patient has the required HbA1c levels.\nThe patient note does not provide information about the patient's HbA1c levels. Therefore, we cannot determine if the patient meets the inclusion criteria for HbA1c levels.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "516": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 46 years old, which is over 18 years of age, so this criterion is met.\n\nStep 2: Determine if the patient requires diagnostic cardiac catheterization.\nThe patient has a family history of CAD, dizziness, and frequent headaches, and has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). These factors suggest that the patient may require diagnostic cardiac catheterization, so this criterion is likely met.\n\nStep 3: Assess if the patient has any of the following conditions: chest pain syndrome with normal coronary arteries, coronary artery disease, or heart failure.\nThe patient has severe stenosis in the LICA and moderate stenosis in the RICA, which indicates coronary artery disease. Therefore, this criterion is met.\n\nStep 4: Check if the patient has any of the following exclusion criteria: unstable angina, significant left main disease, recent myocardial infarction, pregnancy, lactation, allergy to losartan, renal failure, or inability to withdraw ACE inhibitors.\nThe patient does not have any of these exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "517": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 46 years old, which is within the age range for postmenopausal women. This meets the inclusion criteria.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a man, which does not meet the inclusion criteria for postmenopausal women. This is an exclusion criterion.\n\nStep 3: Compare the patient's medical history to the inclusion criteria.\nThe patient has a family history of CAD, but no other cardiovascular risk factors. The inclusion criteria state that there should be no history of coronary artery disease or carotid artery disease or stroke. This is an exclusion criterion.\n\nStep 4: Compare the patient's use of medications to the inclusion criteria.\nThe patient reported no use of lipid-lowering medications. The inclusion criteria state that there should be no use of estrogen therapy within 2 months of the study. This meets the inclusion criteria.\n\nStep 5: Compare the patient's laboratory values to the inclusion criteria.\nThe patient's fasting glucose and triglyceride levels are within normal limits. The inclusion criteria state that triglycerides should be less than 400 mg/dL. This meets the inclusion criteria.\n\nStep 6: Compare the patient's blood pressure to the inclusion criteria.\nThe patient's blood pressure is not provided, so we cannot determine if it meets the inclusion criteria.\n\nTrial-level eligibility: 0) Excluded",
        "label": 0
    },
    "518": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the age range in the inclusion criteria.\nThe patient is 46 years old, which is within the age range of 18-40 years for the clinical trial.\n\nStep 2: Compare the patient's medical history to the inclusion criteria.\nThe patient has no history of diabetes, smoking, high blood pressure, or heart disease, which matches the inclusion criteria.\n\nStep 3: Compare the patient's lipid profile to the inclusion criteria.\nThe patient has an LDL-C level of 545 mg/dL, which is above the normal range. However, the inclusion criteria do not specify a maximum LDL-C level. Therefore, we cannot determine eligibility based on the lipid profile alone.\n\nStep 4: Compare the patient's carotid artery status to the inclusion criteria.\nThe patient has severe and moderate stenosis in the left and right internal carotid arteries, respectively. This condition is not mentioned in the inclusion criteria, so we cannot determine eligibility based on this factor.\n\nStep 5: Determine the overall trial-level eligibility.\nSince we cannot determine eligibility based on the lipid profile and carotid artery status, we cannot definitively conclude whether the patient is eligible or not.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "519": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information in the patient note and the clinical trial.\n\nPatient note:\n- 46-year-old man\n- Family history of CAD\n- No other cardiovascular risk factors\n- Physically active\n- LDL-C: 545 mg/dL, HDL-C: 53 mg/dL\n- Fasting glucose: 85 mg/dL, triglyceride: 158 mg/dL\n- No use of lipid-lowering medications\n- Systolic murmur 3+/6+ in the neck, radiating to the skull\n- Severe stenosis in LICA, moderate stenosis in RICA\n- PSV and EDV values for LICA and RICA\n- Plaque observed in the internal carotid artery and common carotid artery\n\nClinical trial:\n- Title: Carotid Atherosclerosis Follow-up Study\n- Summary: To determine whether the degree of carotid artery atherosclerosis predicts the development of myocardial infarction, stroke, and all-cause mortality in patients with angiographically defined coronary status.\n- Inclusion criteria: None\n\nStep 2: Compare the patient's information with the inclusion criteria of the clinical trial.\n\nThe patient has no known cardiovascular risk factors, and there are no inclusion criteria for the clinical trial. Therefore, we can proceed to the next step.\n\nStep 3: Determine if the patient meets any exclusion criteria (if any).\n\nSince there are no inclusion criteria, there are no exclusion criteria to consider.\n\nStep 4: Assess the patient's eligibility based on the information provided.\n\nThe patient meets the inclusion criteria (none) and does not meet any exclusion criteria (since there are none).\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "520": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note\nThe patient is a 46-year-old man with dizziness and frequent headaches. He has a family history of CAD but no other cardiovascular risk factors. His LDL-C and HDL-C levels are high, and he has a history of neck auscultation revealing a systolic murmur. Ultrasonography of the carotid arteries shows severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\nStep 2: Analyze the clinical trial\nTitle: Genetics of Low Density Lipoprotein Subclasses in Hypercholesterolemia\nSummary: To perform genetic studies of low density lipoprotein (LDL) subclasses in 160 families in whom the probands had metabolically defined hypercholesterolemia.\nInclusion criteria: No eligibility criteria\n\nStep 3: Compare the patient note to the inclusion criteria\nSince there are no inclusion criteria for this clinical trial, we can move on to the exclusion criteria to determine the patient's eligibility.\n\nStep 4: Analyze the exclusion criteria (if any)\nThere are no exclusion criteria mentioned for this clinical trial.\n\nStep 5: Determine the patient's eligibility\nAs there are no inclusion or exclusion criteria, the patient is considered eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "521": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n\n- Age: 46 years old\n- Gender: Male\n- Dizziness and frequent headaches\n- Family history of CAD\n- No other cardiovascular risk factors\n- Physically active\n- LDL-C: 545 mg/dL, HDL-C: 53 mg/dL\n- Fasting glucose: 85 mg/dL, Triglyceride: 158 mg/dL\n- No use of lipid-lowering medications\n- Systolic murmur 3+/6+ in the neck, radiating to the skull\n- Severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA)\n- Plaque observed in the anterior and posterior walls of the internal carotid artery and common carotid artery\n\nStep 2: Compare the patient's information with the inclusion criteria of the clinical trial.\n\nInclusion criteria: No eligibility criteria\n\nSince there are no eligibility criteria mentioned for this clinical trial, we can move on to the next step.\n\nStep 3: Determine if there are any exclusion criteria that would disqualify the patient from participating in the trial.\n\nExclusion criteria: None mentioned\n\nStep 4: Assess the patient's eligibility based on the information provided.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "522": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note.\n\nThe patient is a 46-year-old man with dizziness and frequent headaches. He has a family history of CAD but no other cardiovascular risk factors. His LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. His fasting glucose and triglyceride levels were within normal limits. The patient reported no use of lipid-lowering medications. He has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\nStep 2: Analyze the clinical trial.\n\nThe clinical trial is focused on studying the genetic cause of low HDL-C, a risk factor for premature atherosclerotic vascular disease in patients with normal total cholesterol. The inclusion criteria are not specified.\n\nStep 3: Compare the patient note to the clinical trial.\n\nThe patient has a normal total cholesterol and low HDL-C levels, which makes him a potential candidate for the clinical trial. There are no specific exclusion criteria mentioned in the trial.\n\nStep 4: Determine the trial-level eligibility.\n\nSince the patient meets the inclusion criteria (low HDL-C and normal total cholesterol) and there are no exclusion criteria, the trial-level eligibility is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "523": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics and compare them to the inclusion criteria.\n\nPatient's characteristics:\n- Age: 46 years old\n- Gender: Male\n- Dizziness and frequent headaches\n- Family history of CAD\n- No other cardiovascular risk factors\n- Physically active\n- LDL-C: 545 mg/dL\n- HDL-C: 53 mg/dL\n- Fasting glucose: 85 mg/dL\n- Triglycerides: 158 mg/dL\n- No use of lipid-lowering medications\n- Neck auscultation: 3+/6+ systolic murmur, radiating to the skull\n- Ultrasonography revealed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA)\n\nInclusion criteria:\n- Case: History of surgical carotid endarterectomy or carotid or CT angiogram showing greater than or equal to 80% stenosis in one or more internal carotid artery\n- Control: Ultrasound documenting internal carotid artery stenosis less than 15% bilaterally\n\nStep 2: Determine if the patient meets the inclusion criteria.\n\nThe patient does not have a history of surgical carotid endarterectomy, but the ultrasonography revealed severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). This meets the inclusion criteria for the case group.\n\nStep 3: Determine if the patient meets any exclusion criteria (if provided).\n\nNo exclusion criteria are provided in the given information.\n\nStep 4: Assess the patient's eligibility.\n\nSince the patient meets the inclusion criteria and there are no exclusion criteria, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "524": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nThe patient is a 46-year-old man.\n\nStep 2: Check for any of the high-risk factors for an acute myocardial infarction.\nThe patient has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus.\n\nStep 3: Check for any of the other inclusion criteria.\nThe patient does not have active angina, a history of coronary heart disease, past history of myocardial infarction, diabetes mellitus, or renal dialysis.\n\nStep 4: Assess the patient's eligibility based on the inclusion and exclusion criteria.\nThe patient meets the age criterion but does not meet any of the other inclusion criteria. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "525": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age.\nThe patient is 46 years old.\n\nStep 2: Check if the patient's age is within the range of 18-85 years.\nThe patient's age is within the range of 18-85 years.\n\nStep 3: Check if the patient is competent to give informed consent.\nThe patient note does not provide information about the patient's competence to give informed consent.\n\nStep 4: Check if the patient is legally an adult.\nThe patient note does not provide information about the patient's legal adulthood.\n\nStep 5: Check if the patient is geographically accessible and reliable for follow-up.\nThe patient note does not provide information about the patient's geographical accessibility and reliability for follow-up.\n\nStep 6: Check if the patient has a history of TIA or stroke within 120 days prior to the projected performance date of PET.\nThe patient note does not provide information about the patient's history of TIA or stroke within 120 days prior to the projected performance date of PET.\n\nStep 7: Check if the patient has vascular imaging demonstrating occlusion of one or both internal carotid arteries.\nThe patient note does not provide information about the patient's vascular imaging.\n\nStep 8: Check if the patient has a Modified Barthel Index > 12/20 (60/100).\nThe patient note does not provide information about the patient's Modified Barthel Index.\n\nStep 9: Check if the patient has language comprehension intact, motor aphasia mild or absent.\nThe patient note does not provide information about the patient's language comprehension and motor aphasia.\n\nStep 10: Check if the patient has no other exclusion criteria.\nThe patient note does not provide information about other exclusion criteria.\n\nSince we do not have sufficient information about the patient's competence to give informed consent, legal adulthood, history of TIA or stroke, vascular imaging, Modified Barthel Index, and language comprehension and motor aphasia, we cannot determine the patient's eligibility for the clinical trial.\n\nTrial-level eligibility",
        "label": 1
    },
    "526": {
        "output": "GPT4 Correct Assistant: Step 1: Identify patient's age\nThe patient is 46 years old, which meets the age requirement of being at least 45 years old.\n\nStep 2: Identify patient's atherothrombotic risk factors\nThe patient has a family history of CAD but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. The patient does not meet the criteria for any major or minor atherothrombotic risk factors listed in the inclusion criteria.\n\nStep 3: Identify patient's carotid stenosis\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). This meets the criterion for asymptomatic carotid stenosis >= 70%.\n\nStep 4: Identify patient's other medical conditions\nThe patient does not have any of the other medical conditions listed in the inclusion criteria, such as type I or II diabetes, diabetic nephropathy, ankle brachial index < 0.9, at least one carotid plaque, systolic blood pressure >= 150 mmHg, primary hypercholesterolemia, current smoking > 15 cigarettes per day, male >= 65 years, female >= 70 years, documented cerebrovascular disease, documented coronary artery disease, and/or documented symptomatic PAD.\n\nStep 5: Determine patient's eligibility\nSince the patient meets the age requirement and has severe carotid stenosis, but does not meet any of the other inclusion criteria, the patient is not eligible for the CHARISMA trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 2
    },
    "527": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's relevant information from the patient note:\n- Age: 46 years old\n- Dizziness and frequent headaches\n- Family history of CAD\n- No other cardiovascular risk factors\n- LDL-C: 545 mg/dL, HDL-C: 53 mg/dL\n- Fasting glucose: 85 mg/dL, triglyceride: 158 mg/dL\n- No use of lipid-lowering medications\n- Systolic murmur 3+/6+ in the neck, severe stenosis in the left internal carotid artery (LICA), moderate stenosis in the right internal carotid artery (RICA)\n- Plaque observed in the anterior and posterior walls of the internal carotid artery and common carotid artery\n\nStep 2: Compare the patient's information to the inclusion and exclusion criteria of the clinical trial:\n\nInclusion Criteria:\n- Documented history of hypertension on two or more anti-hypertensive medications\n- Renal dysfunction, defined as Stage 3 or greater chronic kidney disease (CKD) based on the new National Kidney Foundation (NKF) classifications (estimated glomerular filtration rate [GFR] less than 60 mL per minute per 1.73 m^2, calculated by the modified Modification of Diet in Renal Disease [MDRD] formula)\n- One or more severe renal artery stenoses by any of the following pathways:\n  a. Angiographic: greater than or equal to 60% and less than 100% by renal angiogram\n  b. Duplex: systolic velocity of greater than 300 cm/sec\n  c. Core Lab approved Magnetic Resonance Angiogram (MRA) (refer to the protocol for specific criteria) demonstrating stenosis greater than 80% or stenosis greater than 70% with spin dephasing on 3D phase contrast MRA\n  d. Clinical index of suspicion combined with a Core Lab approved Computed Tomography Angiography (CTA) demonstrating Stenosis is greater than 80% by",
        "label": 0
    },
    "528": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note to determine if the patient meets the inclusion criteria.\n\n- Age: The patient is 46 years old, which is within the range of 18-80 years.\n- Gender: The patient is male.\n- Asymptomatic: The patient has not experienced any stroke or TIA within 180 days prior to the procedure.\n- Warfarin usage: The patient is not taking warfarin.\n- Informed consent: The patient has signed a written informed consent.\n- Carotid stenosis: The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n- Target ICA vessel diameter: The patient's target ICA vessel diameter is not provided.\n- Successful stent delivery: The patient's anatomy is not described in detail, so it's unclear if the stent can be delivered successfully.\n\nStep 2: Analyze the clinical trial inclusion criteria.\n\n- Age: The patient is within the age range of 18-80 years.\n- Gender: The patient is male.\n- Asymptomatic: The patient is asymptomatic.\n- Warfarin usage: The patient is not taking warfarin.\n- Informed consent: The patient has signed a written informed consent.\n- Carotid stenosis: The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which meets the criteria for carotid stenosis.\n- Target ICA vessel diameter: The patient's target ICA vessel diameter is not provided.\n- Successful stent delivery: The patient's anatomy is not described in detail, so it's unclear if the stent can be delivered successfully.\n\nStep 3: Determine the patient's eligibility based on the inclusion criteria.\n\nSince the patient meets all the inclusion criteria except for the target ICA vessel diameter and successful stent delivery, we cannot determine if the patient is eligible for the trial. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1",
        "label": 1
    },
    "529": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note for relevant information.\n- The patient is a 46-year-old man.\n- He has dizziness and frequent headaches.\n- He has a family history of CAD, but no other cardiovascular risk factors.\n- He is physically active.\n- His LDL-C and HDL-C levels are 545 and 53\u2009mg/dL, respectively.\n- His fasting glucose and triglyceride levels are within normal limits.\n- He reported no use of lipid-lowering medications.\n- He has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\nStep 2: Compare the patient's information to the inclusion and exclusion criteria of the clinical trial.\n\nInclusion Criteria for Right Heart Catheterization and Stress Echo:\n- Either gender, aged greater than 18 years\n- Diagnosis of sickle cell disease (electrophoretic documentation of SS, SC, or S Beta-thalassemia genotype is required)\n- Hematocrit greater than 18 % (with an absolute reticulocyte count greater than 100,000/ml)\n\nExclusion Criteria for Right Heart Catheterization and Stress Echo:\n- Pregnancy or lactation\n- Known or suspected coronary artery disease\n- Hematocrit less than 18 %\n- Significant renal insufficiency (patient on hemodialysis or estimated creatinine clearance less than 30% of normal\n- Cerebrovascular accident within the last six weeks\n- New diagnosis of pulmonary embolism within the last three months\n- History of retinal detachment\n- Patients with PAH known to be secondary to other causes, such as systemic lupus erythematosus, other collagen vascular diseases, valvular heart disease, congenital heart disease\n- Poor echo windows\n- Any other condition that would prevent participation in the study (for example HIV infection)\n\nInclusion Criteria for Non-Invasive Procedures:\n- Either gender, aged greater than",
        "label": 0
    },
    "530": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 46 years old, which is within the age range of 18 years or older.\n\nStep 2: Compare the patient's symptoms to the inclusion criteria.\nThe patient presents with dizziness and frequent headaches, which could be symptoms of an ischemic stroke.\n\nStep 3: Compare the patient's carotid stenosis to the inclusion criteria.\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which are both greater than 50%.\n\nStep 4: Compare the latency between the onset of stroke symptoms and the intended administration of the study drugs.\nThe patient's symptoms started recently, but the exact latency is not provided in the patient note.\n\nStep 5: Compare the latency between the intended administration of the study drugs and the intended carotid endarterectomy.\nThe patient's intended carotid endarterectomy is also not provided in the patient note.\n\nSince some information is missing, we cannot determine if the patient is eligible for the trial based on all the inclusion criteria. Therefore, the trial-level eligibility is: 1) Not relevant.",
        "label": 1
    },
    "531": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the key information from the patient note.\n\n- The patient has dizziness and frequent headaches.\n- The patient has a family history of CAD, but no other cardiovascular risk factors.\n- The patient is physically active.\n- The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively.\n- The patient's fasting glucose and triglyceride levels were within normal limits.\n- The patient reported no use of lipid-lowering medications.\n- The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\nStep 2: Compare the patient's information to the inclusion and exclusion criteria of the clinical trial.\n\nInclusion Criteria:\n- Diagnosis of Heterozygous Familial Hypercholesterolemia\n- At least 18 years of age\n\nExclusion Criteria (not provided in the trial information, but we can assume some general exclusion criteria):\n- Significant cardiovascular disease or unstable angina\n- Severe stenosis in the carotid arteries (as it may increase the risk of stroke)\n\nStep 3: Determine the patient's eligibility based on the comparison.\n\nThe patient does not have a diagnosis of Heterozygous Familial Hypercholesterolemia, so they do not meet the inclusion criteria. Additionally, they have severe stenosis in the left internal carotid artery, which may be an exclusion criterion. Therefore, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "532": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note and the clinical trial.\n\nFrom the patient note, we have the following information:\n- The patient has a family history of CAD, but no other cardiovascular risk factors.\n- The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n- The patient has plaque in the anterior and posterior walls of the internal carotid artery and common carotid artery.\n\nFrom the clinical trial, we have the following information:\n- The trial is for patients with a diagnosis of Homozygous Familial Hypercholesterolemia.\n\nStep 2: Compare the patient's information with the inclusion criteria of the clinical trial.\n\nThe patient note does not provide any information about the patient's cholesterol levels or a diagnosis of Homozygous Familial Hypercholesterolemia. Therefore, we cannot determine if the patient meets the inclusion criteria based on the information provided.\n\nStep 3: Assign the appropriate scale for the assessment of eligibility.\n\nSince there is not enough information to determine if the patient meets the inclusion criteria, the appropriate scale for the assessment of eligibility is 1) Not relevant.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "533": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age.\nThe patient is 46 years old.\n\nStep 2: Identify the patient's diagnosis.\nThe patient has a family history of CAD, but no other cardiovascular risk factors. The patient does not have Heterozygous Familial Hypercholesterolemia.\n\nStep 3: Check if the patient meets the age criteria.\nThe patient is 18 years or older.\n\nStep 4: Compare the patient's diagnosis to the inclusion criteria.\nThe patient does not have Heterozygous Familial Hypercholesterolemia.\n\nStep 5: Determine the trial-level eligibility.\nSince the patient does not have Heterozygous Familial Hypercholesterolemia, they are not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "534": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nPatient's age: 46 years old\nInclusion criteria: American Indian men and women 40 years of age or older\nThe patient does not meet the age inclusion criteria.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nPatient's gender: Male\nInclusion criteria: American Indian men and women\nThe patient does not meet the gender inclusion criteria.\n\nStep 3: Compare the patient's ethnicity to the inclusion criteria.\nPatient's ethnicity: Not mentioned\nInclusion criteria: American Indian men and women\nThe patient does not meet the ethnicity inclusion criteria.\n\nStep 4: Compare the patient's type 2 diabetes mellitus (DM) status to the inclusion criteria.\nPatient's DM status: Not mentioned\nInclusion criteria: Type 2 DM (according to 1997 ADA criteria and/or previously diagnosed by former ADA or WHO criteria): fasting plasma glucose >= 7.0 mmol/L (126 mg/dL) or 2-hour glucose >= 11.0 mmol/L (>200 mg/dL) after a 75-gram oral glucose tolerance test.\nThe patient does not meet the DM status inclusion criteria.\n\nStep 5: Compare the patient's LDL cholesterol level to the inclusion criteria.\nPatient's LDL cholesterol level: 545 mg/dL\nInclusion criteria: LDL cholesterol >= 100 mg/dL within the previous 12 months.\nThe patient does not meet the LDL cholesterol inclusion criteria.\n\nStep 6: Compare the patient's systolic blood pressure (BP) to the inclusion criteria.\nPatient's systolic BP: Not mentioned\nInclusion criteria: Systolic BP >= 130 mm Hg within the previous 12 months.\nThe patient does not meet the systolic BP inclusion criteria.\n\nTrial-level eligibility: 0) Excluded",
        "label": 1
    },
    "535": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note for inclusion and exclusion criteria.\n\nPatient Note:\n- 46-year-old man\n- Dizziness and frequent headaches\n- Family history of CAD\n- No other cardiovascular risk factors\n- Physically active\n- LDL-C: 545 mg/dL, HDL-C: 53 mg/dL\n- Fasting glucose: 85 mg/dL, triglyceride: 158 mg/dL\n- No use of lipid-lowering medications\n- Systolic murmur 3+/6+ in the neck, radiating to the skull\n- Severe stenosis in LICA, moderate stenosis in RICA\n- Plaque observed in the internal carotid artery and common carotid artery\n\nInclusion Criteria:\n- Untreated dyslipidemic (LDL cholesterol >110 mg/dl)\n- Documented atherosclerosis in at least 1 vascular territory\n- At least moderate (\u22654.0mm) aortic atherosclerosis by transesophageal echocardiography or CT/MRI\n- Angiographically documented with coronary artery stenosis (\u226550% luminal stenosis)\n- Ultrasonographically documented significant extracranial arterial stenosis (\u226550%)\n- History of ischemic stroke and transient ischemic attack (TIA)\n- Documented peripheral vascular disease\n\nExclusion Criteria:\n- Acute illness, infection, inflammation or major systemic diseases\n- T-Bil >3 mg/dl\n- Creatinine >3 mg/dl\n\nStep 2: Compare the patient note with the inclusion and exclusion criteria.\n\nPatient Note vs Inclusion Criteria:\n- The patient is dyslipidemic with an LDL-C level of 545 mg/dL, which meets the inclusion criteria.\n- The patient has severe stenosis in the LICA, which meets the inclusion criteria for documented atherosclerosis in at least 1 vascular territory.\n\nPatient Note vs Exclusion Criteria:\n-",
        "label": 2
    },
    "536": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nPatient age: 46 years old\nInclusion criteria: The subject must be > 18 years of age.\nThe patient meets the age requirement.\n\nStep 2: Compare the patient's stenosis to the inclusion criteria.\nPatient stenosis: severe stenosis in the left internal carotid artery (LICA), moderate stenosis in the right internal carotid artery (RICA)\nInclusion criteria: The subject should have a stenosis in the common or internal carotid artery of at least 70% determined by one of the modalities listed below.\nThe patient meets the stenosis requirement.\n\nStep 3: Compare the patient's risk factors to the inclusion criteria.\nPatient has no cardiac or pulmonary dysfunction, no multi-system dysfunction, no anatomic issues, and no increased anesthetic risk.\nInclusion criteria: The subject should be considered a relatively high risk for carotid endarterectomy. High risk considerations should include at least one of the following:\n- Cardiac dysfunction.\n- Pulmonary dysfunction.\n- Multi-system dysfunction.\n- Anatomic issues.\n- Age >80 AND symptomatic.\n- General debilitation documented by the subject's primary physician.\n- Increased anesthetic risk as documented by an anesthesiologist.\nThe patient does not meet any of the high-risk criteria.\n\nStep 4: Compare the patient's symptomatic status to the inclusion criteria.\nPatient is not symptomatic.\nInclusion criteria: Subjects can be either clinically symptomatic or asymptomatic (less than 80 years of age).\nThe patient meets the symptomatic status requirement.\n\nStep 5: Compare the patient's pregnancy status to the inclusion criteria.\nThe patient is a male, and the inclusion criteria mention \"Female subjects of childbearing potential must have a documented negative pregnancy test during the index hospitalization.\"\nThe patient does not meet the pregnancy status requirement, but since the requirement only applies to female subjects, it does not disqualify the patient.\n\nStep 6: Compare the patient's creatinine level to the",
        "label": 1
    },
    "537": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age with the inclusion criteria\n\nPatient age: 46 years\nInclusion criteria: The patient must be > 18 years of age.\n\nThe patient meets the age criteria.\n\nStep 2: Compare patient symptoms with the inclusion criteria\n\nPatient symptoms: Dizziness and frequent headaches\nInclusion criteria: The patient must be clinically symptomatic, i.e., within the previous 120 days have experienced in the ipsilateral carotid artery distribution, either 1) one or more TIAs, characterized by distinct focal neurologic dysfunction or monocular blindness with clearing of signs and symptoms within 24 hours, or 2) one or more completed strokes (as defined by this protocol) with persistence of symptoms or signs for more than 24 hours (the most recent event is used as the qualifying event).\n\nThe patient's symptoms do not meet the criteria for TIAs or completed strokes, so the patient does not meet this criterion.\n\nStep 3: Compare patient carotid artery stenosis with the inclusion criteria\n\nPatient carotid artery stenosis: Severe stenosis in the left internal carotid artery (LICA), 40-50%; Moderate stenosis in the right internal carotid artery (RICA), 40-50%\nInclusion criteria: Except as excluded below, the patient must have documented stenosis > 60%, of the common or internal carotid artery. For an asymptomatic patient to be considered, the patient must have a > 70% diameter stenosis of the internal or common carotid artery without neurological symptoms.\n\nThe patient does not meet the stenosis criteria for inclusion.\n\nStep 4: Check other inclusion criteria\n\nOther criteria are not applicable to this patient, such as angiogram and ultrasound requirements, stenosis measurements, and patient consent.\n\nStep 5: Determine trial-level eligibility\n\nSince the patient does not meet the majority of the inclusion criteria, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded",
        "label": 1
    },
    "538": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze patient note and trial inclusion criteria\n\nPatient note:\n- 46-year-old man\n- Dizziness and frequent headaches\n- Family history of CAD\n- No other cardiovascular risk factors\n- LDL-C: 545 mg/dL, HDL-C: 53 mg/dL\n- Fasting glucose: 85 mg/dL, triglyceride: 158 mg/dL\n- No use of lipid-lowering medications\n- Systolic murmur 3+/6+ in the neck, radiating to the skull\n- Severe stenosis in the left internal carotid artery (LICA)\n- Moderate stenosis in the right internal carotid artery (RICA)\n- Plaque observed in the anterior and posterior walls of the internal carotid artery and common carotid artery\n\nInclusion criteria:\n- Patient age >=18\n- Symptomatic or asymptomatic patient meeting angiographic and clinical inclusion criteria\n- Patient has no childbearing potential or a negative pregnancy test within 30 days of study procedure\n- Patient or legally authorized representative and the patient's physician agree to have the patient return for all required clinical contacts following study enrollment\n- Patient must meet two or more of the criteria listed in a-e OR one or more of the criteria listed in f-q below\n\nStep 2: Compare patient note with inclusion criteria\n\n1. Patient age >=18: The patient is 46 years old, which meets the age requirement.\n2. Symptomatic or asymptomatic patient meeting angiographic and clinical inclusion criteria: The patient has severe stenosis in the LICA and moderate stenosis in the RICA, which meets the angiographic criteria. He also has a family history of CAD and presents with dizziness and frequent headaches, which could be considered as symptomatic.\n3. Patient has no childbearing potential or a negative pregnancy test within 30 days of study procedure: The patient note does not provide information about the patient's childbearing potential or pregnancy status.\n4. Patient or legally authorized representative and the patient's physician agree to have the",
        "label": 1
    },
    "539": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria\nThe patient is 46 years old, which is greater than 18 years, so the age criterion is met.\n\nStep 2: Compare patient's carotid artery stenosis with the inclusion criteria\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). The inclusion criteria state that the patient must have a 50% stenosis or >80% diameter stenosis of the common or internal carotid artery. Since the patient has severe stenosis in both LICA and RICA, the stenosis criterion is met.\n\nStep 3: Compare patient's symptoms with the inclusion criteria\nThe patient has dizziness and frequent headaches but does not have any TIAs, completed strokes, or other neurological symptoms within the previous 180 days. The inclusion criteria state that the patient must be clinically symptomatic within the previous 180 days. Since the patient does not meet this criterion, the symptom criterion is not met.\n\nStep 4: Compare patient's medical conditions with the inclusion criteria\nThe patient has a family history of CAD but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. The patient also has no history of heart failure, recent MI, unstable angina, severe pulmonary disease, contralateral carotid occlusion, laryngeal palsy, post-radiation treatment, previous CEA, recurrent stenosis, high cervical ICA lesions, CCA lesions below the clavicle, severe tandem lesions, or an abnormal stress test. The inclusion criteria state that the patient must have one or more of the listed conditions. Since the patient does not meet this criterion, the medical condition criterion is not met.\n\nStep 5: Compare the qualifying ultrasound or angiogram with the inclusion criteria\nThe qualifying ultrasound or angiogram was performed less than 30 days prior to study entry. However, the stenosis measurements (PSV and EDV) for both LICA",
        "label": 1
    },
    "540": {
        "output": "GPT4 Correct Assistant: Step 1: Check if the patient meets the age criteria.\nThe patient is 46 years old, which is within the range of 18 years and above.\n\nStep 2: Check if the patient has carotid artery stenosis.\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\nStep 3: Check if the patient is clinically symptomatic within the previous 180 days.\nThe patient has a family history of CAD and presents with dizziness and frequent headaches, but there is no mention of any TIAs or completed strokes within the previous 180 days.\n\nStep 4: Check if the patient meets any of the additional inclusion criteria.\nThe patient does not have any of the following conditions: congestive heart failure (class III/IV) and/or known severe left ventricular dysfunction LVEF < 30%, open heart surgery within six weeks, recent MI (>24 hours and <4 weeks), unstable angina (CCS class III/IV), synchronous severe cardiac and carotid disease requiring open heart surgery and carotid revascularization, or age greater than 80 years as a single risk factor.\n\nBased on the information provided, the patient does not meet the inclusion criteria for the clinical trial. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded",
        "label": 1
    },
    "541": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n- The patient has a family history of CAD but no other cardiovascular risk factors.\n- The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n- The patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively.\n- The patient's fasting glucose and triglyceride levels were within normal limits.\n- The patient reported no use of lipid-lowering medications.\n\nStep 2: Compare the patient's information with the inclusion criteria of the clinical trial.\n- The inclusion criteria require coronary artery stenosis >50% and either carotid or brain artery stenosis >50%.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n- The patient has severe stenosis in the LICA, which is >50%.\n- The patient has moderate stenosis in the RICA, which is not >50%.\n\nStep 4: Assess the patient's eligibility based on the inclusion criteria and exclusion criteria (if any).\n- The patient meets the inclusion criteria for coronary artery stenosis >50%.\n- The patient does not meet the inclusion criteria for carotid or brain artery stenosis >50%.\n\nStep 5: Repeat Trial-level eligibility.\nTrial-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).",
        "label": 1
    },
    "542": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nThe patient is a 46-year-old man.\n\nStep 2: Determine if the patient meets the age criteria for the trial.\nThe trial includes males over 45 years and females over 55 years of age with at least one additional risk factor for coronary artery disease. Since the patient is a male over 45 years old, he meets the age criteria.\n\nStep 3: Determine if the patient has any additional risk factors for coronary artery disease.\nThe patient has a family history of CAD but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. This means the patient has one additional risk factor for coronary artery disease.\n\nStep 4: Determine if the patient meets any other inclusion criteria.\nThe patient does not meet any other inclusion criteria, such as being a female between 45-54 years old with a family history of CHD in a first-degree relative.\n\nStep 5: Determine if the patient meets any exclusion criteria.\nThere are no specific exclusion criteria mentioned in the trial summary.\n\nStep 6: Assess the patient's eligibility for the trial.\nSince the patient meets the age criteria and has at least one additional risk factor for coronary artery disease, and there are no exclusion criteria that apply, the patient is eligible for the trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "543": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 46 years old. The inclusion criteria do not mention any specific age requirement, so the patient meets this criterion.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a male. The inclusion criteria state that \"Female subjects must be of non-childbearing potential.\" Since the patient is a male, he meets this criterion.\n\nStep 3: Compare the patient's medical history to the inclusion criteria.\nThe patient has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. The inclusion criteria state that the subject must have stable CHD or CHD-risk equivalent. The patient's medical history suggests he may have CHD-risk equivalent, but we do not have enough information to confirm this. Therefore, the patient does not meet this criterion.\n\nStep 4: Compare the patient's lipid levels to the inclusion criteria.\nThe patient's LDL-C level is 545 mg/dL, and his HDL-C level is 53 mg/dL. The inclusion criteria state that subjects must have been on a stable dose of a statin for =4 weeks with LDL <130 mg/dL (3.4 mmol/L) or off statin therapy for =4 weeks with LDL <160 mg/dL (4.1 mmol/L). The patient's LDL-C level is above both of these thresholds, so he does not meet this criterion.\n\nStep 5: Compare the patient's use of medications to the inclusion criteria.\nThe patient has not used lipid-lowering medications. The inclusion criteria state that subjects must be on a stable dose of at least one oral antiplatelet agent (e.g., aspirin, clopidogrel, or ticlopidine). The patient is on an antiplatelet agent, so he meets this criterion.\n\nStep 6: Compare the patient's other medical conditions to the exclusion criteria.\nThe patient has a history of CAD and severe stenosis in the left internal carotid artery (",
        "label": 0
    },
    "544": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria\nThe patient is 46 years old, which is within the age range of 18 years or older.\n\nStep 2: Assess the patient's symptoms and carotid artery stenosis\nThe patient has symptoms (dizziness and frequent headaches) and has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\nStep 3: Compare the degree of stenosis to the inclusion criteria\nThe LICA has a stenosis of 100% (severe) and the RICA has a stenosis of 40-50% (moderate). The inclusion criteria require either symptomatic patients with lesions >= 50% stenosis or asymptomatic patients with lesions >= 75% stenosis in at least one carotid artery. Since the patient is symptomatic and has a severe stenosis in the LICA, he meets the inclusion criteria for carotid artery stenosis.\n\nStep 4: Check for bilateral carotid disease and staging\nThe patient has bilateral carotid disease (severe stenosis in LICA and moderate stenosis in RICA). The procedures need to be staged greater than 30 days apart, which is not specified in the patient note. However, this does not disqualify the patient from the trial.\n\nStep 5: Check for pregnancy and informed consent\nThe patient's gender and reproductive status are not specified in the patient note. The patient's ability to give informed consent is not specified in the patient note.\n\nBased on the information provided, the patient meets the inclusion criteria for carotid artery stenosis, but there is not enough information to determine if the patient meets the other inclusion criteria. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "545": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's disease\nThe patient note states that the patient has dizziness and frequent headaches, but there is no mention of a diagnosis of gastrointestinal cancer. Therefore, the patient does not meet the disease characteristic inclusion criteria.\n\nStep 2: Check for receiving or planning to receive 8 months of oxaliplatin-based chemotherapy\nThe patient note does not mention oxaliplatin-based chemotherapy. Therefore, the patient does not meet this inclusion criterion.\n\nStep 3: Check for pre-existing neuropathy\nThe patient note does not mention any pre-existing neuropathy. Therefore, the patient meets this inclusion criterion.\n\nStep 4: Check for CNS disease or cerebral metastases\nThe patient note does not mention any CNS disease or cerebral metastases. Therefore, the patient meets this inclusion criterion.\n\nStep 5: Check for WHO 0-1, life expectancy \u2265 12 weeks, no biliary or gastro-duodenal obstruction, and no familial, social, geographical, or psychological condition that would preclude study treatment\nThe patient note does not provide enough information to determine whether the patient meets these inclusion criteria.\n\nStep 6: Check for no other concurrent drug or agent that is potentially neurotoxic\nThe patient note states that the patient reported no use of lipid-lowering medications. Therefore, the patient meets this inclusion criterion.\n\nConclusion: Based on the information provided in the patient note, the patient does not meet the inclusion criteria for the clinical trial. Trial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "546": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nPatient age: 46 years\nInclusion criteria: Age 60 years or greater\nThe patient does not meet the age requirement.\n\nStep 2: Compare the patient's testosterone levels to the inclusion criteria.\nThe patient note does not provide information about the patient's testosterone levels.\n\nStep 3: Compare the patient's general health to the inclusion criteria.\nThe patient note does not provide information about the patient's general health.\n\nStep 4: Compare the patient's education to the inclusion criteria.\nThe patient note does not provide information about the patient's education.\n\nStep 5: Compare the patient's ability to pass a screening test for dementia to the inclusion criteria.\nThe patient note does not provide information about the patient's ability to pass a screening test for dementia.\n\nStep 6: Compare the patient's ability to give informed consent to the inclusion criteria.\nThe patient note does not provide information about the patient's ability to give informed consent.\n\nSince the patient does not meet the age requirement, we cannot determine if the patient meets the other inclusion criteria. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "547": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note with inclusion criteria\n\n1.1 Patient symptoms: The patient presents with dizziness and frequent headaches. This aligns with the inclusion criteria of syncope, pre-syncope, or palpitations less frequently than every 24 hours.\n\n1.2 Pre-syncope definition: The patient's symptoms are described as transient dizziness, which falls under the definition of pre-syncope in the inclusion criteria.\n\n1.3 Non-diagnostic monitoring: The patient has undergone non-diagnostic monitoring related to symptoms within 45 days of enrollment, as evidenced by the neck auscultation and ultrasonography findings.\n\n1.4 Informed consent: The patient is able to understand, assent to, and willing to sign the Informed Consent Form.\n\nStep 2: Check for exclusion criteria\n\nThere are no specific exclusion criteria mentioned in the provided information.\n\nStep 3: Determine trial-level eligibility\n\nBased on the comparison of the patient note with the inclusion criteria and the absence of exclusion criteria, the patient appears to be eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "548": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 46 years old, which is within the age range of 18 to 90 years.\n\nStep 2: Check if the patient has the capacity to give written informed consent.\nThe patient note does not provide information on the patient's capacity to give consent.\n\nStep 3: Compare the patient's carotid stenosis to the inclusion criteria.\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). This is greater than 30% stenosis by ultrasound criteria.\n\nStep 4: Compare the patient's LDL cholesterol level to the inclusion criteria.\nThe patient's LDL-C level is 545 mg/dL, which is greater than 100 mg/dL.\n\nStep 5: Check the patient's systolic and diastolic blood pressure.\nThe patient note does not provide information on the patient's blood pressure.\n\nStep 6: Check if the patient is female and of child-bearing potential.\nThe patient note does not provide information on the patient's gender or reproductive status.\n\nSince we do not have information on the patient's capacity to give consent, blood pressure, and gender/reproductive status, we cannot determine if the patient is eligible or not. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "549": {
        "output": "GPT4 Correct Assistant: Step 1: Check the age of the patient.\nThe patient is 46 years old, which meets the inclusion criteria for males and females greater than or equal to 18 years of age.\n\nStep 2: Check the gender of the patient.\nThe patient is a male, which meets the inclusion criteria for males.\n\nStep 3: Check the LDL-C level of the patient.\nThe patient's LDL-C level is 545 mg/dL, which is greater than the NCEP goals.\n\nStep 4: Check the risk category for coronary heart disease and coronary heart disease equivalent with LDL goal of < 100 mg/dL.\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which indicates a high risk of coronary heart disease.\n\nStep 5: Check the baseline lipid criteria.\nThe patient's triglyceride level is within the normal range (85 mg/dL).\n\nStep 6: Check the normal thyroid function tests.\nThere is no information about the patient's thyroid function tests in the patient note.\n\nStep 7: Check the Hemoglobin A1C level.\nThere is no information about the patient's Hemoglobin A1C level in the patient note.\n\nStep 8: Check the patient's use of lipid-modifying pharmacotherapy.\nThe patient has not used lipid-lowering medications.\n\nStep 9: Check if the patient is able to give informed consent.\nThere is no information about the patient's ability to give informed consent in the patient note.\n\nBased on the available information, the patient meets the inclusion criteria for age, gender, LDL-C level, and risk category for coronary heart disease. However, there is not enough information to determine if the patient meets the criteria for normal thyroid function tests, Hemoglobin A1C level, and the ability to give informed consent. Therefore, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "550": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note\n- The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n- The patient has measurable carotid plaque.\n- The patient has no other cardiovascular risk factors.\n- The patient has not used lipid-lowering medications.\n\nStep 2: Compare the patient information with the inclusion criteria of the clinical trial\n- Inclusion Criteria: Subjects with measurable carotid plaque with lipid and are eligible for statin therapy.\n\nStep 3: Determine the patient's eligibility based on the comparison\n- The patient has measurable carotid plaque with lipid.\n- The patient does not have any other cardiovascular risk factors or use of lipid-lowering medications, making them eligible for statin therapy.\n\nStep 4: Assign the trial-level eligibility based on the assessment\n- Trial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "551": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with the inclusion criteria.\nThe patient is 46 years old, which falls within the age range of 18 to 85 years specified in the inclusion criteria.\n\nStep 2: Compare patient's symptoms and medical history with the inclusion criteria.\nThe patient presents with dizziness and frequent headaches, which could be symptoms of ischemic heart disease. However, the patient does not have a history of coronary artery disease (CAD), which is a requirement for inclusion in the trial.\n\nStep 3: Compare the number of de novo lesions with the inclusion criteria.\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). However, the inclusion criteria require the treatment of 1 or 2 de novo lesions in a native coronary artery. The carotid arteries are not native coronary arteries, so the patient does not meet this criterion.\n\nStep 4: Compare the patient's willingness to comply with the follow-up evaluation and informed consent with the inclusion criteria.\nThe patient's note does not provide information about their willingness to comply with the follow-up evaluation or whether they have provided informed consent. Therefore, this criterion is not relevant for this patient.\n\nStep 5: Repeat Trial-level eligibility.\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "552": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nAge: 46 years old\nGender: Male\n\nStep 2: Check if the patient has a history of carotid artery disease or known atherosclerosis.\nThe patient note mentions \"severe stenosis in the left internal carotid artery (LICA), as well as moderate stenosis in the right internal carotid artery (RICA)\". This indicates that the patient has carotid artery disease.\n\nStep 3: Check if the patient is capable of giving informed consent.\nThe patient note does not provide information about the patient's ability to give informed consent.\n\nStep 4: Check if the patient has a history of peripheral or coronary artery disease.\nThe patient note does not provide information about the patient's history of peripheral or coronary artery disease.\n\nStep 5: Check if the patient has a history of neoplastic disease or chemotherapy treatment.\nThe patient note does not provide information about the patient's history of neoplastic disease or chemotherapy treatment.\n\nStep 6: Check if the patient is taking any immunosuppressive medications.\nThe patient note does not provide information about the patient's medication history.\n\nStep 7: Check if the patient has normal total cholesterol and blood pressure.\nThe patient note mentions LDL-C and HDL-C levels of 545 and 53\u2009mg/dL, respectively, which are outside the normal range. However, the patient has not been taking lipid-lowering medications, and their blood pressure is not mentioned.\n\nStep 8: Check if the patient has abnormal liver and renal function tests or is taking a statin or ACE inhibitor medication.\nThe patient note does not provide information about the patient's liver and renal function tests or medication history.\n\nStep 9: Determine the patient's eligibility based on the inclusion and exclusion criteria.\nThe patient meets the inclusion criteria for having carotid artery disease, but there is not enough information to determine if they meet the other inclusion criteria or exclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 2
    },
    "553": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's type 2 diabetes status.\nThe patient note states that the patient has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. Therefore, the patient's diabetes status is not clear from the information provided.\n\nStep 2: Identify the patient's angina pectoris status.\nThe patient note states that the patient presents with dizziness and frequent headaches, but there is no mention of angina pectoris. Therefore, we cannot determine the patient's angina pectoris status from the information provided.\n\nStep 3: Identify the patient's coronary lesion status.\nThe patient note states that the patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). However, there is no mention of coronary lesions. Therefore, we cannot determine the patient's coronary lesion status from the information provided.\n\nStep 4: Identify the patient's age.\nThe patient note states that the patient is 46 years old. This meets the age requirement of 18 years or older.\n\nStep 5: Identify the patient's sex.\nThe patient note states that the patient is a man. This meets the sex requirement of male or female.\n\nStep 6: Identify the patient's history of myocardial infarction, liver disease, renal function, brachytherapy, heart transplant, pregnancy, life expectancy, bleeding diathesis, intolerance/contradication to Aspirin, Ticlopidine/Clopidogrel, or pioglitazone treatment, participation in another study, leukopenia, neutropenia, documented peptic ulcer or gastric/intestinal bleeding, and thrombocytopenia.\n\nThe patient note does not provide enough information to determine the patient's history in these areas.\n\nConclusion: Based on the information provided in the patient note, we cannot determine the patient's eligibility for the clinical trial. The assessment of eligibility has a three-point scale: 0) Excluded (patient meets inclusion criteria, but is excluded on",
        "label": 1
    },
    "554": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\n1. Age: The patient is 46 years old, which meets the requirement of being at least 30 years old.\n2. Gender: The patient is male, which meets the requirement of including both male and female subjects.\n3. Disease: The patient has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. The patient does not have atherosclerotic coronary or vascular disease, and does not meet any of the coronary risk equivalents (diabetes mellitus, multiple coronary risk factors with a Framingham Risk Score > 2% per year, or an elevated coronary calcium score).\n4. Treatment: The patient is not currently being treated with a statin, which is a requirement for inclusion in the trial.\n5. Lipid levels: The patient's LDL-C and HDL-C levels are 545 and 53 mg/dL, respectively. This does not meet the requirement of having LDL-C < 100 mg/dL and HDL-C < 50 mg/dL (men) or < 55 mg/dL (women).\n\nStep 2: Determine patient eligibility\n\nBased on the comparison of the patient note and the inclusion criteria, the patient does not meet the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 0) Excluded",
        "label": 1
    },
    "555": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information in the patient note.\n- The patient has a family history of CAD, but no other cardiovascular risk factors.\n- The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n- The patient has no neurological symptoms.\n\nStep 2: Compare the patient's information to the inclusion criteria of the clinical trial.\n- The patient has carotid artery stenosis.\n- The patient does not have a history of non-disabling stroke or transient ischemic attack (TIA) within 180 days of the procedure.\n- The patient does not have neurological symptoms.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n- The patient meets the criteria for being asymptomatic with carotid artery stenosis.\n- The patient does not meet the criteria for being symptomatic or having a history of non-disabling stroke or TIA within 180 days of the procedure.\n- The patient does not meet the criteria for being at high risk for carotid endarterectomy based on anatomical and co-morbid factors.\n\nStep 4: Assign the appropriate scale for the assessment of eligibility.\n- The patient meets the inclusion criteria for being asymptomatic with carotid artery stenosis, but does not meet the criteria for being at high risk for carotid endarterectomy.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "556": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 46 years old, which falls within the age range of 50 to 75 years specified in the inclusion criteria.\n\nStep 2: Compare the patient's family history of CAD with the inclusion criteria.\nThe patient has a family history of CAD, which is one of the risk factors specified in the inclusion criteria.\n\nStep 3: Compare the patient's medical history with the inclusion criteria.\nThe patient has type 2 diabetes mellitus, which is the primary inclusion criterion. However, the patient does not have dyslipidemia, hypertension, or smoking history. The patient also does not have a history of cardiovascular disease.\n\nStep 4: Determine the patient's eligibility based on the comparison.\nSince the patient meets the age and family history of CAD criteria, but does not meet the other criteria, the patient's eligibility cannot be determined based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "557": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nThe patient is a 46-year-old man.\n\nStep 2: Check for neurological symptoms due to ischemia in the carotid artery territory.\nThe patient presents with dizziness and frequent headaches.\n\nStep 3: Check for carotid stenosis between 30% and 69% as detected by ultrasound examination.\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which are within the 30-69% range.\n\nStep 4: Check for any exclusion criteria.\nThere are no exclusion criteria mentioned in the patient note.\n\nStep 5: Determine the trial-level eligibility.\nThe patient meets the inclusion criteria of having neurological symptoms due to ischemia in the carotid artery territory and having a carotid stenosis between 30% and 69% as detected by ultrasound examination. The patient does not have any exclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "558": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note for inclusion criteria\n- Age: The patient is 46 years old, which is within the range of 40-75 years.\n- Gender: The patient is a man, which is included.\n- Blood pressure: The patient's blood pressure is not mentioned in the note.\n- Fasting glucose: The patient's fasting glucose is 85 mg/dL, which is within the range of 100-126 mg/dL.\n- Waist circumference: The patient's waist circumference is not mentioned in the note.\n\nStep 2: Analyze the patient note for exclusion criteria\n- The patient has a family history of CAD, but no other cardiovascular risk factors are mentioned.\n- The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n- The patient has plaque in the anterior and posterior walls of the internal carotid artery and common carotid artery.\n\nStep 3: Determine the patient's eligibility based on inclusion and exclusion criteria\n- The patient meets the inclusion criteria for age and fasting glucose.\n- The patient does not meet the exclusion criteria for other cardiovascular risk factors.\n- The patient does not meet the inclusion criteria for blood pressure, waist circumference, and has a history of CAD.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "559": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nPatient's age: 46 years\nInclusion criteria: age <50 years\nThe patient does not meet the age inclusion criteria.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nPatient's gender: male\nInclusion criteria: male gender\nThe patient meets the gender inclusion criteria.\n\nStep 3: Compare the patient's body mass index (BMI) with the inclusion criteria.\nInclusion criteria: body mass index <30 Kg/m2\nThe patient's BMI is not provided in the patient note. Therefore, the assessment of eligibility is not relevant for this criterion.\n\nStep 4: Compare the patient's family and personal history of cardiovascular diseases with the inclusion criteria.\nPatient's family history: CAD\nInclusion criteria: no familial or personal history of cardiovascular diseases\nThe patient does not meet the family history inclusion criteria.\n\nStep 5: Compare the patient's history of GH treatment with the inclusion criteria.\nInclusion criteria: no previous GH treatment\nThe patient's history of GH treatment is not provided in the patient note. Therefore, the assessment of eligibility is not relevant for this criterion.\n\nStep 6: Compare the patient's concomitant treatment with drugs known to interfere with glucose or lipid metabolism or to influence blood pressure with the inclusion criteria.\nInclusion criteria: no concomitant treatment with drugs known to interfere with glucose or lipid metabolism or to influence blood pressure at the time of study entry\nThe patient's concomitant treatment is not provided in the patient note. Therefore, the assessment of eligibility is not relevant for this criterion.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "560": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n\n- Age: 46 years old\n- Gender: Male\n- Dizziness and frequent headaches\n- Family history of CAD\n- No other cardiovascular risk factors (smoking, high blood pressure, diabetes mellitus)\n- Physically active\n- LDL-C: 545 mg/dL\n- HDL-C: 53 mg/dL\n- Fasting glucose: 85 mg/dL\n- Triglycerides: 158 mg/dL\n- No use of lipid-lowering medications\n- Systolic murmur 3+/6+ in the neck, radiating to the skull\n- Severe stenosis in the left internal carotid artery (LICA)\n- Moderate stenosis in the right internal carotid artery (RICA)\n- PSV and EDV cutoff values for LICA and RICA\n- Plaque observed in the anterior and posterior walls of the internal carotid artery and common carotid artery\n\nStep 2: Compare the patient's information with the inclusion criteria of the clinical trial.\n\nInclusion Criteria: Diagnostic criteria for definitive diagnosis of LCH\n\nThe patient note does not provide any information about the diagnostic criteria for LCH.\n\nStep 3: Determine the eligibility of the patient based on the available information.\n\nSince there is not enough information to determine if the patient meets the inclusion criteria for the clinical trial, the eligibility assessment is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "561": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender\nThe patient is a 46-year-old man.\n\nStep 2: Identify the patient's medical history and conditions\nThe patient has a family history of CAD but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. The patient is physically active.\n\nStep 3: Identify the patient's laboratory values\nThe patient's LDL-C and HDL-C levels were 545 and 53\u2009mg/dL, respectively. The patient's fasting glucose and triglyceride levels (85 and 158\u2009mg/dL, resp.) were within normal limits.\n\nStep 4: Identify the patient's symptoms and physical examination findings\nThe patient presents with dizziness and frequent headaches. Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull.\n\nStep 5: Identify the patient's imaging findings\nUltrasonography of the carotid arteries revealed severe stenosis in the left internal carotid artery (LICA), as well as moderate stenosis in the right internal carotid artery (RICA) estimated between 40% and 50%. Plaque was observed in the anterior and posterior walls of the internal carotid artery and common carotid artery.\n\nStep 6: Compare the patient's information with the inclusion criteria of the clinical trial\nThe patient has atherosclerosis, and the patient has an asymptomatic stenosis >80% in the LICA. The patient's neurologist has consented to potentially perform CAS.\n\nStep 7: Determine the patient's eligibility for the clinical trial\nThe patient meets the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "562": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's LDL-C levels with the inclusion criteria\nPatient's LDL-C levels: 545 mg/dL\nInclusion criteria: LDL-c between >130 mg/dl and <189 mg/dl\n\nThe patient's LDL-C levels are above the upper limit of the inclusion criteria. Therefore, the patient does not meet this inclusion criterion.\n\nStep 2: Compare patient's age with the inclusion criteria\nPatient's age: 46 years old\nInclusion criteria: Age above 45 years in men and 55 years in women\n\nThe patient's age is below the age limit for men in the inclusion criteria. Therefore, the patient does not meet this inclusion criterion.\n\nStep 3: Compare patient's HDL-C levels with the inclusion criteria\nPatient's HDL-C levels: 53 mg/dL\nInclusion criteria: HDL-c < 40 mg/dl in men and <46 mg/dl in women\n\nThe patient's HDL-C levels are within the limit for men in the inclusion criteria. Therefore, the patient meets this inclusion criterion.\n\nStep 4: Compare patient's cardiovascular risk factors with the inclusion criteria\nPatient has no cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus.\nInclusion criteria: Presence at least 1 of the cardiovascular risk factor defined as: age above 45 years in men and 55 years in women, smoker, high blood pressure, HDL-c < 40 mg/dl in men and <46 mg/dl in women, family background of early heart disease\n\nThe patient does not meet any of the cardiovascular risk factors listed in the inclusion criteria. Therefore, the patient does not meet this inclusion criterion.\n\nStep 5: Compare patient's family background of early heart disease with the inclusion criteria\nPatient has a family history of CAD, but no other cardiovascular risk factors.\nInclusion criteria: Family background of early heart disease\n\nThe patient has a family history of CAD, which is considered a cardiovascular risk factor. Therefore, the patient meets this inclusion criterion.",
        "label": 1
    },
    "563": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n- The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n- The peak-systolic (PSV) and end-diastolic velocity (EDV) cutoff values for LICA were 208.5\u2009cm/s and 54.5\u2009cm/s, respectively; RICA PSV was 91.72\u2009cm/s and RICA EDV was 37.37\u2009cm/s.\n\nStep 2: Compare the patient's information with the inclusion criteria of the clinical trial.\n- Inclusion Criteria: Carotid stenosis >50% according to NASCET criteria\n\nStep 3: Determine the patient's eligibility based on the comparison.\n- The patient has severe stenosis in the LICA and moderate stenosis in the RICA. The exact percentage of stenosis is not provided, but the velocities given suggest that the stenosis is likely greater than 50%.\n\nStep 4: Assign the trial-level eligibility score.\n- Trial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "564": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's HDL-C levels to the inclusion criteria.\nThe patient's HDL-C levels are 53\u2009mg/dL, which is within the normal range for both males and females. Therefore, the patient does not meet the first inclusion criterion.\n\nStep 2: Compare the patient's other characteristics to the inclusion criteria.\nThe patient does not have a waist circumference of \u2265 102 cm for males or \u2265 88 cm for females.\nThe patient does not have elevated triglyceride levels of \u2265 150 mg/dL (1.7 mmol/L).\nThe patient does not have elevated blood pressure of \u2265 130 mmHg systolic or \u2265 80 mmHg diastolic, and does not require anti-hypertensive treatment.\nThe patient does not have elevated fasting glucose levels of \u2265 100 mg/dL or on drug treatment for elevated fasting glucose.\n\nStep 3: Determine the trial-level eligibility.\nSince the patient does not meet any of the inclusion criteria, the patient is not eligible for the clinical trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "565": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's medical conditions from the patient note.\nThe patient has dizziness, frequent headaches, and a family history of CAD. The patient does not have diabetes, high blood pressure, or a history of smoking. The patient's LDL-C and HDL-C levels are 545 and 53\u2009mg/dL, respectively, and fasting glucose and triglyceride levels are within normal limits. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\nStep 2: Compare the patient's medical conditions with the inclusion criteria of the clinical trial.\nThe patient has a family history of CAD, which is included in the inclusion criteria. The patient does not have diabetes, high blood pressure, or a history of smoking, which are also included in the inclusion criteria. Therefore, the patient meets all the inclusion criteria.\n\nStep 3: Determine if the patient meets any exclusion criteria.\nThere are no exclusion criteria mentioned in the clinical trial summary.\n\nStep 4: Assess the patient's eligibility for the clinical trial.\nSince the patient meets all the inclusion criteria and there are no exclusion criteria, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "566": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics and compare them to the inclusion criteria.\n\nPatient characteristics:\n- Age: 46 years old\n- Gender: Male\n- Family history of CAD, but no other cardiovascular risk factors\n- LDL-C: 545 mg/dL\n- HDL-C: 53 mg/dL\n- Fasting glucose: 85 mg/dL\n- Triglyceride: 158 mg/dL\n- No use of lipid-lowering medications\n- Carotid artery stenosis\n\nInclusion criteria:\n- Moderately obese with hyperlipidemia\n\nStep 2: Determine if the patient meets the inclusion criteria.\n\nThe patient's characteristics do not match the inclusion criteria for the clinical trial. The inclusion criteria require the patient to be moderately obese, which is not mentioned in the patient note. Therefore, the patient does not meet the inclusion criteria.\n\nStep 3: Determine the trial-level eligibility.\n\nSince the patient does not meet the inclusion criteria, the trial-level eligibility is:\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "567": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age to the inclusion criteria\nThe patient is 46 years old, which meets the inclusion criteria of age 18 or older.\n\nStep 2: Compare patient's history to the inclusion criteria\nThe patient has a family history of CAD, but no other cardiovascular risk factors, and is physically active. This information is not directly related to the inclusion criteria of childhood scalp irradiation or matched controls.\n\nStep 3: Compare patient's lipid profile to the inclusion criteria\nThe patient's lipid profile (LDL-C and HDL-C levels, fasting glucose, and triglyceride levels) is within normal limits. This information is not directly related to the inclusion criteria of childhood scalp irradiation or matched controls.\n\nStep 4: Compare patient's carotid artery condition to the inclusion criteria\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). This information is not directly related to the inclusion criteria of childhood scalp irradiation or matched controls.\n\nStep 5: Compare patient's consent to the inclusion criteria\nThe patient has written informed consent, which meets the inclusion criteria of written informed consent.\n\nStep 6: Determine if the patient meets the inclusion criteria\nThe patient meets the inclusion criteria of age 18 or older, childhood scalp irradiation or matched controls, written informed consent.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "568": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age and gender with the inclusion criteria.\nThe patient is a 46-year-old man. The inclusion criteria specify \"stable women on statin therapy.\" The patient does not meet the gender and stability criteria.\n\nStep 2: Compare the patient's LDL-C and triglyceride levels with the inclusion criteria.\nThe patient's LDL-C level is 545 mg/dL, which is outside the inclusion criteria range of 90-135 mg/dL. The patient's triglyceride level is 158 mg/dL, which is within the inclusion criteria range of > 150 mg/dL.\n\nStep 3: Compare the patient's medical history and treatment with the inclusion criteria.\nThe patient is not taking a statin, and the trial is specifically for women already taking a statin. Therefore, the patient does not meet the inclusion criteria.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "569": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the trial's age requirement.\nThe patient is 46 years old, and the trial does not specify an age requirement. Therefore, this factor is not relevant.\n\nStep 2: Compare the patient's gender to the trial's gender requirement.\nThe trial does not specify a gender requirement, so this factor is not relevant.\n\nStep 3: Compare the patient's carotid stenosis to the trial's carotid stenosis requirement.\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). The trial requires carotid stenosis requiring revascularization and indicating either symptomatic status, with carotid stenosis \u2265 50% OR asymptomatic status with carotid stenosis \u2265 80%. Since the patient's stenosis does not meet the trial's requirements, this factor is not relevant.\n\nStep 4: Compare the patient's target lesion location to the trial's target lesion location requirement.\nThe patient's target lesion is in the internal carotid artery (ICA), which is included in the trial's target lesion locations. This factor is relevant.\n\nStep 5: Compare the patient's anatomic risk for adverse events from CEA to the trial's anatomic risk requirement.\nThe patient's medical history and examination findings do not indicate an increased anatomic risk for adverse events from CEA. This factor is not relevant.\n\nStep 6: Compare the patient's co-morbid risk for adverse events from CEA to the trial's co-morbid risk requirement.\nThe patient has no history of smoking, high blood pressure, or diabetes mellitus, and is physically active. This factor is not relevant.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "570": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 46 years old, which is within the range of the inclusion criteria for age.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nThe patient is a male, which matches the inclusion criteria for gender.\n\nStep 3: Compare the patient's LDL-C and total cholesterol:HDL-cholesterol ratio to the inclusion criteria.\nThe patient's LDL-C is 545 mg/dL, which is above the inclusion criteria of LDL < 2.5 mmol/L (approximately 115 mg/dL).\nThe patient's total cholesterol:HDL-cholesterol ratio is not provided in the patient note.\n\nStep 4: Compare the patient's blood pressure to the inclusion criteria.\nThe patient's blood pressure is not provided in the patient note.\n\nStep 5: Compare the patient's personal and family history of CVD to the inclusion criteria.\nThe patient has a family history of CAD but no other cardiovascular risk factors, which does not meet the inclusion criteria of no personal or family history of CVD.\n\nStep 6: Compare the patient's history of proteinuria or renal failure to the inclusion criteria.\nThe patient's history of proteinuria or renal failure is not provided in the patient note.\n\nStep 7: Compare the patient's medication history to the inclusion criteria.\nThe patient is not taking any lipid-lowering medications, which matches the inclusion criteria of taking atorvastatin (Lipitor) with a dosage \u2264 10 mg, equivalent dosages for other statins follow this requirement.\n\nStep 8: Compare the patient's risk calculated by the UKPDS Risk Engine to the inclusion criteria.\nThe patient's risk calculated by the UKPDS Risk Engine is not provided in the patient note.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 0
    },
    "571": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 46 years old, which is within the age range of 18 years and older.\n\nStep 2: Determine the patient's gender.\nThe patient is a man, which matches the inclusion criteria for both men and women.\n\nStep 3: Check if the patient is expected to have an endarterectomy on each carotid artery.\nThe patient note does not mention if the patient is expected to have an endarterectomy on each carotid artery. Therefore, we cannot determine if this criterion is met.\n\nStep 4: Check for contraindications for atorvastatin.\nThe patient note does not mention any contraindications for atorvastatin. Therefore, we cannot determine if this criterion is met.\n\nStep 5: Assess the patient's cardiovascular health.\nThe patient has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. The patient is physically active. Therefore, the patient has stable cardiovascular health.\n\nStep 6: Check the duration of lipid-lowering treatment.\nThe patient note states that the patient has not used lipid-lowering medications. Therefore, the criterion of lipid-lowering treatment less than 6 months duration is met.\n\nStep 7: Assess the patient's diabetes status.\nThe patient note does not mention diabetes, but it does say that the patient's fasting glucose and triglyceride levels are within normal limits. Therefore, we cannot determine if this criterion is met.\n\nStep 8: Check if the patient is claustrophobic.\nThe patient note does not mention if the patient is claustrophobic. Therefore, we cannot determine if this criterion is met.\n\nStep 9: Assess if the patient has evaluable carotid plaques.\nThe patient note mentions severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). Therefore, the patient has evaluable carotid plaques.\n\nBased on the information",
        "label": 1
    },
    "572": {
        "output": "GPT4 Correct Assistant: Step 1: Check age eligibility\nThe patient is 46 years old, which falls within the age range of 18 to 75 years for the trial.\n\nStep 2: Check family history of CAD\nThe patient has a family history of CAD, but this is not an exclusion criterion for the trial.\n\nStep 3: Check for other cardiovascular risk factors\nThe patient does not have other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus.\n\nStep 4: Check LDL-C and HDL-C levels\nThe patient's LDL-C level is 545 mg/dL, which is above the range of 3.3 mmol/L (130 mg/dL) to 4.6 mmol/L (180 mg/dL) for the trial. The HDL-C level is within the normal range.\n\nStep 5: Check triglyceride levels\nThe patient's triglyceride level is within the normal range of <3.99 mmol/L (350 mg/dL).\n\nStep 6: Check for a history of coronary heart disease (CHD)\nThe patient has a history of severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which are forms of CHD.\n\nStep 7: Check for previous statin use\nThe patient has not used any statins, and there is no previous history of statin use.\n\nStep 8: Check liver transaminases and CK levels\nThe patient's liver transaminases and CK levels are within the normal range.\n\nStep 9: Check cholesterol-lowering diet and exercise program\nThe patient has failed a cholesterol-lowering diet and exercise program of at least 4 weeks duration prior to the trial.\n\nStep 10: Check for stable weight history\nThe patient has a stable weight history for at least 4 weeks prior to the trial.\n\nStep 11: Check for hormonal therapy and birth control\nThe patient's hormonal therapy and birth control status are not mentioned in the patient note.\n\nStep 1",
        "label": 1
    },
    "573": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient note: A 46-year-old man with dizziness and frequent headaches.\nInclusion criteria: Patients suffering from stable CAD, on chronic ASA therapy\n\nStep 2: Determine if patient meets inclusion criteria\n\nThe patient note does not provide information about the patient's CAD status or ASA therapy. Therefore, we cannot determine if the patient meets the inclusion criteria.\n\nStep 3: Assess trial-level eligibility\n\nSince we cannot determine if the patient meets the inclusion criteria due to insufficient information, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant",
        "label": 1
    },
    "574": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 46 years old, which is within the age range of 18 years or older.\n\nStep 2: Compare the patient's carotid artery stenosis to the inclusion criteria.\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which is greater than 70% stenosis.\n\nStep 3: Check if the patient's attending physician of the department of surgery concurs with the assessment.\nThis information is not provided in the patient note.\n\nStep 4: Check if the patient has provided informed consent.\nThis information is not provided in the patient note.\n\nConclusion:\nSince we do not have information about the patient's attending physician's concurrence and informed consent, we cannot determine the patient's eligibility for the clinical trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "575": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the age range in the inclusion criteria.\nThe patient is 46 years old, which falls within the age range of 18 to 65 years for the trial.\n\nStep 2: Compare the patient's gender with the gender requirement in the inclusion criteria.\nThe patient is a male, which matches the requirement for both male and female participants in the trial.\n\nStep 3: Compare the patient's lipid values with the lipid values in the inclusion criteria.\nThe patient's HDL-C level is 53\u2009mg/dL, which is equivalent to 1.36 mmol/l. This is above the inclusion criterion of HDL-C < 1.6 mmol/l.\nThe patient's triglyceride (TG) level is 158\u2009mg/dL, which is below the inclusion criterion of TG < 4.5 mmol/l.\n\nStep 4: Compare the patient's medical condition with the medical condition requirement in the inclusion criteria.\nThe patient has Type II hyperlipidaemia, which matches the inclusion criterion of patients with Type II hyperlipidaemia.\n\nStep 5: Check for any exclusion criteria that may apply to the patient.\nThe patient has a family history of CAD, but there is no information about other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. The patient's LDL-C level is 545\u2009mg/dL, which is high, but there is no specific exclusion criterion for LDL-C levels. The patient has carotid artery stenosis, but this is not mentioned as an exclusion criterion in the trial.\n\nConclusion:\nBased on the comparison of the patient's information with the inclusion and exclusion criteria, the patient meets the inclusion criteria for Type II hyperlipidaemia and lipid values. The patient does not meet any specific exclusion criteria. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "576": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient's age with inclusion criteria\nThe patient is a 46-year-old man. The inclusion criteria state that male subjects aged 45 years or above are eligible. Since the patient is 46 years old, he meets the age requirement.\n\nStep 2: Compare patient's gender with inclusion criteria\nThe patient is a male, and the inclusion criteria state that male subjects are eligible. Therefore, the patient meets the gender requirement.\n\nStep 3: Compare patient's medical history with inclusion criteria\nThe patient has a family history of CAD but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. This meets the inclusion criteria for having at least one other risk factor for CVD.\n\nStep 4: Compare patient's willingness to participate with inclusion criteria\nThe patient is willing to participate in the survey and complies with the study by signing a written informed consent. This meets the inclusion criteria for willingness to participate.\n\nStep 5: Compare other factors not mentioned in the patient note with inclusion criteria\nThere are no other factors mentioned in the patient note that are relevant to the inclusion criteria.\n\nConclusion: The patient meets all the inclusion criteria for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 2
    },
    "577": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 46 years old. The inclusion criteria do not mention any specific age requirement.\n\nStep 2: Compare the patient's gender with the inclusion criteria.\nThe patient is a man. The inclusion criteria do not mention any specific gender requirement.\n\nStep 3: Compare the patient's medical history with the inclusion criteria.\nThe patient has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. The inclusion criteria require a clinically established coronary artery disease or carotid artery disease with greater than 15% stenosis by ultrasound. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which meet the criteria.\n\nStep 4: Compare the patient's Apolipoprotein B level with the inclusion criteria.\nThe patient's LDL-C level is 545 mg/dL. The inclusion criteria require an Apolipoprotein B level greater than or equal to 120 mg/dL (LDL level should be between 100 and 190 mg/dL without medication). The patient's LDL-C level is above the specified range without medication, so the patient meets this criterion.\n\nStep 5: Compare the patient's lipid therapy history with the inclusion criteria.\nThe patient reported no use of lipid-lowering medications. The inclusion criteria require that the patient has been undergoing lipid therapy for no more than 12 months before study entry. The patient meets this criterion.\n\nStep 6: Compare the patient's medical stability and ability to undergo MRI with the inclusion criteria.\nThe patient's medical history and physical examination findings are not provided. Therefore, we cannot determine if the patient is medically stable and able to undergo MRI.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "578": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's hip and groin pain duration\nThe patient note states that the patient presents with dizziness and frequent headaches, but there is no mention of hip or groin pain. Therefore, we cannot determine the patient's hip and groin pain duration.\n\nStep 2: Determine if the patient is physically active\nThe patient note states that the patient is physically active.\n\nStep 3: Compare the patient's information to the inclusion criteria\nThe inclusion criteria require the patient to have hip and groin pain for more than 6 weeks and be physically active. Since we do not have information about the patient's hip and groin pain duration, we cannot determine if the patient meets the inclusion criteria.\n\nStep 4: Assess the patient's eligibility\nBased on the available information, the patient does not have sufficient information to qualify for the trial (scale 1).\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "579": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's characteristics that are relevant to the inclusion criteria.\n\nFrom the patient note, we can gather the following information:\n- The patient has a family history of early-onset cardiovascular disease (CAD), but no other cardiovascular risk factors.\n- The patient has high LDL-C levels (545 mg/dL) and normal HDL-C levels (53 mg/dL).\n- The patient has no history of diabetes, hypertension, or kidney disease.\n- The patient has no history of smoking or physical inactivity.\n- The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\nStep 2: Compare the patient's characteristics to the inclusion criteria.\n\nThe patient meets the following inclusion criteria:\n- Familiar History of early-onset cardiovascular disease (male < 55 or female < 65).\n- The presence of two or more of the following:\n  - Severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\nStep 3: Determine the patient's eligibility.\n\nThe patient meets the inclusion criteria, and there are no exclusion criteria mentioned in the patient note. Therefore, the patient is eligible for the clinical trial.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "580": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note and the clinical trial.\n\nPatient Note:\n- 46-year-old man\n- Dizziness and frequent headaches\n- Family history of CAD\n- No other cardiovascular risk factors\n- Physically active\n- LDL-C: 545 mg/dL, HDL-C: 53 mg/dL\n- Fasting glucose: 85 mg/dL, triglyceride: 158 mg/dL\n- No use of lipid-lowering medications\n- Systolic murmur 3+/6+ in the neck, radiating to the skull\n- Severe stenosis in the left internal carotid artery (LICA)\n- Moderate stenosis in the right internal carotid artery (RICA)\n- PSV and EDV cutoff values for LICA and RICA\n- Plaque observed in the anterior and posterior walls of the internal carotid artery and common carotid artery\n\nClinical Trial:\nTitle: EEG, Cerebral Oximetry, and Arterial to Jugular Venous Lactate to Assess Cerebral Ischemia During Carotid Endarterectomy\n\nInclusion Criteria:\n- All adult patients undergoing carotid endarterectomy\n\nStep 2: Compare the patient's information with the inclusion criteria.\n\nThe patient is an adult and is undergoing carotid endarterectomy, which matches the inclusion criteria of the clinical trial.\n\nStep 3: Determine the trial-level eligibility.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 1
    },
    "581": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note with inclusion criteria\n- The patient is 46 years old, which meets the inclusion criterion of being \u2265 18 years old.\n- The patient is a candidate for single lesion carotid artery stenting using a femoral arterial approach, which meets the inclusion criterion.\n- The patient is willing and able to comply with follow-up evaluations, which meets the inclusion criterion.\n- The patient understands the nature of the procedure and provides informed consent, which meets the inclusion criterion.\n\nStep 2: Compare patient note with exclusion criteria\n- The patient has not participated in any other clinical study, which meets the exclusion criterion.\n- The patient does not have chronic or paroxysmal atrial fibrillation, which meets the exclusion criterion.\n- The patient has not undergone prior stenting of the ipsilateral carotid artery, which meets the exclusion criterion.\n- The patient's life expectancy is more than twelve months, which meets the exclusion criterion.\n- The patient is not suffering from dementia, which meets the exclusion criterion.\n- The patient does not have an allergy or contraindication to acetylsalicylic acid, which meets the exclusion criterion.\n- The patient does not have a documented allergy to the device materials, which meets the exclusion criterion.\n- The patient does not have a documented allergy or contraindication to both clopidogrel and ticlopidine, which meets the exclusion criterion.\n- The patient has not had active bleeding diathesis requiring blood transfusion within one month prior to the index procedure, which meets the exclusion criterion.\n- The patient has not had an MI within 72 hours prior to carotid stenting, which meets the exclusion criterion.\n- The patient has not had coronary artery bypass graft (CABG) or vascular surgery within 30 days prior to the index procedure, which meets the exclusion criterion.\n- The patient has not had a major residual neurological deficit, which meets the exclusion criterion.\n- The patient has not had a transient is",
        "label": 1
    },
    "582": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient age to inclusion criteria\nThe patient is 46 years old, which is within the 18+ age range for inclusion.\n\nStep 2: Compare patient's medical history to inclusion criteria\nThe patient has a family history of CAD but no other cardiovascular risk factors. He is physically active and has normal LDL-C and HDL-C levels. This aligns with the general inclusion criteria.\n\nStep 3: Compare patient's medical history to exclusion criteria\nThe patient has no life expectancy of less than 24 months due to another medical condition, no history of hypersensitivity to paclitaxel or structurally related compounds, no cardiogenic shock, no evidence of acute or chronic renal dysfunction, no planned cardiac surgery procedure within 9 months, no myocardial infarction within 72 hours prior to the index procedure, no acute ST segment elevation MI within 72 hours prior to the index procedure, no CVA including stroke or TIA within previous 3 months, no leukopenia, no thrombocytopenia or thrombocytosis, no contraindication to ASA, clopidogrel, or ticlopidine, no planned treatment with warfarin or possibility of treatment with warfarin during the following 6 months post index procedure, no treatment with paclitaxel or other chemotherapeutic agents within 12 months prior to planned index procedure, no anticipated treatment with paclitaxel or oral rapamycin during any period in the 9 months after the index procedure, no drug eluting stent within 12 months prior to planned index procedure, no previous or planned treatment with intravascular brachytherapy in target vessel, no known allergy to stainless steel, no intention to procreate within 3 months after the index procedure, no female of childbearing potential with a positive pregnancy test within 7 days before the index procedure or lactating or intends to become pregnant during the 9 months post index procedure, no evidence of probable or definite thrombus of the study vessel, no study lesion is totally occluded (TIMI flow <= 1) either at baseline or before predilatation, no study lesion or the study vessel proximal to the study lesion is",
        "label": 0
    },
    "583": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's carotid artery stenosis to the inclusion criteria.\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). The inclusion criteria state that the stenosis must be 70% or more by carotid artery duplex, CTA, or MRA. The patient's stenosis does not meet this criterion.\n\nStep 2: Compare the patient's medical history to the inclusion criteria.\nThe patient has no evidence of TIA or CVA originating in the area of the brain supplied by the carotid artery under study in the four months preceding treatment. This meets the inclusion criteria.\n\nStep 3: Compare the patient's eligibility for both treatment options to the inclusion criteria.\nThe patient is suited for operative treatment as assessed by an anesthesiologist. This meets the inclusion criteria.\n\nStep 4: Compare the patient's anatomy and thrombus status to the inclusion criteria.\nThe patient has no significant atherosclerosis within the arch of the aorta, no torturous anatomy of the common and internal carotid artery, and no thrombus in the area of stenosis. This meets the inclusion criteria.\n\nStep 5: Determine the trial-level eligibility based on the comparison.\nSince the patient's stenosis does not meet the inclusion criteria, the trial-level eligibility is 0) Excluded.",
        "label": 1
    },
    "584": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 46 years old, and the inclusion criteria require the patient to be at least 18 years old. The patient meets this criterion.\n\nStep 2: Compare the patient's medical history to the inclusion criteria.\nThe patient has a family history of CAD but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. The inclusion criteria mention that the patient must have a solid malignant tumor or malignant lymphoma that is refractory to currently available treatment or for which no standard treatment exists. The patient's medical history does not match the inclusion criteria.\n\nStep 3: Compare the patient's performance status to the inclusion criteria.\nThe patient's ECOG performance status is not mentioned in the patient note. We cannot determine if the patient meets this criterion.\n\nStep 4: Compare the patient's organ and marrow function to the inclusion criteria.\nThe patient's LDL-C and HDL-C levels, fasting glucose, and triglyceride levels are not mentioned in the patient note. We cannot determine if the patient meets this criterion.\n\nStep 5: Compare the patient's ability to understand and willingness to sign a written informed consent document to the inclusion criteria.\nThe patient's ability to understand and willingness to sign a written informed consent document is not mentioned in the patient note. We cannot determine if the patient meets this criterion.\n\nConclusion:\nSince we cannot determine if the patient meets several of the inclusion criteria, we cannot definitively determine the patient's trial-level eligibility. However, based on the available information, the patient does not appear to meet the inclusion criteria related to the patient's medical history and organ and marrow function.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "585": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria for age.\nThe patient is 46 years old, which falls within the age range of 21 to 75 years, inclusive.\n\nStep 2: Compare the patient's medical history and physical examination findings to the inclusion criteria for the target IA.\nThe patient has a family history of CAD, but no other cardiovascular risk factors. The patient does not have any information about a specific target IA in the anterior or posterior circulation.\n\nStep 3: Compare the patient's informed consent and mental capacity to the inclusion criteria.\nThe patient has not provided written informed consent, and there is no information about the patient's mental capacity.\n\nStep 4: Determine the trial-level eligibility based on the comparison.\nSince the patient does not have sufficient information to qualify for the trial, the trial-level eligibility is 1) Not relevant.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "586": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 46 years old, and the inclusion criteria require patients to be \u2265 21 years old. Since the patient is within the age range, this criterion is met.\n\nStep 2: Compare the patient's medical history and current condition with the inclusion criteria.\nThe patient has a family history of CAD but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. The inclusion criteria require patients to have atherosclerotic coronary artery disease with \u2265 75% stenosis in the right coronary artery and the circumflex artery. The patient's medical history and current condition do not match the inclusion criteria.\n\nStep 3: Compare the patient's ability to give informed consent with the inclusion criteria.\nThe patient is able to give their informed written consent, which matches the inclusion criteria.\n\nStep 4: Compare the patient's target coronary arteries with the inclusion criteria.\nThe patient's medical history and current condition do not provide enough information to determine if they have appropriately sized and accessible target coronary arteries with a minimum diameter of 1.5 mm and a lack of calcification at the anastomotic site.\n\nBased on the comparison, the patient does not meet all the inclusion criteria. Therefore, the trial-level eligibility for this patient is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "587": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 46 years old, and the inclusion criteria state that the patient must be older than 14 years old. The patient meets this criterion.\n\nStep 2: Compare the patient's symptoms to the inclusion criteria.\nThe patient presents with dizziness and frequent headaches, which match the symptoms listed in the inclusion criteria for Vertical Heterophoria.\n\nStep 3: Compare the duration of the patient's symptoms to the inclusion criteria.\nThe patient's symptoms have been present for more than 4 months, which meets the inclusion criteria.\n\nStep 4: Compare the patient's previous evaluations to the inclusion criteria.\nThe patient has been evaluated for these symptoms by at least one other doctor, which meets the inclusion criteria.\n\nStep 5: Compare the patient's willingness to wear glasses to the inclusion criteria.\nThe patient is willing to wear glasses, which meets the inclusion criteria.\n\nStep 6: Compare the patient's ability to sign informed consent to the inclusion criteria.\nThe patient (or their representative) must be able and willing to fill out extra paperwork and sign informed consent, which meets the inclusion criteria.\n\nStep 7: Compare the patient's ability to have a driver for follow-up visits to the inclusion criteria.\nThe patient (or their representative) must have a driver for follow-up visits where control and treatment glasses are dispensed, and when the washout period is initiated, which meets the inclusion criteria.\n\nStep 8: Compare the patient's previous negative neuroimaging to the inclusion criteria.\nThe patient must have previous negative neuroimaging (HCT or MRI) that was ordered to assess for headache and/or dizziness, which meets the inclusion criteria.\n\nTrial-level eligibility: 2) Eligible.",
        "label": 0
    },
    "588": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age.\nThe patient is 46 years old.\n\nStep 2: Identify the patient's gender.\nThe patient is a man.\n\nStep 3: Identify the patient's medical history.\nThe patient has a family history of CAD but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus.\n\nStep 4: Identify the patient's lipid levels.\nLDL-C: 545 mg/dL\nHDL-C: 53 mg/dL\n\nStep 5: Identify the patient's fasting glucose and triglyceride levels.\nFasting glucose: 85 mg/dL\nTriglycerides: 158 mg/dL\n\nStep 6: Identify the patient's use of lipid-lowering medications.\nThe patient has not used lipid-lowering medications.\n\nStep 7: Identify the patient's carotid artery stenosis.\nSevere stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA)\n\nStep 8: Compare the patient's characteristics to the inclusion criteria of the clinical trial.\n\n1. Diabetes: The patient does not have diabetes.\n2. Current Smoking: The patient is not a current smoker.\n3. Hypertension: The patient does not have hypertension.\n4. Family history of heart disease: The patient has a family history of heart disease.\n5. High LDL Cholesterol (>130 mg/dl): The patient has high LDL-C levels (545 mg/dL).\n6. Low HDL CHolesterol (<40 mg/dl): The patient has low HDL-C levels (53 mg/dL).\n7. Body Mass Index of 30 kg/m^2: The patient's BMI is not provided.\n8. Waist circumference: The patient's waist circumference is not provided.\n9. Report intake of at least one drink in the last month: The patient has not used lipid-lower",
        "label": 1
    },
    "589": {
        "output": "GPT4 Correct Assistant: Step 1: Analyze the patient note for relevant information\n- Age: 46 years old\n- Gender: Male\n- Dizziness and frequent headaches\n- Family history of CAD\n- No other cardiovascular risk factors\n- Physically active\n- LDL-C: 545 mg/dL, HDL-C: 53 mg/dL\n- Fasting glucose: 85 mg/dL, triglyceride: 158 mg/dL\n- No use of lipid-lowering medications\n- Systolic murmur 3+/6+ in the neck, radiating to the skull\n- Severe stenosis in LICA, moderate stenosis in RICA (40-50%)\n- PSV and EDV cutoff values for LICA and RICA\n- Plaque observed in the internal carotid artery and common carotid artery\n\nStep 2: Compare the patient note to the inclusion criteria of the clinical trial\n1. Type 2 Diabetes: The patient note does not mention diabetes mellitus.\n2. Metabolic Syndrome: The patient note does not mention metabolic syndrome.\n3. Not all risk factors at goal: The patient note does not mention if all risk factors are at goal.\n4. Willingness to attend frequent clinic visits: The patient note does not mention willingness to attend frequent clinic visits.\n5. No coronary stenosis greater than 50% found on catheterization: The patient note mentions severe stenosis in LICA and moderate stenosis in RICA, which are greater than 50%.\n\nStep 3: Determine the patient's eligibility based on the comparison\n- The patient does not meet criteria 1, 2, 3, and 4, and does not meet criterion 5 due to the presence of coronary stenosis greater than 50%.\n\nTrial-level eligibility: 0) Excluded",
        "label": 1
    },
    "590": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age with the inclusion criteria.\nThe patient is 46 years old, which meets the inclusion criteria of being \u2265 18 years old.\n\nStep 2: Compare the patient's eligibility for carotid artery revascularization with the inclusion criteria.\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA), which makes him eligible for carotid artery revascularization.\n\nStep 3: Compare the patient's stenosis with the inclusion criteria.\nThe patient has significant stenosis in the LICA, which is \u2265 50% diameter stenosis (DS). The RICA has moderate stenosis, which is \u2265 80% DS. Therefore, the patient meets the inclusion criteria for stenosis.\n\nStep 4: Determine if the patient is symptomatic.\nThe patient presents with dizziness and frequent headaches, which could be symptoms of carotid artery stenosis. However, the patient does not have a history of TIA, amaurosis fugax, ischemic stroke, or retinal infarction within 6 months prior to enrollment. Therefore, the patient does not meet the symptomatic criteria.\n\nStep 5: Compare the patient's clinical conditions with the inclusion criteria.\nThe patient's clinical conditions are not mentioned in the patient note, so we cannot determine if they are suitable for DW-MRI.\n\nStep 6: Check if the patient has given written informed consent.\nThe patient note does not mention if the patient has given written informed consent, so we cannot determine this.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "591": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nPatient's age: 46 years\nInclusion criteria: men and women over the age of 50 years\nThe patient does not meet the age requirement for the trial.\n\nStep 2: Compare the patient's gender to the inclusion criteria.\nPatient's gender: Male\nInclusion criteria: Men and women\nThe patient meets the gender requirement for the trial.\n\nStep 3: Compare the patient's medical history and conditions to the inclusion criteria.\nThe patient has a family history of CAD but no other cardiovascular risk factors. The trial is focused on metabolic syndrome and cardiovascular disease, but the patient does not have metabolic syndrome or cardiovascular disease.\n\nStep 4: Compare the patient's laboratory values to the inclusion criteria.\nThe patient's LDL-C and HDL-C levels are 545 and 53 mg/dL, respectively. The trial does not mention specific laboratory values as inclusion criteria.\n\nStep 5: Compare the patient's treatment history to the inclusion criteria.\nThe patient reported no use of lipid-lowering medications. The trial does not mention specific treatment history as inclusion criteria.\n\nConclusion:\nThe patient does not meet the age requirement, but meets the gender requirement. The patient does not have metabolic syndrome or cardiovascular disease, and the trial does not mention specific laboratory values or treatment history as inclusion criteria. Therefore, the patient is not eligible for the trial.\n\nTrial-level eligibility: 0) Excluded.",
        "label": 1
    },
    "592": {
        "output": "GPT4 Correct Assistant: Step 1: Compare patient note and inclusion criteria\n\nPatient Note: The patient has severe stenosis in the left internal carotid artery (LICA), and moderate stenosis in the right internal carotid artery (RICA). The stenosis is estimated to be between 40% and 50% for both LICA and RICA.\n\nInclusion Criteria: Unilateral or bilateral carotid artery stenosis that was considered to be severe (carotid artery diameter reduction 70%-79% on ultrasound)\n\nThe patient's stenosis is not severe enough (70%-79%) as required by the inclusion criteria.\n\nStep 2: Compare patient note and other criteria\n\nPatient Note: The patient has no known circumstance or condition likely to preclude long-term follow-up, and the neurologist has given explicit consent to potentially perform CEA.\n\nInclusion Criteria: The patient had no known circumstance or condition likely to preclude long-term follow-up, and neurologist's explicit consent to potentially perform CEA.\n\nThe patient meets these criteria.\n\nStep 3: Determine eligibility\n\nThe patient does not meet the inclusion criteria for severe carotid artery stenosis, but meets the other criteria. Therefore, the patient's eligibility is:\n\nTrial-level eligibility: 0) Excluded (patient meets inclusion criteria, but is excluded on the grounds of the trial's exclusion criteria).",
        "label": 1
    },
    "593": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n- The patient has a family history of CAD.\n- The patient has no other cardiovascular risk factors.\n- The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n- The patient's LVEF is not mentioned in the patient note.\n\nStep 2: Compare the patient's information with the inclusion criteria of the clinical trial.\n- The inclusion criteria require an LVEF of 40% or less.\n\nStep 3: Determine the patient's eligibility based on the comparison.\n- The patient's LVEF is not mentioned in the patient note, so we cannot determine if the patient meets the inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "594": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 46 years old, which is within the age range of 18 years or older. So, this criterion is met.\n\nStep 2: Compare the patient's carotid artery stenosis to the inclusion criteria.\nThe patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). The inclusion criteria require a significant diameter reduction of the extracranial or intracranial internal or common carotid artery, defined as \u226550% stenosis for symptomatic patients or \u226580% stenosis for asymptomatic patients. Since the patient has stenosis in both LICA and RICA, this criterion is met.\n\nStep 3: Check if the patient has a negative pregnancy test (for female patients with child-bearing potential).\nThe patient note does not provide information on the patient's gender or whether they are of child-bearing potential. Therefore, this criterion is not relevant for this patient.\n\nStep 4: Check if the patient agrees to return for follow-up evaluations.\nThe patient note does not provide information on whether the patient and their physician agree to return for follow-up evaluations. Therefore, this criterion is not relevant for this patient.\n\nStep 5: Check if the reference vessel diameter is between 3.5 mm and 9.0 mm.\nThe patient note does not provide information on the reference vessel diameter. Therefore, this criterion is not relevant for this patient.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 1
    },
    "595": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender\nThe patient is a 46-year-old man.\n\nStep 2: Check if the patient meets the age criteria\nThe trial includes subjects of either sex and more than or equal to 18 years of age. The patient is 46 years old, which meets the age criteria.\n\nStep 3: Check if the patient has a confirmed malignancy\nThe patient note mentions dizziness and frequent headaches, but no mention of a confirmed malignancy. We do not have enough information to determine if the patient meets the inclusion criteria for having a solid malignant tumor or hematologic malignancy.\n\nStep 4: Check if the patient has a refractory malignancy\nSince we do not have enough information about the patient's malignancy, we cannot determine if the patient has a refractory malignancy.\n\nStep 5: Check if the patient meets other inclusion and exclusion criteria\nThe patient note does not mention any information about the patient's performance status, life expectancy, laboratory values, medical history, or ability to sign a consent form. We do not have enough information to determine if the patient meets the other inclusion and exclusion criteria.\n\nConclusion:\nSince we do not have enough information about the patient's malignancy and other criteria, the patient's trial-level eligibility is 1) Not relevant.",
        "label": 0
    },
    "596": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender\nThe patient is a 46-year-old man, which meets the age and gender criteria for the trial.\n\nStep 2: Identify the patient's medical condition\nThe patient has dizziness and frequent headaches, but the note does not mention type 2 diabetes mellitus. Therefore, we cannot determine if the patient meets this criterion.\n\nStep 3: Check the patient's HbA1c level\nThe patient's HbA1c level is not mentioned in the note, so we cannot determine if the patient meets this criterion.\n\nStep 4: Check the patient's treatment history\nThe patient is not treated with oral anti-diabetic drugs or diet, which meets this criterion.\n\nStep 5: Determine the trial-level eligibility\nSince we do not have enough information about the patient's medical condition and HbA1c level, we cannot determine if the patient is eligible for the trial.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "597": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the relevant information from the patient note.\n\n- Age: 46 years old\n- Gender: Male\n- Symptoms: Dizziness, frequent headaches\n- Family history of CAD\n- No other cardiovascular risk factors\n- No use of lipid-lowering medications\n- LDL-C and HDL-C levels: 545 and 53\u2009mg/dL, respectively\n- Fasting glucose and triglyceride levels: 85 and 158\u2009mg/dL, respectively\n- Neck auscultation revealed a systolic murmur 3+/6+ in the neck, radiating to the skull\n- Severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA)\n- Plaque observed in the anterior and posterior walls of the internal carotid artery and common carotid artery\n\nStep 2: Compare the patient note information with the inclusion criteria of the clinical trial.\n\nInclusion Criteria:\n- Enrollment in A5257 and intent to enroll in A5001 (ALLRT)\n- Signed informed consent\n- For A5257 inclusion criteria, please see ClinicalTrials.gov identifier NCT00811954\n\nStep 3: Determine if the patient meets the inclusion criteria.\n\n- The patient note does not mention enrollment in A5257 or intent to enroll in A5001 (ALLRT).\n- The patient note does not mention signed informed consent.\n- The patient note does not provide information on the A5257 inclusion criteria.\n\nStep 4: Determine the patient's eligibility based on the available information.\n\nSince the patient note does not provide sufficient information to determine if the patient meets the inclusion criteria, the patient's eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "598": {
        "output": "GPT4 Correct Assistant: Step 1: Check if the patient's age meets the inclusion criteria.\nThe patient is 46 years old, and the inclusion criteria require participants to be 18 years old or older. The patient meets this criterion.\n\nStep 2: Check if the patient has a history of heart failure.\nThe patient presents with dizziness and frequent headaches, but there is no mention of heart failure in the note. We cannot determine if the patient meets this criterion based on the information provided.\n\nStep 3: Check if the patient is in NYHA class II, III, or IV and clinically stable.\nThere is no information about the patient's NYHA class or clinical stability in the note. We cannot determine if the patient meets this criterion based on the information provided.\n\nStep 4: Check if the patient has a left ventricular ejection fraction <50%.\nThere is no information about the patient's left ventricular ejection fraction in the note. We cannot determine if the patient meets this criterion based on the information provided.\n\nStep 5: Check if the patient has a GFR \u2264 40 ml/min/1.73m\u00b2.\nThere is no information about the patient's GFR in the note. We cannot determine if the patient meets this criterion based on the information provided.\n\nSince we cannot determine if the patient meets the majority of the inclusion criteria based on the information provided, the trial-level eligibility is:\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "599": {
        "output": "GPT4 Correct Assistant: Step 1: Identify the patient's age and gender.\nThe patient is a 46-year-old man.\n\nStep 2: Determine if the patient meets the age and gender criteria for the trial.\nThe trial includes males aged 45-75 with at least 5 years of SCI, females aged 45-50 with at least 10 years of SCI, and females aged 50-75 with at least 5 years of SCI. Since the patient is a male, he must meet the male criteria.\n\nStep 3: Determine if the patient has a history of SCI.\nThe patient note does not mention any history of SCI.\n\nStep 4: Determine if the patient has other relevant medical conditions or factors.\nThe patient has a family history of CAD but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. He is physically active and has normal lipid and glucose levels. The patient reported no use of lipid-lowering medications. The patient has severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA).\n\nStep 5: Determine if the patient meets the inclusion criteria for the trial.\nThe patient meets the age and gender criteria for the trial, but there is not enough information to determine if he has a history of SCI or if he meets any other inclusion criteria.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    },
    "600": {
        "output": "GPT4 Correct Assistant: Step 1: Compare the patient's age to the inclusion criteria.\nThe patient is 46 years old, which is within the inclusion criteria of 25-35 kg/m2.\n\nStep 2: Compare the patient's BMI to the inclusion criteria.\nThe patient's BMI is not provided in the note, so we cannot determine if they meet this criterion.\n\nStep 3: Compare the patient's willingness to use cell phones and other technology to the inclusion criteria.\nThe patient's willingness to use technology is not mentioned in the note, so we cannot determine if they meet this criterion.\n\nStep 4: Compare the patient's weight stability to the inclusion criteria.\nThe patient's weight stability is not mentioned in the note, so we cannot determine if they meet this criterion.\n\nStep 5: Compare the patient's medical history and conditions to the exclusion criteria.\nThe patient has a family history of CAD, but no other cardiovascular risk factors such as smoking, high blood pressure, and diabetes mellitus. The note also mentions severe stenosis in the left internal carotid artery (LICA) and moderate stenosis in the right internal carotid artery (RICA). These conditions are not mentioned in the exclusion criteria, so the patient does not meet any exclusion criteria based on the information provided.\n\nTrial-level eligibility: 1) Not relevant.",
        "label": 0
    }
}